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A presente tese reporta a aplicação da metabolómica ao estudo de tecidos e 
biofluidos humanos (plasma sanguíneo e urina), com o intuito de caracterizar a 
assinatura metabólica do cancro pulmonar primário. No Capítulo 1, apresenta-
se uma breve introdução sobre a epidemiologia e a patogénese deste tipo de 
cancro, bem como um sumário das principais alterações metabólicas 
tipicamente associadas ao cancro em geral. Descreve-se ainda a abordagem 
metabolómica, nomeadamente os métodos analíticos e estatísticos utilizados, 
assim como o estado da arte da sua aplicação em estudos clínicos do cancro 
do pulmão. 
No Capítulo 2, apresentam-se os detalhes experimentais deste trabalho, no 
que diz respeito ao grupo de indivíduos envolvidos, à colheita e análise das 
amostras e ao posterior tratamento dos dados. 
O Capítulo 3 descreve a caracterização metabólica de tecidos do pulmão (de 
56 doentes) por espetroscopia de Ressonância Magnética Nuclear (RMN) de 
alta resolução com rotação no ângulo mágico. Após a otimização cuidada das 
condições de aquisição e a identificação detalhada dos sinais espetrais (mais 
de 50 metabolitos identificados), os perfis metabólicos dos tumores e dos 
tecidos adjacentes não envolvidos (controlos) foram comparados por análise 
multivariada, tendo sido discriminados com uma exatidão de 97%. Os 
metabolitos que mais significativamente contribuíram para esta diferenciação 
foram: glucose e acetato (diminuídos nos tumores), lactato, alanina, glutamato,  
GSH, taurina, creatina, fosfocolina, glicerofosfocolina, fosfoetanolamina, 
nucleótidos de uracilo e péptidos (aumentados nos tumores). Algumas destas 
variações corroboraram alterações típicas do metabolismo do cancro (e.g., 
glicólise e glutaminólise aumentadas), enquanto outras sugeriram novas pistas 
sobre a possível relevância de processos como a proteção antioxidante e a 
degradação proteica. Um outro resultado novo e importante descrito neste 
capítulo foi a dependência da assinatura metabólica em relação ao tipo 
histológico do tumor. Enquanto as principais alterações observadas nos 
adenocarcinomas (AdC) se relacionaram com o metabolismo fosfolipídico e 
proteico, os carcinomas de células escamosas (SqCC) apresentaram perfis 
glicolíticos e glutaminolíticos mais pronunciados, sendo possível construir um 
modelo válido para a discriminação destes subtipos.  
No Capítulo 4, apresenta-se o estudo metabolómico por RMN de plasma 
sanguíneo de mais de 100 doentes e quase 100 controlos saudáveis, do qual 
resultou um modelo multivariado com  uma taxa de classificação de 87%. A 
distinção entre os grupos foi feita essencialmente com base nos níveis de 
lactato, piruvato, acetoacetato, lipoproteínas LDL+VLDL e glicoproteínas 
(aumentados nos doentes), juntamente com os níveis de glutamina, histidina, 
valina, metanol, lipoproteínas HDL e dois compostos não identificados 
(diminuídos nos doentes). Estas variações foram detetadas desde os estádios 
iniciais da doença e a magnitude de algumas delas dependeu do tipo 
histológico, embora não permitindo discriminar AdC de SqCC. Para além 
disso, mostra-se neste capítulo que o desequilíbrio dos grupos controlo e 
cancro em termos da idade dos indivíduos poderá ter alguma influência nos 
resultados, e apresenta-se uma tentativa exploratória de validação externa, 
que resultou numa taxa de classificação de 85%. 
O estudo por RMN do perfil metabólico da urina dos doentes com cancro do 
pulmão e dos controlos é apresentado no Capítulo 5. Comparativamente ao 
plasma, o modelo construído com os perfis urinários apresentou uma taxa de 
 
   
 classificação superior (97%). Após uma avaliação cuidada da possível  
influência  do género, idade e hábitos tabágicos, um conjunto de 19 
metabolitos foi proposto como estando relacionado com a doença (incluindo 3 
compostos desconhecidos e 6 parcialmente identificados como metabolitos N-
acetilados). Tal como no caso do plasma, estas variações foram detetadas em 
doentes no estádio inicial e mostraram alguma dependência em relação ao tipo 
histológico, obtendo-se um modelo válido para a discriminação AdC vs. SqCC, 
ainda que com um poder preditivo modesto. Para além disso, o teste preliminar 
de validação externa revelou 100% de sensibilidade e 90% de especificidade, 
o que é um resultado bastante promissor em termos da potencial utilização dos 
perfis urinários em aplicações clínicas futuras. 
No Capitulo 6, descreve-se a caracterização dos perfis metabólicos da urina 
(de um subgrupo de indivíduos) por cromatografia líquida de ultra-eficiência 
acoplada a espetrometria de massa (UPLC-MS). Embora não avançando  
muito na identificação estrutural de possíveis marcadores, este estudo reforçou 
o valor diagnóstico da urina, já que os modelos multivariados resultantes 
apresentaram taxa de classificação e poder preditivo elevados. 
Finalmente, no Capítulo 7, apresentam-se as principais conclusões deste 
trabalho, realçando o contributo da metabolómica integrada de tecidos e 
biofluidos para a compreensão do metabolismo alterado do cancro do pulmão 
e para a deteção de novos perfis marcadores com valor diagnóstico.  
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abstract 
 
This thesis reports the application of metabolomics to human tissues and 
biofluids (blood plasma and urine) to unveil the metabolic signature of primary 
lung cancer. In Chapter 1, a brief introduction on lung cancer epidemiology and 
pathogenesis, together with a review of the main metabolic dysregulations 
known to be associated with cancer, is presented. The metabolomics approach 
is also described, addressing the analytical and statistical methods employed, 
as well as the current state of the art on its application to clinical lung cancer 
studies. 
Chapter 2 provides the experimental details of this work, in regard to the 
subjects enrolled, sample collection and analysis, and data processing. 
In Chapter 3, the metabolic characterization of intact lung tissues (from 56 
patients) by proton High Resolution Magic Angle Spinning (HRMAS) Nuclear 
Magnetic Resonance (NMR) spectroscopy is described. After careful 
assessment of acquisition conditions and thorough spectral assignment (over 
50 metabolites identified), the metabolic profiles of tumour and adjacent control 
tissues were compared through multivariate analysis. The two tissue classes 
could be discriminated with 97% accuracy, with 13 metabolites significantly 
accounting for this discrimination: glucose and acetate (depleted in tumours), 
together with lactate, alanine, glutamate, GSH, taurine, creatine, 
phosphocholine, glycerophosphocholine, phosphoethanolamine, uracil 
nucleotides and peptides (increased in tumours). Some of these variations 
corroborated typical features of cancer metabolism (e.g., upregulated glycolysis 
and glutaminolysis), while others suggested less known pathways (e.g., 
antioxidant protection, protein degradation) to play important roles. Another 
major and novel finding described in this chapter was the dependence of this 
metabolic signature on tumour histological subtype. While main alterations in 
adenocarcinomas (AdC) related to phospholipid and protein metabolisms, 
squamous cell carcinomas (SqCC) were found to have stronger glycolytic and 
glutaminolytic profiles, making it possible to build a valid classification model to 
discriminate these two subtypes. 
Chapter 4 reports the NMR metabolomic study of blood plasma from over 100 
patients and near 100 healthy controls, the multivariate model built having 
afforded a classification rate of 87%. The two groups were found to differ 
significantly in the levels of lactate, pyruvate, acetoacetate, LDL+VLDL 
lipoproteins and glycoproteins (increased in patients), together with glutamine, 
histidine, valine, methanol, HDL lipoproteins and two unassigned compounds 
(decreased in patients). Interestingly, these variations were detected from initial 
disease stages and the magnitude of some of them depended on the 
histological type, although not allowing AdC vs. SqCC discrimination. 
Moreover, it is shown in this chapter that age mismatch between control and 
cancer groups could not be ruled out as a possible confounding factor, and 
exploratory external validation afforded a classification rate of 85%.  
The NMR profiling of urine from lung cancer patients and healthy controls is 
presented in Chapter 5. Compared to plasma, the classification model built with 
urinary profiles resulted in a superior classification rate (97%). After careful 
assessment of possible bias from gender, age and smoking habits, a set of 19 
metabolites was proposed to be cancer-related (out of which 3 were unknowns 
and 6 were partially identified as N-acetylated metabolites). As for plasma, 
these variations were detected regardless of disease stage and showed some 
dependency on histological subtype, the AdC vs. SqCC model built showing 
modest predictive power. In addition, preliminary external validation of the 
urine-based classification model afforded 100% sensitivity and 90% specificity, 
which are exciting results in terms of potential for future clinical application.  
   
 Chapter 6 describes the analysis of urine from a subset of patients by a 
different profiling technique, namely, Ultra-Performance Liquid Chromatography 
coupled to Mass Spectrometry (UPLC-MS). Although the identification of 
discriminant metabolites was very limited, multivariate models showed high 
classification rate and predictive power, thus reinforcing the value of urine in 
the context of lung cancer diagnosis. Finally, the main conclusions of this thesis 
are presented in Chapter 7, highlighting the potential of integrated 
metabolomics of tissues and biofluids to improve current understanding of lung 
cancer altered metabolism and to reveal new marker profiles with diagnostic 
value. 
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1 GENERAL INTRODUCTION 
 
The present chapter starts by briefly describing some general information on the 
epidemiology, pathogenesis, classification, diagnosis and treatment of lung cancer. Then, 
current knowledge on cancer cell metabolic reprogramming is presented, addressing also 
how this information has been exploited in cancer diagnosis and treatment. Thirdly, the 
metabolomics approach is described, addressing the principles of the analytical and 
statistical methods employed and presenting a short state of the art of its application in 
clinical oncology, particularly in the study of lung cancer. In the last section, the scope and 
aims of this thesis are presented. 
 
1.1 About lung cancer 
1.1.1 Epidemiology, aetiology and pathogenesis 
The global burden of cancer has doubled in the last third of the twentieth century, 
and, in 2008, there were 12.7 million cases and 7.6 million deaths worldwide (Ferlay et al. 
2010). Based on the continued growth and ageing of the world‟s population and on the 
increasing incidence in low- and middle-income countries, this burden could achieve, by 
2030, 27 million incident cases and 17 million deaths per year, (Boyle and Levin 2009).  
According to the GLOBOCAN database, and as shown in Figure 1.1, lung cancer is 
one of the cancer types with highest incidence and mortality in the world, being the first 
cause of cancer-related deaths in men (22.5%) and the second in women (13.8%) (Ferlay et 
al. 2010). In Portugal, the estimated incidence of lung cancer was (in 2008) 7.6% of all 
tumours, after colorectal, breast and prostate cancers, while mortality reached 13.7% of 
cancer-related deaths, when considering both genders (Ferlay et al. 2010). Regarding lung 
cancer survival rates, the overall 5-year prevalence (percentage of survivors five years after 
diagnosis) was only 5.8% worldwide and 3.2% in Portugal (Bray et al. 2013), as illustrated 
in Figure 1.1. Diagnosis at advanced disease stage largely accounts for these numbers, as 
they significantly improve for regional (25%) and localized disease (52%) (Ridge et al. 
2013). Unfortunately, due to the asymptomatic development of lung tumours and the lack 
of appropriate screening tools, lung cancer diagnosis usually occurs at late stages of 
tumour progress, resulting in a poor prognosis for the patient.  
CHAPTER 1 – GENERAL INTRODUCTION 
 
2 
 
Figure 1.1 Statistical data of cancer incidence, mortality and five-year survival rates worldwide 
(left) and in Portugal (right). (Adapted from Ferlay et al. 2010). 
 
It is estimated that about 89% of lung cancers in men and 72% in women are caused 
by carcinogens present in tobacco smoke (e.g., polycyclic aromatic hydrocarbons and 
tobacco-specific nitrosamines) (Hecht 2012). Concordantly, lung cancer risk increases 
proportionally with smoke exposure (Boyle and Levin 2009), and global trends in lung 
cancer incidence and mortality are, to a certain extent, a reflection of population changes in 
smoking habits (including dose, duration and type of tobacco used). Indeed, age-
standardised incidence and mortality rates are, on average, higher in developed regions 
than in developing countries, reflecting the longer-term smoking habits in the former, 
while the recent smoking epidemic in medium- and low-resource countries is expected to 
result, in the future, in a greater number of cancers in those regions (Boyle and Levin 
2009). Also, different worldwide trends of tobacco smoking for men and women (smoking 
prevalence peaked about two decades earlier in men than in women, Alberg et al. 2013) 
WORLD PORTUGAL
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explains why the mortality rate for men began to decline in the early 90s, while for women 
it started to decrease later, in 2003 (Ridge et al. 2013). Another interesting relationship 
with smoking habits regards the shift in the prevalence of different histological types, 
observed in developed countries over the past 50 years. While adenocarcinoma has become 
more common, squamous cell carcinoma, which is strongly related to tobacco smoking, 
has declined, probably as a reflection of changes in cigarette design and composition, as 
well as in cigarette smoke inhalation patterns (Khuder 2001; Pesch et al. 2012). 
In spite of tobacco smoking being, by far, the major aetiological agent for lung 
cancer, a considerable number of new cases develop in never smokers (25% of all cancer 
cases, Thun et al. 2008), suggesting other factors to play a role in cancer development. 
Such factors include family history/heritable factors, exposure to second-hand smoke, 
occupational and environmental carcinogens (asbestos, polycyclic hydrocarbons, heavy 
metals and silica, arsenic and chromium VI compounds, diesel engine exhaust), hormonal 
factors, pre-existing lung disease (chronic obstructive pulmonary disease – COPD, 
pneumonia, tuberculosis), human immunodeficiency virus infection, human papilloma 
virus infection, and exposure to ionizing radiation (Alberg et al. 2013; Ridge et al. 2013). 
The synergistic interaction between exposure to these aetiological agents and individual 
susceptibility to their effects is at the origin of lung cancer. Nevertheless, reduction of 
tobacco smoking remains the key strategy for the prevention of lung cancer (Boyle and 
Levin 2009).  
As for cancer in general, lung cancer is characterized by a multitude of genetic and 
epigenetic alterations, through which normal cells are progressively transformed into 
tumour cells undergoing uncontrolled proliferation (Weinberg 2013). Among the many 
genetic alterations associated with lung cancer, the more frequently observed changes 
include several chromosomal aberrations (aneuploidy, specific allelic loss or gain), 
activation of key oncogenes (resulting in persistent upregulation of mitogenic growth 
signals which induce cell growth), and inactivation of tumour suppressor genes (Larsen 
and Minna 2011). One of such genetic abnormalities present in approximately 70% of 
patients with non-small cell lung cancer (NSCLC) is the overexpression of the epidermal 
growth factor receptor (EGFR), a tyrosine kinase (TK) receptor (Franklin et al. 2002). 
EGFR signalling activates two major pathways in solid tumours, the 
RAS/RAF/MEK/MAPK pathway and the phosphatidylinositol 3-kinase 
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(PI3K)/AKT/mTOR pathway, which collectively promote cancer cell growth, 
proliferation, invasion, metastatic spread, apoptosis and tumour angiogenesis 
(Reungwetwattana et al. 2012). EGFR tyrosine kinase inhibitors (TKIs), like gefitinib and 
erlotinib, are important examples of targeted therapy used in the treatment of this type of 
lung cancer. Another frequently mutated gene in lung cancer is the KRAS gene, found in 
10-15% of NSCLC, especially in adenocarcinomas (20-30%) (Sekido et al. 2003). KRAS 
mutations result in activation of downstream signalling pathways, such as the PI3K and 
MAPK, rendering KRAS mutant tumours independent of EGFR signalling and therefore 
resistant to EGFR TKIs (Larsen and Minna 2011). Other commonly activated oncogenes 
include ERBB2, MYC, MET, CCND1, CDK4, EML4-ALK fusion and BCL2, as reviewed 
in Larsen and Minna 2011. 
Alterations on growth-inhibitory tumour suppressor pathways are also present during 
lung carcinogenesis, the most important being the p53 pathway (Sato et al. 2007), which is 
inactivated in ca. 90% of SCLC and 50% of NSCLC (Takahashi et al. 1989). Other 
recurrently inactivated tumour suppressor genes in lung cancer include RB1, STK11, 
CDKN2A and FHIT (Larsen and Minna 2011). Most inactivating mutations are point 
mutations on the DNA binding domain, hence reinforcing the correlation between such 
mutations and DNA adduct formation by smoke carcinogens (Wang et al. 1995). 
 
1.1.2 Screening and diagnosis 
Based on its high incidence and mortality, strongly related to late detection, lung 
cancer would constitute a good candidate for screening within the general population or 
high-risk groups. However, randomised, controlled trials performed during the 1970s and 
1980s, based on the use of periodical chest X-rays and/or sputum cytology, did not validate 
the principle that the detection of localised and resectable tumours would greatly improve 
patients‟ prognosis (results reviewed by Bach 2003; Aberle et al. 2011; Xiang et al. 2013). 
Indeed, while more early-stage cancers were detected, mortality rates did not improve and 
there was no evidence that the tumours found through screening would have developed to 
an advanced stage (Bach et al. 2007). More recently, in 2011 and 2013, a trial conducted 
by the National Lung Screening Trial (NLST) used low-dose computed tomography 
(LDCT), a more sensitive screening modality, together with chest radiography, to detect 
lung tumours in current or former heavy smokers (Aberle, Berg, et al. 2011). The results 
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showed a 20% reduction in lung cancer-related deaths within this high-risk group. Despite 
the promising outcome, this screening tool is not yet ready for a wide population-based 
implementation, as several issues remain to be addressed: definition of the at-risk 
population; timing, interval and method of computed tomography; how to handle false 
positives; the potential toxicity from radiation exposure; and, particularly, the cost-
effectiveness when compared with, for example, smoking cessation alone (Aberle et al. 
2013). In addition, other screening approaches for the early detection of lung cancer are 
currently under investigation, such as the search for molecular biomarkers of the disease. 
Some of the most extensively studied examples are free circulating DNA and RNA, 
exosomal mRNA, circulating tumour cells, and various lung cancer specific antigens 
(carcinoembryonic antigen – CEA, serum cytokeratin 19 fragment – CYFRA, and 
progastrin-releasing peptide - ProGRP), as it has been recently reviewed (Hassanein et al. 
2012; Xiang et al. 2013; Brothers et al. 2013). 
Lung cancer accurate diagnosis is of paramount importance for establishing the 
patients‟ treatment and prognosis. Clinical practice guidelines concerning diagnosis and 
management of lung cancer were recently revised by the American College of Chest 
Physicians (ACCP) (Detterbeck et al. 2013) and the European Society for Medical 
Oncology (ESMO) (Vansteenkiste et al. 2013). However, the definition of the diagnostic 
workflow is usually decided on a case-by-case basis, largely depending on the overall 
clinical evaluation of the patient (including physical examination, medical history and 
performance status), the size and location of the tumour and the presumed stage of disease 
(Detterbeck et al. 2013; Gould et al. 2013).  
Available diagnostic tools typically comprise imaging techniques, laboratory testing 
and tissue microscopic examination after collection of a biopsy. The overall sensitivity and 
specificity of some of these tools are summarised in Table 1.1. Imaging methods like 
computed tomography (CT) scans are useful to determine the size and location of the 
tumours and to detect affected mediastinal/regional lymph nodes, while positron emission 
tomography (PET) scans may further assist in the differentiation of benign and malignant 
tumours (based on their metabolic activity) and in detecting metastasis to distant sites. 
Laboratory testing, such as sputum cytology and measurement of circulating tumour 
markers, may be performed when lung cancer is suspected, although poor sensitivity 
and/or specificity are usually achieved. Examination of a tissue sample under the 
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microscope is crucial for a definite diagnosis. Several techniques may be used for 
collecting a tissue biopsy, such as flexible bronchoscopy (FB, especially useful for 
biopsying tumours in the central part of the lung), transthoracic needle aspiration (TNA, 
recommended for peripheral lesions) and mediastinoscopy (Detterbeck et al. 2013). 
Subsequent histopathological study of tissue biopsies comprises their morphological 
assessment by light microscopy and, eventually, immunohistochemical testing, which is 
especially useful in cases of poorly differentiated tumours or small biopsy specimens. 
 
Table 1.1 Sensitivity and specificity of several lung cancer diagnostic tools. 
Diagnostic tools 
Sensitivity 
(%) 
Specificity 
(%) 
CT
a
 60 77 
FDG-PET
b
 97 78 
Sputum cytology
 c
 66 99 
Pleural fluid cytology
d
 72 --- 
CEA, in blood
e
 69 68 
CYFRA 21-1, in blood
e
 43 89 
Flexible bronchoscopy (FB), for central endobronchial lesions
c
 88 --- 
Flexible bronchoscopy (FB), for peripheral lesions
c
 34-63 --- 
Transthoracic needle aspiration (TNA) or biopsy
c
 90 --- 
a
 Dwamena et al. 1999; 
b
 Gould et al. 2001; 
c
 Rivera and Mehta 2007; 
d
 Rivera et al. 2013; 
e
 
Okamura et al. 2013. 
 
1.1.3 Main histological types of lung tumours 
According to the World Health Organization (WHO) (Travis et al. 2004, Travis et al. 
2013), malignant epithelial lung tumours are classified into seven main categories (as listed 
in Table A1 of Annex I): adenocarcinoma, squamous cell carcinoma, adenosquamous 
carcinoma, sarcomatoid carcinoma, carcinoid tumour, large cell carcinoma and small cell 
carcinoma, the first six categories traditionally being grouped as a larger class designated 
as non-small cell lung carcinoma (NSCLC). Accurate tumour subtyping is a major 
requirement as several clinical trials have demonstrated differing efficacy and/or toxicity 
of particular treatments depending on tumour histological type (Cooper et al. 2011; Kerr 
2012). This task is typically based on stained hematoxylin and eosin (H&E) histological 
sections, as well as on immunohistochemical assays. The following sub-sections describe 
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in more detail the main histological, cytological and clinical features of the tumour types 
included in this work. 
 
1.1.3.1 Adenocarcinoma (AdC) 
Adenocarcinoma is a malignant epithelial tumour 
with glandular differentiation or mucin production, 
showing one or a mixture of the following histological 
patterns: acinar, papillary, bronchioloalveolar (BAC), 
solid with mucin production (Travis et al. 2004). 
Adenocarcinomas of mixed patterns are by far the most 
frequent subtype, representing ca. 80% of resected 
adenocarcinomas (Terasaki et al. 2003), and often 
presenting several degrees of differentiation. Typical 
cytomorphological features of AdC include three-dimensional cellular clusters of large 
vacuolated cells, with variable cell size and cytoplasm volume (Figure 1.2) (Travis et al. 
2004; Idowu and Powers 2010). The nuclei are usually single, eccentric and round to oval. 
The chromatin tends to be finely regular and evenly dispersed in well-differentiated 
tumours, while coarse and irregularly distributed in poorly differentiated tumours (Travis 
et al. 2004). Adenocarcinoma spreads primarily by lymphatic and haematogenous routes, 
with nearly one fifth of the newly diagnosed adenocarcinomas presenting distant 
metastasis, mainly to the brain, bone, adrenal glands or liver (Quint et al. 1996). The 
immunohistochemical features of AdCs may vary according to the subtype and degree of 
differentiation. The expression of epithelial markers (cytokeratins AE1/AE3, CAM 5.2 and 
CK7, epithelial membrane antigen – EMA, and carcinoembryonic antigen – CEA) is 
typical of this type of tumour, as well as the presence of thyroid transcription factor 1 
(TTF1) staining, in particular in better-differentiated tumours (Rubin et al. 2001; Lau et al. 
2002; Yatabe et al. 2002). Nevertheless, mucinous tumours may represent exceptions to 
these markers. In terms of incidence, adenocarcinoma has surpassed squamous cell 
carcinoma as the commonest histological subtype of lung cancer, largely associated with 
the introduction of filter cigarettes (Ito et al. 2011). Incidence rates go up to 41.5 % and 
39.6% in the USA and Portugal, respectively (Hespanhol et al. 2013; Howlader et al. 
2014). 
Figure 1.2 Solid adenocarcino-
ma with mucin (hematoxylin-
eosin). (Adapted from Travis et 
al. 2004). 
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1.1.3.2 Squamous cell carcinoma (SqCC) 
Squamous cell carcinoma, also referred to as 
epidermoid carcinoma, is a type of malignant epithelial 
tumour, usually located centrally in the mainstem, lobar 
or segmental bronchi (Tomashefski et al. 1990), although 
an increase of the frequency of peripheral carcinomas has 
been noted (Funai et al. 2003). The variants of this 
histological type are: papillary, clear cell, small cell and 
basaloid carcinomas. Well-differentiated squamous cell 
carcinomas show keratinisation and/or intercellular 
bridges that arise from bronchial epithelium and pearl formation (Figure 1.3). Tumour cells 
tend to be large with abundant dense cytoplasm, central and irregular hyperchromatic 
nuclei and small nucleoli (Travis et al. 2004). In the case of poorly-differentiated tumours, 
these features can be present, although only focally. Metastases to distant organs are less 
frequent than in other histological types of primary lung cancer (Quint et al. 1996). The 
majority of squamous cell carcinomas consistently express high-molecular weight keratin 
(34βE12), cytokeratin CK5/6 and CEA. In addition, these carcinomas frequently express 
protein P63 and are negative for TTF1 (Travis et al. 2004; Drilon et al. 2012). Over 90% of 
cases with SqCC occur in cigarette smokers (Spiro and Porter 2002). Being the second 
most common type of lung cancer, incidence rates reach 22.0% and 26.8 % in the USA and 
Portugal, respectively (Hespanhol et al. 2013; Howlader et al. 2014). 
 
1.1.3.3 Adenosquamous carcinoma (ASqCC) 
Adenosquamous carcinoma is characterised by 
showing components of both AdC and SqCC with each 
comprising at least 10% of the tumour, as identified by 
light microscopy, thus resection specimens are required for 
diagnosis. This hybrid type of tumour accounts for 0.6-
2.3% of all lung cancers worldwide (Takamori et al. 1991; 
Sridhar et al. 1992; Ishida et al. 1992) and for 0.9% in 
Portugal (Hespanhol et al. 2013). ASqCCs are usually 
located in the periphery of the lung and may contain a 
Figure 1.3 Squamous cell 
carcinoma (hematoxylin-eosin). 
(Adapted from Travis et al. 
2004). 
Figure 1.4. Adenosquamous 
carcinoma, showing a 
squamous cell lobe on the left, 
adjacent to an acinar 
adenocarcinoma. (Adapted from 
Travis et al. 2004). 
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central scar. Immunohistochemical findings also recapitulate both squamous and 
adenocarcinoma characteristics, so they express cytokeratins with a wide molecular weight 
range including AE1/AE3, CAM 5.2, KL1, and CK7, but usually not CK20. EMA is 
positive and TTF1 positivity is confined to the adenonocarcinoma component (Travis et al. 
2004). 
 
1.1.3.4 Sarcomatoid carcinoma (SC) 
Sarcomatoid carcinoma is a poorly differentiated 
carcinoma which contains a component of sarcoma or 
sarcoma-like differentiation. Five subtypes can be 
recognised within sarcomatoids: pleomorphic, spindle cell, 
giant cell carcinomas, carcinosarcoma and pulmonary 
blastoma (Travis et al. 2004). SCs can arise in the central 
or peripheral lung, accounting for only 0.3-1.3% of all lung 
malignancies (Fishback et al. 1994; Nakajima et al. 1999; 
Rossi et al. 2003; Travis 2010a). Pleomorphic carcinomas 
tend to be large, peripheral tumours that can invade the 
chest wall, and are often associated with poor prognosis (Travis 2010a). They consist of 
malignant giant and/or spindle cells (at least 10%) and epithelial components, such as 
squamous or adenocarcinoma (Figure 1.5) (Travis et al. 2004; Travis 2010a), their 
diagnosis usually requiring a resection specimen. On the other hand, the spindle and/or 
giant cells can occur as cohesive aggregates, lacking any glandular or squamous 
differentiation, forming the spindle cell or the giant cell carcinoma, respectively. 
Sarcomatoid cells often co-express cytokeratins, vimentin, CEA and smooth markers 
(Addis et al. 1988; Chejfec et al. 1991; Attanoos et al. 1998; Fishback et al. 1994; Rossi et 
al. 2003) and TTF1 may be positive in giant cell carcinomas. 
 
 
 
 
 
 
Figure 1.5. Pleomorphic 
carcinoma, composed of 
squamous cell carcinoma (left) 
and a malignant spindle cell 
proliferation (right) (hemato-
xylin-eosin). (Adapted from 
Travis 2011). 
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1.1.3.5 Carcinoid tumour 
Carcinoid tumour cells are characterised by growth 
patterns (organoid, trabecular, insular, palisading, ribbon, 
rosette-like arrangements) that suggest a neuroendecrine 
differentiation (Travis et al. 2004), with nuclei posessing 
finely granular chromatin in eosinophilic cytoplasm. They 
can be classified as typical carcinoid (tumour with fewer 
than 2 mitoses per 2 mm
2
 and lacking necrosis) and atypical 
carcinoid (tumour with 2-10 mitoses per 2 mm
2
 and/or focal 
presence of necrosis, still below the mitotic rates of large 
cell neuroendocrine and small cell lung carcinomas) (Travis et al. 1991; Travis et al. 1998). 
Carcinoids account for 1-2% of all invasive lung malignancies (Travis et al. 1995), 50% of 
patients being asymptomatic at presentation (Travis et al. 1995; Asamura et al. 2006; 
Travis 2010b). The 5-year survival rates of typical carcinoid (90-95%) largely surpass the 
ones of atypical carcinoid (50-60%) (Travis 2011). Carcinoid tumours stain for 
neuroendocrine markers, such as chromogranin, synaptophysin and CD56 (neural cell 
adhesion molecule – NCAM) (Travis et al. 2004). 
 
1.1.3.6 Large cell carcinoma (LCC) 
Large cell carcinoma is an undifferentiated cell 
carcinoma without cytological and architectural features 
of neither small cell carcinoma nor glandular or squamous 
differentiation, so it is diagnosed by exclusion (Travis et 
al. 2004). Large cell neuroendocrine carcinoma, combined 
large cell neuroendocrine carcinoma, basaloid carcinoma, 
lymphoepithelioma-like carcinoma, clear cell carcinoma 
and large cell carcinoma with rhabdoid phenotype 
comprise the list of this tumour variants. This type of lung tumour accounts for 
approximately 3% of all lung carcinomas (Iyoda et al. 2001; Hespanhol et al. 2013) and 
typically presents as large, peripheral masses (although central location may also be 
found). Cell nuclei vary from round to extremely irregular, with irregular chromatin 
Figure 1.7 Large cell 
carcinoma (hematoxylin-eosin). 
(Adapted from Travis et al. 
2004). 
Figure 1.6. Atypical carcinoid 
with foci of necrosis in the 
center of several organoid nests 
of uniform tumour cells. 
(Adapted from Travis 2011). 
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distribution (Burns et al. 1989). Patients with this type of lung cancer have a poor 
prognosis, worse than patients with other carcinomas, in particular adenocarcinomas 
(Travis et al. 1998; Jiang et al. 1998; Iyoda et al. 2001). 
 
1.1.3.7 Small cell carcinoma (SCLC) 
Small cell carcinoma of the lung is a malignant 
epithelial tumour comprised of small cells with a round to 
fusiform shape, scant cytoplasm, ill-defined cell borders, 
finely granular and uniformly distributed nuclear chromatin 
(„salt and pepper‟ effect) and absent or inconspicuous 
nucleoli. Tissue necrosis is typically extensive and the 
mitotic count is high (average rate of 80 mitoses/2 mm
2
) 
(Nicholson et al. 2002; Travis et al. 2004; Travis 2010b). 
Two variants are small cell lung cancer and combined small cell lung cancer (with an 
additional component of any of the histological types of non-small cell carcinoma). 
Immunohistochemistry is positive for neuroendocrine markers CD56, chromogranin and 
synaptophysin in most cases (Guinee et al. 1994; Nicholson et al. 2002), and for TTF1 in 
up to 90% of the cases (Folpe et al. 1999; Kaufman and Dietel 2000). SCLC comprises up 
to 13% of all lung cancers (Travis et al. 1995; Hespanhol et al. 2013; Howlader et al. 2014) 
and often presents an aggressive clinical course, with tendency to metastasise (widespread 
at presentation and poor responsiveness to chemotherapy).  
 
1.1.4 Staging and treatment 
Lung cancer staging is based on the internationally accepted tumour-node-metastasis 
(TNM) staging system, which assesses the extent of the primary tumour (T), the absence or 
presence of regional lymph node involvement (N), and the absence or presence of 
intrathoracic or distant metastasis (M) (Lababede et al. 2011; Mirsadraee et al. 2012). 
Disease stages range from I (less advanced) to IV (more advanced), each comprising 
different TNM classifications (Tables A2 and A3 of Annex II). 
 
Figure 1.8. Small cell 
carcinoma. (Adapted from 
Travis 2011). 
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The treatment strategy is largely defined based on tumour histology and stage, other 
factors taken into account include the patients‟ age, performance status, comorbidities and 
preferences. The primary curative approach to early-stage NSCLC (I and II) is usually 
surgery, either by removing part of the lung (lobectomy) or all of the lung 
(pneumonectomy), depending on the location of the tumour (Vansteenkiste et al. 2013). If 
tumour resection is complete, adjuvant chemotherapy is administered to lower the risk of 
recurrence. In cases of incomplete resection, postoperative radiotherapy is usually offered. 
For treating locally advanced NSCLC of stage III, surgery may also be considered, 
preferably in patients in whom resection by lobectomy is expected to be successful. 
Moreover, for both resectable and unresectable tumours, regimens of chemotherapy 
(mostly cisplatin-based), delivered concurrently with radiotherapy, are recommended 
(Vansteenkiste et al. 2013). As for stage IV NSCLC patients, chemotherapy is often used 
to control the disease for as long as possible, while radiation may be used for palliative 
care. Among the drugs most commonly used for NSCLC treatment are cisplatin or 
carboplatin, plus docetaxel, gemcitabine, paclitaxel, vinorelbine or pemetrexed 
(Vansteenkiste et al. 2013; Peters et al. 2012). In cases of advanced tumours with specific 
molecular markers, targeted therapies may also be employed, alone or in combination with 
conventional chemotherapy (e.g., erlotinib to treat EGFR mutated tumours). 
Recommended treatment regimens for SCLC differ significantly, as this type of 
cancer is characterised by rapid growth, high response rates to both chemo and 
radiotherapy, and development of treatment resistance in patients with metastatic disease 
(Früh et al. 2013). In this case, surgery may benefit a small percentage of patients (5% of 
SCLC patients with stage I localized disease), while chemotherapy is essential at all stages. 
Patients with limited-stage SCLC are often treated with concurrent chemotherapy (using 
drug combinations like etoposide and cisplatin) and thoracic radiotherapy. Treatment of 
advanced SCLC is mostly palliative, while in patients with relapsed or refractory SCLC 
(patients not responding or progressing during chemotherapy), the administration of 
second-line, single agent chemotherapy, or participation in a clinical trial is recommended 
(Früh et al. 2013; Detterbeck et al. 2013). 
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1.2 Metabolic reprogramming in cancer 
Tumour development involves a complex network of events, such as oncogene 
activation, insensitivity to anticancer signalling and evasion to apoptosis, high replicative 
potential, sustained angiogenesis and metastasis, and metabolic dysregulation (Hanahan 
and Weinberg 2000; Hanahan and Weinberg 2011). In particular, altered metabolism of 
cancer cells has been recently recognised as an emergent cancer hallmark, resulting from 
changes in signalling pathways, protein expression and other molecular mechanisms, but 
also reflecting specific biochemical adaptations during carcinogenesis, with extensive 
cross-talk between events, as well as important feedback loops (Hanahan and Weinberg 
2011). This means that the metabolic status of tumour cells will reflect not only the 
endpoint of oncogenic activation, but may also actively participate in the process of tumour 
development by conferring malignant cells survival advantages. Thus, an accurate mapping 
of tumour metabolic signatures may potentially provide new insights into tumour cell 
biology and offer new options for diagnosing and treating cancer.  
 
1.2.1 Altered metabolic pathways in cancer and their regulation 
Over the last decades, studies on diverse types of tumour cells have allowed 
consistent alterations in multiple metabolic pathways to be identified. In general, 
metabolism in these cells is characterised by high rates of glycolysis and/or glutaminolysis, 
to fuel cell proliferation, and increased biosynthetic processes to provide essential building 
blocks (nucleotides, lipids and other macromolecules), as well as reducing power 
(NADPH) for redox regulation. The following sections will summarily describe the most 
widely recognised metabolic alterations in cancer, addressing also their regulation 
mechanisms. An overview representation of cancer metabolic pathways and the key 
oncogenes and tumour suppressors involved in their regulation is shown in Figure 1.9. 
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Figure 1.9 Overview of altered cancer metabolic pathways and their regulation. Key oncogenic 
pathways are shown in green and key tumour suppressor pathways are shown in red. (Reprinted 
from Jones and Schulze 2012, Copyright © 2011 with permission from Elsevier). 
 
1.2.1.1 Tumour energy supply: glycolysis and glutaminolysis 
In contrast to nonproliferating (differentiated) cells, which depend primarily on 
oxidative phosphorylation for ATP production, proliferative tissues or tumour cells rely 
preferentially on glycolysis to satisfy their energetic needs, even in the presence of oxygen 
(aerobic glycolysis) (Figure 1.10). Glycolysis is the process by which glucose enters the 
cell and is degraded, via a cascade of reactions in the cytosol, into pyruvate, which can 
then either be incorporated into the tricarboxylic acid (TCA) cycle or be converted to 
lactate (Nelson and Cox 2004). The glycolytic degradation into pyruvate releases only a 
small fraction of the total available energy from glucose. So, under aerobic conditions, this 
energy can be further extracted by oxidative reactions in the TCA cycle and through 
oxidative phosphorylation pathway, in the mitochondria. Oppositely, under low oxygen 
conditions (hypoxia), pyruvate is reduced into lactate by lactate dehydrogenase (LDH). As 
firstly observed by Otto Warburg in 1924, tumour cells are characterised for uptaking more 
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glucose than normal cells and for having a higher glycolytic capacity and higher rate of 
lactate production, even in the presence of oxygen (Warburg et al. 1924; Warburg 1956); a 
phenomenon called the „Warburg effect‟.  
 
 
Figure 1.10 Schematic representation of the different utilization of glucose by differentiated and 
proliferative or tumour tissues. From Heiden et al. 2009, reprinted with permission from AAAs. 
 
Tumour cells commonly experience hypoxia, as they initially lack an extensive 
capillary network to supply the tumour with oxygen. In these conditions, cells adjust their 
cellular physiology and metabolism, switching from the oxygen-dependent oxidative 
phosphorylation to the oxygen-independent glycolysis. In mammalian cells, this metabolic 
response to oxygen limitation is coordinated by the transcription factor hypoxia-inducible 
factor 1α (HIF-1α) encoded by the HIF-1A gene (Semenza 2003; Gordan and Simon 
2007). The activation of HIF-1A gene in cancer cells drives the overexpression and 
increased activity of several glycolysis-related protein isoforms that differ from those 
found in non-malignant cells, including hexokinase HK2 and phosphofructokinase PFK1, 
as well as of glucose transporters (GLUT1), pyruvate dehydrogenase kinase (PDK1), 
which blocks the entry of pyruvate into the TCA, and lactate dehydrogenase LDHa 
(Macheda et al. 2005; Kim et al. 2006; Marín-Hernández et al. 2009) (Figure 1.9). 
However, hypoxia cannot be completely responsible for the elevated glucose 
transport and increased glycolysis, as these alterations have also been verified in cultured 
cells under normoxic conditions. In fact, recent studies demonstrated that besides the 
referred HIF-induced alterations in the expression of key glycolytic enzymes, other 
changes contribute to the „Warburg effect‟ in cancer cells, namely the inactivation of p53, 
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a tumour suppressor gene that promotes oxidative phosphorylation and inhibits glycolysis 
(Gottlieb and Vousden 2010), and the activation of several oncogenes, including MYC, 
RAS, SRC and AKT (Dang and Semenza 1999; Bensaad and Vousden 2007; Young and 
Anderson 2008). For instance, the activation of the PI3K/AKT pathway and MYC can 
result in the increase of glucose uptake and activation of several glycolytic enzymes 
(Elstrom et al. 2004; Yeung et al. 2008), as shown in Figure 1.9.  
Although glycolysis appears to be an inefficient way of energy production (low ATP 
yield per glucose molecule consumed), it provides several advantages for tumour cells. 
First, glycolytic ATP production is independent of oxygen availability and, if the 
glycolytic flux is high enough, it can be a faster way of obtaining energy than oxidative 
phosphorylation. Second, glycolysis provides cells with metabolic intermediates necessary 
for biosynthetic processes (as described in the next section), the high glycolytic rate 
allowing those lower-flux pathways to be finely controlled. Thirdly, the high rate of lactate 
production from glycolysis results in an acidic, toxic microenvironment that can actually 
favour tumour cells as, contrarily to other local cell populations, these cells tend to develop 
a phenotype resistant to hypoxia and to acid-induced cell death (necrosis or apoptosis). 
Ultimately, this promotes extracellular matrix degradation and aids invasiveness and 
metastasis (Fang et al. 2008). 
In addition to glycolysis, glutaminolysis is also recognised as a key feature of cancer 
cells‟ metabolism. Glutamine, the most abundant free amino acid in plasma, serves as a 
carbon source for energy production, contributes with carbon and nitrogen to biosynthetic 
reactions, and helps regulating the redox status (Daye and Wellen 2012). It is known, since 
decades, that the high consumption rate of glutamine observed in cancer cells largely 
exceeds the one necessary for amino acid and protein synthesis (Eagle et al. 1956). Later 
studies showed glutamine to be partially oxidised into lactate, and established glutamine as 
an additional source of energy in tumour cells (Reitzer et al. 1979). This catabolic 
degradation of glutamine into lactate is termed glutaminolysis, another hallmark in cancer 
cell metabolism. 
Glutaminolysis starts with transport of glutamine into the cell by transporters ASCT2 
and SN2, and proceeds with glutamine deamidation to glutamate via glutaminase (GLS), 
yielding ammonium. Glutamate can be excreted or further metabolised to α-ketoglutarate 
via transaminase alanine aminotransferase (ALT). In the mitochondria, α-ketoglutarate is 
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used in the production of malate, which can then be oxidized to pyruvate via malic enzyme 
(ME), ultimately leading to the secretion of lactate into the extracellular medium (Wise et 
al. 2008) (Figure 1.11). 
 
 
Figure 1.11 Glutaminolytic and glycolytic pathways showing the synthetic endpoints of their 
metabolic intermediates. (Reprinted from Wise et al. 2008, Copyright © 2008 by The National 
Academy of Sciences of the USA.). 
 
Although little is known about the regulation of glutamine uptake and of 
glutaminolysis, recent studies have proposed an important role for the oncogene MYC 
(Wise et al. 2008; Gao et al. 2009). In particular, Gao and colleagues have reported that the 
overexpression of MYC results in a greater expression of mitochondrial glutaminase, 
leading to the upregulation of mitochondrial glutamine metabolism (Gao et al. 2009), as 
shown in Figure 1.9. In addition to MYC, tumour suppressor p53 also regulates glutamine 
metabolism by inducing the expression of GLS2, leading to increased mitochondrial 
oxidative phosphorylation and energy production from glutaminolysis (Daye and Wellen 
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2012). Also, GLS2 was found to increase glutathione levels and to reduce ROS levels, 
conveying protection against oxidative stress-induced apoptosis (Hu et al. 2010).  
Together, glucose and glutamine serve as the primary nutrients to fuel cancer cell 
proliferation. Recent data indicate that the metabolism of these two nutrients is actively 
coordinated, as cells can switch the carbon source or compensate for reduced availability 
of one nutrient by utilizing more of the other (Yang et al. 2009; Cheng et al. 2011). 
However, in contrast to glycolytic ATP production, glutaminolytic ATP generation 
depends on oxygen supply and takes place mainly in small tumours with good 
vascularisation and adequate oxygen levels (Vaupel et al. 1989). 
 
1.2.1.2 Tumour cell biosynthetic pathways 
Proliferating cells, in particular tumour cells, depend on the availability of metabolic 
precursors for the synthesis of cellular building blocks needed for maintaining their high 
proliferative capacity. One paradigmatic example comprises the diversion of glycolytic 
intermediates into the pentose phosphate pathway (PPP) and the use of nonessential amino 
acids, derived from glucose and glutamine catabolism, for de novo nucleotide biosynthesis 
(Figure 1.12). Purine and pyrimidine synthesis utilizes ribose 5-phosphate (R5P) that can 
be either synthesised from glucose-6-phosphate (glucose-6-P), by the oxidative branch of 
PPP, or from fructose-6-phosphate (fructose-6-P) and glyceraldehyde-3-phosphate 
(GA3P), by the non-oxidative branch of PPP (Figure 1.12). Along with the production of 
R5P, the oxidative PPP also regenerates NADPH, which is the hydrogen donor in fatty 
acid synthesis, as well as an important regenerator of reduced glutathione, promoting the 
scavenging of reactive oxygen species (ROS) (Wood 1986). 
Unlike normal cells, which produce most of the R5P for nucleotide biosynthesis 
through the oxidative arm of PPP, there is evidence that, in cancer cells, the non-oxidative 
pathway is the main source for R5P synthesis (Boros et al. 1998; Cascante et al. 2000), as 
corroborated by the increased activity of transketolase and transaldolase enzymes 
(Heinrich et al. 1976; Coy et al. 2005). All the reactions in the non-oxidative PPP are 
reversible, meaning that the direction of this pathway is determined by the relative levels 
of metabolic substrates and products. Therefore, in order to divert glycolytic metabolites 
into PPP through the non-oxidative branch, cancer cells have to maintain high levels of 
fructose 6-phosphate and/or GA3P. The activity of phosphofructokinase 1 (PFK-1), an 
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important control point in glycolysis, and the levels of fructose 1,6-biphosphate (F1,6BP), 
which then breaks down into GA3P by aldolase, have been found increased in cancer cells 
and tissue,
 
and thought to contribute to this redirection (Sanchez-Martinez and Aragon 
1997; Tong et al. 2009). Along with PFK-1, pyruvate kinase M2 (PK-M2), another rate-
limiting enzyme in glycolytic degradation, also contributes to divert the carbon flux from 
glycolysis into PPP (Mazurek et al. 2005). Moreover, besides stimulating anaerobic 
glycolysis like previously explained, HIF-1a also has an important role in this preference 
for the non-oxidative PPP, namely by inducing the expression of TKT and PK-M2 (Tong 
et al. 2009). Furthermore, MYC-induced glutamine catabolism provides the cell with an 
abundant supply of aspartate and amine groups to support nucleotide biosynthesis, together 
with NADPH. This is especially important for tumour cells relying on the non-oxidative 
arm of PPP for R5P production, as the activity of glucose-6-phosphate dehydrogenase 
(G6PD) is inhibited and the oxidative arm of PPP cannot be used to produce NADPH to 
support macromolecular biosynthesis. 
 
 
Figure 1.12 Metabolic pathways active in proliferating cells, where the diversion from glycolysis 
into the pentose phosphate pathway (PPP) is put in evidence. From Heiden et al. 2009, reprinted 
with permission from AAAs. 
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Another branch diverting from glycolysis and implicated in cancer is the serine 
biosynthesis pathway, in which the glycolytic intermediate 3-phosphoglycerate is 
converted into serine following a three-step enzymatic reaction, accompanied by glutamate 
breakdown to α–ketoglutarate (Figure 1.13), thereby coupling glycolysis with 
glutaminolysis. Genetic and functional studies have suggested the serine biosynthetic 
pathway to be activated in cancer pathogenesis, with p53 having been associated with 
tumour cells‟ capacity to deal with serine depletion and oxidative stress (Maddocks et al. 
2013). Moreover, serine can act as an allosteric regulator of PKM2, since when serine is 
abundant this pyruvate kinase is fully activated allowing the consumption of glucose 
through aerobic glycolysis (Ye et al. 2012; Chaneton et al. 2012). Upon serine deprivation, 
PKM2 activity is reduced, and pyruvate is directed to mitochondria and glycolysis 
metabolites are diverted to serine biosynthetic pathways to sustain cell proliferation. 
 
 
Figure 1.13 Serine biosynthesis pathway. (Reprinted from Jones and Schulze 2012, Copyright © 
2011 with permission from Elsevier). 
 
When serine is metabolized to glycine, tetrahydropholate (THF) is converted to 5,10-
methylene-THF, which is a critical step in maintaining the folate cycle for nucleotide 
synthesis. Moreover, glycine can be directed to the synthesis of purines giving two carbon 
and one nitrogen atoms in the purine ring. Also, glycine is an integral component of 
glutathione, the main cellular antioxidant. It has been recently suggested a key role for 
glycine in cancer cell proliferation (Jain et al. 2012), making it another target for therapy 
intervention. 
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In addition to glycolysis, the TCA cycle also acts in tumour cells as a hub for 
biosynthesis, resulting in a continuous efflux of intermediates (cataplerosis). A prime 
example is the de novo synthesis of lipids (fatty acids, cholesterol and isoprenoids), 
observed in many tumour cells irrespective of the levels of extracellular lipids. In this 
pathway (Figure 1.14), mitochondrial citrate is exported to the cytosol to be converted into 
the lipogenic precursor acetyl-CoA. A portion of acetyl-CoA is then carboxylated to 
malonyl-CoA, and the consecutive condensation of the two coenzymes produces palmitate 
and other saturated long chain fatty acids (FA), which can be further modified to form 
more complex FA used in the synthesis of various cellular lipids (phospholipids, 
triglycerides and cholesterol esters) or in the modification of proteins, thus influencing cell 
signalling and growth. This increased lipogenic activity impacts on the fraction of 
mitochondrial citrate available for oxidation, thus resulting in a so called „truncated‟ TCA 
cycle (Mazurek 2007). As already described, tumour cells tend to compensate for this and 
to sustain the TCA cycle through anaplerotic processes like glutaminolysis. 
 
 
Figure 1.14 Glucose metabolism provides cells with a lipogenic precursor acetyl-CoA for fatty 
acid synthesis, which is enhanced in tumours due to oncogene-driven expression of ACL, ACC and 
FAS enzymes. (Reprinted from DeBerardinis et al. 2007, Copyright © 2008 with permission from 
Elsevier). 
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Consistent with high lipogenesis is the increased expression of lipogenic enzymes, 
observed in several tumour cells, namely ATP-citrate lyase (ACL, involved in the 
synthesis of acetyl-CoA from citrate), acetyl-CoA carboxylase (ACC, which catalyzes the 
production of malonyl-CoA from acetyl-CoA) and fatty acid synthase (FAS, a multi-
enzyme complex catalysing fatty acid synthesis) (Swinnen et al. 2006). In fact, in vitro 
and/or in vivo inhibition of all these enzymes resulted in diminished cell proliferation, loss 
of cell viability or decrease of tumour (Kuhajda et al. 1994; Pizer et al. 1996; 
Hatzivassiliou et al. 2005; Brusselmans et al. 2005). It is established that tumour cells 
achieve rapid fatty acid synthesis through multiple effects of oncogenic mutations, 
particularly those involving the phosphatidylinositol-3 kinase PI3K/Akt/mTOR signalling 
pathway. This system stimulates expression of lipogenic genes through the activation of 
the sterol regulatory element binding protein-1 (SREBP-1), a transcription factor that 
targets ACL, ACC and FAS enzymes (Porstmann et al. 2005).  
 
1.2.2 Exploiting tumour metabolism in cancer diagnosis and therapy 
Knowledge of altered metabolism in cancer is at the basis of new diagnostic tools 
and anticancer drugs. One of the most emblematic examples, firmly implemented in the 
clinics, is 
18
fluoro-2-deoxyglucose-positron emission tomography (FDG-PET) to image 
tumour development and regression. This technique, developed with basis on the „Warburg 
effect‟, uses a radiolabelled glucose analogue to track its uptake, generally increased in 
several tumour types and shown to correlate with tumour aggressiveness (Gatenby and 
Gillies 2007). As a result, FDG-PET imaging has been successfully used in the diagnosis, 
staging and treatment monitoring of several cancers, including lung cancer (Zhu et al. 
2011). In cases where tumours do not show pronounced „Warburg effect‟, or when 
malignant lesions affect organs that normally take up (central nervous system) or excrete 
(kidneys, bladder and prostate) FDG, this method has, however, poor performance. Hence, 
other PET tracers have been developed for oncological purposes, focusing on metabolic 
pathways other than glycolysis. Examples include 
11
C-acetate, a precursor of membrane 
fatty acids, and 
18
F-choline, a substrate of choline kinase in choline metabolism, in prostate 
cancer (Grassi et al. 2012; Hausmann et al. 2014), 
11
C-methionine, a precursor of 
adenosylmethionine required for polyamine synthesis, in brain tumour (Glaudemans et al. 
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2013), and 
18
F-glutamine and 
18
F-glutamate, targeting glutaminolysis (Lieberman et al. 
2011; Ploessl et al. 2012). 
Other tools under development for cancer diagnosis, based on altered tumour 
metabolism, include magnetic resonance spectroscopy imaging (MRSI) and dynamic 
nuclear polarization (DNP)-MRS. MRSI has expanded dramatically over the past decades 
as an adjunct technique to magnetic resonance imaging (MRI), being commonly applied to 
measure the levels of metabolites like N-acetylaspartate (NAA) in brain (Griffin and 
Kauppinen 2007), citrate in prostate (Swanson et al. 2006) and also choline compounds in 
breast (Bartella and Huang 2007), brain (Dowling et al. 2001) and prostate tumours (Seitz 
et al. 2009). DNP-MRS is a novel imaging technique that provides tens of thousands fold 
signal enhancement for stable isotope carbon-13 enriched compounds, making it possible 
to detect 
13
C NMR signals from the substrate as well as from its metabolic products 
(Ardenkjaer-Larsen et al. 2003; Golman et al. 2003). Mainly due to its central role in 
cellular metabolism and favourable relaxation properties (Kurhanewicz et al. 2011), [1-
13
C] pyruvate has been the most widely explored substrate in DNP-MRS. The first clinical 
trial of DNP-MRS using this substrate for the evaluation of prostate cancer is ongoing 
(Nelson et al. 2013), thus anticipating the rapid translation of this technique to clinical 
research and even clinical practice (Kurhanewicz et al. 2011). 
Research on altered tumour metabolism has also allowed novel therapeutic targets to 
be identified, stimulating the development of multiple anticancer drugs targeting metabolic 
enzymes with key roles in tumour growth. A list comprising examples of such potential 
therapeutic compounds, together with their main targets, is shown in Table 1.2.  
 
Table 1.2 Examples of anticancer strategies targeting glucose, glutamine and purine metabolisms. 
(Adapted from Madhok et al. 2011). 2DG: 2-deoxyglucose; 3PO: 3-(3-pyridinyl)-1-(4-pyridinyl)-2-
propen-1-one; L-DON: 6-diazo-5-oxo-L-norleucine; 5-FU: 5-fluorouracil; NCT: National Clinical 
Trial. 
Strategy Compound 
Drug 
development 
Reference/NCT number 
Inhibition of glycolytic enzymes 
 
Hexokinase Lonidamine 
Clinical trials, 
approved in Europe 
Gatzemeier et al. 1991; Gadducci et 
al. 1994; De Lena et al. 2001 
 
 2DG Clinical trials Mohanti et al. 1996; Raez et al. 2013 
 
6-Phoshofructo-1-kinase 3PO Preclinical Clem et al. 2008 
 Pyruvate kinase TLN-32 Clinical trials Thallion Pharmaceuticals 2009 
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Table 1.2 (continued) 
Strategy Compound 
Drug 
development 
Reference/NCT number 
Inhibition of pentose  phosphate pathway 
 Transketolase Oxythiamine Preclinical Ra  s et al. 1999 
Promotion of oxidative phosphorylation 
 Inhibition of lactate dehydrogenase RNA interference Preclinical Xie et al. 2009 
Attenuation of HIF1 activity 
 
Inhibition of HIF1α translation Topotecan 
Approved by FDA, 
clinical trials 
NCT00770536, NCT00698516, 
NCT00770731 
 Inhibition of HIF1α stability YC-1 Preclinical Yeo et al. 2003; Kim et al. 2006 
Inhibition of glutamine metabolism 
 Glutaminase L-DON Clinical trials 
Ahluwalia et al. 1990; Mueller et al. 
2008 
Inhibition of purine synthesis 
 Thymidylate synthase 5-FU Clinical trial 
Garcia et al. 2003; O‟Connell et al. 
2006 
 Dihydrofolate reductase Methotrexate Registered  
 
Targeting glucose metabolism is one of the most explored strategies, comprising 
different approaches: i) inhibition of glycolytic enzymes, generally aimed at depriving 
tumour cells of ATP; ii) inhibition of the PPP, with a view to decrease the production of 
NADPH (which plays an important role in preventing oxidative stress) and of pentoses 
(required for nucleic acids synthesis); iii) promotion of oxidative phosphorylation, in order 
to shift the cells from the dependence on glycolysis and reactivate apoptosis through the 
mitochondrial pathway; and iv) attenuation of HIF1 activity, a critical upstream regulator 
of glucose metabolism. Other cancer therapy targets extensively studied are the glutamine 
metabolism and the purine synthetic pathways, as exemplified in Table 1.2. 
 
1.3 Metabolomics in clinical oncology 
Before the last decade, knowledge of altered tumour metabolism was largely inferred 
from gene and protein expression changes. However, this approach does not account for 
factors such as post-translational modifications, allosteric regulation or metabolic 
compartmentalization, eventually providing an incomplete picture of the malignant 
metabolic phenotype. The technological developments employing advanced analytical 
techniques, such as nuclear magnetic resonance (NMR) spectroscopy or mass spectrometry 
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(MS), have enabled the direct assessment of the metabolic composition of biological 
tissues and fluids, thereby providing unique and complementary insights into tumour 
metabolism. The so called metabolomics approach has thus entered the „omics‟ world to 
nicely complement genomics, transcriptomics and proteomics (Figure 1.15), by offering a 
direct window into potential metabolic diagnostic markers or therapeutic targets, and 
eventually allowing a more comprehensive and interpretable picture of cellular phenotypes 
to be obtained. The general strategy employed in metabolomics, as well as the 
fundamentals of the main analytical and statistical tools used will be described in the next 
sections. 
 
 
Figure 1.15 Comparison between omic sciences. From Davis et al. 2011, Copyright © 2010 Wiley-
Liss, Inc. 
 
1.3.1 The metabolomics approach: concept and strategy 
Metabolomics has initially been described as „the comprehensive identification and 
quantification of all metabolites in a biological system‟ (Fiehn 2002), while the similar 
term metabonomics, devised by Nicholson et al. in the late 1990s, has been defined as „the 
quantitative measurement of the dynamic multiparametric response of living systems to 
pathophysiological stimuli or genetic modification‟ (Nicholson et al. 1999). Although, 
historically, there are some conceptual differences between the two terms, today they are 
often used interchangeably to express the fluctuations on the inventory of endogenous 
metabolites (the metabolome) upon a given perturbation (e.g., disease, environment, 
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dietary or therapeutic regimens, genetic modification). The term metabolomics will be 
used hereafter in this thesis. 
Metabolites are small molecules (typically with less than 1 kDa) involved in 
intermediary metabolism, their levels depending on (and affecting) upstream modifications 
in genes and protein expression. Metabolite abundances are also modulated by several 
factors unrelated to genome, such as interaction with commensal microorganisms, 
nutritional and other lifestyle-related aspects. Therefore, by reflecting the complex 
interplay between the genome (and encoded proteins) and the environment, the 
metabolome closely expresses the overall physiological status of an organism. By having 
the ability to capture a comprehensive, non-selective picture of variations in the 
metabolome, metabolomics has great potential for revealing new insights into disease 
biochemistry or identifying possible disease markers. 
Different types of samples may be used in metabolomic studies, including cultured 
cells, tissues and several biofluids (e.g., urine, blood plasma/serum, bile, cerebrospinal 
fluid). Generally, the strategy followed, depicted in Figure 1.16, involves: i) sample 
collection, ii) sample analysis using one or more analytical platforms (mainly 
1
H NMR 
spectroscopy and hyphenated MS), iii) assignment of spectral data, and iv) application of 
bioinformatic tools to maximise information recovery from the complex datasets produced. 
 
 
Figure 1.16 Typical workflow diagram applied in metabolomic studies. 
 
The choice of the analytical platform greatly depends on the analysis‟ purposes, the 
type of compounds targeted and the biological specimen to be analysed. In spite of being 
inherently less sensitive than MS, NMR allows the direct analysis of tissue/cells (by 
HRMAS, described in section 1.3.2.4), it is highly reproducible, non-destructive (allowing 
for sample recovery), and gives non-selective, qualitative and quantitative information on 
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the main metabolites present (with a limit of detection typically in the sub-milimolar range, 
Wishart 2013). On the other hand, MS-based methods like LC-MS or GC-MS generally 
have greater sensitivity, with detection limits reaching <1 nM (Wishart 2013), thus 
enabling the detection of hundreds to thousands of compounds. However, the number of 
molecules actually identified is usually much inferior, as automated approaches of 
chemical identification are still lacking. Moreover, although analyte quantification is 
possible, it can be impaired by variable ionization and ion suppression effects (Lindon et 
al. 2007). Finally, MS studies must carefully consider reproducibility, as it may be affected 
by changes in response over time, arising from the physical interaction of samples with the 
instrument (Dunn et al. 2011). 
In this project, 
1
H NMR spectroscopy was the main platform used for the analysis of 
tissue, plasma and urine samples, while MS (coupled to liquid chromatography) was only 
preliminarily explored in urine analysis. The following sections describe the basic 
principles of these techniques and how they can be employed in metabolomic studies. 
 
1.3.2 Nuclear Magnetic Resonance (NMR) spectroscopy 
1.3.2.1 Basic principles 
Quantum physics postulates that the nuclei of certain atoms possess an angular 
momentum, P, which in turn is responsible for originating a small magnetic dipole 
moment, μ. The relationship between magnetic moment and angular momentum is given 
by Equation 1.1. 
 
      Equation 1.1 
 
where γ (in rad∙T-1∙s-1) is the magnetogyric ratio, an isotope-specific constant. Angular 
momentum and nuclear magnetic moment are quantized (can only adopt discrete values), 
so, in the z-direction of an arbitrarily chosen Cartesian coordinate system, they can be 
defined as follows (Equation 1.2 and Equation 1.3), 
 
         Equation 1.2 
         Equation 1.3 
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with mz being the magnetic quantum number and ħ=h/2π (where h is Planck‟s constant). 
The magnetic quantum number is, in turn, defined as mz=-I, -I+1, -I+2, ..., I, where I is the 
nuclear spin quantum number. I may be equal to zero (nuclei with even number of protons 
and neutrons, e.g., 
12
C, not detectable by NMR) or multiple of ½ (either integer, in the case 
of isotopes with odd number of protons and neutrons, or half-integer values). For a spin of 
quantum number I≠0, there exist 2I+1 possible spin orientations (nuclear spin states) 
relative to an axis. In the case of a nucleus with spin ½ (
1
H, 
13
C, 
15
N, 
19
F and 
31
P), there are 
two possible orientations: the spin state with mI=+½, denoted α, and the spin state with 
mI=-½, denoted β. Both α and β states have the same energy, that is, they are degenerate. 
However, when placed in an external static magnetic field, B0, this degenerancy is lifted as 
a result of the interaction of the nuclear magnetic moment μ with B0 (Figure 1.17).  
 
 
Figure 1.17 Schematic representation of the nuclear spin energy levels of a spin-½ nucleus in a 
magnetic field. 
 
The energy difference between the two states (Eβ-Eα), given by Equation 1.4, is 
proportional to the strength of B0 and is called the Zeeman effect.  
 
         Equation 1.4 
 
The α and β states are filled according to the Boltzmann distribution (Equation 1.5), 
where Nα,β represents the number of nuclei in each spin state, ΔE is the energy difference 
between the two states, k is the Boltzmann constant (1.381×10
-23
 J∙K-1) and T is the 
absolute temperature.  
 
 
  
  
                       
    
    
 Equation 1.5 
β
α
ΔE=ħB0
mI= -½
mI= +½
Field off 
(B0=0)
Field on 
(B0>0)
B0
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Since ΔE is very small, at equilibrium, there will be a slight excess of nuclei in the 
lower energy α state, compared to the β state, giving rise to a macroscopic magnetic 
moment, the so-called magnetization, M0 (       ). This small energy difference 
between spin states explains the inherently low sensitivity of NMR, which can be increased 
by raising the magnetic field strength or by lowering the temperature (Equation 1.5) 
(Günther 2013). 
The effect of a static magnetic field can also be described as the magnetic moment of 
an individual spin precessing about the axis of the external magnetic field B0 (Larmor 
precession) (Figure 1.18a), with a certain angular velocity,  called the Larmor frequency 
(Equation 1.6 ), which divided by 2π, gives the resonance frequency in Hz, ν0 (Equation 
1.7). ν0 is thus the basic frequency of a specific isotope at a given field strength. 
 
 
Figure 1.18 a) Precession of an individual magnetic moment  about the external magnetic field 
B0. b) Precession of magnetic moments in the α (mI=+½) and β (mI=-½) spin states. c) Resultant 
magnetic moment M0 of a large number of equivalent nuclei, showing a small excess population of 
nuclei in the α spin state. (Adapted from Reynolds 1999). 
 
                  (rad∙s
-1
) Equation 1.6 
    
     
  
                (Hz) Equation 1.7 
 
In simple terms, to observe an NMR signal, the energy necessary to stimulate the 
transition between states must match the resonance frequency, thus meeting the resonance 
condition. In an NMR experiment, that energy is provided by applying radiofrequency 
(RF) radiation for a short period (RF pulse, typically of the order of s) in the transverse 
plane (perpendicular to B0) (Figure 1.19). This pulse is produced by a small coil 
z’ z’ z’ 
y’ y’ y’ 
x’ x’ x’ 
b) a) c) 
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surrounding the sample, its magnetic component B1 oscillating at the Larmor frequency of 
the spins. As the RF pulse is applied, the net magnetization M0 is tilted away from 
alignment with B0 toward the x’y’-plane (a rotating frame is used to simplify visualization 
of concomitant rotating fields and precessing vectors). Once the RF pulse is off, the 
magnetization in the transverse plane gradually disappears and is re-established along the 
z-axis, through a relaxation process (further described below). Precession of the 
magnetization in the x’y’-plane induces an oscillating signal in the detection coil, 
designated free induction decay (FID). This time-domain signal is then transformed into 
the frequency-domain spectrum through Fourier transform (FT). 
 
  
Figure 1.19 Schematic representation of the basic steps of an NMR experiment. (Adapted from 
Keeler 2010). 
 
1.3.2.2 Chemical shift and scalar coupling 
The electrons surrounding the nucleus create a local magnetic field (Bloc), opposite to 
B0, which causes a shielding effect and makes the effective magnetic field (Beff) 
experienced by the nucleus to be: 
 
                      Equation 1.8 
 
where ζ is a shielding constant for a given nucleus at a particular position in the molecule 
(Jacobsen 2007). Thus, nucleus with different chemical environments (non-equivalent) will 
feel different effective fields and will resonate at slightly different frequencies, giving rise 
to different positions in the NMR spectrum. These positions are indicated by chemical shift 
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values (δ), in parts per million (ppm), expressed by the resonance frequency of a given 
nucleus (ν), relative to a standard (e.g., tetramethylsilane, TMS) and normalized with 
respect to the frequency of that standard (νref) (Equation 1.9). 
 
   
       
    
     Equation 1.9 
 
In this way, chemical shifts obtained from different instruments can be compared, 
being characteristic for a certain nucleus in a specific compound, in a particular solvent, 
regardless of the operating frequency of the spectrometer. Generally, more shielded nuclei 
resonate at lower frequencies (lower chemical shifts), whereas less shielded nuclei, such as 
those with electronegative neighbours (e.g., N, O, Cl), resonate at higher frequencies 
(higher chemical shift). This valuable property has been used since the early days of NMR 
to retrieve structural information on molecules. Figure 1.20 shows the typical 
1
H chemical 
shift ranges of some functional groups in organic compounds. 
 
 
Figure 1.20 Typical 
1
H chemical shift ranges (in ppm) of some functional groups. (Adapted from 
Günther 2013). 
 
Another important feature of NMR signals is their splitting pattern, which reflects the 
interaction between neighbouring spins, via the electrons in the chemical bond – a 
phenomenon designated scalar, spin-spin or J-coupling. For nuclei with spin quantum 
number I=½, the multiplicity of the line splitting equals n+1, where n is the number of non-
-101234567891011
chemical shift (ppm)
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equivalent nuclei in the neighbouring group, and the line separation (in Hertz) corresponds 
to the coupling constant, J, between the nuclei under consideration. The magnitude of J 
generally decreases as the number of bonds between the coupled nuclei increases. 
Coupling between like spins (same isotope) is called homonuclear coupling and that 
between different types of isotopes is called heteronuclear coupling. 
 
1.3.2.3 Spin relaxation 
There are two different processes by which nuclear spins return to the thermal 
equilibrium: longitudinal (or spin-lattice) relaxation and transverse (or spin-spin) 
relaxation. Longitudinal relaxation is responsible for the recovery of magnetization along 
the z-axis, the energy lost by the spins being transferred into the surroundings in the form 
of heat. The longitudinal relaxation efficiency is characterised by a time constant T1 and its 
behaviour as function of time is described by Equation 1.10. 
 
             
 
 
    Equation 1.10 
 
Transverse relaxation, on the other hand, describes the fanning-out (loss of phase 
coherence) of spins in the x’y’-plane as they precess at different rates, leading to no net 
magnetization in the transverse plane. Dipolar interactions with nearby spins are the main 
contributor for this relaxation mechanism, hence named spin-spin relaxation. Again, this 
type of relaxation is assumed to occur with an exponential decay, characterised by the 
transverse relaxation time constant T2 (Equation 1.11). 
 
           
      Equation 1.11 
 
In an NMR experiment, T1 values should be taken into account to define the 
interscan delay (recycle time), as incomplete recovery of z-magnetization between scans 
will lead to signal saturation (non-quantitative conditions). In order to have quantitative 
conditions the recycle time should be at least five times the longest T1 (99% of 
magnetization recovered, Bharti and Roy 2012). T2 values, in turn, determine how fast the 
signal decays and thereby influence the signal line width. As the line width is proportional 
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to 1/π∙T2, molecules with shorter T2 display broader lines. Another important contribution 
to the decay of the signal and, hence, to line broadening, is the B0 inhomogeneity, taken 
into account by specifying the effective transverse relaxation time constant   
  (Equation 
1.12), where          refers to T2 relaxation in a perfectly homogenous B0 field. 
 
 
 
  
  
 
        
 
 
          
 Equation 1.12 
 
The different dependencies of T1 and T2 with respect to overall molecular tumbling 
rate or correlation time (ηc) is shown in (Figure 1.21). For small and medium-sized organic 
molecules in solution (with rapid tumbling, hence short ηc), 
1
H T1 values are typically of 
the order of seconds and T2 values are similar to corresponding T1‟s. For macromolecules 
(with larger ηc), T2 values are generally much smaller and can be of a few milliseconds. 
Increasing solvent viscosity or reducing sample temperature (hence, decreasing tumbling 
rates) can also reduce T2 time constants, thus broadening NMR resonances. 
 
 
Figure 1.21 Dependence of T1 and T2 relaxation time constants as function of correlation time, ηc 
(the average time it takes a molecule to rotate one radian). (Adapted from Claridge 2000). 
 
1.3.2.4 High-resolution magic angle spinning (HRMAS) 
In the solution state, where molecules have fast isotropic motions, nuclear 
interactions are dominated by the Zeeman effect (interaction with the external static 
magnetic field, described above), and chemical shifts and coupling constants show discrete 
average values. Conversely, in the solid state, where molecular motion is restricted due to 
T1
intermediate 
motion
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motion
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the relatively fixed orientation of molecules, additional interactions, which contribute to 
broaden spectral lines, have to be considered. These include, chemical shift anisotropy 
(CSA, resulting from non-spherical electron distribution), through space dipole-dipole 
interactions and, for nuclear spins with I >½, quadrupolar interactions. The typical 
magnitudes are shown in Table 1.3. Dipolar couplings are on the order of many tens of 
kHz and CSA can also cover hundreds of parts per million, thus leading to very broad 
lines. 
 
Table 1.3 Typical magnitude of nuclear spin interactions in the solid state (Fyfe 1983). 
Interaction Typical magnitude 
Zeeman  1-1000 MHz 
Quadrupolar 0-1000 MHz 
Chemical shift 0-100 kHz 
Dipole-dipole 0-100 kHz 
Scalar coupling 0-10 kHz 
 
In the late 1950s, a technique was devised to minimise the above mentioned 
anisotropic interactions and allow NMR signals of solids to be recovered with improved 
resolution (Andrew and Newing 1958; Lowe 1959). This technique, called magic angle 
spinning (MAS), consists of rapidly spinning the sample at an angle of 54.74º (the magic 
angle) relative to the applied magnetic field (Figure 1.22a). For ½-spin nuclei, the main 
anisotropic interactions (CSA and dipolar couplings) have an angular dependence of 
(3cos
2θ-1)/2, where θ is the angle between the static magnetic field (B0) and the 
internuclear vector responsible for the interaction (Figure 1.22b). 
For example, the Hamiltonian operator for the dipolar coupling may be written as: 
 
   
   
        
      
 
            
 
               Equation 1.13 
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where    and    are, respectively, the magnetogyric ratio constants of spins i and j, h is 
Planck‟s constant,     is the distance between the two coupled nuclei, θij is the angle the 
connecting vector makes to the external field, and I is the spin-operator. 
Spinning the sample at an angle β relative to the magnetic field imposes an additional 
dependence on the factor (3cos
2β-1)/2, which is zeroed when β=54.74º, causing anisotropic 
interactions to be averaged out (as long as spinning rates are high enough) and spectral 
lines to be significantly narrowed. 
 
 
Figure 1.22 Schematic representation of a) MAS rotor in a magnetic field, B0, where β is the magic 
angle 54.7º, and ωr is the spinning rate. b) Two nuclei i and j in a solid under the same conditions 
as in a), where rij is the internuclear distance. (Adapted from Sitter et al. 2009). 
 
For semi-solid samples, such as tissue biopsies, which retain a great deal of 
molecular motion, the anisotropic interactions referred above are partially averaged and 
their effect on line broadening greatly reduced. For 
1
H nuclei, chemical shift anisotropies 
are generally rather small, hence the major causes for line broadening in the 
1
H NMR 
spectra of tissue samples are residual dipolar couplings (of a few hundred Hertz) and 
anisotropic susceptibility effects. These effects consist of variations in local magnetic 
susceptibility due to the heterogeneous nature of the sample, as different sample regions 
will be magnetized to different extents by the applied magnetic field. This magnetic 
susceptibility inhomogeneity (which in proton spectra is usually of the order of a few tens 
of Hz) has also an angular dependence on the factor 3cos
2θ-1, and, thus, can be greatly 
attenuated by MAS. Normally, removal of line broadening effects in tissues using MAS 
requires a spinning rate of a few hundred Hz, but this would produce spinning side bands 
(SSB) near the central region of the spectrum, which could obscure metabolite signals of 
θ
a) b) 
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interest. Therefore, spinning rates that allow SSB to be out of the region of interest are 
typically of a few kHz (e.g., 4 kHz for 400 MHz 
1
H observation). 
The analysis of intact tissues (and other biological samples) has also significantly 
benefited from the development of high resolution probes allowing magic angle spinning 
(HRMAS probes). This type of probes enables a lock system to ensure long-term stability 
of the magnetic field and pulsed field gradients to be used, allowing for pulse sequences 
from liquid state NMR to be applied without modifications. In this thesis, 
1
H HRMAS was 
used to record well-resolved spectra from intact lung tissues, as will be shown in Chapter 
3. 
 
1.3.2.5 Main one- and two-dimensional NMR experiments  
Acquisition of one-dimensional (1D) 
1
H NMR spectra of biological samples 
typically requires the use of solvent suppression schemes, as the dominant water signal 
would obscure the unsuppressed spectrum and cause dynamic range problems. One of the 
most popular experiments is the 1D NOESY-presat sequence (named as „standard 1D‟ 
throughout this thesis), as it provides good water suppression while maintaining a flat 
baseline. In this pulse sequence, the water resonance is saturated by selectively irradiating 
it during the interscan relaxation delay (RD) and the mixing time (ηm) of the pulse 
sequence (Figure 1.23). 
 
 
Figure 1.23 Schematic illustration of the 1D NOESY-presat pulse sequence. The solvent is 
presaturated by application of a weak RF field during the interscan relaxation delay (RD) and 
mixing time (ηm). (Adapted from Zerbe and Jurt 2014). 
 
For samples with large superimposition of signals from small metabolites and larger 
molecules (e.g., tissues and blood plasma), additional 1D experiments are useful, in order 
to selectively observe those two types of compounds. The T2-edited Carr-Purcell-
Meiboom-Gill (CPMG, Meiboom and Gill 1958) experiment (schematically represented in 
90
τm
90 90
RD
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Figure 1.24) is usually recorded to attenuate the signals of fast-relaxing macromolecules, 
improving the visibility of narrow signals from small metabolites. This sequence uses a 90º 
pulse followed by a spin-echo period (delay-180º-delay), repeated n times. During the total 
echo time (2ηn), Mxy decays at a rate that is inversely proportional to T2. Thus, by choosing 
an appropriate echo time, the signals of macromolecules (with shorter T2‟s) can be 
attenuated in relation to those of small molecules with slower T2-relaxation. 
 
 
Figure 1.24 Schematic illustration of the Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence. 
(Adapted from Zerbe and Jurt 2014). 
 
Oppositely, the 1D diffusion-edited experiment is used to retain the signals of large 
macromolecules (e.g., lipids, proteins) or compounds with restricted mobility. The 
principle behind diffusion-editing lies in the application of a first gradient to dephase 
magnetization, followed by a delay time during which molecules diffuse, and a later 
gradient (of opposite sign to the initial) that refocuses magnetization. Those molecules 
which diffuse faster (smaller molecules) will have lost magnetization after the delay time, 
whereas slow-diffusing molecules will preserve their signals in the spectrum. 
One-dimensional 
1
H spectra of biological samples are typically characterised by 
hundreds of overlapping peaks, their unambiguous assignment requiring the use of two-
dimensional (2D) experiments, as 2D spectra show increased signal dispersion and are able 
to provide information on connectivities between signals. 2D NMR experiments are 
composed of four building blocks: preparation (or excitation), evolution, mixing and 
detection (Figure 1.25a). In the preparation time, the sample is excited by one or more 
pulses, depending on the sequence, and the resulting magnetization is allowed to evolve 
during the time period t1. Then, further pulse(s) is(are) applied during the mixing time 
(transfer of magnetization from one spin to another, via scalar or dipolar coupling, or via 
exchange processes), after which the signal is recorded as a function of the second time 
90x 180y
τ τ
n
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variable, t2 (analogous to the detection period of any 1D experiment). The entire 
experiment is repeated with step-wise incrementation of t1, to allow monitoring the 
evolution of the prepared spin state. Fourier transformation with respect to t2 will result in 
a set of spectra in which signal intensities are modulated as a function of t1. FT with 
respect to t1 converts the frequency modulation into peaks in the 2D spectrum (Figure 
1.25b). 
 
 
Figure 1.25 a) Basic building blocks of 2D NMR experiments. b) Schematic illustration of the 
principle behind 2D NMR spectroscopy. (Adapted from Zerbe and Jurt 2014). 
 
Some of the most commonly used 2D experiments in metabolomics are those 
revealing homonuclear connectivities, such as 
1
H-
1
H correlation spectroscopy (COSY) and 
total correlation spectroscopy (TOCSY), which rely on scalar couplings between protons. 
In particular, COSY detects couplings between protons that are 2-3 bonds apart, whereas 
TOCSY further shows connectivities for protons that are up to 5 or more bonds apart, 
allowing for complete spin systems to be assigned (Jacobsen 2007). Detection of long 
range correlations in the TOCSY experiment relies on the coherence transfer between spins 
at a temporary state of strong coupling, which is achieved by using a mixing (spin-lock) 
sequence. A typical spin-lock sequence is the Malcolm Levitt (MLEV) sequence, which 
comprises 16 composite pulses followed by a regular uncompensated 180º pulse (Bax and 
Davis 1985). A schematic representation of a TOCSY experiment incorporating in the 
evolution mixingpreparation
t1 t2
detection
a) 
b) 
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mixing period an MLEV-17 spin-lock and two trim pulses (at the beginning and end of the 
mixing period to defocus any magnetization that is not parallel to the x axis) is shown in 
Figure 1.26. 
 
 
Figure 1.26 Schematic illustration of the TOCSY experiment based on the MLEV-17 mixing 
scheme. SL: spin-lock trim pulses. (Adapted from Claridge 2000). 
 
Heteronuclear correlation experiments, namely those showing 
1
H-
13
C correlations, 
can also be very useful for assignment purposes. One of the most frequently used is the 
heteronuclear single-quantum coherence (HSQC) experiment, whereby the chemical shift 
of 
13
C is correlated to the chemical shift of the directly bound proton (via 
1
H-
13
C scalar 
coupling) (Bodenhausen and Ruben 1980). This experiment is based on the transfer of 
magnetization from the proton to the heteronucleus using an INEPT (insensitive nuclei 
enhancement by polarization transfer) block, followed by the recovery of magnetization 
from the carbon to the proton before acquisition (Figure 1.27). This allows the detection of 
proton magnetization, instead of carbon‟s, making HSQC more sensitivity than other 
heterocorrelation pulse sequences (like HETCOR).  
 
 
Figure 1.27 Schematic representation of the 
1
H-
13
C HSQC pulse sequence. t1 is the evolution time 
and t2 is the acquisition time, and JHC is ca. 150 Hz. (Adapted from Keeler 2010). 
 
Another useful 2D experiment is the J-resolved (JRES), which separates chemical 
shifts and scalar couplings into F1 and F2 dimensions, respectively (Ludwig and Viant 
2010). This enables spectral complexity to be significantly reduced and information on 
signal multiplicity and coupling constants to be more easily extracted. One of the most 
1H
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basic pulse sequences of 2D JRES is illustrated in Figure 1.28a. After the 90º pulse to 
create transverse magnetization, the chemical shift evolution is refocused by applying a 
180º pulse, while scalar coupling remains active, so that the F1 dimension only contains 
coupling information. On the other hand, during t2, both chemical shift and J-coupling 
evolution are active, resulting in proton multiplets in the F2 dimension (Figure 1.28b), 
which complicate spectral interpretation. A processing procedure consisting of tilting the 
multiplets by 45º about their midpoints is then applied, to retain only the chemical shift 
information in the F2 dimension (Figure 1.28c). 
 
 
Figure 1.28 a) Schematic representation of the 2D 
1
H J-resolved pulse sequence, where t1 is an 
incremented time delay and t2 is the acquisition time. b) and c) Schematic representation of a 2D 
JRES NMR spectrum after Fourier transform (b), and after tilting the spectrum by 45º (c), where 
JHH is the J-coupling constant between protons. (Adapted from Ludwig and Viant 2010). 
 
1.3.3 Mass Spectrometry (MS) 
1.3.3.1 Basic principles 
The core principle of mass spectrometry is the measurement of mass-to-charge ratios 
(m/z) of ionised molecules, clusters of molecules, complexes or fragments. Simplistically, 
the mass spectrometer comprises the following elements: an ion source, a mass analyser, a 
detector and a data system (Figure 1.29). In general, the analytes are ionised (either at high 
90 180
t1/2 t1/2
t2
b) 
a) 
c) 
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vacuum pressure or at atmospheric pressure) and transferred (in the gas phase) to the high 
vacuum region of the mass spectrometer, where they are separated according to their m/z 
and detected. The separation and detection steps take place under high vacuum pressure to 
reduce the number of ion-ion and ion-molecule collisions, which can influence the mass 
resolution, mass accuracy and sensitivity of instruments (Dunn et al. 2011). The resulting 
mass spectrum is a plot of m/z vs. signal intensity (reflecting ion abundance) (Hoffmann 
and Stroobant 2007).  
 
 
Figure 1.29 Basic components of an Electrospray Ionisation (ESI) mass spectrometer. (Adapted 
from Wang and Griffiths 2008). 
 
A number of different types of ionisation methods can be employed for generating 
gas-phase ions, including: electron ionisation (EI), chemical ionisation (CI), electrospray 
ionisation (ESI), atmospheric pressure chemical ionisation (APCI) and desorption 
electrospray ionisation (DESI) (Wang and Griffiths 2008). Also, mass analysers can be of 
different types, the most popular in metabolic profiling studies being the linear quadrupole, 
the quadrupole ion-trap and the time-of-flight (ToF) analysers (Wang and Griffiths 2008). 
In the present work, the analysis of urine samples by hyphenated mass spectrometry was 
performed by using electrospray ionisation (ESI) coupled to a ToF analyser; therefore 
these methods will be described in more detail.  
Electrospray is a commonly used ionisation source because it allows low chemical 
specificity, the ions produced are stable and the ionisation process is unlimited in mass 
(Wilm 2011). In addition, its ability to ionise samples directly from the liquid phase at 
atmospheric pressure makes it highly compatible with traditional chromatographic 
separation techniques. In ESI, a high voltage (positive in the ESI+ mode, negative in the 
ESI- mode) is applied to a metal capillary needle (anode/cathode for ESI+/ESI-), through 
which the analyte solution flows (Figure 1.30). This causes the liquid to assume a conical 
shape, known as the Taylor cone (Taylor 1964), and to form a mist of charged droplets 
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(aerosol) of the same charge as the needle. Since the droplets are charged, they repel each 
other and are drawn toward a counter electrode (cathode/anode for ESI+/ESI-), in the 
direction of the sampling orifice, losing solvent, shrinking and breaking up into smaller 
droplets. Continuous solvent evaporation-Coulomb fission cycles produce gas-phase ions 
that will travel to the vacuum chamber of the mass spectrometer (Wang and Griffiths 
2008). 
 
 
Figure 1.30 Schematic representation of an ESI ion source. (Adapted from Banerjee and 
Shyamalava Mazumdar 2012). 
 
In ToF analysers (Figure 1.31), after the sample is ionised, ions are accelerated 
through a potential V, and will gain a kinetic energy, so that 
 
           Equation 1.14 
 
where m is the mass of the ion, z the number of charges on the ion and e the charge of an 
electron. Then: 
 
            Equation 1.15 
                       Equation 1.16 
 
where t is the time needed for the ion to travel down a drift tube of length d and reach the 
detector. Therefore, for a given instrument operating at constant accelerating potential, d 
liquid-phase 
analyte
gas-phase 
analyte
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and V are constants, and           , i.e., m/z values are determined by measuring the 
time that ions take to travel from the source to the detector. 
 
 
Figure 1.31 Schematic representation of a linear ToF mass spectrometer. (Adapted from Wang and 
Griffiths 2008). 
 
1.3.3.2 Liquid chromatography-mass spectrometry (LC-MS) 
Although samples can be directly injected into a mass spectrometer (direct infusion 
mass spectrometry, DIMS), MS metabolic profiling studies of biofluids commonly involve 
prior chromatographic separation, to reduce ion suppression resulting from many 
competing analytes entering the spectrometer at the same time (Want et al. 2007). Liquid 
chromatography (LC), which separates metabolites based on their different affinity to the 
liquid mobile phase and the solid stationary phase, is one of the methods most often 
coupled to MS. Compared to gas-chromatography (GC), it offers the advantage of allowing 
the analysis of metabolites which are not readily volatilised (such as nucleosides, amino 
acids and sugars), thus avoiding the need for complex derivatization procedures, often 
required in GC-MS studies. Moreover, the multiple combinations of mobile phases and 
separation columns make LC-MS a highly flexible method with great metabolic coverage 
potential (Lenz and Wilson 2007). Conventional LC-MS based on high performance liquid 
chromatography (HPLC) may, however, show important limitations in terms of 
chromatographic resolution, sensitivity and analysis times. An important upgrade to 
overcome these limitations has been the introduction of ultra-performance liquid 
chromatography – mass spectrometry (UPLC-MS) about ten years ago, which, by 
employing smaller diameter column packing (1.4-1.7 μm particles), smaller columns (2.1 
mm i.d.), increased pressures (up to 15 kpsi) and high flow rates (up to ca. 600 μL∙min-1), 
has allowed great improvements in resolution and sensitivity (Figure 1.32) (Lenz and 
Wilson 2007; Want et al. 2007). 
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Figure 1.32 Comparison between UPLC-MS and HPLC-MS chromatograms. (Adapted from Want 
et al. 2007). 
 
Depending on the biological matrix investigated and also on the main target analytes, 
different LC columns may be used, such as reverse phase (RP) columns for separating 
medium polar and nonpolar metabolites, and hydrophilic interaction chromatography 
(HILIC) columns for analysing highly polar metabolites which are not retained well in RP 
columns (Want et al. 2007). In general, UPLC-MS can provide the detection of thousands 
of features in a given sample, the main difficulty being the identification of those features. 
Indeed, extensive LC-MS databases are still lacking, hampering the fast, automated 
identification of metabolites, and unambiguous structural information often requires the 
acquisition of tandem (MS/MS) mass spectral data to obtain fragmentation patterns (Want 
et al. 2007). 
 
1.3.4 Statistical tools in metabolomics 
Metabolomic datasets are typically composed of several tens to hundreds of complex 
metabolic profiles, each comprising thousands of variables. The analysis of such a sheer 
data volume to extract relevant information is only possible with the help of appropriate 
statistical tools, such as multivariate methods. These tools are generally applied with the 
purpose of providing graphical overviews of data, discriminating between sample classes 
and highlighting the variables important for classifications. Some of these methods, 
namely those employed in this thesis, will be described in the following sections, 
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addressing also the necessary data pre-treatment steps and the validation procedures 
carried out to verify the robustness of multivariate models. 
 
1.3.4.1 Data pre-treatment 
Prior to applying multivariate methods, spectral datasets are typically organized into 
tables, where each row constitutes an i observation (e.g., samples spectra) and columns 
represent j variables (e.g., spectral intensities) forming an i×j matrix X. A number of pre-
treatment steps may then follow: i) peak alignment, ii) normalisation and iii) scaling and/or 
transformation (Veselkov et al. 2011). 
Peak alignment aims at minimizing shifts in the position of signals corresponding to 
a same metabolite, from sample to sample. In 
1
H NMR, these shifts may originate from 
small differences in pH, ionic strength or temperature, as these parameters affect the 
effective shielding of protons, by altering the ionisation state of ionisable functional groups 
(e.g., carboxyl or amino), the binding to ionic metal species (e.g., citrate binding to Ca
2+
 or 
Mg
2+
) or the strength of hydrogen bonds (Xiao et al. 2009). One of the approaches used to 
minimize NMR signal drifts is called spectral binning or bucketing and consists of dividing 
the spectrum into intervals of fixed/variable width (usually ranging from 0.01 to 0.05 ppm) 
and taking the areas of those intervals as variables. Although this allows mitigating small 
deviations in peak positions across samples (as well as reducing the number of variables), 
spectral resolution is greatly reduced, hampering the later interpretation of variations. 
Alternatively, peak alignment algorithms have been developed to align NMR signals 
without affecting spectral resolution. Examples of such algorithms include genetic 
algorithms (Forshed et al. 2003), recursive segment-wise peak alignment (RSPA) 
(Veselkov et al. 2009), correlation shifting of spectral intervals combined with fast Fourier 
transform (icoshift) (Savorani et al. 2010) or hierarchical cluster-based peak alignment 
(CluPA) (Vu et al. 2011). With regard to LC-MS data, shifts in retention times between 
samples may occur due to the slight variable interaction of the analytes with the stationary 
phase of the chromatographic column throughout the run. Therefore, after peak picking 
(the first step in the pre-treatment of LC-MS data) alignment strategies may also be 
employed to minimise variations in peak positions (Katajamaa et al. 2006; Smith et al. 
2006).  
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Spectral normalization, a table row operation, is applied to compensate for 
differences in sample concentration or amount, allowing all samples to be directly 
comparable (Craig et al. 2006). There are several approaches to normalise data, the most 
common being normalization to total area, where each variable is divided by the total 
integral of the spectrum. This method assumes that the total spectral area depends only on 
sample dilution (concentration). However, in cases where samples contain extreme 
amounts of single metabolites (as is often the case in urine, due to food or xenobiotics 
ingestion, or in tissues containing high lipid amounts), this assumption may be wrong and 
cause individual peak variations to be masked. Hence, other normalization methods were 
developed, namely probabilistic quotient normalization (also known as median fold-change 
normalization) (Dieterle et al. 2006; Veselkov et al. 2011), locally weighted scatter plot 
smoothing (LOESS) (Veselkov et al. 2011) or group aggregating normalization (GAN) 
(Dong et al. 2011). The choice of the best normalization method will depend on sample 
type, size of dataset and on the problem to be addressed (Dieterle et al. 2006; Veselkov et 
al. 2011; Dong et al. 2011; Kohl et al. 2012). In this work, all data were normalized 
through PQN (although, in some instances, other normalization procedures were also 
tested). PQN is based on the calculation of the most probable dilution factor by looking at 
the distribution of the quotients resulting from dividing each signal intensity in a test 
spectrum by the corresponding intensity in a reference spectrum (usually, the median 
spectrum of the control group). The resulting factors are then used to normalize the data. 
Another important pre-treatment step consists of scaling, a table column operation 
aiming at reducing the weight given by multivariate projection methods to high intensity 
peaks (variables) compared to smaller ones (Craig et al. 2006). This operation is performed 
on each variable across all samples before multivariate analysis, and commonly starts by 
subtracting the column mean from each value in the column (mean-centering). Afterwards, 
each variable is divided by a scaling factor, for instance the standard deviation of the 
respective column (UV – unit variance scaling) or the square root of the standard deviation 
of the respective column (Par – pareto scaling). 
Detailed information about the pre-treatment strategies applied in this work to NMR 
and UPLC-MS data are present in the subchapters 2.3.5 and 2.4.3, respectively. 
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1.3.4.2 Multivariate analysis (MVA) 
 
Principal Component Analysis 
Principal component analysis (PCA) is a projection method used for exploratory data 
analysis, which does not assume any particular distribution of data, thus being classified as 
a non-supervised method. The principle behind PCA is to convert the original variables 
into a set of uncorrelated (orthogonal) new variables, called principal components (PCs, 
PC1, PC2, ..., PCn), thereby defining a lower n-dimensional space to represent the data. 
The PCs are linear combinations of the original variables (Equation 1.17, where a11, a12, 
etc. are appropriate weighing coefficients and d1, d2, ..., dn the original variables), 
computed so that the first PC accounts for most of the variation in the dataset, the second 
PC accounts for the second largest variation, and so on, always obeying the constraint that 
all PCs are linearly orthogonal to each other. 
 
 
                        
                       ,      
Equation 1.17 
 
As a result, the original data matrix X can be decomposed in to a scores matrix T 
(containing information on the position of samples in the new lower-dimensional space), a 
loadings matrix P (representing the way in which the original variables contribute to the 
scores), and a residuals matrix E (part of X that is not explained by the model), as shown in 
Equation 1.18 (where t denotes the transpose) (Trygg et al. 2007). 
 
         Equation 1.18 
 
By plotting PCA scores and loadings (Figure 1.33), a graphical overview of data is 
obtained, allowing groups, trends and outliers to be identified. In a scores scatter plot, each 
point represents an observation (sample) and the proximity between points reflects sample 
similarity, whereas the loadings plot shows the influence (weight) of individual X-variables 
on the observed scores distribution. 
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Figure 1.33 Geometrical representation of principal component analysis (PCA). (Adapted from 
Trygg et al. 2007).  
 
Partial-Least Squares- and Orthogonal Projection to Latent Structures-Discriminant 
Analysis 
Partial-least squares (PLS) is a pattern recognition method used to assess the 
quantitative relationship between the original data matrix X and a second matrix Y 
containing quantitative values (e.g., age of subjects, metabolite concentrations, etc.) (Wold 
et al. 2001; Trygg et al. 2007). As in PCA, the new variables defined, called latent 
variables (LVs), are linear combinations of the original variables; however, in PLS, LVs 
are iteratively obtained to model both the data matrix X and the correlation with Y (unlike 
PCs which only model X), so that the first LV is the best predictor for the information 
contained  in the Y matrix. PLS models can be defined by the following equations: 
 
                    Equation 1.19 
                    Equation 1.20 
 
where t denotes the transpose, T represents the scores matrix (common to both X and Y), P 
and C the loadings matrices, and E and F the residuals of X and Y, respectively (Trygg et 
al. 2007). The T scores are linear combinations of the original X variables and the weights 
W (quantitative relation between X and Y) and, therefore, T can be expressed as: 
             Equation 1.21 
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By combining Equation 1.20 and Equation 1.21, the PLS regression can be defined by: 
        Equation 1.22 
 
where B contains the PLS regression coefficients defined as B=W(P
t
W)
-1
C
t
. An important 
parameter for assessing variable relevance in PLS regression is the variable importance in 
the projection (VIP). VIP values reflect the variables‟ importance both with respect to X 
and Y, i.e., their correlation to all the responses, and can be defined as  
 
              
                 
 
           
 
   
  Equation 1.23 
 
where SSY is the sum of squares of the Y matrix for a given dimension a. Variables with 
large VIP (typically >1), are the most relevant for explaining Y. B coefficients and VIP 
values may be used for variable selection, as discussed ahead. 
Metabolomic studies frequently aim at differentiating sample classes (e.g., control 
vs. disease, treated vs. non-treated, male vs. female), therefore, PLS regression is often 
used in combination with discriminant analysis (PLS-DA). In PLS-DA, the Y matrix 
contains qualitative values and all the above principles apply, the goal being to define the 
LVs which maximize class discrimination (Trygg et al. 2007) (Figure 1.34, left). 
PLS (or PLS-DA) models are negatively affected by systematic variation in the X 
matrix that is not related to the Y matrix. Orthogonal projection to latent structures (OPLS) 
is a pre-processing method aiming at removing variation from X (descriptor variables) that 
is not correlated to Y (property variables) (Trygg and Wold 2002). In mathematical terms, 
this is equivalent to separate the systematic variation in X in two parts, one that is linearly 
related to Y and one that is unrelated (orthogonal) to Y. These are the Y-predictive (TPPP
t
) 
and the Y-orthogonal (TOPO
t
) variations; only the first is used for modelling Y (TPCP
t
), as 
expressed in the equations below, where E and F are residual matrices of X and Y, 
respectively (Trygg et al. 2007). 
 
                  
      
    Equation 1.24 
                  
    Equation 1.25 
CHAPTER 1 – GENERAL INTRODUCTION 
 
50 
Thus, in OPLS-DA, the between-class and the within-class variations are separated, 
facilitating model interpretation (Figure 1.34 right). The direction separating the classes is 
available as a single Y-predictive score vector, which simplifies the interpretation of the 
corresponding loadings profile.  
 
 
Figure 1.34 Geometrical representation of PLS-DA and OPLS-DA models. (Adapted from Trygg 
et al. 2007). 
 
1.3.4.3 Variable selection 
In some instances, the complex nature and large variability of metabolomic datasets 
may hamper the building of robust classification models. Variable selection based on 
multivariate methods constitutes a good approach to deal with this problem, as the removal 
of irrelevant, unreliable or noisy variables can reduce model complexity, improve model 
predictive power and facilitate the interpretation of results (Andersen and Bro 2010). 
Several methods of variable selection have been described in the literature, namely those 
based on the variable importance in the projection (VIP) values (Quintás et al. 2011; Sun et 
al. 2012), genetic algorithms (Cavill et al. 2009; Di Anibal et al. 2011; Lin et al. 2011), 
interval partial least-squares discriminant analysis (i-PLS) (Di Anibal et al. 2011), random 
forest (Lin et al. 2011; Kaur et al. 2013), among others. In this work, an in-house 
developed variable selection method was applied in some cases to enhance models‟ 
predictive accuracy (Diaz et al. 2013). This method is based on the intersection of three 
variable selection methods, which rely on the assessment of model parameters resulting 
PLS-DA model OPLS-DA model
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from a first PLS-DA, namely VIP values, their standard errors (VIPcvSE), b-coefficients and 
their standard errors (bcvSE). 
 
1.3.4.4 Validation of classification models 
The apparent separation of sample classes in a scores plot is not sufficient to attest 
the validity or predictive power of a classification model. In metabolomic studies, the often 
small number of samples compared to the high number of variables can lead to overfitting 
and optimistic predictive results. Hence, proper validation strategies must be applied in 
order to estimate how well a PLS-DA model can classify samples and predict class 
membership. Several approaches can be used, namely cross validation (CV) methods and 
permutation testing (randomisation) (Westerhuis et al. 2008). Cross validation consists of 
splitting the data into calibration and validation subsets. Two commonly used variations of 
this type of validation (used in this work) are k-fold (e.g., seven-fold) and Monte Carlo 
cross validation (MCCV). In the k-fold cross validation, the data are divided into k 
mutually exclusive subsets of equal size and each subset is used as training set for the 
remaining subsets pooled together. When k equals the number of samples, this method is 
called leave-one-out cross validation. In Monte Carlo cross validation, 40-60% of samples, 
randomly selected, are used as calibration set to predict the class of the remaining samples 
(Xu and Liang 2001). This procedure is repeated n times, typically 500-1000 times (or 
iterations), each time randomly changing the composition of the calibration and validation 
subsets. In this way, a higher number of possible combinations for dataset partitioning is 
performed, while for k-fold CV each sample is tested only once. 
One of the outputs of cross validation methods is a confusion matrix expressing the 
difference between actual (observed) and predicted classes (Table 1.4). If the two classes 
compared are named „positive‟ and „negative‟ (e.g., for designating disease and control 
classes), the confusion matrix will show the number of „positive‟ and „negative‟ samples 
correctly classified (true positives and true negatives, respectively), as well as the number 
of misclassified samples (false positives and false negatives), thus allowing the 
determination of model sensitivity, specificity and classification rate (Fawcett 2006). 
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Table 1.4 Confusion matrix obtained by CV of two classes. 
 
 
Sensitivity (also called true positive rate) expresses the proportion of true positives 
correctly identified as such (Equation 1.26), while specificity (or true negative rate) 
expresses the proportion of negatives correctly classified (Equation 1.27). The 
classification rate expresses the overall accuracy, i.e. the proportion of samples correctly 
classified (Equation 1.28). 
 
                   
  
     
 Equation 1.26 
                     
  
     
 Equation 1.27 
                          
     
           
 Equation 1.28 
 
The sensitivity and 1-specificity results can then be plotted as coordinates in a 
receiver operating characteristic (ROC) space plot (Figure 1.35). A perfect classification 
model would have both sensitivity and specificity equal to 1, while one with no predictive 
ability would have sensitivity equal to 1-specificity (Fawcett 2006). 
Another useful parameter to evaluate the robustness of a classification model is the 
Q
2
 value, which expresses the model‟s predictive power, and is given by 
      
         
 
 
         
 Equation 1.29 
 
where    refers to the predictive value of class membership for sample i and   refers to the 
mean value of y for all samples (Westerhuis et al. 2008). The closer Q
2
 is to 1, the higher is 
Observed
Predicted Positive Negative
Positive
True Positive 
(TP)
False Positive 
(FP)
Negative
False Negative 
(FN)
True Negative 
(TN)
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the model‟s predictive power. An optimal Q2 of 1 is difficult to obtain as it will depend not 
only on inter-class variability, but also on intra-class variability, making it difficult to 
define a general Q
2
 value that corresponds to a good discrimination. One way to assess 
how good Q
2
 values are consists of comparing their distributions in original and permuted 
models (Westerhuis et al. 2008). 
 
 
Figure 1.35 ROC space plot illustrating a perfect classification (TPR=1 and FPR=0) and a random 
classification (TPR=FPR). Models falling above the dashed line classify better than those falling 
below. 
 
Permutation testing consists of randomly changing class membership (Y matrix), 
leaving the X matrix intact, and repeating the cross validation procedures mentioned above. 
The model with permuted classes is expected to clearly show lower classification accuracy 
and predictive power (compared to the model with true classes assigned), as the randomly 
formed groups are not expected to show consistent differences between them (Westerhuis 
et al. 2008).  
Ultimate validation of a classification model can be performed by predicting class 
membership of independent samples from a plausible related population. This type of 
validation is called external validation (Bleeker et al. 2003; Steyerberg et al. 2003). 
Although generally less optimistic (because classification models tend to perform better on 
data used for model building), external validation resembles a more realistic scenario in 
which a classification model is used for diagnostics or screening. Therefore, it should be 
performed whenever the experimental setup (e.g., the number of samples available) allows 
it.  
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1.3.4.5 Univariate statistics 
In addition to multivariate analysis, univariate calculations are often included in 
metabolomic studies to assess the relevance of a given variable (metabolite). Unlike MVA, 
classical univariate analysis is applied to one variable at the time, and includes, e.g., 
significance tests (t-test, Wilcoxon test, Mann-Whitney test) and analysis of variance 
(ANOVA) (Sokal and Rohlf 2012). Although the need of applying univariate analysis after 
performing MVA is subject of discussion, a recent paper on this matter concluded that both 
methodologies give complementary information, as long as they are interpreted within the 
corresponding statistical framework (uni or multivariate) (Saccenti et al. 2013). In the 
context of this thesis, the univariate Wilcoxon signed rank test (paired samples) and the 
Wilcoxon rank sum test (unpaired samples) were performed to statistically evaluate the 
difference in specific metabolite levels between two groups.  
While p-values report the statistical significance of variations, they do not provide 
any information about the magnitude of the effect of interest or its precision, besides being 
influenced by sample size (Nakagawa and Cuthill 2007). Therefore, to address these 
issues, another parameter has been suggested to be included in biological studies: the effect 
size (d). In addition to providing information about the direction and strength of the 
relationship between variables, effect size estimates are not sensitive to sample size, 
providing a common metric to compare results across studies (Berben et al. 2012). This 
parameter and respective confidence interval for 95% confidence may be calculated 
according to Equation 1.30, Equation 1.31 and Equation 1.32, where     and     are the 
averages,    and    are the standard deviations, and    and    are the number of samples 
of groups 1 and 2, respectively. 
 
   
       
 
 
Equation 1.30 
    
         
           
 
       
 
Equation 1.31 
 
       
     
    
 
  
        
 
Equation 1.32 
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1.3.4.6 Correlation analysis 
Assessing the statistical correlation between two variables (metabolites) can be 
useful to assist the biochemical interpretation of their variations. For normally distributed 
variables (x and y, forming n pairs) the Pearson correlation coefficient, r, estimates the 
degree of linear association between variables and is given by: 
 
   
             
 
   
                 
 
   
 
   
 
Equation 1.33 
 
When the variables are not normally distributed or the relationship between them is 
not linear, the measurement of Spearman rank correlation coefficient, rS, may be more 
appropriate (Zou et al. 2003). Correlation coefficients vary between -1 (perfectly negative 
association between variables) and 1 (perfectly positive association between variables), 
r=0 meaning no association at all.  
Correlation analysis is also at the basis of a method developed primarily to help the 
identification of metabolites in NMR metabolomic studies, the so-called Statistical Total 
Correlation Spectroscopy (STOCSY) (Cloarec et al. 2005). STOCSY is based on the 
properties of the correlation matrix C, computed from a set of sample spectra according to 
Equation 1.34, 
 
   
 
   
  
    Equation 1.34 
 
where X1 and X2 denote the experimental matrices and C is the correlation matrix where 
each value represents the correlation coefficient between two variables of the matrices X1 
and X2 (Cloarec et al. 2005). In general, STOCSY takes advantage of the multicollinearity 
of the intensity variables in a set of spectra to generate a plot where highly correlated 
signals are highlighted, thus providing information on molecular or biochemical 
relationships. This can be applied to data obtained from a single NMR experiment type (
1
H 
NMR, Figure 1.36a), as well as to data generated by the NMR observation of different 
nuclei (e.g., 
1
H and 
31
P NMR, designated heteronuclear STOCSY, HET-STOCSY) (Wang 
et al. 2008). A further development of this method consists of applying it to data obtained 
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by different analytical techniques, for instance 
1
H NMR and MS (Figure 1.36b) (Crockford 
et al. 2006), or 
1
H NMR and mid-infrared (MIR) (Graça et al. 2013). This 
multispectroscopic approach is designated statistical heterospectroscopy (SHY) (Crockford 
et al. 2006). 
 
 
Figure 1.36 a) 
1
H-
1
H NMR STOCSY map (adapted from Keun et al. 2008) and b) UPLC-MS – 1H 
NMR SHY map showing positive correlations of hippurate in both spectroscopic domains. 
(Adapted from Crockford et al. 2008). 
 
1.3.5  Metabolomics of lung cancer: state of the art 
The application of metabolomics to the study of cancer has intensified over the years, 
as seen by the exponential increase in the number of papers published in the field (Figure 
1.37a). Regarding the biological matrix used, the first studies were based on the analysis of 
tissue samples, while biofluid analysis has been increasingly performed over the last ten 
years (Figure 1.37a), blood serum/plasma and urine being the most studied biofluids. In 
terms of the analytical techniques employed, NMR has been preferred for tissues, likely in 
relation with the possibility of direct analysis by HRMAS, whereas biofluids have been 
mostly studied by MS methods, taking advantage of their generally higher sensitivity 
(Figure 1.37b). 
Concerning the types of cancer studied, breast, colorectal, lung, brain and prostate 
cancers have been the main focus in metabolomics, constituting over 60% of the published 
papers in this area (Figure 1.37c). These numbers likely reflect cancer incidence, as breast, 
colorectal and lung cancers are those with highest prevalence worldwide (Figure 1.1). Still, 
r r
a) b) 
CHAPTER 1 – GENERAL INTRODUCTION 
 
57 
other less frequently cancer types have also been investigated namely hepatocellular and 
renal cell carcinomas, ovarian and cervical, gastric and oesophageal cancers, among others. 
 
 
Figure 1.37 Estimate number of published papers on metabolomics applied to human cancer 
studies distributed by a) year and biological matrix (other matrices include bile, saliva, exhaled 
breath condensate, cerebrospinal fluid, pleural effusion, seminal fluid and prostatic fluid), b) 
biological matrix and analytical platform used, c) type of cancer studied (other types of cancer 
include thyroid, myeloma, liposarcoma and osteosarcoma). d) Number of papers published on 
clinical metabolomic studies of human lung cancer. Source: Web of Science database (all years, up 
to June 2014). 
 
The metabolomic study of lung cancer has grown considerably over the last five 
years (Figure 1.37d). Indeed, when the research presented in this thesis was initiated, the 
information on the metabolic behaviour of lung tumours and on their signatures in 
biofluids was very limited, thus justifying the relevance and novelty of the work 
conducted. In this section, the studies using metabolomics to characterize human lung 
cancer will be reviewed, starting by the analysis of tissues (or their extracts) and presenting 
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thereafter the most important findings emerging from the analysis of biofluids (blood 
plasma or serum, urine and others), using either targeted profiling of specific compound 
families (earlier studies) or global untargeted metabolomics (studies performed over the 
last five years). A table listing all the studies mentioned in this section, with details on the 
sample numbers, the analytical techniques and the multivariate analysis methods used, is 
presented in Annex III. 
Earlier metabolic studies of lung tumours were based on the NMR analysis of tissue 
extracts to measure differences in the levels of specific metabolites (e.g., lactate, creatine, 
choline) and assess their diagnostic and prognostic value (Hanaoka et al. 1993; Guo et al. 
2004; Yokota et al. 2007). In another study using NMR and GC-MS stable isotope 
resolved metabolomics (SIRM), 
13
C enrichment of particular metabolites (lactate, 
succinate, citrate, alanine, glutamate, aspartate), after infusion of uniformly labelled 
13
C-
glucose into patients, suggested more active glycolysis and TCA cycle in tumour tissues 
(Fan et al. 2009). More recently, the composition of lung tissue extracts has been more 
comprehensively investigated by capillary electrophoresis (CE)-ToF MS and the levels of 
several amino acids, adenylates and guanylates, lactate and other organic acids were found 
to be increased in tumours compared to surrounding normal tissue (Kami et al. 2013). 
However, the low number of patients considered (n 9) precludes solid conclusions from 
this study. Moreover, metabolic profiling of tissue extracts has some important limitations, 
such as the potential loss or modification of cellular components, and the selectivity of the 
extraction procedures towards more hydrophilic or lipophilic compounds, which may limit 
the information about the metabolic events taking place in vivo. 
High-resolution angle magic spinning (HRMAS) NMR spectroscopy, on the other 
hand, enables the direct analysis of intact tissue biopsies, having been increasingly applied 
to characterize the metabolic profile of tumour tissues (Sitter et al. 2009; Moestue et al. 
2011). In regard to lung cancer, the first HRMAS NMR studies of human lung tumours 
thoroughly describing the tissue metabolome and the differences between tumour and non-
involved adjacent (control) tissues have been published by our group (Rocha et al. 2010; 
Duarte et al. 2010). Although involving relatively low number of patients (twelve in the 
first study, twenty four in the second), these papers provided consistent evidence of distinct 
metabolic profiles for tumour and control tissues, mainly based on the levels of glucose, 
lactate, choline-containing compounds, acetate and inositols. A subsequent study by Chen 
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et al. corroborated several of these findings and showed that some metabolite levels (lipids, 
lactate, glucose, aspartate and choline metabolites) depended on the site of tissue collection 
(centre or periphery of the tumour) (Chen et al. 2011). Also, the above mentioned studies 
suggested a dependency of the tissue metabolic profiles relatively to the tumour 
histological type. This dependency was also explored by Jordan et al., who attempted the 
distinction between adenocarcinomas (AdC) and squamous cell carcinomas (SqCC), based 
on the correlation between tissue and serum profiles (from fourteen patients). However, no 
detailed information on possible metabolic markers was advanced in that study (Jordan et 
al. 2010). More recently, resulting from the work presented in Chapter 3 of this thesis, our 
group has reported the analysis of a considerably large sample set (over one hundred tissue 
samples from fifty six patients) (Rocha et al. 2014), further demonstrating the potential of 
NMR metabolomics for the differential classification of AdC and SqCC. 
Up to 2010, the studies addressing the metabolic composition of biofluids in the 
context of lung cancer were focused on the targeted analysis of specific compounds. In the 
case of blood, circulating plasma free amino acids (PFAA) have been the main targeted 
family investigated, based on the early studies (reviewed in Lai et al. 2005) suggesting a 
link between abnormal PFAA composition and cancer-induced alteration in protein 
metabolism. In particular, a Japanese research group has reported consistenly altered 
PFAA profiles in lung cancer patients, using HPLC-MS analysis, and proposed a 
diagnostic index based on PFAA concentrations (known as the „AminoIndex‟ technology) 
(Maeda et al. 2010; Miyagi et al. 2011; Shingyoji et al. 2013). Blood phospholipids were 
another class of compounds targeted for the discrimination between lung cancer patients 
and healthy controls. Particularly, lysophosphatidylcholines (sn-1 lysoPC 16:0, sn-2 
lysoPC 16:0, sn-1 lysoPC 18:0, sn-1 lysoPC 18:1 and sn-1 lysoPC 18:2) identified by 
UPLC-ToFMS were found to be decreased in cancer patients (Dong et al. 2010), whereas 
in a different study using direct infusion (DI)-Fourier transform ion cyclotron resonance 
(FTICR)-MS, oleamides, long chain acylcarnitines, LPC (18:1), LPC (20:4), LPC (20:3), 
LPC (22:6) and SM (16:0/1) were responsible for the discrimination between the two 
groups (Guo et al. 2012).  
Regarding the untargeted analysis of blood serum/plasma, a study published in 2010 
has reported the potential of NMR of serum to differentiate between two lung cancer 
histological types and also from controls (Jordan et al. 2010). However, sample numbers 
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were very limited (fourteen patients and seven controls) and no information was provided 
on putative metabolic differences between groups. Subsequently, our group has reported a 
more detailed NMR study of blood plasma from a significantly larger dataset (eighty five 
patients and seventy eight controls) (Rocha et al. 2011). As thoroughly described in 
Chapter 4 of this thesis (for an even larger number of subjects), this analysis has enable 
patients to be discriminated from healthy controls with sensitivity and specificity levels 
around 90%, the main metabolic differences relating to lipoproteins, organic acids, glucose 
and several amino acids. 
Since then, a number of metabolomic studies addressing plasma/serum composition 
have been published, all based on MS methods. In the work by Hori and co-workers, based 
on GC-MS, metabolites such as TCA cycle intermediates, amino acids and their 
derivatives and fatty acids or related compounds, were found to significantly vary between 
patients and controls (Hori et al. 2011). In a different work, based on UPLC-MS, nineteen 
ions were suggested as potential biomarkers for lung cancer, but only two of them were 
identified: p-hydroxyphenyllactic acid and proline betaine (Cai et al. 2011). Another 
important outcome of this work was the difference encountered between patients at 
different stages of radiotherapy treatment, suggesting that the proposed methodology could 
be useful in the evaluation of treatment effects. In addition, Lokhov et al. published two 
reports focused on the analysis of deproteinized blood plasma of lung cancer patients and 
age-matched controls by DI-ESIMS. In the first work, a model with a classification 
accuracy of 92-94% was obtained, regardless of disease stage (Lokhov et al. 2012), and in 
the second work, addressing the same dataset, seventy metabolite ions were found to be 
strongly associated with lung cancer (Lokhov et al. 2013). In an interesting study, using 
different UPLC-MS platforms, urea, bilirubin and 3-hydroxybutanoic acid were reported to 
be negatively correlated with survival time of SCLC patients, suggesting elevated levels of 
these metabolites to be present in the blood of subjects with a poorer prognosis (Vaughan 
et al. 2012). Finally, in a recent study using both GC- and LC-MS, plasma from stage I 
lung adenocarcinoma patients and healthy controls was compared (Wen et al. 2013). 
Results from OPLS-DA modelling afforded thirty seven metabolites (related to amino 
acids, lipids and fatty acids metabolism) to contribute for class differentiation. 
In the case of urine, a first study reported the targeted analysis of modified 
nucleosides and ribosylated metabolites from patients with different types of cancer, 
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including lung cancer (Bullinger et al. 2008). Two subsequent studies, published in 2010, 
focused on the development of improved LC-MS methods for the untargeted profiling of 
urine, either by using an integrated ionization approach (An et al. 2010) or a home-devised 
system based on HILIC/RPLC-MS (Yang et al. 2010). Each study reported the 
identification of eleven candidate biomarkers, including aromatic amino acids and 
modified nucleosides in one case (An et al. 2010) and mainly amino acids in the other case 
(Yang et al. 2010). Very recently, UPLC-MS has been applied to the urinary profiling of a 
relatively small set of subjects (twenty controls and twenty patients), whereby twenty 
discriminant metabolites (including carnitine and acylcarnitines) were identified (Wu et al. 
2014). Moreover, another untargeted LC-MS study comprising a much larger population 
(over four hundred patients and five hundred controls) highlighted creatine riboside and N-
acetylneuraminic acid as being associated with early lung cancer diagnosis and worse 
prognosis (Mathe et al. 2014). 
In 2011, our group has published the first untargeted NMR study of urine in the 
context of lung cancer (Carrola et al. 2011). At the time, the results referred to about one 
hundred and twenty subjects (a number that has almost doubled up to the completion of 
this thesis) and showed the potential of NMR metabolomics of urine to discriminate 
between early stage cancer patients and healthy controls. The possible confounding 
influence of factors like gender and age have also been modelled and found to have much 
lower predictive power than the presence of the disease. In other subsequent works, NMR 
urinary profiles have been used to attempt the prediction of cancer-associated skeletal 
muscle wasting (Eisner et al. 2011), and of variations in lean muscle and fat mass, in 
patients with advanced cancer (Stretch et al. 2012). 
Other biofluids have also been investigated in the context of lung cancer, namely 
bronchoalveolar lavage fluid (BALF), exhaled breath condensate (EBC) and pleural 
effusions. A report addressing the composition of BALF and EBC samples from patients 
with primary lung cancer focused on a specific group of compounds, eicosanoids, assessed 
by enzymatic assays (Ciebiada et al. 2012). Patients presented higher levels of cysteinyl 
leukotrienes and leukotriene B4 in both biofluids leading the authors to propose the 
analysis of these compounds, known to be related to lung carcinogenesis, as a 
complementary detection and monitoring method. In another work, malignant and benign 
pleural effusions from patients with lung cancer and metastasis to the pleura were analysed 
CHAPTER 1 – GENERAL INTRODUCTION 
 
62 
by 
1
H NMR (Zhou et al. 2012). By applying multivariate analysis, malignant effusions 
could be differentiated from benign pleural effusions, based on metabolites like lactate, 
acetoacetate, trimethylamine-N-oxide and glucose. The low molecular weight volatile 
organic fraction of pleural effusions has also been assessed by headspace-solid phase 
microextraction (HS-SPME) GC-MS (Liu et al. 2014). The authors highlighted the levels 
of cyclohexanone, 2-ethyl-1-hexanol, 2-phenyl-2-propanol, 1,2,4,5-tetramethylbenzene 
and longifolene to be significantly different between benign and malignant pleural 
effusions. 
Overall, by compiling the biochemical information provided in the studies mentioned 
above, it is found that over 150 metabolites, detected in several biological matrices by 
different metabolomic analytical platforms, have been related to lung cancer altered 
metabolism. Figure 1.38 summarises this information in the form of a heatmap where blue 
and red colours represent, respectively, decreases and increases in either lung tumour 
tissues or lung cancer patients in relation to control pulmonary tissues or healthy subjects. 
Several interesting observations emerge from this Figure. Firstly, it is seen that some 
changes are consistent across studies (e.g., increased lactate and decreased glucose), while 
others show large variability (e.g. some amino acids like alanine, glycine or tyrosine). This 
variability may be a reflection of several factors, including differences in the population 
groups studied (e.g. genetic background, lifestyle/dietary habits), but also differences in 
sample handling and analysis procedures. Secondly, the large majority of variations was 
detected in a single biological matrix, thus showing the importance of analysing different 
sample types in order to achieve wider metabolome coverage and get a more complete 
picture of metabolic events. Finally, it is important to recall that many of these studies 
were performed on low sample numbers (as it is clear from Table A4 in Annex III) and 
that many of the variations listed were not quantitatively measured or statistically 
validated, thus justifying the need for in-depth, rigorous studies of lung cancer‟s metabolic 
signature, as it has been attempted in this thesis.  
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Tissue extracts Intact tissue Blood serum/plasma U     EBC BALF 
acetate   
  
          
    
  
  
    
   
    
 
  
acetoacetate   
  
    
 
    
       
    
   
       
N-acetylneuraminic acid   
  
    
 
    
       
    
  
     
 
  
N-acetylornithine   
  
    
 
    
       
    
   
    
 
  
acryloylglycine   
  
    
 
    
       
    
 
 
 
    
 
  
acylcarnitines (long chain)   
  
    
 
    
   
 
   
    
 
  
 
    
 
  
5-adenosylhomocysteine   
  
    
 
    
       
    
   
    
 
  
ADP   
  
    
 
    
       
    
   
    
 
  
alanine   
 
     
 
    
 
 
  
 
  
    
   
       
AMP   
  
    
 
    
       
    
   
    
 
  
amylose   
  
    
 
    
       
    
   
    
 
  
androsterone sulphate   
  
    
 
    
       
    
   
    
 
  
arginine   
  
    
 
    
       
    
   
    
 
  
argininosuccinate   
  
    
 
    
       
    
   
    
 
  
asparagine   
  
    
 
      
     
    
   
    
 
  
aspartate   
 
     
 
    
     
 
 
    
   
    
 
  
ATP   
  
    
 
    
       
    
   
    
 
  
benzoate   
  
    
 
    
     
 
 
    
   
    
 
  
betaine   
  
    
 
    
       
     
  
    
 
  
bilirubin   
  
    
 
    
       
    
   
    
 
  
carnitine   
  
    
 
    
       
      
 
    
 
  
CDP-choline   
  
    
 
    
       
    
   
    
 
  
ceramide (42:0)   
  
    
 
    
       
    
   
    
 
  
choline    
 
    
 
    
       
    
   
    
 
  
citrate   
 
     
 
    
    
 
  
    
   
    
 
  
citrulline   
  
    
 
      
     
    
   
    
 
  
cortisol sulphate   
  
    
 
    
       
    
  
     
 
  
creatine    
 
    
 
    
       
    
   
    
 
  
creatine riboside   
  
    
 
    
       
    
  
     
 
  
creatinine   
  
    
 
    
       
    
   
    
 
  
cyclohexanone   
  
    
 
    
       
    
   
    
 
  
cys-LTs   
  
    
 
    
       
    
   
    
 
  
deoxycholic acid glycine conjugate   
  
    
 
    
       
    
   
    
 
  
DGDP   
  
    
 
    
       
    
   
    
 
  
DHAP   
  
    
 
    
       
    
   
    
 
  
5,6-dihydrouridine   
  
    
 
    
       
    
   
    
 
  
dimethylarginine   
  
    
 
    
       
    
 
 
 
    
 
  
dimethylguanosine   
  
    
 
    
       
    
   
    
 
  
ethanolamine phosphate   
  
    
 
    
       
    
   
    
 
  
2-ethyl-1-hexanol   
  
    
 
    
       
    
   
    
 
  
F1,6P   
  
    
 
    
       
    
   
    
 
  
F6P   
  
    
 
    
       
    
   
    
 
  
formate   
  
    
 
    
    
 
  
    
   
    
 
  
fumarate   
  
    
 
    
     
 
 
    
   
    
 
  
GABA   
  
    
 
    
       
    
   
    
 
  
gluconate   
  
    
 
    
       
    
   
    
 
  
glucose   
 
          
    
 
  
    
   
       
glutamate   
 
      
 
    
     
 
 
    
   
    
 
  
glutamine   
 
      
 
     
   
 
  
    
   
    
 
  
glycerate   
  
    
 
    
     
 
 
    
   
    
 
  
glycerol   
  
    
 
    
     
  
 
    
   
    
 
  
glycerophosphocholine   
  
         
       
    
   
    
 
  
glycine   
  
            
     
    
   
    
 
  
GMP   
  
    
 
    
       
    
   
    
 
  
GSH   
  
         
       
    
   
    
 
  
GTP   
  
    
 
    
       
    
   
    
 
  
guanidoacetate   
  
    
 
    
       
    
   
    
 
  
HDL   
  
    
 
    
    
 
  
    
   
    
 
  
3-hexaprenyl-4-hydroxy-5-methoxybenzoate   
  
    
 
    
       
     
  
    
 
  
2-hexenedionate   
  
    
 
    
     
 
 
    
   
    
 
  
hippurate   
  
    
 
    
       
      
 
    
 
  
histidine   
  
    
 
      
  
 
  
    
   
    
 
  
2-hydroxybutyrate   
  
    
 
    
       
    
   
    
 
  
3-hydroxybutyrate   
  
    
 
    
     
 
 
    
   
    
 
  
p-hydroxyphenyl lactate   
  
    
 
    
      
     
   
    
 
  
2-hydroxyisobutyrate   
  
    
 
    
     
 
 
    
   
    
 
  
3-hydroxyisobutyrate   
  
    
 
    
       
    
   
    
 
  
2-hydroxyisovalerate   
  
    
 
    
     
 
 
    
   
    
 
  
3-hydroxyisovalerate   
  
    
 
    
       
    
   
    
 
  
4-hydroxyproline   
  
    
 
    
     
 
 
    
   
    
 
  
5-hydroxytryptophan   
  
    
 
    
       
    
   
    
 
  
hypotaurine   
  
    
 
    
       
    
   
    
 
  
indoxyl   
  
    
 
    
       
    
   
    
 
  
inosine/adenosine   
  
    
 
    
       
    
   
    
 
  
isoleucine   
  
    
 
      
     
    
   
    
 
  
kynurenine   
  
    
 
    
       
    
   
    
 
  
lactate              
    
  
 
    
   
       
lauric acid   
  
    
 
    
     
  
 
    
   
    
 
  
LDL+VLDL   
  
    
 
    
    
 
  
    
   
    
 
  
leucine   
  
    
 
     
      
    
   
    
 
  
leucylproline   
  
    
 
    
       
     
  
    
 
  
linoleic acid   
  
    
 
    
       
    
   
    
 
  
logifolene   
  
    
 
    
       
    
   
    
 
  
LPC (16:0)   
  
    
 
    
  
 
    
    
   
    
 
  
LPC (18:0)   
  
    
 
    
  
  
    
    
   
    
 
  
LPC (18:1)   
  
    
 
    
  
   
   
    
   
    
 
  
LPC (18:2)   
  
    
 
    
  
  
    
    
   
    
 
  
LPC (20:3)   
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Tissue extracts Intact tissue Blood serum/plasma Urine EBC BALF 
LPC (20:4)   
  
    
 
    
   
  
   
    
   
    
 
  
LPC (22:6)   
  
    
 
    
   
  
   
    
   
    
 
  
LTB4   
  
    
 
    
       
    
   
    
 
  
lysine   
  
         
       
    
   
    
 
  
malate   
  
    
 
    
     
 
 
    
   
    
 
  
malonate   
  
    
 
    
     
  
 
    
   
    
 
  
maltitol   
  
    
 
    
       
    
   
    
 
  
methanol   
  
    
 
    
    
 
  
    
   
    
 
  
methionine   
  
           
     
    
   
    
 
  
3-methyl histidine   
  
    
 
    
       
    
   
    
 
  
N(6)-methyl lysine   
  
    
 
    
       
    
   
    
 
  
5'-methylthioadenosine   
  
    
 
    
       
    
   
    
 
  
myo-inositol   
  
         
       
    
   
    
 
  
NAD   
  
    
 
    
       
    
   
    
 
  
nicotinamide   
  
    
 
    
       
    
   
    
 
  
octanoate   
  
    
 
    
     
 
 
    
   
    
 
  
oleamide   
  
    
 
    
   
 
   
    
   
    
 
  
oleic acid   
  
    
 
    
       
    
   
    
 
  
ornithine   
  
    
 
      
     
    
   
    
 
  
5-oxoproline   
  
    
 
    
     
 
 
    
   
    
 
  
palmitic acid   
  
    
 
    
       
    
   
    
 
  
palmitoelyl ethanolamide   
  
    
 
    
       
    
   
    
 
  
PTC (34:4)   
  
    
 
    
       
    
   
    
 
  
PTEs   
  
    
 
    
       
    
   
    
 
  
PEP   
  
    
 
    
       
    
   
    
 
  
3PG   
  
    
 
    
       
    
   
    
 
  
phenylacetylglutamine   
  
    
 
    
       
     
  
    
 
  
phenylalanine   
  
    
 
     
      
      
  
    
 
  
2-phenyl-2-propanol   
  
    
 
    
       
    
   
    
 
  
phosphocholine   
  
         
       
    
   
    
 
  
phosphoethanolamine   
  
    
 
    
       
    
   
    
 
  
phosphoric acid   
  
    
 
    
     
 
 
    
   
    
 
  
phosphotyrosine   
  
    
 
    
       
    
 
 
 
    
 
  
pipecolic acid   
  
    
 
    
       
     
  
    
 
  
pregnenolone sulphate   
  
    
 
    
       
    
   
    
 
  
proline   
  
    
 
      
  
 
  
    
   
    
 
  
proline betaine   
  
    
 
    
      
      
  
    
 
  
propionate   
  
    
 
    
       
    
   
    
 
  
2-propyl glutarate   
  
    
 
    
     
 
 
    
   
    
 
  
PS (38:4)   
  
    
 
    
       
    
   
    
 
  
pyruvate   
  
    
 
    
    
 
  
    
   
    
 
  
SAM   
  
    
 
    
       
    
   
    
 
  
sarcosine   
  
    
 
    
     
 
 
    
   
    
 
  
scyllo-inositol   
  
         
       
    
   
    
 
  
serine   
  
    
 
     
      
    
   
    
 
  
SM (16:0/1)   
  
    
 
    
   
 
   
    
   
    
 
  
succinate   
 
     
 
    
       
    
   
    
 
  
succinyladenosine   
  
    
 
    
       
    
   
    
 
  
taurine   
  
         
       
      
 
    
 
  
testosterone sulphate   
  
    
 
    
       
    
   
    
 
  
1,2,4,5-tetramethylbenzene                                   
threonine   
  
    
 
    
     
  
 
    
   
    
 
  
threonylcarbonyl adenosine   
  
    
 
    
       
    
 
 
 
    
 
  
TMAO   
  
    
 
    
       
    
   
       
trigonellinamide   
  
    
 
    
       
    
   
    
 
  
trigonelline   
  
    
 
    
       
    
   
    
 
  
trimethyl lysine   
  
    
 
    
       
    
   
    
 
  
tryptophan   
  
    
 
      
     
    
   
    
 
  
tyrosine   
  
    
 
    
    
 
  
    
 
 
 
    
 
  
ubiquinol   
  
    
 
    
       
    
   
    
 
  
ubiquinone   
  
    
 
    
       
    
   
    
 
  
UDP/UTP   
  
         
       
    
   
    
 
  
UDP-glucose   
  
    
 
    
       
    
   
    
 
  
UMP   
  
    
 
    
       
    
   
    
 
  
uric acid   
  
    
 
    
     
 
 
    
 
 
 
    
 
  
uridine   
  
    
 
    
       
    
   
    
 
  
valine   
  
    
 
    
    
 
  
     
  
       
xanthine   
  
    
 
    
       
    
   
    
 
  
α-aminoadipate   
  
    
 
    
       
    
   
    
 
  
β-alanine   
  
    
 
    
       
    
   
    
 
  
unkonwn peptide                                   
Figure 1.38 Overview of metabolites found to be decreased (in blue) or increased (in red) in either 
lung tumour tissues or lung cancer patients in relation to control pulmonary tissues or healthy 
subjects, based on a literature survey of metabolomic studies of lung cancer, including the reports 
derived from this thesis (highlighted in grey). Metabolites are listed in alphabetic order and 
literature references are given in columns, organized by biological matrices - tissue extract, intact 
tissue, blood serum/plasma, urine, exhaled breath condensate (EBC) and bronchoalveolar lavage 
fluid (BALF). (ADP: adenosine diphosphate; AMP: adenosine monophosphate; ATP: adenosine 
triphosphate; CDP: cytidine diphosphate; cys-LTs: cysteinyl leukotrienes; DGDP: deoxyguanosine 
diphosphate; DHAP: dehydroxyacetone phosphate; F1,6P: fructose 1,6-biphosphate; F6P: fructose 
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6-phosphate; GABA: gamma-aminobutyric acid; GMP: guanosine monophosphate; GSH: reduced 
glutathione; GTP: guanosine triphosphate; HDL: high-density lipoprotein; LDL+VLDL: low/very 
low-density lipoprotein; LPC: lysophosphatidylcholine; LTB4: leukotriene B4; NAD: nicotinamide 
adenine dinucleotide; PEP: phosphoenolpyruvate; 3PG: 3-phosphoglycerate; PS: 
phosphatidylserine; PTC: phosphatidylcholine; PTEs: phosphatidylethanolamines; SAM: S-
adenosyl methionine; SM: sphingomyelin; TMAO: trimethylamine-N-oxide; UDP/UTP: uridine 
di/triphosphate; UMP: uridine monophosphate). 
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1.4 Scope and aims of this thesis 
This work aimed at characterizing the metabolic alterations related to lung 
cancer, with a view to gain new insights into tumour metabolism and to identify 
metabolic markers (or profiles) with potential value in disease screening, diagnosis or 
treatment. Specific objectives were: 
i. To characterize the metabolic differences between lung tumour tissues and 
adjacent non-involved pulmonary parenchyma, and assess their potential for 
discriminating between the two tissue types. The biochemical information 
derived from this study, not available from conventional histopathological 
analysis, is expected to provide important leads for future research on novel 
therapeutic targets or imaging tracers, and will eventually afford additional 
criteria for improving clinical decisions; 
ii. To correlate tissue metabolic profiles with histological parameters, assessing, 
in particular, the metabolic behaviour of different tumour subtypes, with 
emphasis on the most frequent malignant epithelial tumours: adenocarcinoma 
and squamous cell carcinoma. Establishment of such correlations could be 
relevant in the context of lung tumours‟ differential diagnosis; 
iii. To identify putative cancer-related metabolic alterations in easily accessible 
biofluids (blood plasma and urine) and explore their potential for 
discriminating lung cancer patients from healthy controls; 
iv. To assess the possible confounding influence of the inter-individual 
variability arising from demographic or lifestyle factors (e.g., gender, age, 
smoking habits) on the predictive ability of biofluid-based classification 
models; 
v. To identify a systemic metabolic signature for lung cancer, detectable in 
biofluids, and characterize its dependence on tumour histological type and 
stage, the ultimate goal being the development of adjunct, minimally invasive 
screening and/or diagnostic methods that would improve lung cancer 
management. 
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2 MATERIALS AND METHODS 
 
This work has been carried out in the framework of a collaboration with the 
Faculty of Medicine (FMUC) and the University Hospitals of Coimbra (HUC, EPE), 
where patients were recruited. Collaboration with a local company (INDASA S.A.) 
was also established to recruit healthy volunteers, who integrated the control group. 
Support from FCT was granted through the research project 
FCT/PTDC/QUI/68017/2006 (January 2008 – June 2011) and the PhD grant 
SFRH/BD/63430/2009. Moreover, this work has been supported by CIMAGO 
(FMUC, University of Coimbra) and by „Liga Portuguesa Contra o Cancro‟. 
 
2.1 Subjects 
In total, 120 lung cancer patients (39 female, 81 male, average age 62 and median 
age 63, age range 30-81) were included in this study, following protocol approval by the 
Ethics Committee of the University Hospitals of Coimbra (HUC, EPE) and informed 
consent. All patients were diagnosed with primary malignant epithelial tumours of the lung 
and were hospitalized for tumour surgical removal. Final diagnosis and staging were 
established by histopathological evaluation, according to the 2004 World Health 
Organisation (WHO) classification of lung tumours (Travis et al. 2004). The histological 
types included were adenocarcinoma (n 50), squamous cell carcinoma (n 29), carcinoid 
tumour (n 15), sarcomatoid (n 9), large cell carcinoma (n 7), adenosquamous carcinoma (n 
5) and small cell carcinoma (n 5). Based on the TNM staging system, tumours were 
classified as stage I (n 69), stage II (n 26) and stage III (n 13). For the remaining 12 cases, 
staging information was inconclusive or not available. In all cases, the surrounding 
parenchyma (non-involved tissue) presented histological characteristics of „smoking lung‟ 
(emphysema, inflammation, desquamation), indicating exposure to cigarette smoking 
(although information on actual smoking habits was not available for the large majority of 
patients). None of the patients had received radiation or chemotherapy treatment or shared 
any common medication regimen previously to sample collection, although casual intake 
of other medicines (e.g., analgesics, antihypertensive drugs) could not be ruled out. The 
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complete information on the demographic and histopathological data of lung cancer 
patients can be found in Table A5 of Annex IV. 
Regarding the control group, 95 healthy volunteers (46 female, 49 male, average age 
42, median age 45, age range 22-60) were recruited within occupational medicine routine 
exams (at the company INDASA S.A.), after informed and signed consent. Subjects were 
included in the control group on the basis of a physician‟s assessment of their general 
health status (normal values in blood and urine standard clinical tests, as well as absence of 
major illness and chronic medication). Subjects with chronic diseases, namely diabetes, 
dyslipidemia and other lung diseases (e.g., COPD) were not included. The complete 
demographic information of control subjects can be consulted in Table A7 of Annex V. 
 
2.2 Sample collection 
The time span of sample collection and analysis was four years, from 2008 to 2012. 
All patients provided blood and urine samples prior to surgery, while pulmonary tissues 
were only collected for a subset of patients for which redundant tissue (not needed for 
diagnosis) was available. Sample numbers collected and analysed for each group and 
sample type, together with general demographic and histopathological information, are 
summarised in Table 2.1.  
 
2.2.1 Lung tissues 
Tumour and non-involved adjacent control tissue samples were retrieved from 
pulmonary surgical specimens by an experienced pathologist, within a maximum of 30 min 
after tumour resection to minimize ischemia-related changes. Collected tissues were then 
immediately snap-frozen in liquid nitrogen to stop enzymatic/chemical reactions, and 
stored at -80 ºC at HUC, EPE (Coimbra), before being transferred in dry ice to CICECO, 
Department of Chemistry at the University of Aveiro, where they were stored at -80 ºC 
until NMR analysis. The total storage period did not exceed six months, varying between 
one to three months for the majority of samples. Sampling for diagnosis was routinely 
performed and mirror sections of the samples used for NMR analysis were microscopically  
 
  
Table 2.1 Summary of sample types and numbers analysed by the different analytical techniques used in this work. 
Analytical technique 
1
H HRMAS NMR 
1
H NMR UPLC-MS 
Sample type and group 
Tissue Blood plasma Urine Urine 
Patients
a
 Controls Patients Controls Patients Controls Patients 
No. of subjects 56 94 106 91 109 50 48 
Gender
b
        
 Male 40 (71%) 49 (52%) 76 (72 %) 48 (53%) 77 (71%) 25 (50%) 37 (77%) 
 Female 16 (29%) 45 (48%) 30 (28%) 43 (47%) 32 (29%) 25 (50%) 11 (23%) 
Average; median age (range) 62; 64 (36-81) 43; 44 (22-60) 62; 63 (30-81) 42; 45 (22-59) 63; 63 (30-81) 49; 49 (38-59) 61; 61 (30-84) 
Smoking habits
b
        
 Smokers 
„smoking lung‟
c
 
29 (31%) 
„smoking lung‟ 
c
 
28 (30%) 
„smoking lung‟ 
c
 
14 (28%) 
„smoking lung‟
 c
  Non-smokers 44 (47%) 43 (47%) 22 (44%) 
 Ex-smokers 21 (22%) 20 (23%) 14 (28%) 
Histological type
b
        
 Adenocarcinoma 19 (34%) 
- 
40 (38%) 
- 
42 (38%) 
- 
22 (46%) 
 Squamous cell carcinoma 19 (34%) 27 (25%) 27 (24%) 11 (23%) 
 Carcinoid tumour 4 (7%) 15 (14%) 15 (14%) 7 (15%) 
 Sarcomatoid carcinoma 6 (11%) 8 (8%) 8 (7%) 3 (6%) 
 Large cell carcinoma 4 (7%) 7 (7%) 7 (6%) 4 (8%) 
 Small cell carcinoma 2 (4%) 5 (5%) 5 (5%) 1 (2%) 
 Adenosquamous carcinoma 2 (4%) 4 (4%) 7 (6%) 0 (0%) 
TNM stage
b
        
 I 29 (54%) 
- 
61 (64%) 
- 
63 (65%) 
- 
31 (72%) 
 II 19 (35%) 24 (25%) 23 (24%) 5 (12%) 
 III 6 (11%) 10 (11%) 11 (11%) 7 (16%) 
a
 Paired tumour and non-involved (control) tissues were collected for each patient. For one patient, the control sample was not available, while for other 
two patients there were two tumour tissue fragments, giving a total of 115 tissue samples analysed. 
b
 Percentages were calculated within each group. 
c
 
Pulmonary parenchyma with histological characteristics indicating exposure to cigarette smoke; smoking history not available. 
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observed so that the percentages of tumour cells, necrosis and inflammatory tissue could be 
determined.  
 
2.2.2 Biofluids: blood plasma and urine 
All biofluid samples were collected in the morning, after overnight fasting, in order 
to minimise dietary influence, although no control over previous food intake was 
performed. 
Blood was collected by venipuncture into 9 mL sodium heparin tubes (Vacuette®) 
and centrifuged (1500 g, 10 min) within a maximum of 30 min to separate the plasma in 
order to avoid cell rupture/leakage and minimize transport of metabolites between intra and 
extracellular compartments (Teahan et al. 2006). Plasma aliquots of approximately 1 mL 
were then transferred into sterile cryovials, frozen and stored at -80 °C until analysis. 
Urine samples were collected into sterile cups, centrifuged (1500 g, 10 min), divided 
into 1 mL aliquots, frozen and stored at -80ºC until analysis. The maximum storage period 
was four months for blood plasma and six months for urine. 
 
2.3 NMR spectroscopy 
2.3.1 Sample preparation for NMR 
The experimental procedures described below were based on standardised protocols 
reported in the literature (Beckonert et al. 2007; Beckonert et al. 2010). 
 
2.3.1.1 Lung tissue 
At the time of analysis, each frozen tissue fragment was washed with a few drops of 
D2O saline (0.9% NaCl) to remove excess blood (containing paramagnetic species that 
could lead to signal broadening), as well as water (for improved water suppression). About 
40 mg of thawed cold tissue (38.7±7.2 mg) were then cut and packed into a 4 mm 
zirconium HRMAS rotor, fitted with a Teflon® top insert to provide a 50 L sample 
volume with a cylindrical geometry. Ten microliters of D2O saline with 0.25% of 3-
(trimethylsilyl) propionate sodium salt (TSP)-d4 were also added to provide a signal for 
lock (D2O) and for shimming (TSP).  
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2.3.1.2 Blood plasma 
Plasma samples were thawed at room temperature, vortexed and their pH measured 
(7.81±0.13). Then, 400 µL of saline solution (NaCl 0.9% in 10% D2O) were added to 200 
µL of plasma, and the pH measured again (7.85±0.14). After centrifugation (4293 g, 5 
min), 550 µL of the supernatant were transferred into a 5 mm NMR tube.  
 
2.3.1.3 Urine 
At the time of NMR analysis, urine samples were thawed at room temperature and 
their pH measured (6.07±0.86). Samples were then centrifuged (4293 g, 5 min) to remove 
residual cells and other precipitated material. Afterwards, 540 L of supernatant were 
mixed with 60 L of buffer solution (KH2PO4 1.5 M in D2O) containing 0.1% TSP-d4 
(used as chemical shift reference) and 2 mM of sodium azide (NaN3, bacteriostatic agent). 
The pH of the buffered sample was again measured (6.78±0.15), and if necessary a final 
adjustment to pH 7.01±0.01 was carried out by adding a few drops of 4 M KOD or DCl. 
Finally, samples were centrifuged (4293 g, 5 min) and 550 L of supernatant were 
transferred into a 5 mm NMR tube. 
 
2.3.2 Acquisition and processing of HRMAS NMR spectra of tissues 
NMR spectra of intact tissue samples were acquired on a Bruker Avance DRX-500 
spectrometer (University of Aveiro, Portuguese NMR network, Portugal) operating at 
500.13 MHz for 
1
H observation, using a 4 mm HRMAS probe (g-HR MAS 500 SB BL4). 
The rotor containing the sample was spun at the magic angle (54.7º relative to the magnetic 
field) at a 4 kHz spinning rate. A Bruker cooling unit was used to cool down the bearing air 
flowing into the probe in order to keep the temperature at 277 K. 
Three 
1
H 1D NMR experiments were acquired for each sample: i) standard 
1
H NMR 
with water suppression by presaturation during the relaxation delay (RD) and mixing time 
(tm) (noesypr1d pulse programme from Bruker library, RD-90º-t1-90º-tm-90º-ACQ, t1 being 
a short delay of 3 s), ii) T2-edited (Carr-Purcell-Meiboom-Gill, CPMG) 
1
H NMR for 
attenuation of broad signals from fast-relaxing molecules (cpmgpr pulse programme from 
Bruker library, RD-90º-(η-180º-η)n-ACQ, η being the echo time and n the number of loops), 
and iii) diffusion-edited 
1
H NMR for selecting signals of bound or large slow-diffusing 
molecules (ledbpgp2s1dpr pulse programme from Bruker library, RD-90º-G1-180º-G1-
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90º-G2-η-90º-G1-180º-G1-180º-G1-90º-G2-η-90º-ACQ, G1 and G2 being the pulsed-field 
and the spoil gradients, respectively, and η the gradient recovery delay). The main 
acquisition parameters are listed in Table 2.2. Acquisition time for each FID was set to 
2.52 s (to provide adequate digital resolution) and the relaxation delay to 4 s, giving a total 
recycle time of 6.52 s. Based on 
1
H T1 measurements (described in section 2.3.4 and 
shown in Annex VI) these conditions allowed semi-quantitative standard 1D spectra to be 
recorded within a reasonable measurement time (approximately 29 min per sample). 
Spectral processing was performed using Topspin 3.2 (Bruker Biospin, Rheinstetten, 
Germany). Prior to Fourier transform (FT), the FIDs were zero-filled to 64 k points and 
multiplied by an exponential line-broadening window function (LB 0.3 Hz). All 1D spectra 
were manually phased and baseline corrected. Chemical shifts were referenced internally 
to the alanine signal at δ 1.48, since this peak was found to be more reliable than the TSP 
singlet (often broadened or shifted probably due to interaction with macromolecules). Main 
processing parameters of 1D spectra are also listed in Table 2.2.  
 
Table 2.2 Main parameters used for the acquisition and processing of 500 MHz 1D 
1
H HRMAS 
NMR spectra of intact lung tissue. 
 
1
H HRMAS NMR 
Acquisition parameters
 
Experiment standard 1D CPMG diffusion-edited 
Pulse programme
a
 noesypr1d cpmgpr ledbpgp2s1dpr 
Number of scans, NS 256 256 256 
FID data points, TD 32768 32768 32768 
Spectral width (ppm) 13.02 13.02 13.02 
Acquisition time, ACQ (s) 2.52 2.52 2.52 
Relaxation delay, RD (s) 4 4 4 
Mixing time, tm (ms) 100   
Spin echo delay, η (s)  300  
Number of loops, n  150  
Pulsed-field gradient, G1 (s)   200 
Diffusion delay,  (s)   0.1 
Delay for longitudinal eddy currents, η (ms)   5 
Spoil-gradient, G2 (ms)   2 
Gradient pulse, δ/2 (s)   2000 
Processing parameters    
Window function exponential exponential exponential 
Spectrum data points, SI 65536 65536 65536 
Line broadening, LB (Hz) 0.3 0.3 0.5 
a 
Bruker library (pulse programmes can be found in Annex VII). 
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Two-dimensional (2D) 
1
H-
1
H total correlation (TOCSY) spectra, 
1
H-
13
C phase 
sensitive heteronuclear single quantum correlation (HSQC) spectra and J-resolved spectra 
were registered for selected samples to aid spectral assignment. Bruker Avance DRX-500 
(University of Aveiro, Portuguese NMR network, Portugal) and Bruker Avance II 600 
(Bruker Biospin, NMR Division, Rheinstetten, Germany) spectrometers, operating 
respectively at 500.13 and 600.13 MHz for 
1
H observation were used to record 2D spectra. 
Typically, TOCSY spectra were acquired in the phase-sensitive mode using time 
proportional phase incrementation (TPPI) and the MLEV 17 pulse sequence for the spin-
lock (mlevgsst and mlevphpr pulse programmes from Bruker library), 
1
H-
13
C phase 
sensitive (echo/antiecho) HSQC were recorded with inverse detection and carbon 
decoupling (hsqcetgppr and invietgpsi pulse programmes from Bruker library) and J-
resolved spectra with F2 decoupling (jresgpprqf pulse programme from Bruker library). 
For both TOCSY and HSQC spectra, zero filling to 1024 data points and forward linear 
prediction were used in F1 dimension and multiplication by a shifted sine-bell-squared 
apodization function was applied in both dimensions prior to FT and phasing. For the J-
resolved experiments, prior to FT, the FIDs were weighted in both dimensions by a sine-
bell function and zero-filled in the F1 dimension to 256 data points. The spectra were tilted 
by 45º to provide orthogonality of the chemical shift and coupling constant axes were 
subsequently symmetrised about the F1 axis. Main acquisition and processing parameters 
of 2D HRMAS NMR spectra acquired for lung tissues are summarised in Table 2.3. 
 
Table 2.3 Main parameters used for the acquisition and processing of 2D HRMAS NMR (600/500 
MHz) spectra of intact lung tissues. 
 
1
H HRMAS NMR (600 MHz/500 MHz) 
Acquisition parameters 
Experiment 
1
H-
1
H TOCSY 
1
H-
13
C HSQC J-Resolved 
Pulse programme
a
 mlevphpr/mlevgsst hsqcetgppr/invietgpsi jresgpprqf
b
 
FID data points 1
st
 dimension [F1] 2048/1024 1024/1024 16384 
FID data points 2
nd
 dimension [F2] 280/256 200/256 40 
Number of scans 80/32 88/60 48 
Spectral width [F1] (ppm) 12.02/13.02 20.55/13.02 16.66 
Spectral width [F2] (ppm) 12.02/123.02 190.00/249.99 0.13 
Relaxation delay, RD (s) 2/2 4/2 2 
Mixing time, tm (ms) 30/80   
Processing parameters 
Spectrum data points [F1], SI  2048/1024 1024/1024 16384 
Spectrum data points [F2], SI 1024/1024 1024/512 256 
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Table 2.3 (continued) 
 
1
H HRMAS NMR (600 MHz/500 MHz) 
Processing parameters 
Line broadening [F1], LB (Hz) 0.3/0.3 0.3/0.3 0.3 
Line broadening [F2], LB (Hz)  1.0/1.0 0.3 
a 
Bruker library; 
b 
spectra were acquired in the 600 MHz spectrometer only. 
 
2.3.3 Acquisition and processing of NMR spectra of biofluids 
NMR spectra of urine and blood plasma were acquired on a Bruker Avance DRX-
500 spectrometer (University of Aveiro, Portuguese NMR network, Portugal) operating at 
500.13 MHz for 
1
H observation, at 300 K, using a 5 mm BBI probe (BBI 500 MHz SB 5 
mm). 
In the case of plasma three 1D 
1
H NMR experiments were acquired for each sample, 
similarly to what has been previously described for tissues: i) standard 1D with water 
suppression (noesypr1d pulse programme from Bruker library), ii) T2-edited (Carr-Purcell-
Meiboom-Gill, CPMG) (cpmgpr pulse programme from Bruker library) and iii) diffusion-
edited (ledbpgp2s1dpr pulse programme from Bruker library). In the case of urine, only 
the standard 1D 
1
H NMR spectrum was recorded for each sample, given that urine is 
typically free of macromolecular components, thus sparing the need for relaxation- or 
diffusion-edited experiments to be recorded. All 1D spectra were manually phased and 
baseline corrected. The chemical shifts were referenced internally either to the α-glucose 
signal at δ 5.23 in the case of plasma and to the TSP signal at δ 0.00 in the case of urine. 
The main acquisition and processing parameters can be found in Table 2.4. 
 
Table 2.4 Main parameters used for the acquisition and processing of 500 MHz 1D 
1
H NMR 
spectra of blood plasma and urine. 
 Blood plasma Urine 
Acquisition parameters 
Experiment standard 1D CPMG diffusion-edited standard 1D 
Pulse programme
a
 noesypr1d cpmgpr ledbpgp2s1dpr noesypr1d 
FID data points, TD 32768 32768 32768 32768 
Number of scans 128 256 128 128 
Spectral width (ppm) 20.66 20.66 20.66 20.66 
Relaxation delay, RD (s) 4 4 4 4 
Mixing time, tm (ms) 100   100 
Spin echo delay, η (s)  400   
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Table 2.4 (continued) 
 Blood plasma Urine 
Processing parameters 
Number of loops, n  80   
Pulsed-field gradient, G1 (s)   100  
Diffusion delay,  (s)   0.1  
Delay for longitudinal eddy 
currents, η (ms) 
  5  
Spoil-gradient, G2 (ms)   2  
Gradient pulse, δ/2 (s)   1000  
Window function exponential exponential exponential exponential 
Spectrum data points, SI 65536 65536 65536 65536 
Line broadening, LB (Hz) 0.3 0.3 0.5 0.3 
a 
Bruker library (pulse programmes can be found in Annex VII). 
 
2D homonuclear (
1
H-
1
H TOCSY and J-resolved) and heteronuclear (
1
H-
13
C HSQC) 
spectra were also registered for selected biofluid samples to aid spectral assignment. Main 
acquisition and processing parameters of 2D experiments are listed in Table 2.5. 
 
Table 2.5 Main parameters used for the acquisition and processing of 500 MHz 2D NMR spectra 
of blood plasma and urine. 
 Blood plasma/Urine 
Acquisition parameters 
Experiment 
1
H-
1
H TOCSY 
1
H-
13
C HSQC J-resolved 
Pulse programme
a
 clmlevprtp invietgpsi lcjresprqf 
FID data points [F1] 240/256 360/400 80/80 
FID data points [F2] 2048/2048 3072/4096 3072/3072 
Number of scans 48/56 40/40 32/32 
Spectral width [F1] (ppm) 20.66/16.00 200/200 0.19/0.19 
Spectral width [F2] (ppm) 20.66/16.02 20.66/16.02 20.66/20.66 
Relaxation delay, RD (s) 1.5 1.5 2/1 
Mixing time, tm (ms) 80   
Processing parameters 
Window function qsine/qsine qsine/qsine sine 
Spectrum data points [F1], SI 1024/1024 1024/512 16384/16384 
Spectrum data points [F2], SI 4096/4096 4096/4096 4096/4096 
Line broadening [F1], LB (Hz) 0.3/0.3 0.3/0.3 0.3 
Line broadening [F2], LB (Hz)  1.0/1.0 0.3 
a 
Bruker library. 
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2.3.4 1H T1 and T2 measurements 
Proton relaxation parameters, namely spin-lattice (longitudinal) relaxation time 
constant, T1, and spin-spin (transverse) relaxation time constant, T2, were measured for 
selected samples of tissues and biofluids. For measuring 
1
H T1 values a standard inversion-
recovery pulse sequence (RD-180ºx-η1-90ºx-ACQ) was used, while 
1
H T2 values were 
measured using a spin echo experiment (RD-90º-(η-180º-η)n-ACQ). The main acquisition 
and processing parameters are listed in Table 2.6. 
 
Table 2.6 Main parameters used for the acquisition and processing of 
1
H T1 and T2 measurements. 
 Lung tissue Blood plasma Urine 
Acquisition parameters 
Experiment T1 measurement 
Pulse programme
a
 t1irpr t1irpr t1irpr 
FID data points [F1] 26 32 32 
FID data points [F2] 16384 16384 16384 
Number of scans 40 64 64 
Spectral width [F1] (ppm) 2.00 2.00 2.00 
Spectral width [F2] (ppm) 13.02 19.99 19.99 
Relaxation delay, RD (s) 10 10 10 
Range of delays (ms) 0.01-20.00 0.01-25.00 0.01-25.00 
Experiment T2 measurement 
Pulse programme
a
 t2zgpr t2zgpr 
 
FID data points [F1] 30 32 
 
FID data points [F2] 16384 16384 
 
Number of scans 40 64 
 
Spectral width [F1] (ppm) 2.00 2.00 
 
Spectral width [F2] (ppm) 13.02 19.99 
 
Relaxation delay, RD (s) 10 10 
 
Range of loops 5-8000 2-15000 
 
Processing parameters (T1/T2) 
Window function sine/sine sine/sine Sine/ 
Spectrum data points [F1], SI 16384/16384 16384/16384 32768/ 
Spectrum data points [F2], SI 26/30 32/32 32/ 
Line broadening [F1], LB (Hz) 0.3 0.3 0.3 
a
 Bruker library (pulse programmes can be found in Annex VII). 
 
1
H T1 and T2 values were estimated by fitting experimental data using OriginPro 8 
(OriginLab, Northampton, Massachusetts, USA) to exponential decay functions shown in 
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Equation 1.10 and Equation 1.11, respectively. For some spectral regions with overlap of 
sharp and broad signals, a single-exponential decay did not fit the data, thus bi-exponential 
decay functions were applied. 
 
2.3.5 Pre-treatment and multivariate analysis of NMR spectra 
In order to prepare the data for multivariate analysis (MVA), full resolution 
1
H NMR 
spectra (no bucketing) were organised as rectangular n×m (rows×columns) matrices of n 
observations (samples) and m variables (peak intensities), designated X matrices (main 
features shown in Table 2.7), by using Amix 3.9.14 (Bruker Biospin, Rheinstetten, 
Germany). Selected regions were excluded from these matrices, namely the suppressed 
water signal (in all sample types), ethanol and glycol contaminant signals in tissue spectra 
(probably arising, respectively, from the desinfected surgical instruments and the 
cryopreservative embedding medium), and the urea signal in urine spectra (close to water 
and affected by water suppression via proton exchanging).  
The rows in those were then aligned using a recursive segment-wise peak alignment 
(RSPA) algorithm (Veselkov et al. 2009) and normalized by probabilistic quotient 
normalisation (PQN), using the median of the controls as reference spectrum (Dieterle et 
al. 2006). Both procedures were carried out in MATLAB version 7.14.0.739 (The 
MathWorks, Inc., Natick, Massachusetts, USA), using scripts developed at ICL and kindly 
supplied by Dr. Kirill A. Veselkov. Afterwards, the columns were mean centered 
(subtraction by average value) and different scaling types were tested (none – just centered, 
unit variance and pareto scaling), using SIMCA-P 11.5 software (Umetrics, Umeå, 
Sweden). UV scaling was found to give the best results for most models built. 
Multivariate analysis was carried out using SIMCA-P version 11.5 (Umetrics, Umeå, 
Sweden) and comprised principal component analysis (PCA), partial-least squares-
discriminant analysis (PLS-DA) and orthogonal projection to latent structures-discriminant 
analysis (OPLS-DA). The results were visualized through scores scatter plots and 
corresponding loadings plots. In the case of models involving UV scaling, the loadings 
profiles were recovered by multiplying the loading weights w by the standard deviation. 
Colouring by the variable importance in the projection (VIP) was then performed in R 
software version 2.15.0 (R Development Core Team, Vienna, Austria, 2012). In the case of 
models with low predictive power, a variable selection method developed in-house was 
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applied (Diaz et al. 2013). According to this method, the variables kept for further MVA 
and model validation simultaneously obeyed the following criteria: i) VIP>1; ii) VIP/ 
VIPcvSE>1 and iii) |b/bcvSE|>1, where VIPcvSE and bcvSE are, respectively, the standard errors 
of VIP values and b coefficients, obtained in PLS-DA models. 
 
Table 2.7 Information about the 
1
H NMR matrices used for MVA. 
Sample type Lung tissue Blood plasma Urine 
Rows, n samples
a
 115 200 200 
Columns, m variables (intensities) 
 Standard 1D 39539 35961 25125 
 CPMG 37776 22476 n.a. 
 Diffusion-edited 20590 36325 n.a. 
Spectral interval (ppm) 
 Standard 1D 0.25-8.80 -1.50-10.50 0.50-9.40 
 CPMG 0.50-8.80 0.50-8.50 n.a. 
 Diffusion-edited 0.25-4.38 -1.50-10.50 n.a. 
Exclusion areas 
(ppm) 
ethanol (1.15-1.22, 3.63-3.69)
b
 
glycol (3.69-3.73) 
water (4.85-5.20) 
water (4.60-4.85) 
water (4.62-4.90) 
urea (5.50-6.10) 
Integration mode Sum of absolute intensities 
n.a. Not applicable. 
a
 Number of samples in controls vs. cancer MVA models. 
b
 Not detected in 
diffusion-edited spectra. 
 
2.3.6 Model validation 
The robustness of PLS-DA classification models was assessed by Monte Carlo cross 
validation (MCCV) and permutation testing (500 iterations) as explained in subchapter 
1.3.4.4, using an in-house software developed and kindly supplied by Dr. António Barros. 
For each model, a ROC space plot of the true positive rate (TPR or sensitivity) against the 
false positive rate (FPR or 1-specificity), together with a Q
2
 histogram showing the 
distribution of Q
2
 values in original (true classes assigned) and permuted model iterations, 
were used to assess robustness. In particular, PLS-DA models were considered validated 
when there was no overlap in the ROC plot between models obtained for true and 
permuted classes, the true models showing high sensitivity and specificity, and there was 
minimal overlap between original and permuted Q
2
 values, the median Q
2
 being high 
(>0.5) for original models and low or negative for permuted models. 
In the case of biofluids, preliminary external validation was carried out to evaluate 
the performance of MVA models for predicting the class of new samples (SIMCA-P 
version 11.5, Umetrics, Umeå, Sweden). The data was divided into training (or calibration) 
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and test (or validation) sets, the later consisting of forty samples most recently collected 
and analysed (and not included in the training set). Prediction was performed by using 
either the whole dataset (all variables) or the signals found to be most relevant for the 
discrimination between controls and cancer patients. 
 
2.3.7 Spectral integration and univariate statistics 
To evaluate individual metabolite quantitative variations, selected signals (with 
VIP>1) were integrated in the 
1
H NMR spectra and normalised by the corresponding PQN 
quotient. Spectral integration was performed by calculating the area under a certain signal 
for which integration limits were manually defined or, in cases of highly overlapped 
regions, by applying deconvolution using Amix-Viewer 3.9.14 software (Bruker BioSpin, 
Rheinstetten, Germany). Deconvolution using an automated variable Gaussian/Lorentzian 
peak fitting routine based on the Marquardt algorithm was applied to the region of interest, 
and the resulting peak fits were improved by manually adjusting the peak picking until the 
error estimates associated to the intensity, the height at half-width, and the 
Gaussian/Lorentzian proportion were minimised. 
Spectral integrals were statistically compared by applying the Wilcoxon signed rank 
test for paired samples (lung tissues) and the Wilcoxon rank sum test for unpaired samples 
(biofluids). Additionally, Bonferroni correction was applied to minimise false discoveries 
(false positives) in multiple comparisons by adjusting the significance level as a function 
of the numbers of variables tested. Also, for each metabolite, the percentage of variation 
and respective error were calculated, along with the effect size (d) and respective 95% 
confidence interval (according to Equation 1.30, Equation 1.31 and Equation 1.32). 
 
2.4 Ultra-performance liquid chromatography – mass spectrometry 
(UPLC-MS) 
2.4.1 Sample preparation for UPLC-MS 
For UPLC-MS analysis, urine samples were thawed at room temperature and 
centrifuged (9500 g, 10 min) before dilution of the supernatant (1:1 v/v) with HPLC grade 
water. All samples were vortexed, transferred to 96-well plates and kept in the UPLC auto-
sampler unit at a constant temperature of 4º C throughout the entire run. Quality control 
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(QC) samples were also prepared by mixing 10 µL aliquots of all urine samples used in 
this study. 
 
2.4.2 Acquisition and processing of UPLC-MS data 
UPLC-MS analysis of urine was performed in the Biomolecular Medicine 
Department, Division of Surgery and Cancer of the Faculty of Medicine, Imperial College 
of London (ICL), United Kingdom. An Acquity UPLC® System (Waters Corporation, 
Milford, Massachusetts USA) coupled to a LCT Premier ToF mass spectrometer (Waters 
Corporation, Milford, Massachusetts USA) was used. 
With the purpose of achieving an extensive coverage of the urinary metabolic 
content, two complementary chromatographic columns were used in two separate runs: a 
reverse-phase high-strength silica column (2.1×100 mm, 1.8 μm, HSS T3 Acquity 
UPLC®, Waters Corporation, Milford, Massachusetts USA) and a hydrophilic interaction 
chromatography column (2.1×100 mm, 1.7 μm, HILIC BEH Acquity UPLC®, Waters 
Corporation, Milford, Massachusetts USA). Compared to traditional C18 columns, the 
HSS T3 column shows improved performance regarding retention of certain polar 
metabolites (New and Chan 2008), while the HILIC BEH column has the ability of 
improving the profiling of highly polar metabolites (Gika et al. 2008; Spagou et al. 2011). 
Mass spectrometry detection was separately performed in both positive and negative 
ionization modes. Therefore, each sample was analysed four times, using either positive or 
negative ionization mode in each column. The mass analyser was a time-of-flight (ToF) 
analyser interfaced with an electrospray ion source. 
General experimental conditions of liquid chromatography were applied as described 
by Want et al. (Want et al. 2010) and are summarised in Table 2.8. Column temperature 
was maintained at 40ºC and eluent flow rate kept at 0.5 mL∙min
-1
 throughout the analysis. 
The sample volume injected was 5 μL and a different elution gradient was applied to the 
two columns (Table 2.8). For the HSS column the eluent was composed of water with 
0.1% formic acid (AHSS), and acetonitrile with 0.1% formic acid (BHSS), while for the 
HILIC column, the eluent consisted of acetonitrile with 5% ammonium acetate (AHILIC) 
and acetonitrile with 50% ammonium acetate (BHILIC).  
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Table 2.8. Experimental conditions of UPLC urine analysis. 
Column type HSS HILIC 
Main parameters   
Column temperature (ºC) 40 40 
Injection volume (μL) 5 5 
Flow rate (mL∙min-1) 0.5 0.5 
Mobile phase (%) 
A: 0.1% HCOOH in water 
B: 0.1% HCOOH in acetonitrile 
A: 5% CH3COONH4 in acetonitrile 
B: 50% CH3COONH4 in acetonitrile 
Time of run (min) 12 15 
Elution gradient 
Time (min) AHSS (%) BHSS (%) AHILIC (%) BHILIC (%) 
0.0 100 0 99 1 
1.0 100 0 99 1 
3.0 85 15 99 1 
6.0 50 50 99 1 
9.0 5 95 99 1 
10.0 5 95 99 1 
10.1 100 0 99 1 
12.0 100 0 0 100 
12.1   99 1 
15.0   99 1 
 
Column conditioning was performed by running, at the beginning of each analysis, 
ten pooled QC samples, prepared as described in section 2.4.1, in order to achieve stable 
retention times (RT) of the compounds. Moreover, QC samples were also injected every 
ten samples throughout the analytical run to allow stability and quality of the data to be 
assessed (Want et al. 2010). For further evaluation of data quality (RT, peak shape, signal 
intensity) a test mixture, comprising twenty five reference compounds, and a blank (water, 
also used for the mobile phases) were run at the beginning and at the end of the analysis. 
Urine samples of control and cancer groups were analysed in random order. 
Mass spectrometry was performed in both positive and negative ion electrospray 
modes (ESI+ and ESI-), and the general ionisation parameters are listed in Table 2.9. The 
capillary voltage was 3.0 kV (ESI+) and 2.5 kV (ESI-), and the cone voltages were set to 
30 V (ESI+) and 25 V (ESI-). The eluent desolvation temperature was 400 ºC, while the 
source temperature was 120 ºC. Finally, the cone gas flow rate was 25 L∙min
-1
 and the 
desolvation gas flow rate was 800 L∙h
-1
. The LCT Premier was operated in V optics mode 
with a scan time of 0.1 s and an interscan delay of 0.01 s. For exact mass measurements, a 
LockSpray interface was used to correct changes in environment or experimental 
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conditions over the course of the analysis. The reference, or lock mass, used was a 200 
μg∙L-1 leucine enkephalin (555.2645 amu) peptide solution (50/50 acetonitrile/water with 
0.1% v/v formic acid) sprayed at a flow rate of 3 μL∙min-1. Data were collected in centroid 
mode with a scan range of 50-1000 m/z, with lock mass scans being collected every 15 
scans and averaged over 5 scans to perform mass correction.  
 
Table 2.9. MS ionisation parameters for ESI+ and ESI- modes. 
Ionisation mode ESI+ ESI- 
Voltages (V)   
 Capillary 3000 2500 
 Sample cone 30 25 
Temperatures (ºC)   
 Desolvation 400 
 Source 120 
Gas flows   
 Cone (L∙min-1) 25 
 Desolvation (L∙h-1) 800 
 
2.4.3 Pre-treatment and multivariate/univariate analysis of UPLC-MS data 
UPLC-MS data pre-treatment was carried out in R software version 2.15.0 (R 
Development Core Team, Vienna, Austria, 2012), using the freely available software 
package XCMS (Smith et al. 2006), and consisted of several steps as shown in Figure 2.1. 
Raw data was converted to netCDF format using Waters MassLynx™ version 4.1 
Databridge software (Waters Corporation, Milford, Massachusetts USA) and then 
imported to R software for processing. Scripts used here were developed at ICL and kindly 
supplied by courtesy of Dr. Matthew Lewis and Dr. Paul Benton. To carry out peak 
detection, the centWave peak picking algorithm for high resolution datasets was used 
(Tautenhahn et al. 2008), together with a pre-filter to remove mass traces that were not 
detected in at least 5 scans with intensity higher than a 1000. This filter allowed for some 
of the background noise to be reduced. The peakwidth (minimum-maximum) used for peak 
picking was 2-15 s for HSS and 3-60 s for HILIC columns. 
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Figure 2.1. Schematic workflow for pre-treatment of LC-MS data (adapted from Smith et al. 
2006). 
 
After peak detection in individual samples, peaks must be matched across samples to 
allow the calculation of retention time deviations. Hence, peaks within a m/z bandwidth of 
0.05 Da were firstly grouped within an interval of 5 s relatively to the median RT of „well-
behaved‟ peaks, and retention times‟ deviations were calculated. Subsequently, a second, 
more accurate, peak alignment was performed taking into account the new RT deviations 
obtained, namely 4 and 3 s for HSS positive and negative modes, and 6 and 12 s for HILIC 
positive and negative modes, respectively. Missing peaks were identified and their 
intensity measured in raw data. 
A following MinFrac filter was used, in which features not present in at least 50% of 
a sample group (QCs, control and cancer groups) were filtered out and considered to be 
noise. This filter was found to be very effective in removing background features, as a 
previous attempt to process data without applying MinFrac filter resulted in a final matrix 
with several background features. Normalisation of features‟ intensity was performed by 
applying the PQN method (Veselkov et al. 2011). At last, a coefficient of variation (CV)-
based filter was applied, in which spectral features with a CV (%) higher than 30% were 
removed. The CV was calculated only for the QCs analysed between samples (not the QCs 
used for column conditioning). This filter guaranteed that only features with high 
reproducibility throughout the entire run were kept. 
The normalized UPLC data sets were then arranged into n×m matrices, where n are 
the samples (rows) and m are the data features‟ intensities described by specific retention 
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time-m/z pairs. Table 2.10 shows the decreasing number of features present in the UPLC 
matrices with the application of the previously described filters. Datasets were then mean-
centered and subjected to different scaling types (UV scaling, Pareto scaling or logarithmic 
transformation) before MVA. 
 
Table 2.10 Information about the UPLC-MS matrices used for MVA. 
  HSS ESI+ HSS ESI- HILIC ESI+ HILIC ESI- 
Rows, n samples 
 QC 11 
 Control 50 
 Cancer 48 
Columns, m variables (RT_m/z pairs) 
 Raw data 19323 36620 11260 12853 
 After MinFrac filter 4959 8226 3157 3436 
 After CV filter 4434 7312 2628 2412 
 
MVA was carried out in SIMCA-P version 11.5 (Umetrics, Umeå, Sweden). PCA 
and PLS-DA were applied to UPLC-MS data, and extraction of relevant features from 
validated PLS-DA models was performed by applying consecutive selection rules to the 
loadings list. Firstly, S-plots relating covariance (p) and correlation (pcorr) between the 
UPLC-MS variables and the PLS-DA scores were analysed so that only variables with 
p>0.02 and |pcorr|>0.6 were considered relevant. Secondly, the ratio of the absolute mean 
covariance loading and its respective jack-knifed cross-validated standard error (p/pCVSE) 
was calculated and a threshold of 4 (pCVSE below 25%) for keeping features was 
established (Wiklund et al. 2008). Finally, a significance test was applied as explained 
before (subchapter 1.3.4.5).  
As for NMR data, model validation was then performed by MCCV and permutation 
testing to assess PLS-DA models‟ robustness and predictive ability. 
 
2.5 Statistical correlation: STOCSY and SHY 
Statistical total correlation spectroscopy (STOCSY) analysis was applied to NMR 
spectra for helping the assignment of unknown resonances. Pearson correlation coefficients 
(r) were calculated between each unknown signal (driver peak) and the full spectral matrix 
and used to colour the covariance plot, resulting in a 1D STOCSY plot (Cloarec et al. 
2005). To aid the identification of RT_m/z features, statistical heterospectroscopy (SHY) 
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was applied (Crockford et al. 2006). In this case, the correlation between each MS 
(RT_m/z) feature and the full NMR matrix (same samples) was calculated. Statistical 
significance of Pearson correlation coefficients was calculated and a threshold of |r|>0.8 
(p<0.01) was applied in agreement with previous reports using STOCSY (Crockford et al. 
2006; Maher et al. 2011). 
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3 METABOLIC PROFILING OF LUNG TUMOURS BY 
TISSUE NMR METABOLOMICS 
 
This chapter presents the analysis of tumour and non-involved (control) lung tissues 
by 
1
H HRMAS NMR spectroscopy. In the first subchapter, some experimental details are 
discussed, namely regarding the influence of spinning rate, time and temperature on the 
spectral profile of lung tissues, and the use of relaxation- and diffusion-edited experiments 
to deal with spectral overlap. Subsequently, detailed metabolite assignment is pursued with 
the help of 2D NMR spectroscopy and STOCSY. In the third and fourth subchapters, 
MVA is applied to search for metabolic features differentiating lung tumour and control 
tissues, as well as tumour histological types. Finally, the biochemical interpretation of the 
metabolic variations observed is proposed. 
 
3.1 1H HRMAS NMR spectra of lung tissues: setting up the acquisition 
conditions 
The typical standard 1D 
1
H HRMAS NMR spectrum of lung (tumour) tissue, with 
water signal suppression, is shown in Figure 3.1. This spectrum comprises well resolved 
peaks across the whole spectral range (line widths at half-height ≤ 2 Hz for most signals) 
overlapped with some broad resonances arising from lipid and protein components. Before 
going into detail about the assignment of spectral peaks to specific compounds, the 
following sections will address the variations observed in lung tissue NMR profile upon 
sample spinning at different rates, temperatures and time intervals. Moreover, the 
optimization and use of relaxation- and diffusion-edited experiments to deal with the 
spectral overlap observed in the standard 1D spectrum will be described. These 
preliminary tests were important to establish the experimental conditions for acquiring 
informative, reproducible and comparable sample spectra, especially given that no reports 
on the HRMAS analysis of intact lung tissue were available at the beginning of this work. 
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Figure 3.1 600 MHz standard 1D 
1
H HRMAS NMR spectrum of lung tumour tissue. 
 
3.1.1 Influence of spinning rate on the NMR spectral profiles 
As described in section 1.3.2.4, spinning the rotor containing the tissue sample at the 
magic angle (54.74º in relation to the external magnetic field B0) and at a few kHz spinning 
rate, allows line broadening effects to be minimized and well resolved spectra to be 
obtained from intact tissues. 
In order to define the most suitable spinning rate (SR) for recording intact lung tissue 
spectra, consecutive spectra of the same sample were acquired at different SRs, varying 
from 1 to 8 kHz, as shown in Figure 3.2. Probe temperature was kept at 283 K, as this was 
the minimum value achievable at the lowest spinning rate. In general, a significant peak 
narrowing and improvement in resolution was observed when increasing SR from 1 to 2 
kHz, while for the other spinning rates tested the line widths of signals arising from small 
metabolites remained fairly constant and showed little enhancement in spectral resolution 
(Table 3.1). On the other hand, broad resonances from lipids (e.g., at δ 0.89 and δ 1.26), 
which were poorly visible at 1 and 2 kHz spinning rates, became more resolved with 
increasing SR, up to 8 kHz (maximum SR tested, Figure 3.2). This observation suggests  
 
imd_LT5309_1_1
7.50 5.00 2.50
ppm0.5
ppm
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.5
imd_LT5309_1_1
7.50 5.00 2.50
ppm
HDO
CHAPTER 3 – METABOLIC PROFILING OF LUNG TUMOURS BY TISSUE NMR METABOLOMICS 
91 
 
Figure 3.2 Expansion (δ 2.25-0.65) of consecutive standard 1D 1H HRMAS NMR spectra of lung 
tissue acquired with different spinning rates. 
 
Table 3.1 Widths at half-height (ν½) measured for several peaks at different spinning rates (shown 
in order of spectra acquisition). 
 ν½
a
 (Hz) 
Spinning rate 
(kHz) 
valine 
(δ 1.05) 
lactate 
(δ 1.33) 
alanine 
(δ 1.48) 
s-inositol 
(δ 3.35) 
taurine 
(δ 3.43) 
glycine 
(δ 3.56) 
1 3.44 3.24 3.37 3.10 4.24 3.26 
2 2.27 2.10 2.02 2.10 2.78 1.69 
3 2.22 2.23 2.23 2.26 2.83 1.88 
4 2.12 2.14 2.13 2.13 2.73 1.83 
5 2.07 2.01 2.07 2.10 2.64 1.75 
6 2.14 2.10 2.18 2.21 2.78 1.88 
8 2.12 2.01 2.23 2.07 2.69 1.86 
4 2.01 1.88 1.91 1.99 2.49 1.64 
a
 Values measured in spectra processed with LB 0 Hz. 
 
2.00 1.75 1.50 1.25 1.00
ppm
2.00 1.75 1.50 1.25 1.00
ppm1.00 pp1.251.502.00 1.75
1
2
3
4
5
6
8
4
SR (kHz)
CHAPTER 3 – METABOLIC PROFILING OF LUNG TUMOURS BY TISSUE NMR METABOLOMICS 
 
92 
that lipid resonances are affected by line broadening interactions (e.g., residual dipolar 
couplings) of higher magnitude than smaller molecules, possibly in relation to their more 
restrained molecular mobility, as indicated by their lower transverse relaxation time 
constants (T2), compared to those of small molecules (Annex VI, Table A8). 
In addition to line narrowing, a gradual increase in intensity was noted for all signals 
with increasing spinning rate, probably reflecting the progressive disruption of tissue 
integrity. Indeed, while in native tissue structure some metabolites may be partially bound 
to macromolecules or confined to compartments of low molecular mobility, consequently 
affording poor NMR visibility, spinning at high rates may facilitate their release into more 
fluid environments, thereby increasing their mobility and signal intensities. This effect is 
corroborated by the fact that signal intensities remained high when the spinning rate was 
decreased back to 4 kHz (Figure 3.2). A similar observation has been previously noted for 
other tissue types (Martinez-Granados et al. 2006; Swanson et al. 2008; Opstad et al. 
2008). On the other hand, lipid resonances showed higher intensity in the spectrum 
recorded at 8 kHz than in the subsequent spectrum at 4 kHz (Figure 3.2), which is 
consistent with the anisotropic effects affecting their visibility, as previously explained. 
Another variation observed in the spectra recorded at different spinning rates regards 
the small shift to lower frequencies in the water resonance (ca. 0.07 ppm) and in some 
metabolite signals, namely lactate, choline-containing metabolites, creatine and taurine 
(0.001-0.003 ppm). This shift is likely to reflect the increase in temperature arising from 
frictional heating with increasing SR, as temperature influences the strength of hydrogen 
bonds, thus proton shielding and chemical shifts. Indeed, by using Equation 3.1 (Garrod et 
al. 1999), the sample temperature was found to vary in the range 290-291 K for SR below 
5 kHz, and to increase to 293 and 296 K for SR 6 and 8 kHz, respectively. 
 
                           
Equation 3.1 
 
where                          . 
Based on the results presented above, 4 kHz was the spinning rate chosen for 
HRMAS analysis of all tissue samples, as it represented a good compromise between 
reduction of anisotropic interactions, preservation of tissue integrity and also exclusion of 
spinning side bands from the spectral region of interest, as for low SR (1-3 kHz) these 
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were located below 9 ppm, adding an extra difficulty to the analysis of an already complex, 
highly overlapped spectrum. 
 
3.1.2 Stability of NMR spectral profiles during acquisition at different 
temperatures 
The temperature used for storage and spectral acquisition of tissue samples is of 
paramount importance, as the excised tissue is no longer under the enzymatic control of the 
body, and both enzymatic and chemical degradation of metabolites may occur. So, after 
excision, lung tissue samples were immediately snap-frozen in liquid nitrogen and kept at   
-80 ºC until analysis. Samples used in this study were only thawed once just before NMR 
experiments, so no freeze-thaw effects were expected. Nonetheless, chemical and 
enzymatic reactions in tissue may become active once the sample is thawed and prepared 
for NMR analysis. Therefore, it is important to assess the extension of the metabolic 
variations during data acquisition, in order to ensure that the metabolic profiles are not 
strongly affected by uncontrolled degradation effects. In this work, great care was taken to 
keep the time between sample preparation and spectral recording as short and similar as 
possible for all samples (about 5 min at room temperature for rotor assembling and 10-15 
min below 10 ºC for temperature stabilisation and optimization of NMR acquisition). 
Moreover, as recommended in the literature for other tissue types (Sitter et al. 2009), 
spectra were recorded at 277 K (4 ºC). As shown by the results presented below, this 
allowed the alterations in metabolite levels during acquisition time to be significantly 
minimized.  
Tissue sample stability in the spectrometer was assessed by acquiring consecutive 
spectra during 5 hours for two fragments of the same lung tissue sample, one analysed at 
277 K and the other at 293 K (SR 4 kHz in both cases). Then, PCA was applied to these 
spectra in order to highlight the main sources of variability. The resulting PC1 vs. PC2 
scores scatter plot (Figure 3.3a) shows the separation between the two datasets (acquired at 
277 and 293 K) in PC1 (mainly due to the temperature-related drifts in some peaks, as 
discussed in the previous section), while the distribution along PC2 reflects spectral 
changes with time. The dispersion of spectra along PC2 was much higher for the 293 K set 
than for the 277 K set, which is an indication of the larger variation in spectral profiles 
(i.e., reduced sample stability) at higher temperatures, as expected.  
CHAPTER 3 – METABOLIC PROFILING OF LUNG TUMOURS BY TISSUE NMR METABOLOMICS 
 
94 
 
 
Figure 3.3 PCA of consecutive standard 1D 
1
H HRMAS spectra (δ 0.5-4.5) of two fractions of the 
same lung sample recorded at 277 K (black) and 293 K (grey): a) PC1 vs. PC2 scores scatter plot 
and b) PC2 loadings plot. (GPC, glycerophosphocholine; PC, phosphocholine). 
 
Inspection of PC2 loadings (Figure 3.3b) showed that phosphocholine and 
glycerophosphocholine decreased with time, whereas choline and several amino acids 
(alanine, valine, glycine, isoleucine) increased. Spectral integration was then employed to 
verify the magnitude of these variations, as shown in Figure 3.4. Notably, at 293 K, both 
GPC and PC decreased steadily by 10-11% over five hours, while choline increased 15%. 
These variations suggest PC and GPC degradation to choline, as already observed in 
prostate and brain tissues (Swanson et al. 2006; Swanson et al. 2008; Opstad et al. 2008). 
Moreover, several amino acids (glycine, alanine, valine, and isoleucine) exhibited a 
variation of 25-37% at 293 K after 5 h, possibly reflecting proteolytic activity in the tissue. 
Other variations such as those of lipids, lactate, acetate, myo- and scyllo-inositol were 
found to be residual (<5%) during the time window considered. At 277 K, on the other 
hand, the changes over five hours in choline-containing compounds were lower than 5%, 
and the only noticeable changes were seen for amino acid levels (15-23% increase) (Figure 
3.4). 
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Figure 3.4 Variation (%) of the integrals of choline-containing compounds and amino acids during 
acquisition of standard 1D 
1
H HRMAS spectra for 5 hours at SR 4 kHz and two different 
temperatures, 277 K (black) and 293 K (grey), with respect to the first spectrum (time 0). 
 
Stability at 277 K for up to eight hours (SR 4 kHz) was further verified for three 
additional tissue samples and the integrals of selected metabolites were measured in 
spectra recorded at different time points (1.5, 5 and 8 h). The results obtained are expressed 
in Figure 3.5 as a heatmap colour-coded as a function of the percentage of variation 
relative to the initial spectrum (time 0 h). Generally, after 1.5 h, metabolite variations were 
below 10% for all samples, with exception of alanine, glycine and valine. At longer times 
of sample spinning (up to 8 h), amino acids registered the largest variations, while 
metabolites like lactate, taurine, myo-inositol and PC remained reasonably stable. Overall, 
these results highlight the importance of controlling sample acquisition time and shows 
that within the time window used to record the 1D experiments for quantification/ 
multivariate purposes (1.5 h), tissue stability was fairly maintained, therefore ensuring that 
spectral profiles were not significantly affected by sample degradation. It should also be 
noted that 2D spectra with longer acquisition times were exclusively used for assignment 
purposes.  
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Figure 3.5 Heatmap showing metabolite variations in three tissue samples as function of time in 
the spectrometer (HRMAS 4 kHz, 277 K). The colour code reflects the percentage of variation 
relative to the initial spectrum (time 0 h). 
 
3.1.3 Use of relaxation- and diffusion-edited experiments to deal with spectral 
overlap 
As already mentioned, the standard 1D spectra of lung tissues shows the 
contributions of both small metabolites and macromolecular and/or mobility-restricted 
components, the latter originating broad resonances and a broad background on the 
baseline. In order to reduce spectral complexity and overlap, relaxation- and diffusion-
edited experiments were recorded to selectively detect small metabolites and 
macromolecular components, respectively. In particular, the CPMG experiment (explained 
in section 1.3.2.5) was used to attenuate the signals of fast-relaxing molecules such as 
lipids (which, as shown in Annex VI, exhibit shorter T2 time constants). In order to choose 
the most appropriate echo time (2ηn), a series of tests varying the spin echo delay (η) and 
the number of loops (n) was performed. As shown in Figure 3.6, lipid resonances could not 
be fully attenuated without a concomitant large decrease in small metabolite signals, thus 
indicating that the lipid moieties detected had relatively high mobility. Using a total echo 
1.5 h 5 h 8 h 1.5 h 5 h 8 h 1.5 h 5 h 8 h
Sample 1 Sample 2 Sample 3
%
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time of 90 ms, about 50 % reduction of lipid fatty acyl chain resonances was obtained 
compared to the standard 1D spectra, enabling the visibility of narrow signals from low Mw 
metabolites to be improved (Figure 3.7a, b). Therefore, this value was selected for 
recording all CPMG spectra. Similar values have been reported in the literature for lung 
and other tissue types (Imperiale et al. 2011; Yang et al. 2013; Benahmed et al. 2013). 
 
 
Figure 3.6 Integral areas of lipid (CH3) and glycine signals, obtained for different total echo times 
(2ηn) of the CPMG experiment. 
 
Oppositely, the diffusion-edited experiment (described in subchapter 1.3.2.5) selects 
the signals of slow-diffusing macromolecules, such as lipids and peptides. Under the 
conditions selected for this experiment – diffusion time of 100 ms and diffusion gradient 
length of 2 ms, which agree with the values recommended in the literature (Beckonert et al. 
2010) – almost all small metabolite signals were attenuated (Figure 3.7c). However, 
residual signals of lactate and some amino acids (e.g., alanine, taurine) could still be 
observed, indicating their restricted mobility. 
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Figure 3.7 Typical 600 MHz 
1
H HRMAS NMR spectra of lung tumour tissue, used for spectral 
assignment: a) standard 1D, b) CPMG, c) diffusion-edited. Metabolites are numbered in 
accordance with Table 3.2. 
 
 
 
a) 
b) 
c) 
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3.2 Metabolic composition of human lung tissues: spectral assignment 
based on 1D and 2D NMR experiments 
The metabolic composition of intact lung tissue was firstly reported in the literature 
by our group (Rocha et al. 2010), based on the thorough interpretation of 1D and 2D 
HRMAS spectra. Besides the complementary three 1D experiments mentioned above, the 
following 2D experiments have been recorded for selected samples: i) 
1
H-
1
H TOCSY, 
useful for revealing intramolecular spin-spin connectivities; ii) 
1
H-
13
C HSQC, helpful to 
identify singlets or aid the assignment of crosspeaks still overlapped in TOCSY (taking 
advantage of the larger chemical shift dispersion of 
13
C resonances); and iii) J-resolved, 
also very helpful in reducing signal overlap and allowing for information on signal 
multiplicity to be obtained. Figure 3.8 illustrates expansions of typical 2D NMR spectra 
with some assignments indicated. Table 3.2 shows the complete list of compounds 
identified, along with their 
1
H and 
13
C chemical shifts, measured in 1D and 2D HRMAS 
spectra.  
The broad resonances dominating the low-frequency region (δ 0-3) arise mainly from 
lipids, as viewed by the characteristic spin systems of fatty acyl chains found in the 
TOCSY spectrum (Figure 3.8a) and further confirmed by the 
13
C chemical shifts in the 
HSQC spectrum (Figure 3.8b). Peptides are also thought to contribute to the broad profile 
of lung tissues due to the observation of several spin systems (identified in the TOCSY 
spectrum) with patterns slightly shifted from those of free amino acids; in particular, and in 
agreement with published data (Tugnoli et al. 2006), the broad signals centred at δ 4.1-4.4, 
which show spectral correlations to signals in the low-frequency region, are assigned to α-
CH protons of different amino acid residues bonded in a peptidic chain (Figure 3.8a and 
Table 3.2). In addition, some broad resonances in the high-frequency region (δ 6.98, 7.72 
and 8.25-8.75) showed strong STOCSY correlations between each other and with this 
region of α-protons at δ 4.1-4.4, thus suggesting their assignment to backbone and lateral 
chain NH protons (Figure 3.9a). While these protons are expected to be NMR-invisible in 
the solution state, due to rapid chemical exchange with water, their detection in tissue 
indicates a slower exchange rate, possibly in relation with high intracellular viscosity and 
reduced solvent accessibility. 
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Figure 3.8 Expansions of 2D 
1
H HRMAS NMR spectra (600 MHz) of lung tumour tissue, used for 
spectral assignment: a) 
1
H-
1
H TOCSY, b) 
1
H-
13
C HSQC, c) J-resolved. Metabolites are numbered 
in accordance with Table 3.2. 
a) 
b) 
c) 
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Table 3.2 Assignment of resonances in the 500/600 MHz 
1
H NMR spectra of lung tissue; (s, 
singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, double doublet; br, broad). Metabolites 
which, to our knowledge, are newly reported in this work to be present in human lung tissue are 
indicated with an asterisk. 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
1 Acetate  1.93 (s, βCH3)/27.62 
2 Alanine  1.48 (d, βCH3)/19.00; 3.78(q, αCH)/53.41 
3 Alanine (bonded)*  1.41 (d, βCH3)/19.45; 4.31(αCH) 
4 β-Alanine*  2.56 (t, βCH2); 3.18(t, αCH2) 
5 Arginine  1.69 (m, CH2)/26.51; 1.92 (m, CH2)/30.68; 3.24 (t, CH2)/43.31; 
3.78 (CH)/57.39 
6 Ascorbate  3.75 (CH2(OH))/65.38; 4.03 (CH(OH))/72.60; 4.53 (d, C1H)/81.25 
7 Asparagine  2.87 (dd, βCH)/37.35; 2.95 (dd, β‟CH)/37.35; 4.01 (dd, αCH)/54.25 
8 Aspartate  2.69 (dd, βCH)/39.40; 2.82 (dd, β‟CH)/39.40; 3.90 (dd, αCH)/55.17 
9 Aspartate (bonded)*  2.69 (dd, βCH); 2.89 (dd, β‟CH); 4.27 (dd, αCH) 
10 Carnitine  2.44 (m, CH2); 3.45 (m, αCH2) 
11 Choline  3.21 (s, N(CH3)3)/56.75; 3.53 (m, CH2(NH))/70.38; 4.07 (m, 
CH2(OH))/58.63 
12 Citrate   2.52 (d, , CH2); 2.68 (d, ', ‟CH2) 
13 Creatine  3.03 (s, CH3)/40.05; 3.94 (s, CH2)/56.47 
14 Ethanolamine  3.14 (t, CH2(NH2))/41.91; 3.82 (t, CH2(OH))/59.35 
15 Fatty acyl chain 
peaks 
 0.90/0.96 (br,CH3)/16.85/25.48/21.36; 1.29 (br, (CH2)n)/25.20/32.42/ 
34.55; 1.58 (br, CH2-CH2-CO)/25.02; 2.04/2.08 (br, CH=CH-CH2-
CH2)/27.43; 2.25 (br, CH2-CO)/36.43; 2.81 (br, CH=CH-CH2)/28.31; 
5.32 (br, CH=CH)/131.06 
16 Formate*  8.46 (s, CH) 
17 Fumarate  6.52 (s, CH) 
18 α-Glucose  3.40 (t, C4H)/72.48; 3.54 (dd, C2H)/74.10; 3.71 (t, C3H)/75.58; 3.83 
(m, C6H)/63.33; 3.85 (m, C5H)/74.85; 5.24 (d, C1H)/94.9 
19 β-Glucose  3.24 (dd, C2H/77.09; 3.41 (t, C4H)/72.48; 3.47 (dd, C5H)/78.64; 3.49 
(t, C3H)/78.24; 3.74 (dd, C6H)/63.98; 3.90 (m, C6‟H)/63.98; 4.65 (d, 
C1H)/98.78 
20 Glutamate  2.06 (m, βCH)/29.87; 2.13 (m, β‟CH)/29.87; 2.35 (m, CH2)/36.16; 
3.78 (t, αCH)/57.38 
21 Glutamate (bonded)*  1.95 (βCH); 2.04 (β‟CH); 2.30 (CH2); 4.30 (αCH) 
22 Glutamine  2.15 (m, βCH2)/ 29.52; 2.45 (m, CH2)/ 33.65; 3.79 (t, αCH)/57.38 
23 Glutathione (GSH)  2.18 (βCH2 Glu); 2.56 (γCH2 Glu); 2.96 (βCH2 Cys); 3.80 (αCH Gly, 
αCH Glu); 4.58 (αCH Cys); 8.56 (NH Cys); 8.37 (NH Gly) 
24 Glycerol  3.56/3.65 (dd, C1H2/C3H2)/65.29; 3.78 (dd, C2H)/75.12 
25 Glyceryl of lipids  4.09, 4.30 (br, C1H2/C3H2); 5.23 (br, C2H) 
26 Glycerophosphoetha
-nolamine (GPE)* 
 3.30 (CH2(N)); 4.11 (CH2(P)) 
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Table 3.2 (continued) 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
27 Glycerophospho 
-choline (GPC) 
 3.23 (s, N(H3)3)/56.75; 3.71 (‟CH2(N)/68.80; 4.33 
(‟CH2(P))/62.29 
28 Glycine  3.56 (s, αCH2)/68.6923 
29 Glycogen  3.62 (C2H); 5.43 (C1H) 
30 Histidine  7.28 (s, C4H, ring); 8.08 (s, C2H, ring) 
31 -Hydroxybutyrate  1.20 (d, CH3)/21.49 
32 Hypotaurine  2.65 (t, βCH2); 3.35 (t, αCH2) 
33 Hypoxanthine  8.18 (s, C2H); 8.21 (s, C8H) 
34 Inosine/Adenosine  3.86 (C5‟,5‟‟H, ribose); 4.28 (C4‟H, ribose); 4.44 (C3‟H, ribose); 4.78 
(t, C2‟H, ribose);6.10 (d, C1‟H, ribose); 8.23 (s, C2H, ring); 8.36 (s, 
C8H, ring) 
35 myo-Inositol  3.28 (t, C5H)/77.16; 3.54 (C1H, C3H)/74.10; 3.62 (C4H, C6H)/75.30; 
4.06 (t, C2H) 
36 scyllo-Inositol  3.35 (s, CH)/76.70 
37 Isoleucine  0.94 (t, CH3)/13.97; 1.01 (d, ‟CH3)/17.45; 1.26 (m, CH)/27.06; 
1.47 (m, γ‟CH)/27.06; 1.99 (m, βCH)/38.81; 3.65(m, CH)/62.40 
38 Lactate   1.33 (d, βCH3)/20.89; 4.12 (q, αCH)/71.41 
39 Leucine  0.96 (d, CH3)/23.64; 0.97 (d, ‟CH3)/24.93; 1.70 (m, CH)/27.05; 
1.72 (m, βCH2)/42.65; 3.74 (t, CH)/56.10 
40 Lysine  1.47 (m, CH2)/24.28; 1.73 (m, CH2)/29.20; 1.92 (m, βCH2)/32.75; 
3.03 (t, CH2)/42.00; 3.76 (t, αCH)/57.34 
41 Lysine (bonded)*  1.56 (CH2); 1.75 (CH2)/33.37; 1.83 (βCH2); 3.16 (CH2); 4.17 (αCH) 
42 Methionine  2.13 (s, S-CH3)/16.75; 2.14 (m, CH)/32.54; 2.21 (m, ‟CH)/32.54; 
2.64 (t, CH2)/31.51; 3.87 (dd, αCH) 
43 Peptides*  6.98 (br), 7.72 (br), 8.53 (br) 
44 Phenylalanine  3.13 (dd, CH)/39.40; 3.27 (dd, ‟CH)/39.40; 3.99 (dd, CH)/58.98; 
7.32 (m, C2H, C6H, ring)/132.36; 7.37 (m, C4H, ring)/130.42; 7.42 
(C3H, C5H, ring)/132.09 
45 Phosphocholine  3.22 (s, N(CH3)3)/56.75; 3.62 (N-CH2)/69.09; 4.19 (PO3-CH2)/60.92 
46 Phosphoethanol-
amine 
 3.23 (t, N(CH2))/57.39; 3.98 (PO3-CH2)/63.89 
47 Polyamines*  1.79; 2.11; 3.03; 3.14 
48 Proline  2.01 (CH2)/26.69; 2.07 (βCH)/31.89; 2.35 (β‟CH)/31.89; 3.34 
(CH)/48.95; 3.42 (‟CH)/48.95; 4.13 (αCH)/64.10 
49 Proline (bonded)*  1.91 (CH2); 2.03 (βCH)/34.39; 2.32 (β‟CH)/34.39; 3.69 (CH)/ 
65.70; 3.83 (‟CH)/65.70; 4.44 (αCH) 
50 Serine  3.85 (αCH2)/59.34; 3.95 (dd, βCH)/63.25; 3.99 (dd, β‟CH)/63.25 
51 Taurine  3.26 (t, S-CH2)/50.34; 3.43 (t, N-CH2)/38.20 
52 Threonine  1.34 (d, CH3)/19.81; 3.59 (d, αCH)/63.25; 4.26 (m, βCH)/68.72 
53 Threonine (bonded)*  1.22 (d, CH3); 4.26 (d, αCH) 
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Table 3.2 (continued) 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
54 Tyrosine  3.20 (dd, βCH); 3.05 (dd, β‟CH); 3.94 (αCH)/59.26; 6.89 (d, C3H, 
C5H, ring)/118.66; 7.18 (d, C2H, C6H, ring)/133.75 
55 Uracil  5.80 (d, C5H, ring); 7.53 (d, 6H, ring) 
56 Uridine  4.13 (C4‟H, ribose); 4.23 (C3‟H, ribose); 4.35 (C2‟H, ribose); 
5.89/5.92 (d, C1‟H, ribose/C5H, ring) 7.89 (d, C6H, ring) 
57 UDP/UTP  5.97 (C1‟H, ribose); 7.97 (C6H, ring) 
58 Valine  0.99 (d, CH3)/19.45; 1.04 (d, ‟CH3)/20.75; 2.28(m, βCH)/31.99; 
3.62 (d, αCH)/63.34 
59 Valine (bonded)*  0.94 (CH3); 4.11 (αCH) 
 
Reduced glutathione (GHS), a tripeptide of glutamate, cysteine and glycine, was also 
unambiguously identified through the TOCSY correlations between α and β protons of 
glutamate and cysteine, and between α and amide protons of cysteine and glycine. 
Moreover the STOCSY plot obtained when using the glutamate γCH2 signal as driver peak 
(δ 2.56) further confirmed this assignment, as strong correlation was found between all 
signals attributed to GSH, including the NH signals in the high-frequency region (Figure 
3.9b). STOCSY was also useful to corroborate the assignment of glycogen, a 
polysaccharide of glucose, as, in addition to the TOCSY crosspeak between δ 5.43 
(attibuted to C1H of α1→4 linked glucose units) and δ 3.6 (C2H, C4H), strong STOCSY 
correlations were found between the driver peak at δ 5.43 and signals around δ 3.8 (C5H, 
C6H) (Figure 3.9c), thus agreeing with literature (Bollard et al. 2000). 
In terms of low molecular weight metabolites, more than twenty amino acids were 
identified, together with some organic acids (e.g., acetate, lactate, citrate, formate, β-
hydroxybutyrate), nucleosides/nucleotides, glucose, and inositols (Table 3.2). Several 
ethanolamine and choline compounds were also detected, the J-resolved experiment being 
particularly useful in this respect, since the overlapping signals in the δ 3.2-3.3 region were 
clearly separated in the J-resolved spectrum (Figure 3.8c). In total, over fifty compounds 
were identified, together with eight unknown spin systems present in TOCSY and HSQC, 
thus providing valuable information on the metabolic composition of lung tissue and 
setting the basis for interpreting the cancer-related variations discussed in the next 
subchapters. 
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Figure 3.9 STOCSY correlation plots of standard 1D spectra (tumour n 57) of driver peaks: a)  
6.98, b)  2.56 and c)  5.43, used for the assignment of small peptides, reduced glutathione (GSH) 
and glycogen, respectively. 
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3.3 General metabolic features of lung tumour tissues 
The following sections present the NMR metabolic profiles of lung tumour tissues, 
when compared to control tissues and when taking into account different factors, namely 
the percentage of tumour cells, necrosis and tumour stage. 
 
3.3.1 Differentiation between tumour and control tissues 
Figure 3.10 shows the average 
1
H HRMAS NMR spectra of lung tumours and their 
corresponding adjacent non-involved tissues (controls). Visual comparison of the two 
spectra allowed several differences to be anticipated, namely in the levels of lactate, lipids, 
phosphocholine (PC), glycerophosphocholine (GPC), creatine, taurine and glutathione 
(GSH) (increased in tumours), and of acetate and glucose (decreased in tumours). 
Additionally, the majority of tumours presented higher intensity of broad signals in the 
aromatic region, probably arising from peptides (as previously discussed). 
 
 
Figure 3.10 Average standard 1D 
1
H HRMAS NMR spectra of non-involved lung tissues (n 56, 
green) and lung tumour tissues (n 57, red), after PQN normalisation. 
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The metabolic features differentiating tumour and control tissues were further 
investigated by multivariate analysis. Firstly, PCA and PLS-DA were applied to the 
standard 1D spectra of lung controls (n 57) and tumours (n 58). The resulting PCA scores 
scatter plot (Figure 3.11a) already shows a trend for separation between the two tissue 
types, which becomes clearer when PLS-DA is applied (Figure 3.11b). 
PLS-DA model robustness was then verified by MCCV and permutation testing, 
with prediction results being plotted in the ROC space (Figure 3.11c). Whilst the original 
models (true classes assigned) showed 96.1% sensitivity, 97.8% specificity and an overall 
classification rate of 96.9% (Table 3.3), random permutation of class membership resulted 
in a decrease of these parameters to values of no discrimination (approximately 50%). 
Moreover, the Q
2
 values obtained for the original model showed a high median (Q
2
 0.83) 
and a distribution clearly distinct from that obtained for models in which classes were 
permuted (Figure 3.11d), therefore confirming the predictive power of the original model. 
The thorough inspection of PLS-DA LV1 loadings coloured according to variable 
importance in the projection (VIP) (Figure 3.11e) allowed the main compounds 
contributing for tissue discrimination to be identified. Lactate, alanine, glutamate, GSH, 
creatine, taurine, PC, GPC, phosphoethanolamine (PE), uridine di/triphosphate 
(UDP/UTP) and peptide moieties (with negative loadings) were increased in tumours, 
whereas acetate and glucose (positive loadings) were decreased.  
PCA and PLS-DA were also performed using the CPMG and diffusion-edited 
experiments. Again, separation between tumour and control tissue was observed and 
MCCV validated the PLS-DA models obtained, although with inferior classification 
parameters, especially when using the diffusion-edited data (Table 3.3). The PLS-DA 
loadings of the CPMG data (not shown) revealed the same variations as observed when 
using the standard 1D experiment as input for multivariate analysis, although showing 
lower importance for the partially attenuated broad resonances (namely those in the 
aromatic region). Conversely, the PLS-DA loadings of the diffusion-edited model (not 
shown) revealed mainly variations in small metabolites that had not been completely 
attenuated, such as lactate, taurine, alanine, PC and GPC, not adding further information. 
Therefore, the standard 1D experiment was selected for further assessment of lung 
tumours‟ metabolic profile. 
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Figure 3.11 MVA applied to the standard 1D 
1
H HRMAS NMR spectra of lung control (n 57) and 
tumour (n 58) tissues: a) PCA and b) PLS-DA scores scatter plot. The parameters shown on the 
scores plot (PC: principal component, LV: latent variable, R
2
X: variation explained by the X matrix, 
R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive from default 7-fold cross 
validation. c) ROC space (TPR: true positive rate; FPR: false positive rate) and d) Q
2
 histogram 
obtained by MCCV and permutation testing (500 iterations) of the PLS-DA model. e) PLS-DA 
LV1 loadings weights coloured as a function of VIP. Metabolites showing VIP>1 are assigned in 
the plot. (GPC: glycerophosphocholine; GSH: reduced glutathione; PC: phosphocholine; PE: 
phosphoethanolamine; UDP/UTP: uridine di/triphosphate; Un.: unknown).  
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Table 3.3 Prediction results obtained by MCCV (500 iterations) of PLS-DA models assessing the 
discrimination between lung tumour and control tissues. 
PLS-DA models Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Standard 1D 0.83 96.1 97.8 96.9 
CPMG 0.77 93.9 96.6 95.2 
Diffusion-edited 0.55 77.0 87.6 82.3 
13 integrals 0.72 95.6 98.6 97.1 
 
The integrals of all metabolite signals with VIP>1 assigned in Figure 3.11e showed 
statistically significant differences (p<0.004, Bonferroni-corrected) and absolute effect 
sizes greater than 0.5, thus confirming their importance in the discrimination between 
tumour and control tissues. The percentages of variation for each discriminant metabolite 
are presented in Table 3.4 and corresponding boxplot representations are shown in Figure 
3.12.  
 
Table 3.4 Metabolites showing statistically significant differences between lung tumour and 
control tissues. For each metabolite, the average percentage and coefficient of variation were 
obtained by spectral integration of selected signals. Effect sizes and p-values are shown, indicating, 
respectively, the magnitude and statistical significance of the differences. (s: singlet; d: doublet; t: 
triplet; q: quartet; m: multiplet; br: broad). 
Metabolite 
(δ, multiplicity) 
All tumour types (56 pairs)  
% variation  effect size p-value
a
 
Acetate (1.92, s) -57.0±17.2 -0.88±0.39 3.3×10
-6
 
Alanine (1.48, d) 37.1±5.3 1.1±0.40 1.2×10
-6
 
Creatine (3.93, s) 63.9±7.3 1.2±0.40 1.2×10
-8
 
Glucose (4.65, d) -46.3±6.8 -1.7±0.43 7.9×10
-10
 
Glutamate (2.35, m) 38.7±3.8 1.6±0.43 5.8×10
-10
 
GPC (3.23, s) 118.4±10.7 1.3±0.41 5.0×10
-8
 
GSH (2.16, m) 42.8±5.4 1.2±0.40 2.3×10
-9
 
Lactate (4.12, q) 95.6±5.1 2.4±0.49 8.2×10
-11
 
PC (3.22, s) 177.4±18.7 0.95±0.39 6.5×10
-9
 
PE (3.98, m) 30.9±4.5 1.1±0.40 2.0×10
-7
 
Taurine (3.42, t) 56.0±7.3 1.1±0.40 6.6×10
-7
 
UDP/UTP (5.96, m) 255.2±17.4 1.2±0.40 6.3×10
-9
 
Peptide (7.72, br) 17.8±5.8 0.54±0.38 2.2×10
-4
 
a
 Wilcoxon signed rank test p<0.004 (Bonferroni-corrected). 
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Figure 3.12 Boxplots representing the median, 1
st
 and 3
rd
 quartiles (Q1 and Q3), minimum and 
maximum of integral values of selected signals (PQN-normalized) for control (n 57) and tumour (n 
58) tissues. The points above the maximum [>Q3 + 1.5(Q3 - Q1)] or below the minimum [<Q1 - 
1.5(Q3 - Q1)] are outliers. 
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Further confirmation of the discriminatory power of this panel of metabolites was 
achieved by performing PLS-DA of their integrals, as model robustness and accuracy were 
maintained (Table 3.3 and Figure 3.13), with an overall classification rate of 97%. 
 
 
Figure 3.13 PLS-DA applied to 13 selected integrals measured in the standard 1D 
1
H HRMAS 
NMR spectra from lung control (n 57) and tumour (n 58) tissues: a) scores scatter plot and b) LV1 
loadings. The parameters shown on the scores plot (LV: latent variable, R
2
X: variation explained by 
the X matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive from default 
7-fold cross validation. c) ROC space (TPR: true positive rate; FPR: false positive rate) and d) Q
2
 
histogram obtained by MCCV and permutation testing (500 iterations) of the PLS-DA model. 
(GPC: glycerophosphocholine; GSH: reduced glutathione; PC: phosphocholine; PE: 
phosphoethanolamine; UDP/UTP: uridine di/triphosphate). 
 
3.3.2 Impact of the percentage of tumour cells and necrosis on tumour 
metabolic profile 
As the amount of tumour cells on mirror sections of samples analysed by NMR was 
found to vary between 5 and 99% (Table A6, Annex IV), median and mode values being 
50% and 90%, respectively, the possible influence of such variability on tumours‟ 
-3
-2
-1
0
1
2
3
4
5
-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6
L
V
2
 (
1
0
.5
%
)
LV1 (39.7%)
Control Tumour
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
P
L
S
-D
A
 L
V
1
 l
o
a
d
in
g
s
 w
0%
10%
20%
30%
40%
50%
60%
F
re
q
u
e
n
c
y
Q2 values
True classes Permuted classes
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0.0 0.2 0.4 0.6 0.8 1.0
T
P
R
 (
s
e
n
s
it
iv
it
y
)
FPR (1-specificity)
True classes Permuted classes
-350
-250
-150
-50
50
150
250
-400 -200 0 200
P
C
2
 (
1
6
.9
%
)
PC1 (19.1%)
Control Tumour
-350
-250
-150
-50
50
150
250
-400 -200 0 200
P
C
2
 (
1
6
.9
%
)
PC1 (19.1%)
Control Tumour
LV=2
R2X=0.50
R2Y=0.77
Q2=0.73
a) b) 
c) d) 
CHAPTER 3 – METABOLIC PROFILING OF LUNG TUMOURS BY TISSUE NMR METABOLOMICS 
111 
metabolic composition was addressed by PLS1 regression, considering either the full 
spectral profile or the set of 13 discriminant metabolites (listed in Table 3.4). The resulting 
Q
2
 values were very low (about 0.1 in both cases), thus indicating that the metabolic 
profiles of tumour tissues were not strongly determined by the varying proportions of 
stromal and tumour cells on each sample. Moreover, the possible correlation between the 
NMR spectral profiles and the amount of necrotic tissue (Table A6, Annex IV) was also 
investigated through PLS1 regression analysis. The resulting model (n 53) showed a 
reasonable predictive power (Q
2
 of 0.48 for 2 latent variables), with the majority of less 
necrotic samples located in negative LV1 and samples with higher percentage of necrosis 
distributed towards positive LV1 (Figure 3.14a). The corresponding VIP-coloured loadings 
(Figure 3.14b) indicated that higher lipid levels characterised highly necrotic samples, 
which was confirmed by the significant correlations (p<0.003) found between lipid signal 
areas and % necrosis. Detailed analysis of such correlations further showed the ratio 
CH=CH to -CH3 lipid signals (representing the proportion of unsaturated fatty acids) to be 
only moderately correlated with necrosis (r 0.5, p<0.05). Oppositely to what was observed 
for brain tissues (Sjøbakk et al. 2013), this suggests that no particular change in lipids 
unsaturation is associated with necrosis. 
 
 
Figure 3.14 PLS1 regression analysis of standard 1D 
1
H NMR spectra of lung tumour tissues and 
the amount of necrosis (%) in their respective mirror sections: a) scores scatter plot of the first two 
latent variables, where the diameter of each circle represents the % of necrosis, b) LV1 loadings 
plot coloured as a function of VIP (lipid signals are assigned to specific fatty acyl chain protons, in 
italic). The parameters shown on the scores plot (LV: latent variable, R
2
X: variation explained by 
the X matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive from default 
7-fold cross validation. 
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3.3.3 Impact of stage on tumour metabolic profile 
The impact of stage on the tumour profile has been addressed by building separate 
PLS-DA models for each stage (I: 29 pairs, II: 19 pairs, III: 6 pairs). While the stage III 
model couldn‟t be properly validated, likely due to the low number of samples available, 
the classification rates obtained for discriminating stage I or stage II tumours from their 
respective controls were similar to the one achieved when considering the whole dataset 
(Table 3.5).  
 
Table 3.5 Prediction results obtained by MCCV (500 iterations) of tissue PLS-DA models 
assessing the discrimination between different groups of samples, including different histological 
types (T: tumour; C: control; AdC: adenocarcinoma; SqCC: squamous cell carcinoma). 
PLS-DA classes Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
All samples: C (n 57) vs. T (n 58) 0.83 96.1 97.8 96.9 
Stage I: C (n 29) vs. T (n 29) 0.83 97.9 95.6 96.7 
Stage II: C (n 19) vs. T (n 19) 0.79 94.4 93.3 93.9 
AdC: C (n 19) vs. T (n 19) 0.81 86.5 89.1 87.8 
SqCC: C (n 19) vs. T (n 19) 0.80 98.6 96.8 97.7 
AdC (n 18) vs. SqCC (n 18) 
(T38 and T56 excluded) 
0.47 82.4 80.3 81.3 
AdC (n 18) vs. SqCC (n 18)  
(after variable selection) 
0.58 99.2 89.7 94.3 
AdC (n 18) vs. SqCC (n 18)  
(6 signal areas as variables) 
0.54 90.6 75.3 82.8 
 
Moreover, inspection of the loadings profiles (not shown) revealed that the main 
discriminant features were the same for all stages, with the exception of taurine which did 
not appear important in the discrimination of stage III tumours from their controls. 
Concordantly, no valid discrimination could be achieved between tumour tissues of 
different stages, thus indicating that, in the set of samples studied, the metabolic signature 
of tumour did not change significantly with stage.  
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3.4 Metabolic features of different tumour histological types  
3.4.1 Dependence of tumours’ metabolic behaviour on histological type 
Figure 3.15 shows the average spectra of control tissue and of each tumour 
histological type analysed in this study. Some of the differences between tumour profiles 
are highlighted, suggesting that there may be indeed a relationship between tumour 
histomorphology and metabolic composition. For instance, carcinoids were characterized 
by very low lipid levels and high taurine and peptide abundance, whereas small cell 
carcinomas showed prominently high levels of creatine and myo-inositol together with 
absence of glucose. Regarding the other subtypes, there were also several apparent 
differences, for instance in the relative levels of creatine, PC, GPC, glucose and glycogen. 
However, given the low sample numbers representing most types (≤6 patients), only the 
profiles of adenocarcinomas (AdCs) and squamous cell carcinomas (SqCCs) were further 
investigated in this study, with two main purposes: i) to find out if these two types have 
distinct metabolic behaviour, and ii) to evaluate the potential of using NMR metabolomics 
as an adjunct tool in AdC vs. SqCC differential classification. To address the first goal, the 
discrimination between each of the two histological types and their respective control 
tissues was investigated. MCCV-validated PLS-DA models were obtained for both AdC 
and SqCC compared to controls, with overall classification rates being 87.8 and 97.7%, 
respectively (Table 3.5). The corresponding scores scatter plots, ROC maps, Q
2
 
distributions and loadings are shown in Figure 3.16 (a-d for AdC and e-h for SqCC). 
Interestingly, VIP-couloured PLS-DA loadings showed that the importance of 
several metabolites in tumour vs. control discrimination differed between the two types 
(AdC and SqCC), which was indeed confirmed by spectral integration, as shown in Table 
3.6. For instance, adenocarcinomas showed higher increases in PC, GPC, PE, UDP/UTP 
and peptides, together with a higher decrease in acetate, whereas squamous cell carcinomas 
were characterized by higher increases of lactate, glutamate, alanine, GSH and creatine, 
together with a more pronounced decrease of glucose (Table 3.6). 
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Figure 3.15 Average standard 1D 
1
H HRMAS NMR spectra of lung control and tumour tissues of 
different histological types. Some apparent metabolite differences are indicated (FA: fatty acyl 
chains in lipids, PC: phosphocholine, * ethanol contamination). 
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Figure 3.16 Scores scatter plots, ROC spaces, Q
2
 histograms and LV1 loadings plots (coloured as a 
function of VIP) resulting from applying PLS-DA and MCCV (500 iterations) to the standard 1D 
1
H HRMAS NMR spectra of tumour tissues from squamous cell carcinoma (a-d) or 
adenocarcinoma (e-h) and their paired controls. The parameters shown on the scores plots (LV: 
latent variable, R
2
X: variation explained by the X matrix, R
2
Y: variation explained by the Y matrix, 
Q
2
: predictive power) derive from default 7-fold cross validation. (GPC: glycerophosphocholine; 
GSH: reduced glutathione; PC: phosphocholine; PE: phosphoethanolamine; UDP/UTP: uridine 
di/triphosphate; Un.: unknown). 
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Table 3.6 Metabolites showing statistically significant differences between lung tumours and 
control tissues, considering all samples (2
nd
 column), only adenocarcinomas (3
rd
 column) and only 
squamous cell carcinomas (4
th
 column). For each metabolite, the average percentage and 
coefficient of variation were obtained by spectral integration of selected signals. Effect sizes and p-
values are shown, indicating, respectively, the magnitude and statistical significance of the 
differences. (s: singlet; d: doublet; t: triplet; q: quartet; m: multiplet; br: broad; GPC: 
glycerophosphocholine; GSH: reduced glutathione; PC: phosphocholine; PE: 
phosphoethanolamine; UDP/UTP: uridine di/triphosphate). 
Metabolite 
(, multiplicity) 
All tumour types  
(56 pairs)  
Adenocarcinoma 
(19 pairs) 
Squamous cell 
(19 pairs) 
% 
variation  
effect size p-value
a
 
% 
variation  
effect size p-value
a
 
% 
variation  
effect size  p-value
a
 
Acetate (1.92, s) -57.0±17.2 -0.88±0.39 3.3×10-6 -61.9±22.2 -1.3±0.70 1.3×10-4 n.s. 
Alanine (1.48, d) 37.1±5.3 1.1±0.40 1.2×10-6 n.s. 46.9±7.7 1.6±0.73 1.6×10-4 
Creatine (3.93, s) 63.9±7.3 1.2±0.40 1.2×10-8 28.2±6.7 1.2±0.69 6.4×10-4 126.4±12.1 2.1±0.79 3.8×10-6 
Glucose (4.65, d) -46.3±6.8 -1.7±0.43 7.9×10-10 -29.3±10.8 -1.0±0.68 2.0×10-3 -51.4±11.4 -2.0±0.77 3.8×10-6 
Glutamate (2.35, m) 38.7±3.8 1.6±0.43 5.8×10-10 24.2±5.8 1.2±0.69 4.2×10-4 55.8±6.1 2.3±0.82 3.8×10-6 
GPC (3.23, s) 118.4±10.7 1.3±0.41 5.0×10-8 115.2±15.8 1.5±0.72 2.1×10-4 n.s. 
GSH (2.16, m) 42.8±5.4 1.2±0.40 2.3×10-9 n.s. 72.5±9.9 1.7±0.75 3.8×10-6 
Lactate (4.12, q) 95.6±5.1 2.4±0.49 8.2×10-11 84.8±7.4 2.6±0.86 3.8×10-6 121.8±9.1 2.7±0.88 3.8×10-6 
PC (3.22, s) 177.4±18.7 0.95±0.39 6.5×10-9 216.3±21.5 1.6±0.73 1.6×10-4 37.5±11.6 0.88±0.67 2.0×10-3 
PE (3.98, m) 30.9±4.5 1.1±0.40 2.0×10-7 32.5±5.8 1.6±0.73 5.2×10-4 n.s. 
Taurine (3.42, t) 56.0±7.3 1.1±0.40 6.6×10-7 n.s. n.s. 
UDP/UTP (.96, m) 255.2±17.4 1.2±0.40 6.3×10
-9 422.2±40.3 1.1±0.68 8.0×10-4 243.7±25.3 1.4±0.71 1.3×10-4 
Peptide (7.72, br) 17.8±5.8 0.54±0.38 2.2×10-4 28.0±9.2 0.87±0.67 2.0×10-3 n.s. 
a
 Wilcoxon signed rank test p<0.004 (Bonferroni-corrected). n.s. not significant. 
 
Examination of dependencies between metabolite variations further complemented 
this analysis, the results being plotted as correlation heatmaps colour-coded by the strength 
of Spearman correlation coefficients (Figure 3.17). A striking observation was that the 
inter-metabolite correlation pattern was clearly different between adenocarcinomas and 
squamous cell carcinomas. In AdC, significant correlations (rS>|0.7|, p<0.001) involved 
mainly phospholipid-related metabolites (PC, GPC and PE), while the SqCC pattern was 
characterized by correlations involving lactate, glucose, glutamate, alanine, GSH and 
creatine.  
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Figure 3.17 Spearman correlation (rS) heatmaps between metabolites found to be important in 
tumour vs. control discrimination: a) adenocarcinoma and b) squamous cell carcinoma. A cut-off 
value of rS>|0.7| and significance of p<0.001 was applied for visualization purposes. 
 
A selected set of graphs showing the quantitative relationship between metabolites 
found to be highly correlated in either AdC or SqCC are presented in Figure 3.18. 
Regarding the levels of GPC or PE vs. PC, significantly correlated in AdCs, the graphs in 
Figure 3.18a and 3.18b reveal that, in spite of the observed scattering, these relationships 
did show a difference between most AdC tumours compared to their respective controls, 
whereas in SqCC the overlap between groups was much higher. In regard to significant 
correlations in SqCC, the negative correlation between glucose and lactate levels was 
 
a) 
b) 
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Figure 3.18 Graphical representation of integral areas for pairs of metabolites showing significant 
Spearman correlations (p<0.001) in either adenocarcinoma (left) or squamous cell carcinoma 
(right), considering control (green) and tumour (red) tissues: a) GPC vs. PC, b) PE vs. PC, c) 
glucose vs. lactate, d) alanine vs. glutamate, e) GSH vs. glutamate. 
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confirmed for tumour samples and found to be less evident in control tissues (Figure 
3.18c). Also, in SqCC (but not in AdC), alanine and glutamate were positively correlated 
and their relationship followed a very clear linear trend which captured group separation 
(Figure 3.18d), a similar behaviour being observed for the glutamate vs. GSH relationship 
(Figure 3.18e).  
 
3.4.2 Potential for differentiating adenocarcinoma from squamous cell 
carcinoma 
For assessing the potential of metabolomics to discriminate between AdC and SqCC, 
multivariate analysis has been applied to their tumour tissue spectra, leaving out control 
tissues. After excluding two clear outliers (AdC T38 and SqCC T56 characterized by very 
high lipids), the resulting PLS-DA model showed moderate accuracy and predictive power 
(classification rate 81.3% and median Q
2
 0.47), as determined by MCCV (Table 3.5). This 
discrimination could, however, be significantly improved by applying the variable 
selection method described in the subchapter 2.3.5, allowing a model with 94.3% 
classification rate and median Q
2
 0.58 to be built. The corresponding PLS-DA scores plot 
and MCCV validation results are shown in Figure 3.19.  
 
 
Figure 3.19 a) Scores scatter plot of PLS-DA applied to the standard 1D 
1
H HRMAS NMR spectra 
from AdC (n 18) and SqCC (n 18) tissues after variable selection. The parameters shown on the 
scores plot (LV: latent variable, R
2
X: variation explained by the X matrix, R
2
Y: variation explained 
by the Y matrix, Q
2
: predictive power) derive from default 7-fold cross validation. b) ROC space 
(TPR: true positive rate; FPR: false positive rate) and c) Q
2
 histogram obtained by MCCV and 
permutation testing (500 iterations) of the PLS-DA model. 
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In the scores scatter plot, most AdC and SqCC samples are separated along LV1, 
with three SqCC samples clustering further away, likely in relation with their higher lipid 
content. Furthermore, because the AdC and SqCC groups compared were unbalanced in 
terms of gender (AdC: 7M/11F and SqCC: 16M/2F), possible gender-related bias has been 
assessed. The PCA scores plot, where a trend for separation of the two types was clear, 
showed no evidence of gender-related clustering (Figure 3.20a, b).  
 
 
Figure 3.20 PCA scores scatter plot of standard 1D 
1
H HRMAS NMR spectra from 
adenocarcinoma (n 18) and squamous cell carcinoma (n 18) tissues, coloured according to a) 
histological subtype and b) gender. The parameters shown on the scores plots (PC: latent variable, 
R
2
X: variation explained by the X matrix) derive from default 7-fold cross validation. c) ROC space 
(TPR: true positive rate; FPR: false positive rate) and d) Q
2
 histogram obtained by MCCV and 
permutation testing (500 iterations) of the PLS-DA model of male vs. female (adenocarcinoma 
only). 
 
Moreover, when considering only adenocarcinoma samples (7M/11F), no valid 
discrimination could be achieved between males and females, as shown by the 
superimposed Q
2
 distributions and ROC spaces of true and permuted models (Figure 3.20c, 
d). Therefore, gender could be excluded as an important confounding factor. In regard to 
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age, the difference between groups was not statistically significant (median age 64 for both 
AdC and SqCC groups), thus reducing the possibility of any age-related bias. Moreover, 
the subjects‟ age was found to have a negligible impact on the tumour tissue profile as 
expressed by the low Q
2
 values (<0.3, expressing the cross-validated variability related to 
age) of PLS regression models built for each of the two major subtypes (not shown).  
The metabolic features discriminating adenocarcinoma and squamous cell carcinoma 
tumour tissues were then inspected by integrating a number of signals within the variables 
selected. Those showing statistically significant differences (p<0.002, Bonferroni-
corrected) between AdC and SqCC are listed in Table 3.7, along with the percentages of 
variation and effect sizes.  
 
Table 3.7 Metabolites showing statistically significant differences between adenocarcinoma and 
squamous cell carcinoma tumour tissues. For each metabolite, the average percentage and 
coefficient of variation were obtained by spectral integration of selected signals. Effect sizes and p-
values are shown, indicating, respectively, the magnitude and statistical significance of the 
differences. Positive/negative variations refer, respectively, to metabolites increased/decreased in 
squamous cell carcinomas compared to adenocarcinomas. (s: singlet, t: triplet, m: multiplet, GSH: 
reduced glutathione, PC: phosphocholine, PE: phosphoethanolamine). 
Metabolite (, multiplicity) % variation effect size p-value
a
 
Creatine (3.93, s) 55.8±11.7 1.3±0.71 6.1×10-4 
GSH (2.16, m) 36.8±9.8 1.1±0.69 7.0×10-4 
myo-Inositol (3.62, t) -54.5±13.5 -1.8±0.76 8.5×10-6 
PC (3.22, s) -71.6±21.2 -1.7±0.75 2.0×10-6 
PE (3.98, m) -22.4±4.6 -1.8±0.76 3.1×10-6 
Taurine (3.43, t) -29.0±10.1 -1.1±0.69 1.9×10-3 
a
 Wilcoxon signed rank test p<0.002 (Bonferroni-corrected). 
 
Creatine and GSH were found to be relatively higher in SqCC, whereas PC, PE, myo-
inositol and taurine were higher in AdC. Interestingly, the later two metabolites, known to 
play a role in cellular osmoprotection, were not significantly different between each 
histological type and their respective control tissues. The ability of this set of six 
metabolites to discriminate between AdC and SqCC was further evaluated by PLS-DA of 
their signal integrals (Figure 3.21). Separation between the two histological types was 
maintained in the corresponding scores scatter plot and the loadings confirmed the 
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variations previously noted (Figure 3.21a, b). A valid model could still be obtained (Figure 
3.21c, d), although with lower classification rate (82.8%, Table 3.5), thus showing the 
importance of considering a more comprehensive profile. Overall, these results pose an 
opportunity to explore new adjunct methods for the differential diagnosis of the two 
histological tumour types with highest incidence. 
 
 
Figure 3.21 PLS-DA of 6 selected signal integrals measured in the standard 1D 
1
H HRMAS NMR 
spectra from lung adenocarcinoma (n 18) and squamous cell carcinoma (n 18) tissues: a) scores 
scatter plot, b) LV1 loadings. The parameters shown on the scores plot (LV: latent variable, R
2
X: 
variation explained by the X matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive 
power) derive from default 7-fold cross validation. c) ROC space (TPR: true positive rate; FPR: 
false positive rate) and d) Q
2
 histogram obtained by MCCV and permutation testing (500 iterations) 
of the PLS-DA model. (GSH: reduced glutathione; m-Ino: myo-inositol; PC: phosphocholine; PE: 
phosphoethanolamine). 
 
 
 
-3
-2
-1
0
1
2
3
-4 -3 -2 -1 0 1 2 3 4 5
L
V
2
 (
1
4
.8
%
)
LV1 (57.4%)
Adenocarcinoma Squamous cell
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
PE m-Ino PC creatine taurine GSH
P
L
S
-D
A
 L
V
1
 l
o
a
d
in
g
s
 w
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0.0 0.2 0.4 0.6 0.8 1.0
T
P
R
 (
s
e
n
s
it
iv
it
y
)
FPR (1-specificity)
True classes Permuted classes
0%
5%
10%
15%
20%
25%
F
re
q
u
e
n
c
y
Q2 values
True classes Permuted classes
-150
-100
-50
0
50
100
150
200
-200 -100 0 100 200
L
V
2
 (
2
1
.1
%
)
LV1 (35.0%)
Adenocarcinoma Squamous cell
-150
-100
-50
0
50
100
150
200
-200 -100 0 100 200
L
V
2
 (
2
1
.1
%
)
LV1 (35.0%)
Adenocarcinoma Squamous cell
LV=2
R2X=0.72
R2Y=0.62
Q2=0.56
a) b) 
c) d) 
CHAPTER 3 – METABOLIC PROFILING OF LUNG TUMOURS BY TISSUE NMR METABOLOMICS 
123 
3.5 Proposed biochemical interpretation of tumour-related metabolic 
changes 
The results in the preceding sections provide clear evidence of a strong metabolic 
signature for lung tumours, mainly defined by a set of thirteen metabolites with 
significantly altered levels in relation to control pulmonary tissue. Moreover, this signature 
was found to depend on the tumour histological type, showing important differences 
between adenocarcinoma and squamous cell carcinoma. 
One of the main features characterizing all tumours consisted of increased lactate 
levels and depleted glucose levels (Figure 3.22), corroborating the expected increase in 
glycolytic activity („Warburg effect‟) reported in the literature for lung tumours (Fan et al. 
2009; Kami et al. 2013), as well as for other tumour types, including hepatocellular, 
prostate and colorectal cancers (Yang et al. 2007; Tessem et al. 2008; Chan et al. 2009). 
Interestingly, this variation was found in this work to be more pronounced in SqCC than in 
AdC, glucose and lactate showing a significant negative correlation in the former. These 
results highlight the dependency of the known glycolytic phenotype of lung tumours, 
exploited in cancer diagnosis and staging through 
18
fluorodeoxyglucose (FDG) positron 
emission tomography (PET) imaging (Ambrosini et al. 2012), on the histological subtype. 
Concordantly, previous studies have shown that, compared to AdC, SqCC tumors were 
characterized by higher FDG uptake and increased overexpression of key membrane 
glucose transporters, namely GLUT1, necessary to support the high rate of glycolysis 
(Brown et al. 1999; De Geus-Oei et al. 2007; Meijer et al. 2012). 
In addition to lactate, glutamate and alanine were also significantly increased in lung 
tumours, when compared to their paired non-involved tissues. Glutamate may originate 
from hydrolysis of glutamine (glutaminolysis), which, in addition to glucose, is regarded as 
an important source of energy and intermediate building blocks for tumour cell growth and 
proliferation (Wise et al. 2008; Mohamed et al. 2014). Subsequent transamination between 
glutamate and pyruvate, catalysed by alanine transaminase, also produces alanine and α-
ketoglutarate, the latter entering the TCA cycle (Figure 3.22). Thus, the observed 
variations in glutamate and alanine, also reported in studies of tissue extracts (Fan et al. 
2009; Kami et al. 2013), suggest increased glutaminolytic activity in tumour tissues. The 
strong positive correlation between the two metabolites in SqCC tumours corroborates this 
hypothesis. In the case of AdC, however, glutaminolysis appears to be less pronounced, as 
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glutamate registered a smaller increase and alanine did not differ significantly between 
control and tumour tissues. Glutamate may also leave the glutaminolytic pathway and be 
excreted, as an effective way to excrete hydrogen, or to act as immunosuppressive in the 
protection of tumour cells (Mazurek 2007). 
 
 
Figure 3.22 Overview of some possibly altered metabolic pathways in lung tumours. Metabolites 
found to be increased/decreased in tumour tissues relatively to control pulmonary parenchyma are 
highlighted in red/green. 
 
Moreover, together with cysteine and glycine, glutamate is used for the synthesis of 
reduced glutathione (GSH, γ-Glu-Cys-Gly), a key component of the cells‟ defence system 
for detoxification of oxidative stress-causing species or events. In this work, GSH was 
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found to be increased in tumour tissues relatively to controls, this variation being more 
pronounced in SqCC and non-significant in AdC. High intracellular GSH levels together 
with increased activity of GSH-related enzymes are a typical feature of several tumours 
(Gamcsik et al. 2012), including lung tumours (Blair et al. 1997; Ferruzzi et al. 2003; 
Ilonen et al. 2009), and have been associated with chemo-resistance and high metastatic 
potential (Traverso et al. 2013). Regarding GSH variation in lung tumours of different 
histology, our findings are consistent with an early work (Cook et al. 1991), but disagree 
with another study reporting higher GSH increase in AdC than in SqCC, compared to non-
malignant adjacent tissue (Ilonen et al. 2009). It should however be noted that other patient 
characteristics, such as age and smoking habits, are expected to strongly influence the 
oxidative burden, hence the tissue GSH levels. Therefore, data on the subject‟s smoking 
history, which is lacking in our study, would be necessary to further interpret the observed 
discrepancy and achieve solid conclusions. 
Another change that could be related to antioxidant protection mechanisms is the 
increase in taurine, since, among other physiological roles (e.g., osmoregulation, calcium 
signalling), this metabolite is known to have important antioxidant activity, recently 
postulated to be linked to mitochondrial protein synthesis (Jong et al. 2012). According to 
our results, taurine levels were significantly increased when all tumours were considered 
together in comparison to controls, although not reaching statistical significance when AdC 
or SqCC tumours were considered individually. Moreover, it is interesting to note that, 
together with GSH (but in opposite sense), taurine accounted for the differentiation 
between AdC or SqCC tumours, thus suggesting that the variations in this metabolite may 
eventually reflect different antioxidant mechanisms in tumours of different histological 
types. 
Creatine was found to be significantly increased in all tumours, this variation being 
more prominent in SqCC than in AdC (126 vs. 28% increase, respectively). Elevated 
creatine levels in tumour tissues is in agreement with previous findings in lung tissue 
extracts (Yokota et al. 2007) and have been related to altered energetic transfer processes 
(Somashekar et al. 2011; Yang et al. 2013), which may reflect decreased activity of 
creatine kinase (CK). Indeed, CK activity has been previously reported to be lower in both 
AdC and SqCC lung tumours, compared to normal adjacent tissues, although not showing 
a significant difference between both subtypes (Joseph et al. 1997).  
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In regard to phospholipid-related metabolites, PC, GPC and PE were found to be 
increased in tumours relatively to controls. Although, to our knowledge, this has been 
newly reported for lung cancer by our group, altered phospholipid metabolism has often 
been linked to cancer as a means to support accelerated cellular proliferation (Sitter et al. 
2006; Yang et al. 2007; Tessem et al. 2008; De Silva et al. 2009). PC may arise from both 
anabolic and catabolic transformations of phophatidylcholine (PtdCho), the major cell 
membrane phospholipid. A key enzyme involved in this cycle is choline kinase (ChoK), 
which phosphorylates choline to produce PC, as the first step in PtdCho synthesis. ChoK 
has been found overexpressed and highly active in lung tumors and cell lines (Molina et al. 
2002; Molina et al. 2007), and has been proposed as a prognostic factor for early-stage 
NSCLC (Molina et al. 2007). Also, 
11
C-choline PET is being explored as an alternative to 
18
FDG-PET in lung cancer staging, based on increased choline uptake and metabolism by 
rapidly proliferating tumor cells (Li et al. 2013). On the other hand, phospholipid 
breakdown has also been linked to abnormal metabolism in cancer and suggested to 
promote malignant transformation via mitogenic signal transduction (Moestue et al. 2011). 
As GPC is solely a product of PtdCho degradation, it is likely that the observed increases 
of PC and GPC, together with increased PE levels, reflect both anabolic and catabolic 
processes, which our results suggest to be more relevant in AdC. Additionally, 
significantly decreased acetate levels in AdC (not observed in SqCC) may also relate to 
lipid metabolism as this metabolite can be converted to acetyl-CoA to feed de novo 
biosynthesis of lipids. Indeed, the shift from citrate oxidation to lipogenesis is another 
typical feature of cancer metabolism (Costello and Franklin 2005). However, although 
total lipids did show a (non-significant) trend to be higher in tumours, their levels seemed 
to be influenced by other factors like necrosis and did not prove to be determinant in the 
discrimination between malignant and non-malignant tissue.  
Another interesting finding of this work was the increased contribution of peptide 
moieties to lung tumours‟ metabolic profiles, in particular the AdC profile. Concordantly, 
Wu et al. have found elevated levels of 90 dipeptides in lung AdC tissues (from 9 patients) 
relatively to normal tissues (Wu et al. 2013). In another study, 17 dipeptides were found to 
be increased in cancer-associated fibroblasts (CAFs) isolated from non-small cell tumours, 
compared to matched normal fibroblasts obtained from non-neoplastic tissues (Chaudhri et 
al. 2013). The authors postulated that the observed increase could relate to enhanced 
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autophagy, a lysosome-related protein degradation mechanism, which has recently 
emerged as a key regulator of multiple aspects of cancer biology (Kimmelman 2011; Singh 
and Cuervo 2011).  
Finally, uracil nucleotides (UDP and/or UTP) were found to be significantly 
increased in tumours, especially in AdC. Given the important role of these molecules as 
extracellular signalling molecules (Morrone et al. 2003) and in the cancer-related 
glycosylation of proteins and lipids (Christiansen et al. 2014), this is an interesting clue to 
further investigate their biological relevance in the context of lung cancer.  
 
  
 
 
 
 
CHAPTER 4 – NMR METABOLOMIC STUDY OF BLOOD PLASMA TO ASSESS METABOLIC 
ALTERATIONS RELATED TO LUNG CANCER 
 
129 
4 NMR METABOLOMIC STUDY OF BLOOD PLASMA TO 
ASSESS METABOLIC ALTERATIONS RELATED TO 
LUNG CANCER 
 
This chapter addresses the 
1
H NMR analysis of blood plasma from lung cancer 
patients and healthy controls. After a first section describing the NMR assignment of 
plasma metabolites, the discrimination between patients and controls is attempted through 
multivariate analysis. The metabolic differences between the two groups are highlighted, 
addressing also the dependency of the observed variations on the tumour histological type 
and stage. Moreover, the possible confounding influence of the subjects‟ gender, age and 
smoking habits on the classification models built is assessed, and preliminary external 
validation is explored. Then, in the last section, a possible biochemical interpretation for 
the putative cancer-related metabolic variations is presented. 
 
4.1 Metabolic composition of human blood plasma: spectral assignment 
based on 1D and 2D NMR experiments 
Blood plasma is a rich fluid matrix constituted by suspended proteins, particularly 
albumin, immunoglobulins, glycoproteins and lipoproteins, together with a variety of 
inorganic and low-molecular weight (Mw) organic solutes. This complex, multi-
component nature of plasma results in a 
1
H NMR profile characterized by a broad envelope 
of protein signals (mainly lipoproteins) overlapping with narrow signals from small 
metabolites, as shown by the standard 1D spectrum in Figure 4.1a. In order to maximize 
the information retrieved from both macromolecular components and small molecules, in 
addition to the standard 1D spectrum, relaxation- and diffusion-edited experiments have 
also been recorded for all plasma samples. 
As described in subchapter 1.3.2.5, the CPMG experiment enables the attenuation of 
broad protein resonances based on their reduced molecular mobility, hence, shorter T2 
relaxation time constants (Table A9, ANNEX VI). The resulting CPMG spectrum (Figure 
4.1b) showed a substantially flatter baseline and improved visibility of low Mw signals.  
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Figure 4.1 Typical 500 MHz 
1
H NMR spectra of blood plasma of a lung cancer patient, used for 
spectral assignment: a) standard 1D, b) CPMG, c) diffusion-edited, d) 
1
H-
1
H TOCSY and e) 
1
H-
13
C 
HSQC. Metabolites are numbered in accordance with Table 4.1. 
a) 
b) 
c) 
d) e) 
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For instance, in the aromatic region of the spectrum, the broad protein NH 
resonances were fully attenuated, allowing for low abundance metabolites like tyrosine and 
histidine to stand out. Regarding the signals of fatty acyl chains in lipoproteins (e.g., broad 
resonances at δ 0.8-0.9 and δ 1.2-1.3), their attenuation was not complete (thus indicating 
their relatively high mobility), but it was enough to greatly improve the visibility of amino 
acids and other small metabolites in the lower frequency region of the spectrum. 
On the other hand, the diffusion-edited experiment filtered off the sharp signals of 
small metabolites (Figure 4.1c), based on their faster diffusion coefficient (as explained in 
section 1.3.2.6), allowing for the broad macromolecular profile of blood plasma to be 
inspected. While the dominant resonances in this profile belong to lipid moieties (mainly 
composing lipoproteins), albumin lysyl residues, N-acetyl groups of glycoproteins and 
protein NH groups also contributed to the plasma broad envelope. 
Two-dimensional NMR experiments, namely 
1
H-
1
H TOCSY, 
1
H-
13
C HSQC and J-
resolved, were acquired for selected samples, further helping the characterization of 
plasma metabolic composition. In particular, the TOCSY spectrum (expansion shown in 
Figure 4.1d) was very helpful in identifying the spin systems of several amino acids (e.g., 
leucine, valine, alanine, lysine, glutamine, threonine, tyrosine), small organic acids (e.g., 
lactate, citrate), as well as in distinguishing α- and β-glucose resonances, and in identifying 
the homonuclear correlations within the fatty acyl chains of lipoproteins, the glyceryl 
backbone and the choline-containing phospholipids. Furthermore, the HSQC spectrum 
(Figure 4.1e) provided 
13
C chemical shift information which corroborated some of those 
assignments and enabled others to be proposed. For instance, the 
1
H-
13
C correlations for 
the signals at 2.9-3.0 ppm were in agreement with the assignment to albumin lysyl 
residues, according to the previously published spin systems of human serum albumin 
(HSA) (Harris et al. 1996), while those for the singlets at 2.03 and 2.07 ppm matched N-
acetyl groups of mobile carbohydrate side-chains (mostly N-acetylglucosamine and N-
acetylneuraminic acid) of glycoproteins, as suggested by Bell et al. (Bell et al. 1987). 
Statistical correlation spectroscopy (STOCSY) was also applied to the plasma 1D 
spectra for assignment purposes and proved especially useful for assigning broad 
resonances to specific lipoprotein subclasses, strongly superimposed even in 2D spectra. 
As shown in Figure 4.2, the driver peak at δ 0.84 was correlated with broad signals at δ 
1.23, 1.49, 1.96, 2.66-2.80, 3.21 and 5.26 (Figure 4.2a), while the resonance at δ 0.87 was 
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found to be strongly correlated with peaks at δ 1.27, 1.57, 2.00, 2.22, 2.70-2.85 and 5.29, 
and with glyceryl backbone resonances (δ 4.05, 4.28 and 5.20) (Figure 4.2b). Also, 
correlations with different cholesterol resonances (C(18)H3) were obtained in each case. 
Based on the average typical composition of the major lipoprotein subclasses (Nelson and 
Cox 2004) and on literature data focused on the study of serum/plasma lipoproteins by 
1
H 
NMR (Daykin et al. 2001; Liu et al. 2002; Mallol et al. 2013), the first fraction has been 
assigned to HDL and the second to VLDL (with contribution from LDL). Indeed, HDL 
lipoproteins contain large amounts of phospholipids (about 25%), which is consistent with 
the strong correlation to choline headgroup signals, likely arising from phosphatidylcholine 
(Figure 4.2a). 
  
Figure 4.2 STOCSY correlation plots of diffusion-edited spectra (cancer n 106) of driver peaks: a) 
 0.83 and b)  0.87. 
glyceryl backbone
Cho-headgroup
r 
r 
a) 
b) 
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On the other hand, VLDL lipoproteins include a large proportion of triglycerides in 
their composition (about 50%), thus agreeing with the spectral profile shown in Figure 
4.2b. This difference in the chemical shifts of fatty acyl chains associated with different 
lipoproteins was also visible in the 
1
H-
13
C HSQC, particularly with respect to the 
unsaturated carbons (expansion in Figure 4.1e). 
Spiking with standard solutions was also used in some instances to confirm the 
assignment of low intensity singlets for which no TOCSY or HSQC crosspeaks were 
detected (e.g., methanol). The complete assignment of plasma resonances is shown in 
Table 4.1. Overall, based on the detailed assignment information available in the literature 
(Nicholson et al. 1995) and on consultation of spectral databases, namely Bruker‟s 
BBIOREFCODE-2-0-0 database (Bruker Biospin, Rheinstetten, Germany) and other 
available on-line databases (Wishart et al. 2007; Psychogios et al. 2011; Ulrich et al. 2008), 
thirty four compounds have been identified in blood plasma (all previously reported), 
while seven signals remained unassigned. 
 
Table 4.1 Assignment of resonances in the 500 MHz 
1
H NMR spectra of blood plasma; (s, singlet; 
d, doublet; t, triplet; q, quartet; m, multiplet; dd, double doublet; br, broad). 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
1 Acetate  1.91 (s, βCH3) 
2 Acetoacetate  2.22 (s, γCH3) 
3 Alanine  1.47 (d, βCH3)/16.09; 3.78(q, αCH) 
4 Albumin lysyl  2.90 (t, ε-CH2)/39.42; 2.96 (t, ε-CH2)/39.42; 3.01 (t, ε-CH2)/39.59 
5 Arginine  1.68 (m, CH2)/26.52; 1.88 (m, CH2); 3.24 (t, CH2)/42.87; 3.76 
(CH)/54.68 
6 Asparagine  2.83 (dd, βCH); 2.94 (dd, β‟CH) 
7 Aspartate  2.67 (dd, βCH); 2.82 (dd, β‟CH) 
8 Cholesterol  0.65  (br, C18H3 (mainly HDL));  0.68 (br, C18H3 (mainly 
LDL+VLDL)) 
9 Citrate   2.52 (d, , CH2); 2.68(d, ', ‟CH2) 
10 Creatine  3.03 (s, CH3); 3.94 (s, CH2) 
11 Creatinine  3.04 (s, CH3); 4.05 (s, CH2) 
12 Formate  8.45 (s, CH) 
13 α-Glucose  3.40 (t, C4H)/69.69; 3.53 (dd, C2H)/71.65; 3.71(t, C3H)/72.87; 3.82 
(m, C6H)/ 71.60; 3.87 (m, C5H)/60.88; 5.23 (d, C1H)/92.16 
14 β-Glucose  3.24 (dd, C2H/74.36; 3.40 (t, C4H)/ 69.69; 3.47 (dd, C5H)/76.07; 
3.49 (t, C3H)/ 76.07; 3.74 (dd, C6H)/ 60.91; 3.90 (m, C6‟H)/ 60.88; 
4.65 (d, C1H)/ 96.16 
15 Glutamine  2.12 (m, βCH2)/ 26.74; 2.44 (m, CH2)/ 30.99; 3.77 (t, αCH) 
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Table 4.1 (continued) 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
16 Glycerol  3.62 (dd, C1H2/C3H2); 3.76 (dd, C2H) 
17 Glycine  3.55 (s, αCH2)/68.69 
18 Glycoproteins 
(N-acetyl groups) 
 2.03, 2.07 (br s, NHCOCH3)/22.33 
19 Histidine  7.05 (s, C4H, ring); 7.76 (s, C2H, ring) 
20 -Hydroxybutyrate  1.19 (d, CH3)/21.49; 2.35 (m, αα'CH2) 
 Isobutyrate  1.17 (d, CH3) 
22 Isoleucine  0.93 (t, CH3)/13.97; 1.00 (d, ‟CH3); 1.26 (m, CH)/27.87; 1.40 (m, 
γ‟CH)/27.87; 1.96 (m, βCH); 3.65(m, CH)/62.83 
23 Lactate   1.32 (d, βCH3)/22.83; 4.11 (q, αCH)/68.83 
24 Leucine  0.95 (d, CH3); 0.96 (d, ‟CH3); 1.71 (m, CH)/26.56; 1.72 (m, βCH2)/ 
39.94; 3.74 (t, CH)/56.10 
25 Lysine  1.47 (m, CH2); 1.71 (m, CH2); 1.89 (m, βCH2); 3.03 (t, CH2); 3.76 
(t, αCH) 
26 Methanol  3.35 (s, CH3) 
27 Methionine  2.13 (s, S-CH3); 2.14 (m, CH); 2.21 (m, ‟CH); 2.64 (t, CH2) 
28 Phenylalanine  3.10 (dd, CH); 3.29 (dd, ‟CH); 3.97 (dd, CH); 7.32 (m, C2H, 
C6H, ring); 7.37 (m, C4H, ring); 7.42 (C3H, C5H, ring) 
29 Phospholipids (mainly 
in HDL): 
- fatty acyl chains 
 
 
- choline headgroup 
  
 
0.84 (br,CH3)/14.10; 1.23 (br, (CH2)n)/31.75;1.58 (br, CH2-CH2-CO); 
2.00 (br, CH=CH-CH2)/27.11; 2.22 (br, CH2-CO)/33.75; 2.68/2.74 
(br, CH=CH-CH2-CH=CH)/25.60; 5.27 (br, CH=CH)/ 127.88; 
3.21 (br s, N(CH3)3)/54.16; 3.68 (br, CH2(NH))/66.12; 4.30 (br, 
CH2(OH))/59.60 
30 Pyruvate  2.36 (s, CH3) 
31 Threonine  1.31 (d, CH3); 3.58 (d, αCH); 4.29 (m, βCH) 
32 Triglycerides (mainly 
in LDL+VLDL) 
- fatty acyl chains 
 
 
- glyceryl backbone 
  
 
0.87 (br, CH3); 1.27 (br, (CH2)n)/29.57; 1.58 (br, CH2-CH2-CO); 2.00 
(br, CH=CH-CH2)/27.11; 2.22 (br, CH2-CO)/33.75; 2.68/2.74 (br, 
CH=CH-CH2-CH=CH)/25.60; 5.29 (br, CH=CH)/129.53 
4.05, 4.28 (br, C1H2/C3H2); 5.20 (br, C2H) 
33 Tyrosine  6.89 (d, C3H, C5H, ring); 7.18 (d, C2H, C6H, ring) 
34 Valine  0.98 (d, CH3); 1.03 (d, ‟CH3); 2.25(m, βCH); 3.62 (d, αCH)/66.18 
 
4.2 Potential of plasma NMR profile to discriminate between patients 
and control subjects 
Blood is a major vehicle of gases, nutrients, hormones and waste products in the 
body, mediating the metabolic interactions between different organs/tissues. It is therefore 
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reasonable to expect that the metabolic content of blood plasma may mirror the 
biochemical events accompanying a disease such as lung cancer. A first look at the plasma 
average spectra from control and cancer subjects (Figure 4.3) suggested differences in the 
lipoprotein profile and variations in the levels of some small metabolites, namely lactate, 
valine, glutamine, methanol and histidine.  
 
 
Figure 4.3 500 MHz average CPMG 
1
H NMR spectra of blood plasma from controls (n 94, green) 
and lung cancer patients (n 106, red), after PQN normalisation. 
 
Multivariate analysis was then applied to verify the consistency of these and other 
variations. The first step consisted of applying PCA, PLS-DA and OPLS-DA to the three 
NMR experiments recorded (standard 1D, CPMG and diffusion-edited), followed by 
Monte-Carlo cross validation (MCCV) and permutation testing of PLS-DA models. 
Although all three models performed similarly (Table 4.2), the model built with CPMG 
spectra showed slightly higher median Q
2
 (0.59) and sensitivity (85.6%), resulting in an 
overall classification rate of 86.6%. In addition, as the broad background of proteins 
overlapping small metabolites was highly reduced in CPMG, the corresponding loadings 
were more informative concerning small metabolites‟ variations. Thus, the CPMG 
experiment was selected for spectral and multivariate analysis. 
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Table 4.2 Prediction results obtained by MCCV (500 iterations) of plasma PLS-DA models 
assessing the discrimination between lung cancer patients and healthy controls. 
PLS-DA models Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Standard 1D 0.53 79.3 91.6 85.1 
CPMG 0.59 85.6 87.8 86.6 
Diffusion-edited 0.54 83.0 92.4 87.4 
12 integrals 0.56 87.9 85.2 86.6 
 
As it can be seen in Figure 4.4a, control and cancer samples largely overlap in the 
PCA scores scatter plot, their separation being improved in PLS-DA and OPLS-DA score 
scatter plots (Figure 4.4b and 4.4c, respectively). MCCV and permutation testing were then 
used to verify model robustness. The classification results plotted in the ROC space 
(Figure 4.4d) showed that the majority of the real models (iterations with true classes 
assigned) afforded high sensitivity and specificity, whereas the permuted models (class 
membership ramdomly attributed) fell along the diagonal, i.e., the line of no discrimination 
(classification rate about 50%). Moreover, the Q
2
 values were high when the true classes 
were assigned and negative or very low for most permuted models (Figure 4.4e), thus 
validating the predictive ability of the real model. 
The identification of the metabolite variations responsible for class discrimination 
was then performed by inspection of OPLS-DA LV1 loadings, coloured according to 
variable importance in the projection (VIP), as depicted in Figure 4.4f. Lactate, 
acetoacetate and pyruvate showed positive loadings, indicating their increased levels in 
lung cancer patients, whereas methanol and several amino acids (e.g., valine, 
arginine/lysine, glutamine, serine and histidine) presented negative loadings, thus lower 
levels in patients compared to controls. Moreover, two other unidentified small resonances 
in the aromatic region seemed to be important for class separation, but their identification 
was not possible, as they did not show relevant correlations, either in 2D spectra or in 
STOCSY plots. 
Regarding lipoprotein signals, some showed positive loadings, while others had 
negative loadings, suggesting a different proportion of the main lipoprotein subclasses in 
the plasma samples from control and cancer subjects. In particular, negative loadings 
(decreased in cancer patients) were found for broad resonances at δ 0.83, 1.23, 3.21 and 
5.26, assigned to phospholipids composing mainly HDL lipoproteins.
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Figure 4.4 MVA applied to the CPMG 
1
H NMR spectra of blood plasma from controls (n 94) and 
cancer patients (n 106): a) PCA, b) PLS-DA and c) OPLS-DA scores scatter plot. The parameters 
shown on the scores plots (PC: principal components, LV: latent variable, R
2
X: variation explained 
by the X matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive from 
default 7-fold cross validation. d) ROC space (TPR: true positive rate, FPR: false positive rate) and 
e) Q2 histogram obtained by MCCV and permutation testing (500 iterations) of the PLS-DA 
model. f) OPLS-DA LV1 loadings weights coloured as a function of VIP. Metabolites showing 
VIP>1 are assigned in the plot (U1: unkown 1, δ 6.71; U2: unknown 2, δ 2.72). 
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On the other hand, the signals assigned to triglycerides composing LDL+VLDL 
lipoproteins showed positive loadings, indicating their increased levels in patients. Other 
variations observed were the negative loadings for the albumin resonances, indicating a 
decrease of this protein levels in cancer patients, whereas glycoproteins appeared to be 
increased (positive loadings for their N-acetylated groups). 
Following the thorough inspection of the loadings plot, metabolites with VIP>1 were 
integrated in the CPMG spectra, the median values of each group statistically compared by 
the Wilcoxon rank sum test and the corresponding effect size (d) calculated. Some 
resonances, namely those of albumin, lysine, arginine and serine, could not be integrated 
due to severe spectral overlap. Table 4.3 summarises the integration results for the 
metabolites showing statistically significant differences (p<4.2×10
-3
, Bonferroni-corrected) 
between cancer patients and controls. Confirming the observations derived from the 
loadings inspection, acetoacetate, lactate, pyruvate, LDL+VLDL lipoproteins and 
glycoproteins were increased in patients‟ plasma, whereas HDL lipoproteins, amino acids 
(glutamine, histidine and valine), methanol and two unknown peaks in the aromatic region 
(δ 6.71 and δ 7.59) were found to be significantly decreased compared to controls.  
 
Table 4.3 Blood plasma metabolites showing statistically significant differences between lung 
cancer patients and healthy controls. For each metabolite, the average percentage and coefficient of 
variation were obtained by spectral integration of selected signals. Effect sizes and p-values are 
shown, indicating, respectively, the magnitude and statistical significance of the differences 
between the two groups. n.s. not significant;  qualitative decreased (signal not integrated due to 
spectral overlap); s: singlet; d: doublet; t: triplet; q: quartet; m: multiplet; br: broad; br s: broad 
singlet. 
Metabolite 
(δ, multiplicity) 
Cancer vs. Control 
% variation p-value
a
 effect size 
Acetoacetate (2.27, s) 19.6±4.0 5.1×10-7 0.62±0.28 
Albumin (3.00, br)  
Arginine + lysine (1.92, m)  
Glutamine (2.44, m) -14.0±2.2 3.8×10-12 -1.02±0.30 
Glycoproteins (2.02+2.05, br s) 11.7±1.1 <2.2×10-16 1.40±0.31 
Histidine (7.04, s) -17.7±2.3 2.5×10-16 -1.31±0.31 
Lactate (4.11, q) 32.6±3.5 4.9×10-14 1.10±0.30 
Methanol (3.35, s) -33.0±7.5 2.6×10-9 -0.83±0.29 
HDL (3.21, br) -19.0±2.5 2.6×10-14 -1.25±0.30 
Pyruvate (2.36, s) 22.2±2.8 6.0×10-12 0.99±0.29 
Serine (3.96, m)  
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Table 4.3 (continued) 
Metabolite 
(δ, multiplicity) 
Cancer vs. Control  
% variation p-value
a
 effect size 
LDL+VLDL (0.87, br) 31.8±3.7 2.7×10-11 1.02±0.30 
Valine (1.03, d) -8.5±2.2 5.0×10-5 -0.90±0.28 
U1 (6.71, br) -31.7±5.4 1.3×10-13 -1.08±0.30 
U2 (7.59, br) -26.1±3.7 5.2×10-14 -1.19±0.30 
a
Wilcoxon rank sum test p<4.2×10
-3
 (Bonferroni-corrected). 
 
The classification ability of the twelve metabolites integrated was then evaluated by 
applying PLS-DA to their signal areas. As shown in Table 4.2 and Figure 4.5, the MCCV 
results obtained for this model were quite similar to those obtained when modelling the full 
resolution spectra, thus confirming the relevance of these metabolic features as possible 
cancer-related markers. 
 
  
Figure 4.5 PLS-DA applied to 12 signal integrals measured in the CPMG 
1
H NMR spectra of 
blood plasma from controls (n 94) and cancer patients (n 106): a) scores scatter plot and b) LV1 
loadings weights. The parameters shown on the scores plot (LV: latent variable, R
2
X: variation 
explained by the X matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive 
from default 7-fold cross validation. c) ROC space (TPR: true positive rate, FPR: false positive 
rate) and d) Q
2
 histogram obtained by MCCV and permutation testing (500 iterations).7 
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4.3 Impact of tumour histological type on the plasma metabolic 
composition 
As patients included in this study were diagnosed to have tumours of different 
histological type, the possible impact of such heterogeneity on blood plasma composition 
has also been investigated. Firstly, the discrimination between the control group and each 
of the two subgroups corresponding to the main histological types (adenocarcinoma – 
AdC, and squamous cell carcinoma – SqCC) was assessed by PLS-DA and MCCV. As 
presented in Table 4.4, the predictive power for discriminating between controls and AdC 
(Q
2
 0.50) or between controls and SqCC (Q
2
 0.46) was lower than the one obtained for the 
model comprising all samples (Q
2
 0.59). Also, lower sensitivity, specificity and 
classification rate were obtained, although this might be partially due to the unbalanced 
number of samples between the cancer and control groups, as using a smaller control group 
(n 40) afforded an improvement in classification parameters (Table 4.4). 
 
Table 4.4. Prediction results obtained by MCCV (500 iterations) of plasma PLS-DA models, 
assessing the discrimination between different groups of samples (including different histological 
types and stages). AdC: adenocarcinoma; SqCC: squamous cell carcinoma. 
PLS-DA classes 
[n samples; n M/n F; median age] 
Median 
Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
All samples: Control vs. Cancer  
[94; 49/45; 44] vs. [106; 76/30; 63] 
0.59 85.6 87.8 86.6 
Control vs. AdC 
[94; 49/45; 44] vs. [40; 23/17; 66] 
0.50 68.2 67.6 67.9 
Control vs. SqCC 
[94; 49/45; 44] vs. [27; 25/2; 63] 
0.46 64.0 80.5 73.9 
Control vs. AdC
a
 
[40; 22/18; 48] vs. [40; 23/17; 66] 
0.57 73.5 95.9 89.2 
Control vs. SqCC
a
 
[40; 22/18; 48] vs. [27; 25/2; 63] 
0.40 66.3 97.1 90.2 
AdC vs. SqCC 
[40; 23/17; 66] vs. [27; 25/2; 63] 
-0.39 21.9 63.3 46.6 
AdC vs. SqCC
b
 
[40; 23/17; 66] vs. [27; 25/2; 63] 
0.03 50.3 74.1 64.5 
Control vs. Cancer stage I 
[94; 49/45; 44] vs. [61; 44/17; 63] 
0.60 82.0 93.9 89.2 
Cancer stage I vs. Cancer stage II+III 
[61; 44/17; 63] vs. [34; 25/9; 62] 
-0.19 22.2 74.2 55.6 
Cancer stage I vs. Cancer stage II+III
b
 
[61; 44/17; 63] vs. [34; 25/9; 62] 
0.41 77.2 87.1 83.5 
a
 Using balanced sample numbers in the groups compared.
 b
After variable selection. 
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In order to assess if AdC and SqCC tumours impact a different metabolic signature 
on blood plasma of cancer patients, the loadings of the corresponding OPLS-DA models 
(not shown) were analysed and compared to the loadings of the model based on the 
complete dataset. The variations between controls and each histological type were then 
calculated for signals with VIP>1 and are listed in Table 4.5. Interestingly, although most 
significant alterations were common to both histological types (showing similar % 
variations in relation to controls), others seemed to be specific for each tumour type. In 
particular, alanine was found to be significantly decreased in SqCC but not in AdC (or for 
the whole set of patients), while -hydroxybutyrate was increased in the plasma of AdC 
patients only. Furthermore, the decrease in valine levels was not significant in SqCC, and 
acetate (VIP<1 when considering all samples) was found to be important and significantly 
decreased when taking into account each histological type separately (Table 4.5). 
In spite of the few differences described above, the potential discrimination between 
AdC and SqCC patients was attempted by PLS-DA of their plasma spectra (leaving out the 
controls). However, none of the models built (based on full resolution data or after the 
variable selection procedure described in subchapter 2.3.5 could be MCCV-validated, 
showing negative or near zero Q
2
 and poor classification parameters (Table 4.4). Thus, 
while showing great promise in cancer vs. control discrimination, plasma NMR 
metabolomics failed to distinguish between AdC and SqCC patients. 
 
4.4 Impact of tumour stage on the plasma metabolic composition 
In order to assess the possible influence of disease stage on the plasma profiles, the 
patients group was divided into subsets of stages I (n 61), II (n 24) and III (n 10) and 
multivariate analysis was performed to evaluate the differences between each of these 
subsets and the control group (n 94). PLS-DA of stage I patients vs. controls produced an 
MCCV-validated model with a predictive power and classification rate comparable to 
those obtained for the whole dataset (Table 4.4, Figure 4.6a, b). However, there was a 
slight decrease in sensitivity that could be attributable to the lower impact of early stage 
tumours on blood plasma composition, and/or, to some extent, to the unbalanced number 
of samples in each group. In fact, when a model was built with the same number of 
samples in both groups (controls and stage I), sensitivity improved to 87% (not shown).  
  
Table 4.5 Blood plasma metabolites showing statistically significant differences between lung cancer patients and healthy controls, considering all 
samples in the patients group (2
nd
 column), only adenocarcinomas (3
rd
 column) or only squamous cell carcinomas (4
th
 column). For each metabolite, the 
average percentage and coefficient of variation were obtained by spectral integration of selected signals. Effect sizes and p-values are shown, indicating, 
respectively, the magnitude and statistical significance of the same differences. n.s. not significant;  qualitative decreased (signal not integrated due to 
spectral overlap); s: singlet; d: doublet; t: triplet; q: quartet; m: multiplet; br: broad; br s: broad singlet. 
Metabolite 
(, multiplicity) 
Cancer vs. Control 
Cancer vs. Control 
(AdC) 
Cancer vs. Control 
(SqCC) 
% variation effect size p-value
a
 % variation effect size p-value
a
 % variation effect size  p-value
a
 
Acetate(1.92, s) VIP<1 -8.3±2.9 -0.54±0.38 1.2×10-3 -10.8±3.1 -0.71±0.44 1.1×10-3 
Acetoacetate (2.27, s) 19.6±4.0 0.62±0.28 5.1×10-7 20.7±6.9 0.70±0.38 1.4×10-3 22.5±7.9 0.85±0.44 1.6×10-4 
Alanine (1.48, d) n.s. n.s. -10.1±2.7 -0.81±0.44 1.4×10-3 
Albumin (3.00, br)    
Arginine + lysine (1.92, m)    
β-Hydroxybutyrate (2.31, m) n.s. 17.2±3.9 0.83±0.38 8.0×10-4 n.s. 
Glutamine (2.44, m) -14.0±2.2 -1.02±0.30 3.8×10-12 -12.8±2.7 -0.99±0.39 3.0×10-7 -15.3±3.6 -1.15±0.45 1.9×10-5 
Glycoproteins (2.02+2.05, br s) 10.5±1.4 0.98±0.29 3.5×10-10 7.9±1.9 0.88±0.38 4.6×10-5 13.5±2.7 1.42±0.46 1.2×10-6 
HDL (3.21, br)  -19.0±2.5 -1.25±0.30 2.6×10-14 -18.1±2.8 -1.22±0.40 1.5×10-8 -24.8±3.5 -1.63±0.47 2.1×10-9 
Histidine (7.04, s) -17.7±2.3 -1.31±0.31 2.5×10-16 -18.1±2.8 -1.29±0.40 2.5×10-10 -18.3±3.4 -1.28±0.46 1.6×10-6 
Lactate (4.11, q) 32.6±3.5 1.10±0.30 4.9×10-14 32.1±5.4 1.25±0.40 1.1×10-7 31.1±7.1 1.22±0.45 2.3×10-6 
LDL+VLDL (0.87, br) 31.8±3.7 1.02±0.30 2.7×10-11 24.9±5.2 0.96±0.39 7.0×10-6 35.5±7.1 1.32±0.46 2.1×10-6 
Methanol (3.35, s) -33.0±7.5 -0.83±0.29 2.6×10-9 -30.3±8.0 -0.72±0.38 3.9×10-5 -39.0±8.3 -0.94±0.44 8.4×10-9 
Pyruvate (2.36, s) 22.2±2.8 0.99±0.29 6.0×10-12 22.2±3.2 1.29±0.40 1.5×10-9 18.9±3.7 1.11±0.45 3.2×10-6 
Serine (3.96, m)    
Valine (1.03, d) -8.5±2.2 -0.61±0.28 5.0×10-5 -9.7±2.8 -0.64±0.38 5.8×10-4 n.s. 
U1 (6.71, br) -31.7±5.4 -1.08±0.30 1.3×10-13 -36.3±5.7 -1.20±0.40 2.4×10-10 -29.3±6.6 -0.94±0.44 1.7×10-5 
U2 (7.59, br) -26.1±3.7 -1.19±0.30 5.2×10-14 -24.2±4.1 -1.24±0.40 1.4×10-8 -29.8±5.6 -1.45±0.47 2.6×10-7 
a
 Wilcoxon rank sum test p<4.2×10
-3
 (Bonferroni-corrected). 
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Inspection of the corresponding loadings then showed that the metabolic differences 
discriminating controls and stage I patients were highly coincident with those identified 
when considering all three stages together. This is clearly visualized through a VIP-wheel 
representation (devised in-house by colleagues, Diaz et al. 2013), which shows great 
superimposition of the important variables (VIP>1) highlighted in the two models (whole 
dataset and control vs. stage I) (Figure 4.6c). Therefore, this result demonstrates that a 
putative cancer signature is detectable in plasma right from early phases of tumour 
development. Also, it allows excluding the possible metabolic impact of malnutrition and 
weight loss, often affecting advanced stage patients (Okamoto et al. 2009), as an 
important confounder in the whole dataset results. The same kind of analysis was pursued 
for stage II and stage III, and, although PLS-DA models could not be properly validated 
(likely due to the unbalanced number of samples in control and cancer groups), the 
metabolic variations highlighted were again very similar to those identified when 
considering all samples. 
Additionally, the pairwise comparison of all three tumour stages was attempted: 
stage I vs. stage II, stage I vs. stage III and stage I vs. stage II+III. In all cases no valid 
discrimination was achieved (Q
2
<0 and sensitivities below 30%), so that a method of 
variable selection was applied (as described in section 2.3.5). The best result was 
achieved for the discrimination between stage I and stage II+III, for which MCCV 
afforded a classification rate of 83% (Table 4.4). When analysing the variables selected, a 
few metabolites were suggested to be responsible for this separation, namely acetate, 
glutamine, formate and tyrosine (increased in stage I samples), and acetoacetate, 
pyruvate, β-hydroxybutyrate and lactate (increased in stage II+III samples). However, 
none of these variations were confirmed to be statistically significant by spectral 
integration, thus hindering solid conclusions. 
 
4.5 Influence of potential confounders in plasma-based cancer vs. 
control discrimination 
Blood plasma metabolic content is considered to be relatively stable, accounting for 
its homeostatic role in the body. However, several extrinsic and intrinsic factors (e.g., 
diet, lifestyle, age, gender) may be responsible for some inter-individual variability, and 
influence  the  interpretation  of  disease-related  effects.  For  that  reason,  the  groups 
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Figure 4.6 a) ROC space (TPR: true positive rate, FPR: false positive rate) and b) Q
2 
histogram 
obtained by MCCV and permutation testing (500 iterations) of the PLS-DA model built with 
1
H 
NMR spectra of blood plasma to assess control vs. cancer stage I discrimination. c) VIP-wheel 
representation of variables found to have VIP>1 in OPLS-DA models built with: the whole 
dataset (black), the subset with controls and stage I patients (grey). 
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compared (e.g., patients vs. healthy controls) should ideally be matched in terms of 
possible confounding factors. In practice, this condition is often difficult to fulfil, so that 
the contribution of those factors to metabolic variability should be assessed. In this work, 
the influence of gender, age and smoking habits on the plasma metabolic profile and on 
the disease-related classification models was investigated. 
 
4.5.1 Gender-related metabolic features in blood plasma 
Regarding gender, the control group was well balanced with ca. 50% of males and 
females, whilst the cancer group included a higher number of male subjects (72%) 
(p<0.01), and thus possible gender-related bias was evaluated. In a first approach, the 
effect of gender on the metabolic profile of blood plasma was assessed by considering 
only the control group. The MCCV results of the corresponding PLS-DA model (male vs. 
female) afforded a good median predictive ability (Q
2
 0.53), and a classification rate of 
87% (Table 4.6). 
 
Table 4.6 Prediction results obtained by MCCV (500 iterations) of plasma PLS-DA models 
assessing the discrimination between different groups of samples (including groups varying in 
gender, age and smoking habits). 
PLS-DA classes 
[n samples; n M/n F; median age] 
Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Control vs. Cancer 
[94; 49/45; 44] vs. [106; 76/30; 63] 
0.59 85.6 87.8 86.6 
Male vs. Female, controls only 
[49; 49/0; 44] vs. [45; 0/45; 45] 
0.53 84.9 89.0 87.0 
Control vs. Cancer, males only 
[49; 49/0; 44] vs. [76; 76/0; 64] 
0.58 91.4 80.1 87.0 
Control vs. Cancer, females only 
[45; 0/45; 45] vs. [30; 0/30; 58] 
0.47 71.3 88.1 81.4 
Control vs. Cancer, age 41-60 
[42; 21/21; 50] vs. [38; 24/14; 56] 
0.52 66.8 71.9 69.4 
Smoker vs. Never-smoker, controls only 
[29; 17/12; 38] vs. [44; 19/25; 45] 
-0.24 46.0 66.2 58.2 
Control smoker vs. Cancer
a
 
[29; 17/12; 38] vs. [45; 33/12; 60] 
0.54 84.9 85.9 85.3 
Control never-smoker vs. Cancer
a
 
[44; 19/25; 45] vs. [45; 33/12; 60] 
0.58 83.0 88.1 85.5 
a 
Using balanced sample numbers in the groups compared. 
 
The separation between genders was clear in the OPLS-DA scores scatter plot 
(Figure 4.7a) and the metabolic features explaining this discrimination were revealed by 
the corresponding loadings (Figure 4.7b). The main differences between healthy males 
and females were in the lipoprotein profile, with HDL increased in females and 
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LDL+VLDL increased in males, in the levels of creatine (increased in females) and of 
creatinine and valine (increased in males). These findings are in agreement with other 
studies reporting the same gender-related variations in the plasma of healthy subjects 
(Kochhar et al. 2006; Lawton et al. 2008).  
 
 
Figure 4.7 a) OPLS-DA scores scatter plot (LV 1+1, R
2
X 0.17, R
2
Y 0.74, Q
2
 0.53) of the CPMG 
spectra of males (n 49) and females (n 45) of the control group, and b) corresponding loadings 
weights, coloured according to VIP parameter. The parameters shown on the scores plot (LV: 
latent variable, R
2
X: variation explained by the X matrix, R
2
Y: variation explained by the Y 
matrix, Q
2
: predictive power) derive from default 7-fold cross validation. 
 
By confronting these variations with putative disease-related effects (Table 4.7), the 
metabolic features showing the same variations in males (vs. females) and in the cancer 
group (where males predominated) were highlighted as possibly biased. This was the case 
of HDL and LDL+VLDL lipoproteins, which thus required further attention (as described 
below). 
 
Table 4.7 Gender-related metabolic variations in plasma and their comparison with cancer-related 
variations 
Gender-related metabolites 
Variation 
male vs. female 
Variation 
cancer vs. control 
Observations 
Creatine  -  
Creatinine  -  
HDL   Possible biasa 
LDL+VLDL   Possible biasa 
Valine   Opposite variation 
ª Metabolites increased/decreased in both male and cancer groups may potentially bias cancer vs. 
control discrimination as the cancer group comprises ~70% male subjects. 
a) b) 
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Another approach to assess the influence of gender on cancer vs. control 
discrimination consisted of building separate models for males and females and 
reassessing the cancer-related variables. The two models showed good prediction 
parameters, although the female model showed decreased predictive power (Q
2
 0.47) and 
classification rate (81%) compared to the male and the whole dataset models (Table 4.6). 
In regard to discriminant metabolites, there was a large coincidence between the variables 
with VIP>1 resulting from the different OPLS-DA models compared (Figure 4.8). 
 
 
Figure 4.8 VIP-wheel representation of variables found to have VIP>1 in the plasma OPLS-DA 
models built with: the whole dataset (blue), male subjects only (orange) and female subjects only 
(purple). 
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Table 4.8 Blood plasma metabolites showing statistically significant differences between lung cancer patients and healthy controls, considering all 
samples in the patients group (2
nd
 column), only males (3
rd
 column), only females (4
th
 column) or an age-matched subset (5
th
). For each metabolite, the 
average percentage and coefficient of variation were obtained by spectral integration of selected signals. Effect sizes and p-values are shown, indicating, 
respectively, the magnitude and statistical significance of the differences between the two groups. n.s. not significant;  qualitative decreased (signal not 
integrated due to spectral overlap); s: singlet; d: doublet; t: triplet; q: quartet; m: multiplet; br: broad; br s: broad singlet. 
Metabolite 
(, multiplicity) 
Cancer vs. Control (ALL SAMPLES) Cancer vs. Control (MALES ONLY) 
Cancer vs. Control  
(FEMALES ONLY) 
Cancer vs. Control (AGE-MATCHED) 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
Acetate VIP<1 VIP<1 VIP<1 -13.3±3.6 1.7×10-4 -0.86±0.46 
Acetoacetate (2.27, s) 19.6±4.0 5.1×10-7 0.62±0.28 24.3±5.1 4.1×10-5 0.67±0.37 n.s. 17.9±5.6 6.1×10-4 0.69±0.45 
Alanine (1.48, d) n.s. n.s. n.s. -9.5±3.0 1.8×10-3 -0.75±0.45 
Albumin (3.00, br)     
Arginine + lysine (1.92, m)     
Glucose (3.51, m) -1.2±2.4 3.8×10-3 -0.07±0.28 n.s. n.s. -7.4±2.5 2.9×10-4 -0.69±0.45 
Glutamine (2.44, m) -14.0±2.2 3.8×10-12 -1.02±0.30 -16.8±2.6 4.7×10-10 -1.22±0.39 -10.3±3.3 4.1×10-4 -0.80±0.48 -15.2±2.8 5.9×10-7 -1.33±0.48 
Glycoproteins (2.02+ 
2.05, br s) 
11.7±1.1 <2.2×10-16 1.40±0.31 12.4±1.4 1.2×10-10 1.37±0.40 10.2±1.8 5.1×10-7 1.40±0.52 12.6±1.8 3.9×10-8 1.52±0.50 
HDL (δ 3.21, br) -19.0±2.5 2.6×10-14 -1.25±0.30 -17.3±2.9 1.6×10-8 -1.24±0.39 -15.3±3.4 2.6×10-5 -1.2±0.50 -16.1±3.7 9.6×10-6 -1.05±0.47 
Histidine (7.04, s) -17.7±2.3 2.5×10-16 -1.31±0.31 -20.0±3.0 4.1×10-11 -1.42±0.40 -15.1±2.9 2.7×10-7 -1.29±0.51 -12.6±3.2 2.7×10-4 -0.95±0.46 
Lactate (4.11, q) 32.6±3.5 4.9×10-14 1.10±0.30 36.0±4.4 1.5×10-9 1.12±0.38 20.6±5.4 2.2×10-4 0.90±0.49 20.7±6.3 7.9×10-4 0.68±0.45 
LDL+VLDL (0.87, br) 31.8±3.7 2.7×10-11 1.02±0.30 30.1±4.8 8.7×10-6 0.90±0.38 29.4±5.9 4.6×10-6 1.19±0.50 24.7±5.5 1.5×10-4 0.92±0.46 
Methanol (3.35, s) -33.0±7.5 2.6×10-9 -0.83±0.29 -38.2±10.3 1.5×10-6 -0.94±0.38 -21.7±9.5 2.7×10-3 -0.58±0.47 -33.7±11.9 1.3×10-3 -0.74±0.45 
Pyruvate (2.36, s) 22.2±2.8 6.0×10-12 0.99±0.29 24.5±3.5 1.5×10-8 1.02±0.38 19.2±4.8 6.8×10-5 0.97±0.49 20.7±4.7 5.5×10-5 0.91±0.46 
Serine (3.96, m)     
Valine (1.03, d) -8.5±2.2 5.0×10-5 -0.90±0.28 -12.4±2.9 1.1×10-5 -0.91±0.38 n.s. -10.8±3.2 1.3×10-3 -0.77±0.45 
U1 (6.71, br) -31.7±5.4 1.3×10-13 -1.08±0.30 -37.6±7.2 3.8×10-11 -1.34±0.40 -23.9±7.4 1.6×10-4 -0.86±0.48 -24.1±7.1 1.2×10-4 -0.85±0.46 
U2 (7.59, br) -26.1±3.7 5.2×10-14 -1.19±0.30 -29.2±4.6 6.3×10-11 -1.38±0.40 -21.3±6.4 3.1×10-4 -0.94±0.49 -20.4±6.0 2.0×10-4 -0.85±0.46 
a
Wilcoxon rank sum test p<4.2×10
-3
 (Bonferroni-corrected). 
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Indeed, spectral integration confirmed most differences between patients and 
controls to be independent of gender, since the % variation of most metabolites was 
similar when considering the two genders either together or separately (Table 4.8). This 
was valid for HDL and LDL+VLDL lipoproteins, which maintained their importance in 
individual gender models, thus allowing their possible gender-related bias to be 
discarded. On the other hand, variations in acetoacetate and valine were no longer 
significant in the discrimination between female controls and female patients (Table 4.8), 
suggesting that some metabolic alterations in cancer may be gender-specific. 
 
4.5.2 Age-related metabolic features in blood plasma 
This study had a major limitation with regard to age-matching of the control and 
cancer groups, as the average age of the controls was 42 years-old (median 44 years-old), 
while that of lung cancer patients was 62 years-old (median 63 years-old). This twenty-
year difference (p<2.2×10
-16
) was due to the difficulty in finding older healthy volunteers 
to integrate the control group and to the greater prevalence of lung cancer in elderly 
subjects. To address the extent to which age could be reflected in the plasma metabolic 
profile, OPLS regression analysis was applied to the plasma spectra of control subjects 
using their age as classifier (age range 22-60). Although the resulting model showed a 
weak predictive ability (Q
2
 near zero, as assessed by seven-fold cross validation), the 
distribution of scores along LV1 suggested some age-dependency (Figure 4.9a). 
 
 
Figure 4.9 OPLS1 regression of the plasma 
1
H NMR spectra of healthy controls (n 93) and the 
subjects age: a) scores scatter plot of the first two latent variables, where the size of the circle is 
proportional to age, b) LV1 loadings weights, coloured as a function of VIP. The parameters shown on 
the scores plot (LV: latent variable, R
2
X: variation explained by the X matrix, R
2
Y: variation explained 
by the Y matrix, Q
2
: predictive power) derive from default 7-fold cross validation. 
a) b) 
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In the corresponding loadings (Figure 4.9b), the variables important for regression 
were the signals of lipoproteins LDL+VLDL (increased in older subjects), and -
hydroxybutyrate, histidine and albumin (increased in younger subjects). Concordantly, 
histidine has already been pointed out by Yu and colleagues as an age-dependent 
metabolite (Yu et al. 2012). The authors proposed the metabolic conversion of histidine to 
carnosine as a likely explanation for its lower levels in older people, since carnosine (a 
dipeptide formed of -alanine and histidine) is considered to be a natural anti-aging 
molecule due to its role in suppressing biochemical alterations, like oxidative damage and 
protein glycation (Hipkiss 2010). Regarding lipoproteins, a study by Freedman and 
colleagues suggested positive correlations of VLDL and LDL concentrations with age, in 
particular for women, whilst HDL-age correlations were weak for both men and women 
(Freedman et al. 2004). As for albumin, an early paper reported that its concentration in 
human serum decreases with age in healthy subjects (Veering et al. 1990), thus agreeing 
with our results.  
Taking into consideration that the cancer group was composed of older subjects, 
age could indeed be a source of bias regarding the variation of lipoproteins (increased in 
both cancer and older subjects), albumin and histidine (decreased in both cancer and older 
subjects) (Table 4.9), an hypothesis to be more deeply investigated, as described below. 
 
Table 4.9 Age-related metabolic variations in plasma and their comparison with cancer-related 
variations. 
Age-related metabolites 
Variation with 
increasing age 
Variation 
cancer vs. control 
Observations 
Albumin   Possible biasa 
Histidine   Possible biasa 
β-Hydroxybutyrate  - Opposite variation 
LDL+VLDL   Possible bias
a
 
a
 Metabolites increased/decreased in both older subjects and patients may potentially bias cancer 
vs. control discrimination as the median age of the cancer group is significantly higher than that 
of the control group. 
 
In order to further assess possible influence of age on cancer vs. control 
discrimination a more age-balanced subset (n 80) (controls: n 42, 21M/21F, 
average/median age 52/50 years-old; cancer patients: n 38, 24M/14F, average/median age 
55/56 years-old) has been tested. The resulting PLS-DA model could be MCCV-validated 
but showed much lower sensitivity and specificity than the whole dataset model, 
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affording an overall classification rate of 69% (Table 4.6). Thus, age mismatching could 
not be ruled out as an important confounding factor in the plasma-based cancer vs. 
control discrimination achieved in this study. In regard to discriminant metabolites, all 
variations found to be important in the whole dataset model held their importance in the 
subset with improved age-matching, as shown by the superimposition of variables in the 
VIP-wheel (Figure 4.10) and confirmed by spectral integration (Table 4.8). Therefore, the 
possible age-bias suspected for lipoproteins, albumin and histidine was not corroborated. 
On the other hand, decreases in acetate, alanine and glucose emerged as new significant 
changes in the age-matched subset (Table 4.8). 
 
 
Figure 4.10 VIP-wheel representation of variables found to have VIP>1 in the plasma OPLS-DA 
models built with: the whole dataset (black), a subset with improved age-matching between 
controls and patients (blue). 
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4.5.3 Possible impact of smoking habits and other potential confounders 
As a first approach to assess the impact of smoking habits on the plasma 
composition, control subjects were divided into smokers (n 29) and never-smokers (n 44) 
and their spectra subjected to PLS-DA. As shown in Table 4.6, a negative median Q
2
 and 
low classification rate (58.2%) were obtained, clearly showing that the NMR plasma 
profiles from healthy never-smokers could not be discriminated from those of control 
smokers, thus hindering any further assumption about putative plasma metabolites related 
with smoking habits. This finding differed from the results published by Xu et al. 
whereby the effects of smoking and smoking cessation on human serum metabolic profile 
were assessed by untargeted LC-MS. The authors reported twenty-one smoking-related 
metabolites, including amino acids (serine, arginine, aspartate, ornithine and glutamate) 
and phospholipids (phosphatidylcholines, lysophosphatidylcholines and 
hydroxysphingomyelin), and a reversible behaviour of the serum profile after smoking 
cessation (Xu et al. 2013). The discrepancy between this study and ours may eventually 
relate to the different sensitivities of the analytical techniques used or the different 
composition of the groups compared (e.g., in terms of age, cigarette consumption). 
With respect to the influence of smoking habits on cancer vs. control 
discrimination, the heterogeneous nature of the control group, comprising smokers (n 29), 
former smokers (n 21) and never-smokers (n 44), is expected to reduce the possibility of 
smoke-related bias. Still, subgroups of control subjects, divided according to their 
smoking habits, have been modelled by PLS-DA together with cancer patients (using also 
a subset of patients to avoid large imbalance in sample numbers between groups). The 
corresponding MCCV results are shown in Table 4.6. Compared to the whole dataset 
model, these new models showed similar predictive power, sensitivity and specificity, 
thus corroborating the low influence of smoking habits. Indeed, the corresponding 
loadings (not shown) were identical to those explaining the separation between control 
and cancer in the total model. 
Concerning other potential confounders, the dietary influence was tentatively 
minimized by collecting all samples after overnight fasting, thus excluding diurnal 
variations (Park et al. 2009). Nevertheless, the effect of diet on the metabolic content of 
plasma could not be entirely excluded as subjects were not under any 
controlled/standardised dietary regime, and it is known that diet can induce significant 
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alterations, for instance, in the fatty acid composition of plasma (Skeaff et al. 2006). 
Other possible confounding factors which could account for metabolic variations, but 
were not evaluated in this study, are the body mass index (BMI) and weight loss or 
malnutrition. Lawton at al. reported high BMI to be associated with increased plasmatic 
creatine, kynurenine and urea (Lawton et al. 2008). Although in the present study none of 
these metabolites has been proposed to be cancer-related, future studies should entail the 
possible influence of varying BMI. In regard to weight loss, a common condition in 
patients with advanced stage cancer, it has been reported that alterations in glucose and 
alanine metabolism, detected in the plasma of lung cancer patients, may depend on the 
degree of weight loss (Leij-Halfwerk et al. 2000). Although knowing that most patients 
enrolled in our study were at stage I (where weight loss is less common), this parameter 
should also be assessed in future studies. 
 
4.6 Preliminary external validation of plasma-based classification 
models 
An important step in the validation of a biomarker compound or profile consists of 
testing its ability to predict class membership of an external (independent) set of samples 
(Bleeker et al. 2003). Despite no independent set was available, external validation was 
tested by using a subgroup of samples as prediction set (control n 20, cancer n 20), while 
the training set was composed of the remaining samples (control n 74, cancer n 86). 
Samples chosen to constitute the prediction set were the ones collected and analysed more 
recently. Class prediction of these samples was performed based on PLS-DA models built 
with the training set and using either the full resolution data or the twelve metabolites 
previously found to be more relevant in cancer vs. control discrimination. The 
corresponding scores scatter plots are shown in Figure 4.11a and 4.11b and the prediction 
results are presented in Table 4.10. When using the full resolution spectra only, 13 out of 
20 controls (specificity of 65%) and 15 out of 20 cancer patients (sensitivity of 75%) 
were correctly classified, whilst when using the twelve relevant integrals, sensitivity and 
specificity increased to 85%. This result demonstrated that the amount of information 
contained in a full resolution spectrum may not all correlate with cancer vs. control 
discrimination, and that the extraction of the most relevant features can, in some 
instances, improve the classification accuracy.  
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Figure 4.11 Scores scatter plot obtained by PLS-DA of a) full resolution 
1
H NMR plasma spectra 
(LV=2, R
2
X=0.23, R
2
Y=0.65, Q
2
=0.53), and b) 12 signal integrals (LV=2, R
2
X=0.53, R
2
Y=0.89, 
Q
2
=0.87),  using in the calibration set 74 samples from controls and 86 samples from patients. 
The scores corresponding to class prediction of additional 40 samples (20 controls and 20) are 
superimposed in lighter colour. 
 
Table 4.10 Confusion matrix showing the prediction results for an independent test set (20 
controls and 20 patients) obtained by PLS-DA modelling of a calibration set (74 controls and 86 
patients), using either the full resolution plasma spectra or 12 selected signal integrals 
(acetoacetate, glutamine, histidine, lactate, methanol, glycoproteins, pyruvate, U1 and U2, valine, 
HDL and LDL+VLDL). Shaded boxes show the number of samples correctly classified. 
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4.7 Proposed biochemical interpretation of cancer-related metabolic 
variations in blood plasma 
According to the results presented in the preceding sections, the metabolic 
composition of the patients‟ plasma differed significantly from controls in the following 
main aspects: increased levels of lactate, pyruvate, acetoacetate, LDL+VLDL and 
glycoproteins, together with decreased levels of several amino acids (glutamine, histidine, 
valine, serine, arginine/lysine), HDL lipoproteins, methanol and two unknowns. 
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The increased lactate levels in the plasma of cancer patients corroborates the 
glycolytic shift in energy metabolism, already observed through direct tissue analysis 
(subchapter 3.5), and agrees with literature reports on lung cancer (Hori et al. 2011; 
Jordan et al. 2010) and other cancer types, namely kidney (Gao et al. 2008), liver (Gao et 
al. 2009) and colorectal (Qiu et al. 2009) cancers. Moreover, the increase in pyruvate 
(precursor of lactate) and the trend for glucose depletion (which reached statistical 
significance when comparing groups with improved age matching) further agree with 
enhanced glycolysis. 
A number of amino acids, namely glutamine, histidine, valine, serine, 
arginine/lysine, and alanine in SqCC, were found to be depleted in the plasma of cancer 
patients compared to healthy controls. Although one study reported an opposite variation 
for serine and alanine (Maeda et al. 2010), most literature studies are consistent in 
reporting decreased levels of circulating plasma free amino acids (PFFA) in several 
cancer types (Lai et al. 2005), including lung cancer (Miyagi et al. 2011; Shingyoji et al. 
2013; Wen et al. 2013). In fact, the measurement of PFAA levels is at the basis of a 
diagnosis methodology being developed in Japan, the „AminoIndex technology‟ 
(Okamoto 2012). The observed decreased in plasma amino acids may reflect their 
glucogenic conversion to substrates of the TCA cycle, in order to sustain the higher 
energetic and biosynthetic demands of tumour cells. For instance, glutamine and histidine 
can be converted to α-ketoglutarate, valine to succinyl-CoA, and arginine to fumarate 
(Figure 4.12). The decrease in plasmatic glutamine, in particular, has been observed 
across several cancer types, such as renal (Gao et al. 2008; Zira et al. 2010) and 
pancreatic (Urayama et al. 2010) cancers, and has been associated with the upregulation 
of glutaminolysis in cancer. Indeed, our results of tumour tissue profiling (subchapter 3.5) 
also corroborate this finding. 
Acetoacetate, together with -hydroxybutyrate in the case of AdCs, was found to be 
increased in the patients‟ plasma, which, to our knowledge, is a newly reported variation 
in lung cancer. Regarding other cancer types, acetoacetate was elevated in the serum of 
oral cancer patients (Tiziani et al. 2009) and decreased in renal and liver cancer subjects 
(Gao et al. 2008; H. C. Gao et al. 2009). Acetoacetate and -hydroxybutyrate are ketone  
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Figure 4.12 Schematic representation of the conversion of gluconeogenic amino acids to 
substrates of the TCA cycle. Metabolites in red were found increased in the plasma of lung cancer 
patients, whereas metabolites in green were found decreased in relation to controls. 
a
 Variations 
assessed qualitatively; 
b
 significant variation in SqCC (not in AdC). 
 
bodies, the production of which typically occurs in response to low blood glucose 
availability, in order to use energy from fatty acids (Nelson and Cox 2004). The beta-
oxidation of fatty acids forms acetyl-CoA, which can enter the TCA cycle for energy 
production, or in the case of excessive accumulation, can be used for synthesis of ketone 
bodies (Figure 4.13). Interestingly, recent studies have started to bring to light a relevant 
role for fatty acid oxidation in cancer, namely as an alternative source of ATP and 
reducing power (NADPH) in conditions of metabolic stress, thus providing tumour cells 
survival advantages (Carracedo et al. 2013). 
The proportions of the main lipoprotein subclasses, namely HDL and LDL+VLDL 
were also found to be significantly altered in the plasma of lung cancer patients. 
Lipoproteins are complex structures that function as transport vehicles for water-insoluble 
lipids in the blood. In general, they have a spherical structure with a hydrophobic core of 
non-polar triglyceride and cholesterol ester molecules, surrounded by an amphiphilic 
surface of apoliproteins and phospholipids (Ala-Korpela 1995). Previous studies on the  
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Figure 4.13 Schematic representation of the synthesis of ketone bodies (acetoacetate, acetone and 
β-hydroxybutyrate). Metabolites in red were increased in the plasma of lung cancer patients, 
blood. 
a
 Significant variation in AdC (not in SqCC). 
 
serum lipoprotein profile in cancer subjects suggested significant alterations for a variety 
of haematological and solid tumours, including lung cancer (Fiorenza et al. 2000; 
Muntoni et al. 2009). In agreement with our results, Muntoni et al. reported significantly 
decreased HDL levels in over 500 serum samples from patients with different types of 
solid tumours compared to age- and gender-matched healthy controls. Additionally, the 
same authors reported increased triglycerides and decreased LDL levels in the patietns‟ 
serum. Concordantly, triglyceride-rich lilpoprotein (VLDL) were also found increased in 
the present work, whereas the variation of LDL could not be evaluated on its own due to 
spectral overlap. Although the biochemical origin of lipoprotein changes is not well 
understood, a possible explanation for decreased HDL levels is the increased uptake of 
circulating lipoproteins to supply the necessary cholesterol for membrane build-up of 
proliferating tumour cells. Moreover, it has been suggested that the general poor 
nutritional status of cancer patients may also account for an altered lipoprotein profile 
(Fiorenza et al. 1996), although not explaining it entirely (Fiorenza et al. 2000). 
Another significant alteration was the increase in N-acetylated glycoproteins 
detected in the patients‟ plasma, similarly to the findings reported by other metabolomic 
studies of pancreatic (Zhang et al. 2012) and hepatocellular cancers (Nahon et al. 2012). 
Protein glycosylation is a common post-translational modification, known to play 
fundamental roles in numerous biological processes and in the pathogenesis of several 
diseases, including cancer (Kim and Misek 2011). Indeed, cancer cells are known to 
express aberrant glycosylation patterns and several serological cancer biomarkers used 
clinically (such as prostate-specific antigen – PSA, cancer antigen CA15.3, and 
carcinoembryonic antigen – CEA) are glycoproteins. This has in fact stimulated intensive 
acetyl-CoA
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research in the field of glycoproteomics, with several studies having addressed the serum 
glycoproteome of lung cancer patients (Zeng et al. 2010; Tran et al. 2008; Heo et al. 
2007). Thus, in the continuity of this work, it would be very interesting to further 
characterize the glycoprotein fraction detected by NMR through other techniques with a 
higher resolving power, namely using mass spectrometry proteomics. 
Finally, compared to controls, lung cancer patients showed relatively lower 
methanol levels. Endogenous methanol has been reported to the present in the blood 
plasma of healthy individuals (Haffner et al. 1996; Psychogios et al. 2011), but no 
previous record of its variation in cancer patients was found. Being of microbial origin, it 
has been reported in saliva (Takeda et al. 2009) and urine of Pneumoniae-infected 
patients (Slupsky et al. 2009), but no explanation for the decrease of methanol levels in 
the blood plasma of cancer patients could be proposed at this point. 
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5 NMR METABOLOMIC STUDY OF URINE TO ASSESS 
METABOLIC ALTERATIONS RELATED TO LUNG 
CANCER 
 
This chapter describes the results of applying NMR metabolomics to unveil urinary 
cancer-related metabolic features. Following a brief account on the urine composition 
viewed by NMR, the discrimination between lung cancer patients and healthy controls 
through multivariate analysis is presented, and the putative discriminant metabolites are 
highlighted, considering also their dependency on histological type and stage. In a 
subsequent section, the influence of potential confounders (gender, age, smoking habits) is 
evaluated. Finally, tentative biochemical interpretation for some of the main cancer-related 
urinary changes is presented. 
 
5.1 Metabolic composition of human urine: spectral assignment based 
on 1D and 2D NMR experiments 
Urine is an aqueous mixture of numerous compounds, mainly small metabolites, with 
variable concentration levels, giving rise to highly complex 1D 
1
H NMR spectra with 
hundreds of overlapping peaks (Figure 5.1). Hence, spectral assignment of most urine 
metabolites was only possible with the help of 2D NMR experiments, where overlap is 
minimized and the identification of complete spin systems facilitated. 
1
H-
1
H TOCSY and 
1
H-
13
C HSQC experiments were used for this purpose (together with J-resolved) and are 
illustrated in Figure 5.2. 
Inspection of the TOCSY spectrum allowed the spin systems of several amino acids 
and organic acids to be unequivocally identified, whereas the HSQC and J-resolved 
experiment were especially helpful in the assignment of several singlets which, having no 
scalar couplings, did not show crosspeaks in the TOCSY spectrum. For instance, a number 
of singlets in the 1.9-2.1 region were tentatively assigned to N-acetylated metabolites, 
although their detailed identification was not possible due to low signal intensity and lack 
of information on the remaning part of the molecule (STOCSY was applied using these 
singlets as driver peaks, but showed no relevant correlations to other resonances). 
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According to a literature report on the NMR analysis of urine from patients with inborn 
errors of metabolism, where N-acetylated metabolites tend to be exacerbated, these signals 
correspond to a range of N-acetylated amino acids, N-acetylneuraminic acid or N-
acetylated oligosaccharides (Engelke et al. 2004). Other tentative assignments, based on 
previous literature reports, regarded bile acids (Trump et al. 2006), 4-deoxyerythronate and 
4-deoxythreonate (Appiah-Amponsah et al. 2009; Ellis et al. 2012) and medium-chain fatty 
acids (Holmes et al. 1997). 
 
 
Figure 5.1 Typical 500 MHz standard 1D 
1
H NMR spectra of urine from a lung cancer patient used 
for spectral assignment. Metabolites are numbered in accordance with Table 5.1. (U1: unknown 1, 
δ 4.30; U2: unknown 2, δ 5.35). 
 
Moreover, spiking experiments were also performed in order to confirm the 
assignment of the following metabolites: 1-methylhistidine, 3-methylhistidne, pyruvate, 
scyllo-inositol, trimethylamine-N-oxide and betaine. Overall, based on matching chemical 
shifts, multiplicities and coupling constants of urine 1D and 2D spectra with those of 
reference compounds available in Bruker‟s BBIOREFCODE-2-0-0 database (Bruker 
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Biospin, Rheinstetten, Germany), as well as in other available on-line databases (Bouatra 
et al. 2013; Ulrich et al. 2008; Wishart et al. 2007) and literature reports (Holmes et al. 
1997), sixty six metabolites, all of them previously reported, were identified in human 
urine (Table 5.1), and twenty five resonances remained unassigned.  
 
 
Figure 5.2 Expansions of 2D NMR spectra of urine of a lung cancer patient, used for spectral 
assignment: a) and b) 
1
H-
1
H TOCSY, c) and d) 
1
H-
13
C HSQC. Metabolites are numbered in 
accordance with Table 5.1. 
 
a) b) 
c) d) 
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Table 5.1 Assignment of resonances in the 500 MHz 
1
H NMR spectra of human urine; (s, singlet; 
d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; br, broad). 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
1 Acetate  1.92 (s, βCH3)/30.71 
2 Acetoacetate  2.29 (s, γCH3) 
3 Acetone  2.24 (s, CH3) 
4 N-Acetylated metabolites   1.99 (s, CH3)/25.49 
2.01 (s, CH3)/25.20 
2.03 (s, CH3)/24.84 
2.05 (s, CH3) 
2.07 (s, CH3)/25.09 
2.08 (s, CH3)/24.84 
5 cis-Aconitate  3.12 (d, CH); 5.72 (t, CH2) 
6 Alanine  1.48 (d, βCH3)/18.92; 3.79 (q, αCH) 
7 Allantoin  5.39 (CH)/66.21 
8 -Aminoisobutyrate  1.19 (d, CH3); 2.61 (m, CH2); 3.07 (m, CH2) 
9 Arginine  1.75 (CH2); 1.91 (CH2); 3.27 (t, CH2); 3.77 (CH) 
10 Betaine
a
  3.27 (s, CH3)/56.16; 3.90 (s, CH2) 
11 Bile acids  0.54, 0.57 (s, C18-CH3) 
12 Carnitine  2.23 (s, CH3)/57.19; 2.44 (αCH2); 3.42 (CH2) 
13 Choline  3.21 (s, N(CH3)3)/56.86; 3.52 (m, CH2(NH)); 4.06 (m, CH2(OH)) 
14 Citrate  2.54, 2.69 (dd, α,βCH2)/48.84 
15 p-Cresol sulphate
b
  2.35 (s, CH3)/22.88; 7.21 (C2H, C6H)/132.89; 7.28 (C3H, C5H) 
16 Creatine  3.04 (s, CH3)/39.59; 3.94 (s, CH2) 
17 Creatinine  3.05 (s, CH3)/33.20; 4.06 (s, CH2)/59.44 
18 4-Deoxyerythronate  1.23 (d, CH3) 
19 4-Deoxythreonate  1.11 (d, CH3) 
20 Dimethylamine  2.73 (s, CH3)/37.71 
 Ethanolamine  3.15 (CH2(NH2))/44.35; 3.83 (CH2(OH))/60.77 
22 Fatty acids  0.89/0.90/0.93 (br, CH3); 1.30/1.44 (br, -(CH2)n-); 1.55/1.57/1.60 (br, 
CH2-CH2-CO); 2.17/2.20 (br, CH2-CO) 
23 Formate  8.46 (s, CH) 
24 Fumarate   6.53 (s, CH) 
25 2-Furoylglycine  7.70 (C2H); 7.19 (C3H); 6.65 (C4H) 
26 α-Glucosea  3.42 (C4H); 3.54 (C2H); 3.71 (C3H); 3.77 (C6H); 3.84 (C5H); 5.25 
(d, C1H) 
27 β-Glucosea  3.23 (C2H); 3.44 (C4H); 3.47 (C5H); 3.49 (C3H); 3.72 (C6H); 3.90 
(C6‟H); 4.65 (d, C1H) 
28 Glutamine
a
  2.14 (m, βCH2); 2.45 (m, CH2); 3.78 (αCH) 
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Table 5.1 (continued) 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
29 Glycerophosphocholine  3.23 (s, N(H3)3)/56.98 
30 Glycine  3.57 (s, αCH2)/44.59 
31 Hippurate  3.97 (CH2)/46.61; 7.56 (C2H, C6H (ring))/131.64; 7.64 (C3H, C5H 
(ring))/135.06; 7.83 (C4H (ring))/129.99; 8.50 (br, NH) 
32 Histidine  3.17 (CH2); 3.28 (CH2); 4.01 (CH2); 7.13(s, C4H, ring); 7.99 (s, 
C2H, ring) 
33 α-Hydroxybutyrate  0.90 (t, CH3)/21.49; 1.65 (m, βCH); 1.72 (m, β‟CH) 
34 -Hydroxybutyrate  1.19 (d, CH3); 2.31 (CH); 2.42 (‟CH); 4.15 (αCH) 
35 α-Hydroxyisobutyrate  1.36 (s, αCH3) 
36 -Hydroxyisovalerate  1.27 (s, CH3); 2.35 (CH2) 
37 p-Hydroxyhippurate  3.96 (s, αCH2)/46.72; 6.98 (C3H, C5H (ring))/119.62; 7.76 (C2H, 
C6H (ring))/132.45 
38 p-Hydroxyphenyl 
acetate 
 3.45 (s, CH2)/46.49; 6.87 (C3H, C5H (ring))/118.42; 7.17 (C2H, C6H 
(ring))/132.45 
39 Indoxyl sulfate  7.21 (C8H)/122.67; 7.28 (C7H)/125.03, 7.37 (s, C2H)/119.01; 7.51 
(C6H)/115.29; 7.71 (C9H)/120.57 
40 scyllo-Inositol
a
  2.36 (s, CHOH)/76.63 
41 Isobutyrate  1.07 (d, CH3), 2.47 (m, CH) 
42 Isoleucine  0.93 (t, CH3); 1.01 (d, ‟CH3) 
43 Lactate   1.33 (d, βCH3)/22.83; 4.12 (q, αCH)/68.83 
44 Leucine  0.95 (d, CH3); 0.96 (d, ‟CH3); 3.74 (t, CH) 
45 Lysine  1.46 (m, CH2); 1.73 (m, CH2); 1.91 (m, βCH2); 3.04 (t, CH2); 3.76 
(t, αCH) 
46 Malonate  3.11 (s, CH2)/48.87 
47 Mannitol  3.69, 3.85 (α, α‟CH)/75.23; 3.76 (βCH)/78.51; 3.82 (CH)/74.25 
48 Methylguanidine  2.83 (s, CH3) 
49 1-Methylhistidine
a, b
  3.72 (s, NCH3); 7.05 (s, C4H, ring); 7.78 (s, C2H, ring) 
50 3-Methylhistidine
a, b
  3.75 (s, NCH3); 3.28 (CH3); 3.98 (CH2); 7.15 (s, C4H, ring); 8.10 
(s, C2H, ring) 
51 Methylmalonate  1.24 (d, CH3); 3.16 (q, αCH) 
52 3-Methylxanthine  3.52 (s, CH3); 8.03 (s, CH ring) 
53 2-Oxoglutarate  2.45 (t, CH2)/33.82; 3.00 (βCH2) 
54 Phenylacetylglutamine
b
  1.93, 2.11 (‟CH2)/30.87; 2.26 (CH2)/34.74; 4.18 (CH)/57.81; 
3.67 (CH2)/45.15; 7.43 (C3H, C5H, ring)/132.05; 7.36 (C3H, C5H, 
ring)/132.05; 7.96 (NH) 
55 Pyruvate
a
  2.38 (s, CH3) 
56 Succinate  2.41 (s, CH2)/37.06 
57 Tartrate
a
  4.35 (s, CH)/76.97 
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Table 5.1 (continued) 
No. Compound   1H in ppm (multiplicity, assignment) /  13C in ppm 
58 Taurine
a
  3.27 (t, S-CH2)/50.65; 3.43 (t, N-CH2)/38.52 
59 Threonine  1.34 (d, CH3); 3.59 (d, αCH); 4.26 (m, βCH) 
60 Trigonellinamide  4.48 (s, N(CH3))/51.62; 8.18 (m, C5H, ring)/148.50; 8.90 (d, C4H, 
ring); 8.97 (d, C6H, ring); 9.28 (s, C2H (ring) 
61 Trigonelline  4.44 (s, CH3)/51.41; 8.09 (C3H, ring)/130.73; 8.84 (C2H, C4H, 
ring)/148.11, 149.09; 9.12 (s, C6H, ring)/148.91 
62 Trimethylamine-N-oxide
a
  3.28 (s, CH3)/62.31 
63 Tyrosine  6.90 (d, C3H, C5H, ring); 7.20 (d, C2H, C6H, ring) 
64 Uracil  5.80 (d, C5H, ring); 7.53 (d, C6H, ring) 
65 Urea  5.80 (br, NH2) 
66 Valine  0.99 (d, CH3); 1.04 (d, ‟CH3); 3.62 (d, αCH) 
Metabolite assignments confirmed by 
a
 spiking and 
b
 STCOSY. 
 
5.2 Potential of urine NMR profile to discriminate between patients and 
control subjects 
The urinary metabolic content is a reflection of the excretory and homeostatic 
function of urine, having potential to provide information about the metabolic adaptations 
to different stimuli or perturbations like a disease. Several differences were apparent 
between the average standard 1D 
1
H spectra of healthy individuals (controls) and cancer 
subjects, for instance in the levels of hippurate, phenylacetylglutamine, p-cresol sulphate, 
trigonelline, creatine and creatinine, citrate, dimethylamine, some amino acids and N-
acetylated metabolites (Figure 5.3). To further explore these differences and search for 
consistent variation patterns in the urinary profile of patients, compared to that of controls, 
multivariate analysis has been applied to the spectral data. Group separation, already 
suggested in the PCA scores scatter plot (Figure 5.4a), was clearly visible along the first 
latent variable of PLS-DA and OPLS-DA scores scatter plots (Figure 5.4b and Figure 5.4c, 
respectively). Monte Carlo cross validation (MCCV) showed this discrimination to have 
high predictive power (median Q
2
 0.76) and classification rate (96.8%), with sensitivity 
and specificity values above 96% (Table 5.2). Permutation testing further confirmed the 
robustness of this classification, as permuted models fell along the line of no 
discrimination in the ROC space (Figure 5.4d) and showed a Q
2
 distribution centered on 
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very low values and distinct from the one obtained for the original models (true classes 
assigned) (Figure 5.4e). 
 
 
Figure 5.3 Standard 1D 
1
H NMR average spectra of urine from controls (n 91, green) and lung 
cancer patients (n 109, red), after PQN normalisation. (U1: unknown 1, δ 4.30; U3: unknown 3, δ 
7.68). 
 
Table 5.2 Prediction results obtained by MCCV (500 iterations) of urine PLS-DA models assessing 
the discrimination between lung cancer patients and healthy controls. 
PLS-DA models Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Standard 1D 0.76 97.3 96.2 96.8 
24 Integrals 0.72 97.2 94.2 95.8 
 
The assessment of the urinary metabolites responsible for cancer vs. control 
discrimination was carried out by inspection of the OPLS-DA LV1 loadings plot, where 
each variable was coloured as a function of its VIP (variable importance in the projection)  
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Figure 5.4 MVA applied to the standard 1D 
1
H NMR spectra of urine from controls (n 91) and 
cancer patients (n 109): a) PCA, b) PLS-DA and c) OPLS-DA scores scatter plots. The parameters 
shown on the scores plot (PC: principal components, LV: latent variable, R
2
X: variation explained 
by the X matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive from 
default 7-fold cross validation. d) ROC space (TPR: true positive rate, FPR: false positive rate) and 
Q
2
 histogram obtained by MCCV and permutation testing (500 iterations) of the PLS-DA model. f) 
OPLS-DA LV1 loadings weights coloured as a function of VIP. Metabolites showing VIP>1 are 
assigned in the plot (U1: unknown 1, δ 4.30; U2: unknown 2, δ 5.35; U3: unknown 3, δ 7.68). 
 
-100
-50
0
50
100
-100 0 100
L
V
2
 (
3
.1
%
)
LV1 (5.6%)
Control Cancer
-100
-50
0
50
100
-100 0 100
o
-L
V
1
 (
4
.6
%
)
LV1 (4.6%)
Control Cancer
-150
-100
-50
0
50
100
150
-150 -50 50 150
P
C
2
 (
5
.3
%
)
PC1 (6.0%)
Control Cancer
0%
10%
20%
30%
40%
50%
60%
F
re
q
u
e
n
c
y
Q2 values
True classes Permuted classes
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.2 0.4 0.6 0.8 1.0
T
P
R
 (
s
e
n
s
it
iv
it
y
)
FPR (1-specificity)
True classes Permuted classes
PC=31
R2X=0.65
LV=2
R2X=0.09
R2Y=0.83
Q2=0.71
LV=1+1
R2X=0.09
R2Y=0.83
Q2=0.74
a) b) c) 
d) e) 
f) 
CHAPTER 5 – NMR METABOLOMIC STUDY OF URINE TO ASSESS METABOLIC ALTERATIONS 
RELATED TO LUNG CANCER 
 
167 
(Figure 5.4f). This analysis revealed several compounds to be increased in patients‟ urine, 
namely α-hydroxyisobutyrate, several singlets in the δ 1.98-2.10 region attributed to N-
acetylated metabolites, phenylacetylglutamine, p-cresol sulphate, β-hydroxybutyrate, 
citrate, methylguanidine, creatinine, allantoin and also three unknown resonances at δ 4.30 
(multiplet), δ 5.35 (triplet) and δ 7.68 (doublet). Opposite variations (increased levels in 
the control group) were found for fatty acids, 4-deoxythreonate, histidine and 3-
methylhistidine, creatine, tartrate, trigonelline and hippurate. 
To further evaluate the significance and magnitude of the variations highlighted 
through loadings inspection, metabolites with VIP>1 were integrated, the median values of 
each group statistically compared by the Wilcoxon rank sum test and the corresponding 
effect size calculated. Twenty four metabolites, listed in Table 5.3, showed statistically 
significant differences (p<0.0013, Bonferroni-corrected) between control and cancer 
groups, their inter-group variations ranging from 10 to 70%. Multivariate analysis was then 
repeated on this set of 24 signal areas, the results being presented in Figure 5.5 and Table 
5.2. Notably, this new model with a much lower number of variables behaved very well, 
showing MCCV parameters similar to those obtained when modelling the whole spectral 
range. 
 
Table 5.3 Urine metabolites showing statistically significant differences between lung patients and 
healthy controls. For each metabolite, the average percentage and coefficient of variation were 
obtained by spectral integration of selected signals. Effect sizes and p-values are shown, indicating, 
respectively, the magnitude and statistical significance of the differences. n.s. not significant; br: 
broad; d: doublet; dd: double doublet; m: multiplet;.s: singlet. 
Metabolite 
(δ, multiplicity) 
Cancer vs. Control 
% variation p-value
a
 effect size 
Allantoin (5.39, s) 29.0±5.9 4.2×10-6 0.61±0.28 
Citrate (2.54, dd) 41.3±6.2 1.1×10-6 0.75±0.29 
Creatine (3.94, s) -38.6±14.0 2.1×10-4 -0.52±0.28 
Creatinine (4.06, s) 13.8±2.7 3.1×10-5 0.68±0.29 
p-Cresol sulphate (2.35, s) 34.6±7.9 7.4×10-4 0.51±0.28 
4-Deoxythreonate (1.11, d) -17.2±4.8 1.9×10-5 -0.57±0.28 
Fatty acid -CH2- (1.30, br) -15.3±3.2 1.8×10-7 -0.79±0.29 
Hippurate (7.64, m) -50.0±12.2 2.8×10-11 -0.85±0.29 
Histidine (7.13, s) -34.5±7.0 1.1×10-8 -0.91±0.29 
α-Hydroxyisobutyrate (1.36, s) 30.8±3.6 9.2×10-12 1.02±0.30 
β-Hydroxybutyrate (2.42, dd) 20.5±3.9 7.6×10-5 0.64±0.28 
Methylguanidine (2.83, s) 51.8±4.5 1.3×10-15 1.29±0.31 
N-acetylated metabolite 1 (1.99, s) 11.9±1.8 2.7×10-8 0.87±0.29 
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Table 5.3 (continued) 
Metabolite 
(δ, multiplicity) 
Cancer vs. Control 
% variation p-value
a
 effect size 
N-acetylated metabolite 2 (2.01, s) 36.4±2.3 <2.2×10-16 1.78±0.33 
N-acetylated metabolite 3 (2.03, s) 20.1±2.3 4.0×10-12 1.07±0.30 
N-acetylated metabolite 4 (2.05, s) 19.9±1.7 <2.2×10-16 1.42±0.31 
N-acetylated metabolite 5 (2.07, s) 12.5±2.4 1.1×10-10 0.72±0.29 
N-acetylated metabolite 6 (2.08, s) 10.7±1.8 1.7×10-7 0.81±0.30 
Phenylacetylglutamine (2.26, m) 20.6±4.9 2.7×10-4 0.53±0.28 
Tartrate (4.35, s) -69.8±21.0 <2.2×10-16 -0.83±0.29 
Trigonelline (9.12, s) -49.8±11.4 2.5×10-10 -0.89±0.29 
Unknown (4.30, m) 24.9±2.4 <2.2×10-16 1.29±0.31 
Unknown (5.35, m) 50.6±4.8 1.6×10-13 1.16±0.30 
Unknown (7.68, d) 28.3±1.9 <2.2×10-16 1.80±0.33 
 
 
Figure 5.5 PLS-DA applied to 24 signal integrals measured in the standard 1D 
1
H NMR spectra of 
urine from controls (n 91) and cancer patients (n 109): a) scores scatter plot and b) LV1 loadings. 
The parameters shown on the scores plot (LV: latent variable, R
2
X: variation explained by the X 
matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive from default 7-fold 
cross validation. c) ROC space (TPR: true positive rate, FPR: false positive rate) and Q
2
 histogram 
obtained by MCCV and permutation testing (500 iterations). 
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.2 0.4 0.6 0.8 1.0
T
P
R
 (
s
e
n
s
it
iv
it
y
)
FPR (1-specificity)
True classes Permuted classes
0%
10%
20%
30%
40%
50%
60%
F
re
q
u
e
n
c
y
Q2 values
True classes Permuted classes
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
P
L
S
-D
A
 L
V
1
 l
o
a
d
in
g
s
 w
-4
-3
-2
-1
0
1
2
3
4
-8 -3 2 7
L
V
2
 (
8
.6
%
)
LV1 (26.9%)
Control Cancer
-4
-3
-2
-1
0
1
2
3
4
-8 -3 2 7
L
V
2
 (
8
.6
%
)
LV1 (26.9%)
Control ancer
-4
-3
-2
-1
0
1
2
3
4
-8 -3 2 7
L
V
2
 (
8
.6
%
)
LV1 (26.9%)
Control Cancer
LV=2
R2X=0.36
R2Y=0.75
Q2=0.71
a) b) 
d) e) 
CHAPTER 5 – NMR METABOLOMIC STUDY OF URINE TO ASSESS METABOLIC ALTERATIONS 
RELATED TO LUNG CANCER 
 
169 
5.3 Impact of tumour histological type on the urinary metabolic 
composition 
In order to find out if the cancer-related urinary alterations were dependent on 
tumour histological type, the profiles of either adenocarcinoma (AdC) or squamous cell 
carcinoma (SqCC) (the two types for which more samples were available) were compared 
to those of healthy controls through multivariate analysis. The resulting PLS-DA models 
showed equally good MCCV quality parameters for AdC and SqCC, with high predictive 
power (Q
2
 0.68) and classification rates (>94%) (Table 5.4). Compared to the global 
model, sensitivity has however slightly decreased (to around 85%), probably in relation to 
the unbalanced number of samples in control and cancer groups (consisting of either AdC 
or SqCC). Indeed, when using a smaller control group, sensitivity increased to 94% in the 
AdC model and to 90% in the SqCC model (Table 5.4).  
 
Table 5.4 Prediction results obtained by MCCV (500 iterations) of urine PLS-DA models assessing 
the discrimination between different groups of samples (including different histological types and 
stages). AdC: adenocarcinoma; SqCC: squamous cell carcinoma. 
PLS-DA classes 
[n samples, n M/n F, median age] 
Median 
Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Control vs. Cancer  
[91, 48/43, 45] vs. [109, 77/32, 63] 
0.76 97.3 96.2 96.8 
Control vs. AdC 
[91, 48/43, 45] vs. [42, 23/19, 65] 
0.68 85.6 98.0 94.1 
Control vs. SqCC 
[91, 48/43, 45] vs. [27, 25/2, 63] 
0.68 84.7 98.3 95.2 
Control vs. AdC
a
 
[42, 26/16, 47] vs. [42, 23/19, 65] 
0.71 94.2 96.0 95.1 
Control vs. SqCC
a
 
[42, 26/16, 47] vs. [27, 25/2, 63] 
0.67 90.1 96.8 94.2 
AdC vs. SqCC 
[42, 23/19, 65] vs. [27, 25/2, 63] 
-0.24 36.2 71.8 57.9 
AdC vs. SqCC
b
 
[42, 23/19, 65] vs. [27, 25/2, 63] 
0.46 70.0 87.5 80.6 
Control vs. Cancer stage I 
[91, 48/43, 45] vs. [63, 45/18, 63] 
0.68 94.0 97.0 95.8 
Stage I vs. Stage II+III 
[63, 45/18, 63] vs. [34, 25/8, 62] 
-0.21 27.4 70.7 55.5 
Stage I vs. Stage II+III
b 
[63, 45/18, 63] vs. [34, 25/8, 62] 
0.39 62.1 89.4 79.8 
a
 Using balanced sample numbers in the groups compared.
 b
After variable selection. 
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Regarding the metabolic features explaining the discrimination between each 
histological type and the control group, they were largely similar to those highlighted when 
considering the whole dataset, as assessed by the loadings‟ analysis (not shown). However 
spectral integration allowed some differences to be identified, as shown in Table 5.5. In 
particular, neither creatine nor creatinine showed significant differences when assessed in 
each histological type in relation to controls. Moreover, the difference in citrate, p-cresol 
sulphate, 4-deoxythreonate, β-hydroxybutyrate, phenylacetylglutamine and trigonelline 
was only significant when comparing AdC patients and controls, whereas the increase in 
allantoin was only significant for SqCC. In regard to other metabolic features, no apparent 
large differences were noted in their % variation. 
The ability to discriminate between AdC and SqCC based on the urinary metabolic 
profile was then further investigated through multivariate modelling of cancer samples, 
leaving out the control group. When considering the whole spectral rage (over 25000 
variables), class separation was apparent in the PLS-DA scores scatter plot (Figure 5.6a), 
but MCCV did not validate this result, as it can be seen by the superimposition of true and 
permuted models in the ROC space and Q
2
 histogram, shown in Figure 5.6b, c. However, 
after applying the variable selection method described in subchapter 2.3.5 (which reduced 
the number of variables to about 1600), the MCCV quality parameters were significantly 
improved (Table 5.4 and Figure 5.6d-f). After careful inspection of the variables selected, 
twenty six metabolites were integrated and their corresponding p-values and effect sizes 
calculated. However, out of these, none showed statistically significance differences 
between AdC and SqCC urine samples. This discrepancy between multivariate and 
univariate analysis results suggests that the later may be inadequate to capture the subtle 
differences that may be hiding in the complex urinary profiles, thus requiring the more 
holistic multivariate approach. 
 
 
  
Table 5.5 Urine metabolites showing statistically significant differences between lung patients and healthy controls, considering all samples in the 
patients group (2
nd
 column), only adenocarcinomas (3
rd
 comlumn) or only squamous cell carcinomas (4
th
 column). For each metabolite, the average 
percentage and coefficient of variation were obtained by spectral integration of selected signals. Effect sizes and p-values are shown, indicating, 
respectively, the magnitude and statistical significance of the differences. n.s. not significant; AdC: adenocarcinoma; SqCC: squamous cell carcinoma 
br: broad; d: doublet; dd: double doublet; m: multiplet;.s: singlet. 
Metabolite 
(δ, multiplicity) 
Cancer vs. Control Cancer vs. Control (AdC) Cancer vs. Control (SqCC) 
% variation p-valuea effect size % variation p-valuea effect size % variation p-valuea effect size 
Allantoin (5.39, s) 29.0±5.9 4.2×10-6 0.61±0.28 n.s. 43.2±9.3 1.3×10-5 0.89±0.44 
Citrate (2.54, dd) 41.3±6.2 1.1×10-6 0.75±0.29 62.1±10.2 1.5×10-7 1.16±0.39 n.s. 
Creatine (3.94, s) -38.6±14.0 2.1×10-4 -0.52±0.28 n.s. n.s. 
Creatinine (4.06, s) 13.8±2.7 3.1×10-5 0.68±0.29 n.s. n.s. 
p-Cresol sulphate(2.35, s) 34.6±7.9 7.4×10-4 0.51±0.28 48.0±11.9 2.4×10-4 0.73±0.38 n.s. 
4-Deoxythreonate (1.11, d) -17.2±4.8 1.9×10-5 -0.57±0.28 -25.5±4.9 2.4×10-6 -0.89±0.38 n.s. 
Fatty acid -CH2- (1.30, br) -15.3±3.2 1.8×10
-7 -0.79±0.29 -14.8±3.7 1.6×10-4 -0.67±0.37 -17.3±4.1 7.9×10-5 -0.76±0.44 
Hippurate (7.64, ) -50.0±12.2 2.8×10-11 -0.85±0.29 -46.6±11.9 8.1×10-7 -0.67±0.37 -46.7±11.7 6.1×10-5 -0.65±0.44 
Histidine (7.13, s) -34.5±7.0 1.1×10-8 -0.91±0.29 -33.7±7.0 1.8×10-5 -0.79±0.38 -39.4±7.8 1.5×10-5 -0.88±0.44 
α-Hydroxyisobutyrate (1.36, s) 30.8±3.6 9.2×10-12 1.02±0.30 25.9±6.1 1.9×10-5 0.88±0.38 28.0±4.8 1.3×10-6 1.20±0.45 
β-Hydroxybutyrate (2.42, dd) 20.5±3.9 7.6×10-5 0.64±0.28 25.6±5.8 6.9×10-5 0.89±0.38 n.s. 
Methylguanidine (2.83, s) 51.8±4.5 1.3×10-15 1.29±0.31 57.6±6.4 8.1×10-11 1.43±0.40 55.6±8.8 9.5×10-8 1.34±0.46 
N-acetylated metabolite 1 (1.99, s) 11.9±1.8 2.7×10-8 0.87±0.29 12.4±2.2 1.8×10-6 1.06±0.39 14.5±4.1 8.3×10-4 1.03±0.45 
N-acetylated metabolite 2 (2.01, s) 36.4±2.3 <2.2×10-16 1.78±0.33 34.8±3.2 6.4×10-7 2.22±0.45 42.5±6.9 4.2×10-12 1.99±0.50 
N-acetylated metabolite 3 (2.03, s) 20.1±2.3 4.0×10-12 1.07±0.30 23.1±3.6 9.6×10-9 1.26±0.36 24.8±4.6 4.2×10-7 1.39±0.46 
N-acetylated metabolite 4 (2.05, s) 19.9±1.7 <2.2×10-16 1.42±0.31 21.2±2.5 2.4×10-12 1.65±0.42 25.7±2.8 1.0×10-11 2.16±0.51 
N-acetylated metabolite 5 (2.07, s) 12.5±2.4 1.1×10-10 0.72±0.29 12.8±2.9 1.5×10-7 0.71±0.38 17.8±3.6 2.2×10-7 0.94±0.45 
N-acetylated metabolite 6 (2.08, s) 10.7±1.8 1.7×10-7 0.81±0.30 10.5±2.6 8.1×10-5 0.77±0.38 14.0±2.6 9.0×10-6 1.09±0.45 
Phenylacetylglutamine (2.26, m) 20.6±4.9 2.7×10-4 0.53±0.28 24.9±6.3 1.7×10-4 0.71±0.38 n.s. 
Tartrate (4.35, s) -69.8±21.0 <2.2×10-16 -0.83±0.29 -73.2±16.8 1.7×10-12 -0.72±0.38 -64.0±16.7 2.3×10-6 -0.58±0.44 
Trigonelline (9.12, s) -49.8±11.4 2.5×10-10 -0.89±0.29 -56.7±11.3 5.2×10-8 -0.92±0.38 n.s. 
U1 (4.30, m) 24.9±2.4 <2.2×10-16 1.29±0.31 25.0±3.7 6.9×10-10 1.30±0.40 29.2±4.6 2.1×10-8 1.56±0.47 
U2 (5.35, m) 50.6±4.8 1.6×10-13 1.16±0.30 48.0±7.2 2.8×10-8 1.15±0.39 62.5±10.4 2.8×10-7 1.40±0.47 
U3 (7.68, d) 28.3±1.9 <2.2×10-16 1.80±0.33 28.4±2.6 6.8×10-14 1.84±0.43 29.1±3.2 2.4×10-10 1.87±0.49 
a
Wilcoxon rank sum test p<1.4×10
-3
 (Bonferroni-corrected). 
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Figure 5.6 PLS-DA applied to the urine 
1
H NMR spectra of adenocarcinoma and squamous cell 
carcinoma patients, either using the full resolution data (upper row) or after variable selection 
(lower row): a) and d) PLS-DA scores scatter plots, b) and e) ROC spaces (TPR: true positive rate, 
FPR: false positive rate) and c) and f) Q
2
 histograms obtained by MCCV and permutation testing 
(500 iterations) of PLS-DA models. The parameters shown on the scores plots (LV: latent variable, 
R
2
X: variation explained by the X matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive 
power) derive from default 7-fold cross validation. 
 
5.4 Impact of tumour stage on the urinary metabolic composition 
Similarly to the analysis conducted for plasma, the possible influence of disease 
stage on the urinary profiles was assessed, in a first instance, by modelling each stage in 
comparison with the control group and, secondly, by testing pairwise comparisons between 
stages (leaving out the controls). Stage I patients (n 63) could be discriminated from 
healthy controls (n 91) with a robustness comparable to that attained when modelling the 
whole dataset (Table 5.4 and Figure 5.7a, b). Moreover, the analysis of the corresponding 
loadings showed that the variables explaining stage I vs. control discrimination were the 
same as those previously highlighted as important in the discrimination between all 
patients (regardless of disease stage) and controls (Figure 5.7c). In other words, these 
results show that putative cancer-related metabolic alterations are detectable in the urine of 
patients from early stages of cancer progress. The same approach was followed for stage II 
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(n 24) and stage III (n 10) samples and equally coincident signatures were obtained, 
although in some cases, PLS-DA models could not be properly validated, probably due to 
the unbalanced number of samples in the groups compared. 
 
 
Figure 5.7 a) ROC space (TPR: true positive rate, FPR: false positive rate) and b) Q
2 
histogram 
obtained by MCCV and permutation testing (500 iterations) of the PLS-DA model built with 
1
H 
NMR spectra of urine to assess control vs. cancer stage I discrimination. c) VIP-wheel 
representation of variables found to have VIP>1 in the OPLS-DA models built with: the whole 
dataset (black), the subset with controls and stage I patients (grey). 
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In regard to the pairwise comparisons between cancer samples of different stages, the 
only model with reasonable MCCV parameters was obtained for stage I vs. stage II+III, 
after variable selection (Table 5.4). Still, the predictive power and classification rate were 
only of 0.39 and 79.8%, respectively, and further analysis of selected variables by spectral 
integration did not confirm any statistically significant differences. Thus, there seems to be 
a weak relationship between lung cancer stage and the urinary metabolic profile viewed by 
NMR. 
 
5.5 Influence of potential confounders in urine-based cancer vs. control 
discrimination 
As already mentioned in the previous chapter, the control and cancer groups 
available for this study were not perfectly matched in terms of age, gender and smoking 
habits, which, among other factors, are known to possibly influence the biofluids 
composition. Hence, the urinary metabolic variability associated with these factors has 
been investigated, as described in the following sections. 
 
5.5.1 Gender-related metabolic features in urine 
To assess the influence of gender on the urinary metabolic profile, MVA was firstly 
applied to spectral data from control subjects, divided into males (n 48, average age 42) 
and females (n 43, average age 43). PLS-DA afforded a good discrimination between 
genders (0.58 median Q
2
 and 88% classification rate, as determined by MCCV, Table 5.6), 
indicating that gender has a strong impact on the metabolic profile of human urine.  
Indeed, males and females were clearly separated along LV1 in the scores scatter 
plot (Figure 5.8a) the metabolites underlying this separation being identified in the 
corresponding loadings (Figure 5.8b). Females‟ urine was characterized by higher levels of 
phenylacetylglutamine, p-cresol sulphate, creatine, citrate, hippurate and of two unknown 
resonances at δ 2.41 and δ 3.80, while males‟ urine presented higher amounts of 
methylmalonate, creatinine, taurine, s-inositol, tartrate and of a doublet at δ 1.15.  
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Table 5.6 Prediction results obtained by MCCV (500 iterations) of urine PLS-DA models assessing 
the discrimination between different groups of samples (including groups varying in gender, age 
and smoking habits). 
PLS-DA classes 
[n samples; n M/n F; median age] 
Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Control vs. Cancer 
[91; 48/43; 45] vs. [109; 77/32; 63] 
0.76 97.3 96.2 96.8 
Male vs. Female, controls only 
[48; 48/0; 44] vs. [43; 0/43; 46] 
0.58 88.2 87.8 88.0 
Control vs. Cancer, males only 
[48; 48/0; 44] vs. [77; 77/0; 64] 
0.79 97.7 96.8 97.3 
Control vs. Cancer, females only 
[43; 0/43; 46] vs. [32; 0/32; 58] 
0.71 91.6 96.7 94.5 
Control vs. Cancer, age 41-60 
[42; 20/22; 50] vs. [38; 22/16; 56] 
0.70 92.6 88.2 90.3 
Smoker vs. Non-smoker, controls only 
[28; 17/11; 39] vs. [43; 19/24; 45] 
0.38 62.6 81.6 74.1 
Control smoker vs. Cancer
 a 
 
[28; 17/11; 39] vs. [45; 25/20; 57] 
0.70 96.3 92.2 94.7 
Control non-smoker vs. Cancer 
a
 
[43; 19/24; 45] vs. [45; 25/20; 57] 
0.65 95.0 87.6 91.2 
a Using balanced sample numbers in the groups compared. 
 
 
Figure 5.8 OPLS-DA applied to the 
1
H NMR spectra of urine from control males (n 48) and 
females (n 43): a) scores scatter plot and b) LV1 loadings weights, coloured as a function of VIP. 
The parameters shown on the scores plot (LV: latent variable, R
2
X: variation explained by the X 
matrix, R
2
Y: variation explained by the Y matrix, Q
2
: predictive power) derive from default 7-fold 
cross validation. 
 
These variations were not surprising as significant gender-related differences have 
been previously reported in urine (Kochhar et al. 2006; Slupsky et al. 2007; Psihogios et al. 
2008; Zhang et al. 2011; Swann et al. 2013). In agreement with other studies (Kochhar et 
al. 2006; Ramadan et al. 2006; Slupsky et al. 2007; Rasmussen et al. 2011; S. Zhang et al. 
2011; Bouatra et al. 2013; Swann et al. 2013), creatinine excretion was higher in men, 
possibly in relation to their higher muscle mass, when compared to women. Our results 
a) b) 
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were also consistent with the literature regarding elevated levels of taurine and 
methylmalonate in male urine (Kochhar et al. 2006; Ramadan et al. 2006; Bouatra et al. 
2013; Swann et al. 2013) and of creatine, citrate, hippurate and p-cresol sulphate in female 
urine (Slupsky et al. 2007; Swann et al. 2013). In particular, the endogenous synthesis of 
creatine has been proposed to be enhanced in women (Slupsky et al. 2007), while citrate 
levels have been related to estrogen regulation, through the control exerted by this 
hormone on mitochondrial and cytosolic pH and, hence, on citrate transport and excretion 
(Kochhar et al. 2006). The other metabolic variations found to be important in male vs. 
female discrimination, namely increased s-inositol and tartrate in males and 
phenylacetylglutamine in females, have not, to the best of our knowledge, been previously 
reported. 
Amongst the above mentioned gender-related metabolic features, those which could 
potentially be influencing the cancer vs. control discrimination (due to gender 
mismatching) were creatinine (simultaneously elevated in male and cancer groups), 
creatine and hippurate (simultaneously reduced in male and cancer groups), as summarised 
in Table 5.7.  
 
Table 5.7 Gender-related metabolic variations in urine and their comparison with cancer-related 
variations. 
Gender-related 
metabolites 
Variation 
male vs. female 
Variation 
cancer vs. control 
Observations 
Citrate   Opposite variation 
Creatine   Possible bias
a
 
Creatinine   Possible bias
a
 
p-Cresol sulphate   Opposite variation 
Hippurate   Possible biasa 
s-Inositol  -  
Methylmalonate  -  
Phenylacetylglutamine   Opposite variation 
Tartrate   Opposite variation 
Taurine  -  
U1 (δ 1.15, d)  -  
U2 (δ 1.25, d)  -  
U1 (δ 2.41, s)  -  
ª Metabolites increased/decreased in both male and cancer groups may potentially bias cancer vs. 
control discrimination as the cancer group comprises ~70% male subjects. 
 
In order to evaluate the true weight of these metabolites as potential cancer markers, 
multivariate modelling of control and cancer groups was performed separately for each 
gender. The resulting MCCV-validated PLS-DA models afforded, in both cases, high 
classification rates and predictive powers, thus, confirming the discrimination between 
CHAPTER 5 – NMR METABOLOMIC STUDY OF URINE TO ASSESS METABOLIC ALTERATIONS 
RELATED TO LUNG CANCER 
 
177 
patients and controls to be equally good for males and females (Table 5.6). Regarding the 
cancer-related metabolic features highlighted in each OPLS-DA model, these were very 
similar to those seen when considering the whole dataset, as shown by the high degree of 
overlap between variables with VIP>1 in the VIP-wheel representation of the three models: 
cancer vs. control (n 200, whole dataset), cancer vs. control (n 125, males only) and cancer 
vs. control (n 75, females only) (Figure 5.9). However, some differences are worth of 
mention. When assessed within each gender, the difference in creatine and creatinine levels 
between patients and controls was no longer significant (Table 5.8), thus confirming their 
gender-related bias. Hippurate, on the other hand, was confirmed to be important in cancer 
vs. control discrimination regardless of gender. Still of notice is the fact that some 
differences are more relevant in one gender than the other: 4-deoxythreonate is 
significantly different only between female controls and patients, whereas the difference in 
the levels of allantoin, citrate, p-cresol sulphate, fatty acids, histidine, β-hydroxybutyrate, 
one N-acetylated metabolite and phenylacetylglutamine is more pronounced between 
males (Table 5.8). 
 
 
Figure 5.9 VIP-wheel representation of variables found to have VIP>1 in the urine OPLS-DA 
models built with: the whole dataset (blue), male subjects only (orange) and female subjects only 
(purple).  
Control vs. Cancer (whole dataset)
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Table 5.8 Urine metabolites showing statistically significant differences between lung cancer patients and healthy controls, considering all samples in 
the patients group (2
nd
 column), only males (3
rd
 column), only females (4
th
 column) or an age-matched subset (5
th
). For each metabolite, the average 
percentage and coefficient of variation were obtained by spectral integration of selected signals. Effect sizes and p-values are shown, indicating, 
respectively, the magnitude and statistical significance of the differences between the two groups. n.s. not significant;  qualitative decreased (signal not 
integrated due to spectral overlap); s: singlet; d: doublet; dd: double doublet; m: multiplet; br: broad. 
Metabolite 
(δ, multiplicity) 
Cancer vs. Control 
(ALL SAMPLES) 
Cancer vs. Control 
(MALES ONLY) 
Cancer vs. Control 
(FEMALES ONLY) 
Cancer vs. Control 
(AGE-MATCHED) 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
Allantoin (5.39, s) 29.0±5.9 4.2×10-6 0.61±0.28 24.9±7.7 5.7×10-4 0.54±0.37 n.s. 45.6±9.0 4.1×10-5 0.94±0.46 
Citrate (2.54, dd) c 41.3±6.2 1.1×10-6 0.75±0.29 57.6±7.6 7.8×10-6 0.90±0.38 n.s. n.s. 
Creatine (3.94, s) b -38.6±14.0 2.1×10-4 -0.52±0.28 n.s. n.s. n.s. 
Creatinine (4.06, s) b 13.8±2.7 3.1×10-5 0.68±0.29 n.s. n.s. 19.2±4.1 1.7×10-4 0.96±0.29 
p-Cresol sulphate(2.35, s) 34.6±7.9 7.4×10-4 0.51±0.28 55.8±9.0 7.1×10-5 0.77±0.37 n.s. n.s. 
4-Deoxythreonate (1.11, d) -17.2±4.8 1.9×10-5 -0.57±0.28 n.s. -27.0±7.2 6.8×10-4 -0.92±0.48 n.s. 
Fatty acid -CH2- (1.30, br) -15.3±3.2 1.8×10-7 -0.79±0.29 -20.8±4.7 1.6×10-7 -1.07±0.38 n.s. n.s. 
Hippurate (7.64, m) -50.0±12.2 2.8×10-11 -0.85±0.29 -38.2±9.1 1.5×10-7 -1.03±0.38 -54.4±18.1 1.6×10-4 -0.82±0.48 n.s. 
Histidine (7.13, s) c -34.5±7.0 1.1×10-8 -0.91±0.29 -39.9±9.7 6.5×10-8 -1.17±0.39 n.s. n.s. 
α-Hydroxyisobutyrate (1.36, s) 30.8±3.6 9.2×10-12 1.02±0.30 26.0±4.6 6.2×10-6 0.83±0.38 33.6±5.6 1.2×10-6 1.30±0.50 40.7±5.6 1.8×10-8 1.39±0.49 
β-Hydroxybutyrate (2.42, dd) 20.5±3.9 7.6×10-5 0.64±0.28 24.5±4.1 3.0×10-5 0.83±0.37 n.s. 28.4±6.2 1.0×10-4 0.93±0.46 
Methylguanidine (2.83, s) 51.8±4.5 1.3×10-15 1.29±0.31 40.7±5.0 6.4×10-9 1.15±0.39 71.0±8.4 1.8×10-8 1.50±0.51 51.9±7.4 1.3×10-7 1.26±0.48 
N-acetylated metabolite 1 (1.99, s) 11.9±1.8 2.7×10-8 0.87±0.29 14.0±2.3 1.4×10-6 0.95±0.38 10.6±2.9 1.3×10-3 0.88±0.48 n.s. 
N-acetylated metabolite 2 (2.01, s) 36.4±2.3 <2.2×10-16 1.78±0.33 33.2±3.0 5.3×10-15 1.47±0.40 40.9±3.4 1.6×10-14 2.60±0.62 43.4±4.9 1.4×10-15 1.72±0.51 
N-acetylated metabolite 3 (2.03, s) 20.1±2.3 4.0×10-12 1.07±0.30 21.6±2.6 1.9×10-9 1.16±0.39 20.6±4.1 3.5×10-5 1.08±0.49 33.6±4.2 1.1×10-10 1.57±0.50 
N-acetylated metabolite 4 (2.05, s) 19.9±1.7 <2.2×10-16 1.42±0.31 22.2±2.2 1.0×10-12 1.55±0.41 17.1±3.2 8.5×10-6 1.25±0.50 19.9±1.7 <2.2×10-16 1.42±0.31 
N-acetylated metabolite 5 (2.07, s) 12.5±2.4 1.1×10-10 0.72±0.29 13.1±3.7 3.5×10-8 0.66±0.37 11.5±3.0 8.5×10-6 0.90±0.48 16.7±4.6 4.8×10-8 0.73±0.45 
N-acetylated metabolite 6 (2.08, s) 10.7±1.8 1.7×10-7 0.81±0.30 13.8±2.3 2.0×10-7 1.03±0.38 n.s. 16.4±2.6 1.0×10-7 1.34±0.49 
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Table 5.8 (continued) 
Metabolite 
(δ, multiplicity) 
Cancer vs. Control 
(ALL SAMPLES) 
Cancer vs. Control 
(MALES ONLY) 
Cancer vs. Control 
(FEMALES ONLY) 
Cancer vs. Control 
(AGE-MATCHED) 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
% 
variation 
p-valuea effect size 
Phenylacetylglutamine (2.26, m) c 20.6±4.9 2.7×10-4 0.53±0.28 31.6±6.1 6.7×10-5 0.74±0.37 n.s. n.s. 
Tartrate (4.35, s) -69.8±21.0 <2.2×10-16 -0.83±0.29 -76.0±29.8 1.1×10-14 -1.11±0.39 -58.1±26.7 9.0×10-6 -0.59±0.47 -73.6±25.5 1.2×10-9 -0.95±0.46 
Trigonelline (9.12, s) -49.8±11.4 2.5×10-10 -0.89±0.29 -51.1±15.7 1.9×10-6 -1.00±0.38 -50.6±17.8 2.3×10-6 -0.80±0.48 -49.7±16.9 7.3×10-5 -0.84±0.46 
Unknown (4.30, m) 24.9±2.4 <2.2×10-16 1.29±0.31 28.0±2.6 7.0×10-13 1.56±0.41 23.2±4.6 2.5×10-6 1.10±0.49 24.9±2.4 <2.2×10-16 1.3±0.31 
Unknown (5.35, m) 50.6±4.8 1.6×10-13 1.16±0.30 38.5±6.0 3.1×10-06 0.93±0.38 65.4±8.5 1.5×10-8 1.46±0.51 58.5±7.1 5.6×10-9 1.45±0.49 
Unknown (7.68, d) 28.3±1.9 <2.2×10-16 1.80±0.33 34.4±2.3 <2.2×10-16 2.16±0.45 23.5±3.1 7.4×10-9 1.57±0.52 31.3±2.9 2.3×10-13 2.12±0.55 
a
Wilcoxon rank sum test p<1.4×10
-3
 (Bonferroni-corrected). Metabolites found to be affected by 
b
gender- or 
c
age-related bias. 
 
5.5.2 Age-related metabolic features in urine 
The significant difference between cancer and control subjects (median ages of 63 and 45 years old, respectively) can potentially bias 
the results of group discrimination. The extent to which age was reflected on the urinary profile was firstly assessed by OPLS1 regression 
analysis using the spectra from controls and their age as the Y-matrix (age range 22-59). The resulting scores scatter plot suggested a 
relationship with age, with older subjects being located towards positive LV1 (Figure 5.10a). Despite the low predictive power obtained by 
seven-fold cross validation (Q
2
 0.13), the corresponding loadings (Figure 5.10b) were examined and suggested the following age-related 
metabolic features: increased excretion of citrate, dimethylamine, trimethylamine-N-oxide, hippurate and phenylacetylglutamine in older 
subjects, and increased levels of N-acetylated metabolites, creatinine and histidine in younger subjects. 
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Figure 5.10 OPLS regression of the urine 
1
H NMR spectra of healthy controls (n 90) and the 
subjects‟ age: a) scores scatter plot of the first two latent variables, where the size of the circle is 
proportional to age, b) LV1 loadings weights coloured as a function of VIP. The parameters 
shown on the scores plot (LV: latent variable, R
2
X: variation explained by the X matrix, R
2
Y: 
variation explained by the Y matrix, Q
2
: predictive power) derive from default 7-fold cross 
validation. 
 
The increased excretion of trimethylamine-N-oxide, dimethylamine and citrate in 
older subjects has been already reported by Psihogios and co-workers (Psihogios et al. 
2008). They suggested a slight dysfunction of the osmotic role of these metabolites in 
renal medullary tissue as the main reason for this fact. Also, in accordance with what was 
observed in this work, another study involving a Taiwanese and American population, 
reported a positive correlation between the levels of phenylacetylglutamine and age 
(Swann et al. 2013). The decline of creatinine levels in older subjects (Slupsky et al. 
2007) has been associated with decreasing muscle mass and decline in glomerular 
filtration rate (Salek et al. 2007). Concerning hippurate levels, an opposite variation 
(decrease with age) was published by Psihogios and no reference to histidine levels was 
found. Interestingly, blood plasma histidine has also been highlighted in the previous 
chapter to be dependent on age, having shown increased levels in younger subjects (as 
seen for urine). 
By comparing age- and cancer-related variables (Table 5.9) and given that the 
cancer group comprised much older subjects than the control group, it becomes apparent 
that a few of the latter variables may potentially be biased by the age difference between 
groups. This is the case of citrate and phenylacetylglutamine, simultaneously increased 
with age and in cancer, and of histidine, simultaneously decreased in younger subjects 
and in controls. 
a) b) 
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Table 5.9 Age-related metabolic variations in urine and their comparison with cancer-related 
variations. 
Age-related metabolites 
Variation with 
increasing age 
Variation 
cancer vs. control 
Observations 
N-acetylated metabolites   Opposite variation 
Citrate   Possible biasa 
Creatinine   Opposite variation 
Dimethylamine  -  
Hippurate   Opposite variation 
Histidine   Possible biasa 
Phenylacetylglutamine   Possible biasa 
Trimethylamine-N-oxide  -  
a
 Metabolites increased/decreased in both older subjects and patients may potentially bias cancer 
vs. control discrimination as the median age of the cancer group is significantly higher than that 
of the control group. 
 
In order to further investigate this possibility, a subgroup of subjects with a smaller 
age difference between controls (n 42, median age 50 years-old, 20M/22F) and patients (n 
38, median age 56 years-old, 22M/16F) has been considered for multivariate analysis. 
Although absolute matching was not possible, the influence of age is expected to be 
significantly reduced in this subgroup of samples (hereby designated as age-matched). 
Notably, a model with high predictive power (Q
2
 0.70) and classification rate (90.3%) 
could still be obtained (Table 5.6), thus allowing age to be excluded as a strong 
confounding factor. Concerning the comparison of cancer-related variables highlighted in 
the global and age-matched models (Figure 5.11), there are a few differences to note. 
Citrate, histidine and phenylacetylglutamine did not have VIP>1 or statistically 
significant differences between control and cancer age-matched groups, thus confirming 
that their importance as cancer markers in the global model could be biased by age 
mismatching. Moreover, spectral integration also demonstrated the loss of significance 
for other metabolites, previously mentioned as important for group discrimination, 
namely creatine, p-cresol sulphate, 4-deoxythreonate, fatty acids, hippurate and N-
acetylated metabolite δ1.99 (Table 5.8). This result suggested that the metabolic response 
to cancer may differ with age. 
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Figure 5.11 VIP-wheel representation of variables found to have VIP>1 in the urine OPLS-DA 
models built with: the whole dataset (black), a subset with improved age-matching between 
controls and patients (blue). 
 
5.5.3 Possible impact of smoking habits and other potential confounders 
For assessing the possible influence of smoking habits on the urinary metabolic 
composition, control subjects were divided into smokers (n 28) and never-smokes (n 43) 
and their NMR metabolic profiles compared by means of MVA. MCCV of the PLS-DA 
model resulted in a moderate classification rate (74.1%) and relatively low predictive 
power (median Q
2
 0.38) (Table 5.6). This is in accordance with a previous urine NMR 
metabolomics study failing to accurately classify subjects according to their smoking 
habits (Psihogios et al. 2008). The corresponding loadings also reflected the low impact 
of smoke on urine spectra, as only a few variables showed VIP>1 (not shown). These 
included the resonances of trigonelline (increased in smokers‟ urine) and several 
unknown signals, some of which being correlated in STOCSY plots (not shown): doublet 
at δ 2.18 correlated with singlet at δ 9.05, and singlet at δ 4.41 correlated with doublet at δ 
8.79 (increased in smokers‟ urine), together with singlets at δ 3.16 and δ 3.65 ppm 
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(decreased in smokers urine). The possible assignment of these signals to common 
nicotine urinary metabolites (nicotine and cotinine derivatives) has been attempted with 
no success, their identification remaining unknown. In regard to trigonelline, given that 
the cancer group is assumed to be composed mainly by smoke-exposed subjects (based 
on the histological characteristics of their lungs), the opposite variations found for this 
metabolite in smokers vs. non-smokers and cancer vs. control comparisons enables its 
possible bias to be discarded. The role of smoking habits as a possible confounding factor 
in cancer vs. control discrimination was further assessed by considering multivariate 
modelling of each control subgroup (never-smokers and smokers) against the cancer 
group. Both models maintained high predictive power (Q
2
 values 0.6-0.7) and 
classification rate (>90%). Moreover, the loadings profile resulting from these models 
(not shown) were identical to those obtained for the global model, thus confirming the 
small influence of smoking habits on cancer vs. control discrimination.  
With respect to other possible confounding factors, diet is certainly one of the most 
relevant, as it is well known that it can modulate human urinary metabolic composition 
and account for the high inter-individual variability observed in urine spectra (Stella et al. 
2006; Walsh et al. 2006; Winnike et al. 2009; Rasmussen et al. 2011). However, in the 
majority of metabolomic studies there is no dietary restriction, likely to better reflect a 
possible clinical scenario, so that the interpretation of disease biomarkers in urine should 
take the variability introduced by diet into consideration. In this work, dietary influence 
and impact of time of day or circadian rhythms were minimized by collecting all samples 
in the morning, after overnight fasting, as suggested in the literature (Slupsky et al. 2007). 
Still, possible relationships of cancer-related metabolic variations with diet and/or gut 
microflora may be present and will be addressed in section 5.8. Body mass index (BMI) 
has also been reported to be reflected on urine composition, namely on the levels of 
citrate, lactate, dimethylamine and glycine (Kochhar et al. 2006). Amongst these 
metabolites, only citrate has been putatively identified in this work as being cancer-
related (as well as age-related). Therefore, although BMI data was not available for this 
study, based on the literature, it is unlikely that it might have a strong influence on the 
results obtained. 
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5.6 Reassessment of cancer vs. control discrimination after excluding 
possibly biased variables 
Consideration of gender-, age- and smoke-related metabolite variations (described 
in the sections above) led to the identification of citrate, creatine, creatinine, histidine and 
phenylacetylglutamine as possibly biased variables. Thus, reassessment of cancer vs. 
control discrimination after exclusion of those metabolites has been performed, either 
using full-spectral resolution or the relevant integrals for class discrimination. Figure 
5.12a-c shows the MVA results obtained for the comparison of controls and lung cancer 
patients, when using NMR full-resolution data, after excluding biased variables.  
 
 
 
Figure 5.12 MVA applied to the standard 
1
H NMR spectra of urine from controls (n 91) and 
cancer patients (n 109), after exclusion of gender- and age-biased variables: a) OPLS-DA scores 
scatter plot, b) ROC space (TPR: true positive rate, FPR: false positive rate) and c) Q
2
 histogram 
obtained by MCCV and permutation testing (500 iterations) of the PLS-DA models. d) VIP-wheel 
representation of variables found to have VIP>1 in the OPLS-DA models built with: the whole 
spectral range (black) or after exclusion of biased variables (brown). The parameters shown on 
the scores plot (LV: latent variable, R
2
X: variation explained by the X matrix, R
2
Y: variation 
explained by the Y matrix, Q
2
: predictive power) derive from default 7-fold cross validation. 
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The classification results were very similar to the model obtained previously 
(without rejecting any variables) (Table 5.10), indicating the low impact of the excluded 
variables. Also, as seen in the VIP-wheel representation (Figure 5.12d), apart from the 
difference in excluded variables, there was almost perfect overlap between the important 
variables highlighted in the two models. 
 
Table 5.10 Prediction results obtained by MCCV (500 iterations) of urine PLS-DA models 
assessing the discrimination between lung cancer patients and healthy controls: comparison with 
models reassessed after exclusion of gender- and age-biased variables. 
PLS-DA models Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Standard 1D 0.76 97.3 96.2 96.8 
Standard 1D (after exclusion of 
biased variables) 
0.75 96.9 95.6 96.3 
24 Integrals 0.72 97.2 94.2 95.8 
19 Integrals (after exclusion of 
biased variables) 
0.71 94.8 96.2 95.4 
 
A similar evaluation was performed using the integrals found to be relevant in 
cancer vs. control discrimination. So, when excluding citrate, creatine, creatinine, 
histidine and phenylacetylglutamine from the group of twenty four important integrals, 
MCCV afforded comparable quality parameters to those obtained for the model 
comprising all the integrals (Table 5.10 and Figure 5.13). Moreover, compared to the 
results obtained for the model built with full-resolution spectra, MVA of the nineteen 
relevant integrals provided equally good classification rate and predictive ability, 
suggesting these metabolites to be representative of the urinary malignant signature. 
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Figure 5.13 PLS-DA applied to 19 integrals (after exclusion of gender- and age-biased variables) 
measured in the standard 1D 1H NMR spectra of urine from controls (n 91) and cancer patients (n 
109): a) scores scatter plot and b) LV1 loadings weights. The parameters shown on the scores plot 
(LV: latent variable, R
2
X: variation explained by the X matrix, R
2
Y: variation explained by the Y 
matrix, Q
2
: predictive power) derive from default 7-fold cross validation. c) ROC space (TPR: 
true positive rate, FPR: false positive rate) and d) Q
2
 histogram obtained by MCCV and 
permutation testing (500 iterations). 
 
5.7 Preliminary external validation of urine-based classification models 
Although a truly independent sample set was not available in this study, the ability 
of the urine profile to predict class membership of new samples was tested by rebuilding 
the classification model with a smaller group of samples (training set: control n 71, cancer 
n 89) and using this model to predict the class of the remaining samples (prediction set: 
control n 20, cancer n 20). The samples in the prediction set were those collected and 
analysed more recently. PLS-DA models were built using either the full spectral range 
(excluding the biased variables identified in the previous section) or the areas of the 19 
metabolites found to be more relevant in cancer vs. control discrimination. The respective 
scores scatter plots are shown in Figure 5.14a, b and the classification results are 
presented in Table 5.11. Both models predicted correctly 18 out of 20 controls (90% 
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specificity), whereas the integrals-based model showed superior sensitivity (all cancer 
samples were correctly classified versus one sample misclassified by the full resolution 
model). These results are quite promising as they show the potential usefulness of urine 
NMR metabolomics as an adjunct tool in lung cancer detection and screening. Further 
validation of this approach should therefore entail the analysis of an enlarged sample set 
(moving from hundreds to thousands of samples), and the independent measurement of 
the putative metabolite markers by other quantitative methods. Moreover, it would be 
most interesting to assess the specificity of the urinary signature revealed in comparison 
with other diseases, especially other lung diseases. 
 
 
Figure 5.14 Scores scatter plots obtained by PLS-DA of a) full resolution 
1
H NMR urine spectra 
(LV=2, R
2
X=0.09, R
2
Y=0.83, Q
2
=0.70) and b) 19 signal integrals (LV=2, R
2
X=0.37, R
2
Y=0.74, 
Q
2
=0.70), using in the calibration set 71 samples from controls and 89 samples from patients. The 
scores corresponding to class prediction of additional 40 samples (20 controls and 20 patients) are 
superimposed in lighter colour. 
 
Table 5.11 Confusion matrix showing the prediction results for an independent test set (20 
controls and 20 patients) obtained by PLS-DA modelling of a calibration set (71 controls and 89 
patients), using either the full resolution urine spectra (after removal of biased variables) or 19 
selected signal integrals. Shaded boxes show the number of samples correctly classified. 
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5.8 Proposed biochemical interpretation of cancer-related metabolic 
variations in urine 
According to the results presented in the previous sections, the putative urinary 
metabolic signature of lung cancer comprised the main following metabolic features: 
increase levels of β-hydroxybutyrate, α-hydroxyisobutyrate, allantoin, methylguanidine, 
p-cresol sulphate, six N-acetylated metabolites and three unknowns, together with 
decreased levels of fatty acids, trigonelline, tartrate, hippurate and 4-deoxythreonate. 
In agreement with the plasma results, β-hydroxybutyrate has been found increased 
in the urine of cancer patients, particularly AdC patients. As previously mentioned 
(subchapter 4.7), the presence of this ketone body in biofluids may indicate increased 
fatty acid oxidation. The observed decrease in urinary levels of fatty acids further 
supports this hypothesis, corroborating the important role of this pathway in cancer 
metabolism, as recently brought to light by other studies (Carracedo et al. 2013). 
Interestingly, this metabolite has also been associated with muscle loss in patients with 
lung and colon cancers (Eisner et al. 2011). Another hydroxy acid found to be increased 
in the patients‟ urine was α-hydroxyisobutyrate, which has also been associated with 
muscle loss (Eisner et al. 2011), and may reflect the abnormal organic acid excretion 
resulting from metabolic decompensation (Kumps et al. 2002). 
Allantoin is a diureide of glyoxylic acid resulting from the free radical-induced 
oxidation of uric acid (the terminal product of purine metabolism) (Wishart et al. 2007). 
As its urinary levels have been shown to reflect the systemic load of reactive oxygen 
species (ROS), independently of uric acid levels, allantoin has been has been suggested as 
a potential biomarker for oxidative stress (Tolun et al. 2010). Increased levels of allantoin 
have been associated with several diseases, including diabetes, inflammatory and 
autoimmune conditions, cardiovascular and pulmonary diseases (Tolun et al. 2010). In 
this work, allantoin was found elevated in the urine of lung cancer patients, especially 
SqCC. Although no previous accounts on the variation of this metabolite in lung cancer 
were found, increased urinary allantoin has also been reported in ovarian cancer patients 
(Slupsky et al. 2010). Moreover, in a mouse model of S. aureus lung infection, urinary 
allantoin was found to increase upon treatment of infected animals (Slupsky et al. 2009).  
Methylguanidine is a guanidine compound deriving from protein catabolism 
(Wishart et al. 2007) or from the microbial conversion of creatinine (Wyss and Kaddurah-
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Daouk 2000). Increased plasmatic levels of this metabolite have been associated with 
renal failure (Wishart et al. 2007), while its possible anti-inflammatory activity has also 
been demonstrated in a mice model of septic shock (Marzocco et al. 2004). Its possible 
association to cancer has, however, not been documented, except for a study of 
oesophageal cancer where, similarly to our results, methylguanidine was found elevated 
in the urine of patients (Hasim et al. 2012). 
Increased p-cresol sulphate was another feature of the patients‟ urinary profile, 
particularly of AdC patients. This metabolite likely derives from gut microbial-host co-
metabolism and its abnormal systemic levels have been linked to multiple sclerosis, 
cardiovascular disease and oxidative injury (Wishart et al. 2007). In the context of cancer, 
it has been found increased in the urine of colorectal patients (Qiu et al. 2010), although 
an opposite variation was reported in a subsequent study (Cheng et al. 2012). 
A number of signals identified as N-acetylated metabolites were all found increased 
in the urine of lung cancer patients, compared to healthy controls. The increased urinary 
excretion of N-acetylated compounds, including N-acetylated amino acids and N-
acetylneuraminic acid (Neu5Ac), has been linked to inborn errors of metabolism (Engelke 
et al. 2004). In regard to cancer studies, urinary N-acetylaspartate was found to be 
significantly increased in preoperative colorectal cancer patients (Qiu et al. 2010), while 
Neu5Ac was recently reported to be elevated in both tissues and urine of non-small cell 
lung cancer patients (Mathe et al. 2014). The authors highlighted the role of Neu5Ac in 
cell signalling, binding and transportation of positively charged molecules, in particular 
it‟s protecting role of malignant cells from cellular defence systems. Therefore, having 
these findings into account, an important following step in this work would be to identify 
the specific N-acetylated metabolites contributing for the urinary signature of lung cancer, 
in order to further understand their role in cancer metabolism and further assess their 
diagnostic potential.  
In regard to metabolites showing lower levels in the urine of cancer patients 
relatively to controls, most of them seem to share a possible relationship with diet or gut 
microbial activity. Trigonelline is a dietary betaine present in several foodstuffs (e.g., 
coffee), and a product of niacin (vitamin B3) metabolism (Wishart et al. 2007). In a study 
addressing lung function markers in patients with chronic obstructive pulmonary disease 
(COPD), increased urinary levels of trigonelline were linked to improved lung function 
(McClay et al. 2010), whereas decreased levels of this metabolite were observed in the 
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urine of mice infected with S. pneumonia (Slupsky et al. 2009). In cancer studies, urinary 
trigonelline was found to be decreased in patients with pancreatic ductal adenocarcinoma 
(Napoli et al. 2012), bladder cancer (Chen et al. 2012) and ovarian cancer (Slupsky et al. 
2010), similarly to the variation hereby observed. Moreover, trigonelline has been 
highlighted as one of the metabolites correlating with muscle loss in colorectal and lung 
cancers at advanced stage (Eisner et al. 2011). Tartrate is another diet-related metabolite, 
associated with the consumption of wine and fruits (Heinzmann et al. 2012) and its 
possible association with cancer has not been documented. 
Hippurate, an acyl glycine resulting from the conjugation of benzoic acid with 
glycine, is a urinary metabolite arising from several sources, including diet (consumption 
of phenolic-containing products like tea, wine, fruits), exposure to solvents (e.g., toluene) 
or oxidative stressors (e.g., tobacco smoke) and intestinal microfloral activity. Although 
one UPLC-MS study has reported increased hippurate in the urine of lung cancer patients 
compared to controls (Yang et al. 2010), thus contradicting our results, decreased urinary 
hippurate levels have often been reported across several cancer types, namely 
hepatocellular cancer (Shariff et al. 2011), oesophageal cancer (Hasim et al. 2012), oral 
cancer (Xie et al. 2012), osteosarcoma (Zhang et al. 2010), bladder cancer (Van et al. 
2011), pancreatic ductal adenocarcinoma (Napoli et al. 2012) and ovarian and breast 
cancers (Slupsky et al. 2010). 
In regard to decreased levels of 4-dexoythreonate (4-DTA), no interpretation could 
be proposed at this point. 4-DTA is a common urinary metabolite and has been proposed 
to derive from L-threonine (Kassel et al. 1986). In early works it has been associated with 
diabetes mellitus type 1 (Kassel et al. 1986) and uraemia (Bultitude and Newham 1975), 
but no association to cancer was found in the literature.  
As a final remark, it is interesting to note that, while in the case of tissues and 
plasma there were a number of metabolic features pointing directly to pathways known to 
play central roles in cancer metabolism, urinary profiling highlighted a number of novel 
variations which are difficult to explain in the context of current knowledge. While this 
may be somehow frustrating, it also represents a great stimulus to pursue further work 
towards a deeper understanding of urinary changes in cancer and it underlines the 
importance of looking into different, complementary metabolic windows.  
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6 PRELIMINARY UPLC-MS METABOLOMIC STUDY OF 
LUNG CANCER URINARY ALTERATIONS 
 
6.1 UPLC-MS profile of urine 
The analysis of urine by ultra-performance liquid chromatography coupled to mass 
spectrometry (UPLC-MS) allowed four different datasets to be obtained, as each sample 
was separately run in two different chromatographic columns (reverse-phase high strength 
silica – HSS and hydrophilic interaction chromatography – HILIC) and detected using two 
ionisation modes (electrospray positive – ESI+ and negative – ESI-). Figure 6.1 illustrates 
representative total ion chromatograms (TIC) corresponding to the four different datasets 
acquired, demonstrating the ability of this approach for obtaining complementary 
metabolic information depending on the column and ionisation mode chosen. 
 
 
Figure 6.1 Representative UPLC-MS total ion chromatograms (TIC) of urine from a lung cancer 
patient, acquired in two chromatographic columns and two ionisation modes: a) HSS ESI+, b) HSS 
ESI-, c) HILIC ESI+ and d) HILIC ESI-. 
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The quality of UPLC-MS data was evaluated by injecting a quality control (QC) 
sample, composed of aliquots from all urines used in the run, at regular intervals (every ten 
samples), from which stability/variability of the run could be assessed (Want et al. 2010). 
Figure 6.2 shows the scores scatter plot resulting from applying PCA to the study samples 
(n 98) and to the in-run QCs (n 10), after applying different scaling procedures to the data 
(to minimize the dominance of higher intensity signals over less intense ones).  
 
 
Figure 6.2 PCA scores scatter plots of urine UPLC-MS datasets of QC (, n 10) and study (, n 
98) samples using Pareto scaling (left), unit variance scaling (centre) and logarithm transformation 
(right): a) HSS ESI+, b) HSS ESI-, c) HILIC ESI+, d) HILIC ESI-. 
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The fact that QC samples were highly overlapped (no dispersion in the scores scatter 
plot) indicated good stability throughout the four chromatographic runs, which is crucial 
for high quality data to be recorded and further used in multivariate analysis.  
 
6.2 Potential of urine UPLC-MS profile to discriminate between 
patients and control subjects 
After UPLC-MS data pre-treatment (described in section 2.4.3), PCA and PLS-DA 
were applied to all twelve datasets (two columns × two ionization modes × three 
scaling/transformation types) composed by the control group (n 50, 25 males, 25 females, 
average and median age 49, age range 38-59) and the patients group (n 48, 37 males, 11 
females, average and median age 61, age range 30-84). Further details on patients‟ 
histological and stage classifications can be found in Table 2.1. Figure 6.3 shows the PLS-
DA scores scatter plots obtained for all datasets. Similarly to what was obtained for 
1
H 
NMR data of the same sample set (not shown), PLS-DA of UPLC-MS datasets (with 
different scaling/transformation applied) allowed control and cancer urines to be well 
separated along LV1 (Figure 6.3). Model validation was performed by means of MCCV 
and permutation testing (500 iterations) and the corresponding prediction results are shown 
in Table 6.1. In the ROC space plots, models with permuted classes fell along the diagonal 
line (no discrimination), whereas models with true classes assigned were located in the 
upper left corner (Figure 6.4), showing high sensitivity and specificity. Regarding Q
2
, 
histograms showed little overlap between models with true and permuted classes, 
demonstrating once more the robustness of the models built (Figure 6.5). Overall, 
classification rates were higher than 90%, sensitivity and specificity ranged between 88-
97% and 89-100%, respectively, and median Q
2
 ranged between 0.66-0.80. No column 
type, ionisation mode or scaling/transformation procedure performed consistently better 
than the others, demonstrating the usefulness of acquiring data in different experimental 
setups and of applying different scaling/transformation procedures in data pre-treatment.  
Although showing promise and corroborating the potential diagnostic value of 
urinary metabolic profiles, also evidenced by NMR metabolomics, this study was limited 
by imperfect mismatching of control and cancer groups in terms of gender and age. 
Therefore, a subsequent stage of this work should include careful assessment of their 
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possible confounding influence (as performed for NMR data), as well as of the possible 
dependency of UPLC-MS metabolic profiles on cancer histological type and stage. 
 
 
Figure 6.3 PLS-DA scores scatter plots of urine UPLC-MS datasets from controls (n 50) and 
cancer patients (n 48) using Pareto scaling (left), unit variance scaling (centre) and logarithm 
transformation (right): a) HSS ESI+, b) HSS ESI-, c) HILIC ESI+, d) HILIC ESI-. 
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Figure 6.4 ROC space plots (TPR: true positive rate; FPR: false positive rate) obtained by MCCV 
and permutation testing (500 iterations) of the PLS-DA models built with UPLC-MS urine datasets 
from controls (n 50) and cancer patients (n 48) using Pareto scaling (left), unit variance scaling 
(centre) and logarithm transformation (right): a) HSS ESI+, b) HSS ESI-, c) HILIC ESI+, d) HILIC 
ESI-. 
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Figure 6.5 Q
2
 histograms obtained by MCCV and permutation testing (500 iterations) of the PLS-
DA models built with UPLC-MS urine datasets from controls (n 50) and cancer patients (n 48) 
using Pareto scaling (left), unit variance scaling (centre) and logarithm transformation (right): a) 
HSS ESI+, b) HSS ESI-, c) HILIC ESI+, d) HILIC ESI-. 
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Table 6.1 Prediction results obtained by MCCV (500 iterations) of urine UPLC-MS PLS-DA 
models. 
PLS-DA classes 
[n samples, n M/n F, median age] 
Type of 
scaling 
Median Q
2
 
Sensitivity 
(%) 
Specificity 
(%) 
Classification 
rate (%) 
Control vs. Cancer  
[50, 25/25, 49] vs. [48, 37/11, 61] 
HSS ESI+ 
UV 0.73 98.6 91.2 94.8 
Par 0.76 92.5 100.0 96.3 
Log 0.66 87.9 94.3 91.2 
HSS ESI- 
UV 0.74 92.4 98.0 95.2 
Par 0.71 91.2 89.3 90.2 
Log 0.77 92.6 95.3 95.3 
HILIC ESI+ 
UV 0.78 94.2 97.9 96.1 
Par 0.75 92.4 97.2 94.9 
Log 0.80 95.2 100.0 97.6 
HILIC ESI- 
UV 0.78 93.6 97.3 95.5 
Par 0.66 90.7 90.7 90.7 
Log 0.80 95.3 98.0 96.7 
1
H NMR 
UV 0.66 90.1 91.4 90.7 
 
6.3 Selection and tentative identification of UPLC-MS features relevant 
to class discrimination 
In order to extract the features with highest relevance for discriminating between 
lung cancer patients and controls, a few selection steps were applied, as exemplified next 
for the HSS ESI+ Pareto scaling dataset. Firstly, in the S-plot, which depicts the covariance 
and correlation between metabolites, the features with correlation |p(corr)[1]|>0.6 and 
covariance p[1]>0.02 were selected (Figure 6.6a). Secondly, the covariance ratio plot was 
used to select those features with lower jack-knife standard error of covariance across the 
cross validation rounds (p[1]cvSE). The threshold used for variable selection corresponds to 
a standard error of 25%, so features with |p[1]|/p[1]cvSE<4 were excluded (Figure 6.6b). 
Finally, the statistical difference between classes of selected features (p<0.01) was 
evaluated by univariate analysis, namely by the Wilcoxon rank sum test. Table 6.2 shows 
the number of selected variables for all the data analysed across each selection step. In 
total, over 600 MS features were selected.  
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Figure 6.6 Selection of relevant MS features for class discrimination in the urine PLS-DA model 
obtained for cancer vs. control (HSS ESI+; Pareto scaling). a) S-plot (dashed boxes represent 
selected features with |p(corr)[1]>0.6 and |p[1]>0.02) and b) covariance ratio plot (dashed line 
indicates the threshold >4 of covariance ratio above which features were selected). 
 
Table 6.2 Number of relevant variables across each selection step. 
 Scaling 
Start 
number 
|p(corr)|≥0.6 
& 
|p[1]|≥0.02 
|p[1]|/p[1]cvSE 
≥4 
Significant 
p-value
a
  
HSS ESI+ 
UV 
4434 
245 236 50 
Par 113 55 48 
Log 197 196 51 
HSS ESI- 
UV 
7312 
453 436 51 
Par 78 75 51 
Log 319 319 51 
HILIC ESI+ 
UV 
2628 
30 23 23 
Par 6 5 5 
Log 70 70 65 
HILIC ESI- 
UV 
2412 
38 38 36 
Par 26 25 24 
Log 162 162 159 
a
 Wilcoxon rank sum test. 
 
Figure 6.7 shows the variables selected for each dataset, where the different 
scaling/transformation are represented by different colours. It is clear in these plots that, 
although a few variables overlapped, different variables were selected according to the 
scaling/transformation used. This result highlights the importance of using different 
processing approaches to analyse this type of data, as they give complementary 
information. 
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Figure 6.7 Plots representing the variables selected by scaling/transformation for datasets a) HSS 
ESI+, b) HSS ESI-, c) HILIC ESI+ and d) HILIC ESI-. 
 
The selection/identification of MS features relevant in cancer vs. control 
discrimination was then further pursued by carefully inspecting the extracted ion 
chromatogram and mass spectrum of each feature. Background peaks, isotopes and adducts 
of assigned compounds were removed from the final list, so that the final numbers of 
selected features were: HSS ESI+ 118, HSS ESI- 113, HILIC ESI+ 66 and HILIC ESI- 
147. The complete list of selected features is presented in Annex VII. 
The tentative assignment of selected MS features to specific compounds was 
performed based on the comparison of experimental m/z and retention times with data for 
reference compounds compiled in the literature (Roux et al. 2012) and in a database 
available at Imperial College of London, where this analysis was performed. This strategy 
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allowed ten compounds to be tentatively identified (as listed in Table 6.3). One such 
example is phenylacetylglutamine, the corresponding extracted ion chromatogram and 
mass spectrum (obtained from HSS ESI+ detection) being illustrated in Figure 6.8. 
 
Table 6.3 Assigned urinary UPLC-MS features found to be important in cancer vs. control 
discrimination. Features intensities are indicated as: very high (>10
5
), high (>10
4
, <10
5
), low (>10
3
, 
<10
4
) and very low (<10
3
). 
Metabolite  
(adduct/fragment) 
UPLC 
column 
& 
detection 
mode 
m/z 
RT 
(min) 
feature 
intensity 
PLS-DA 
scaling/ 
transfor-
mation 
% 
variation 
p-value
d
 
effect 
size±CI 
Choline  
(M+) 
HSS 
ESI+ 
 
104.10 
0.50 
 
very low 
UV 
 
26.5±6.0 
 
5.6x10-4 
 
0.79±0.41 
Creatinine 
(M+H) 
 
114.07 
0.55 
 
high 
UV 
 
22.1±3.4 
 
8.2x10-8 
 
1.18±0.43 
Trigonelline 
(M+H)c 
 
139.06 
0.57 
 
low 
Log 
 
-59.6±14.9 
 
7.6x10-8 
 
-1.13±0.43 
Pseudouridine 
(M+Na)
c
 
 
269.07 
0.99 
 
low 
Pareto 
 
61.1±8.9 
 
3.4x10-7 
 
1.08±0.42 
Uric acid 
(M+H) 
 
169.03 
1.23 
 
high 
Pareto 
 
48.4±8.8 
 
5.8x10-5 
 
0.90±0.42 
Pantothenic acid 
(M-H+HCOONa)
b
 
 
 
 
 
HSS 
ESI- 
 
286.09 
2.94 
 
low 
Pareto 
 
75.1±13.0 
 
1.8x10-4 
 
0.85±0.41 
Pyrocathecol sulfate 
isomer 
(M-H)
c
 
 
 
189.99 
3.11 
 
 
low 
Pareto 
 
-47.7±11.4 
 
 
5.1x10-8 
 
 
-1.09±0.42 
Hippuric acid 
(M-H)-CO2
a 
(M-H)
c
 
(M-H)
c
 
 
134.06 
179.06 
180.06 
3.86 
 
low 
low 
low 
Pareto 
 
-58.1±11.0 
-55.1±10.6 
-56.4±10.5 
 
1.7x10-11 
1.8x10-10 
7.3x10-11 
 
-1.48±0.45 
-1.42±0.44 
-1.48±0.45 
Phenylacetylglutamine 
(2M-2H+Na)
b
 
(2M-2H+Na)
c 
(2M-2H+Na)
c 
 
 
549.19 
550.20 
551.20 
3.88 
 
low 
high 
low 
Pareto 
 
40.1±7.4 
41.3±7.7 
41.9±8.0 
 
1.6x10-5 
3.7x10-5 
3.7x10-5 
 
0.93±0.42 
0.90±0.42 
0.89±0.42 
Hippuric acid 
(M+H)-(C2H5NO2)
a
 
(M+H) 
HILIC 
ESI+ 
 
105.03 
180.07 
2.79 
 
very low 
low 
Log 
 
-66.5±17.3 
-53.4±13.1 
 
4.8x10-9 
4.9x10-10 
 
-1.13±0.43 
-1.10±0.42 
Hippuric acid 
(M-H)-CO2
a 
(M-H)
c 
(2M-H)
b
 
(2M-H)
c 
(2M-2H+Na)
b
 
 
 
 
 
HILIC 
ESI- 
 
134.06 
179.06 
357.11 
358.11 
379.09 
 
2.81 
2.82 
2.84 
2.85 
2.87 
 
high 
very high 
high 
high 
high 
Pareto 
 
-61.1±12.6 
-53.7±10.4 
-83.6±25.3 
-82.4±24.3 
-76.1±22.3 
 
1.5x10-11 
2.6 x10-11 
3.2x10-6 
3.8x10-5 
8.7x10-7 
 
-1.38±0.44 
-1.40±0.44 
-1.11±0.43 
-1.12±0.43 
-1.08±0.42 
p-Hydroxyhippuric 
acid 
(M-H)-CO2
a 
(M-H) 
 
 
194.04 
150.05 
3.28 
 
 
very high 
low 
Log 
 
 
-47.2±20.7 
-51.8±22.0 
 
 
4.7x10-5 
2.4x10-9 
 
 
-0.60±0.40 
-0.63±0.41 
Phenylacetylglutamine 
(2M-2H+Na)
c 
(2M-2H+Na)
c 
 
 
551.21 
552.21 
3.77 
 
low 
low 
Log 
 
61.8±12.4 
93.0±14.0 
 
7.4x10-9 
1.0x10-4 
 
0.78±0.41 
0.93±0.42 
a
Metabolite fragment. 
b
Metabolite adduct. 
c
Isotope of the molecular peak or adduct. 
d
Wilcoxon 
rank sum test (p<0.01). 
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Figure 6.8 a) Total ion chromatogram (TIC) of representative urine and extracted ion 
chromatogram (EIC) of m/z 265.10. b) Mass spectrum of phenylacetylglutamine showing the main 
adducts formed. 
 
In an attempt to improve the assignment of MS features, statistical correlation 
heterospectroscopy (SHY) of MS data with 
1
H NMR spectra of the same samples was also 
explored. This approach allowed some assignments to be confirmed, namely those of 
hippurate, trigonelline and phenylacetylglutamine. The 2D correlation plot between UPLC-
MS and 
1
H NMR is illustrated in Figure 6.9a, for the HSS ESI- dataset, in which hippurate 
correlation in both domains is highlighted (Figure 6.9a left). This correlation was further 
confirmed by plotting hippurate MS intensities and NMR integral areas for the same 
samples, as illustrated in the scatter graph of Figure 6.9a right, for which a significant  
 
Phenylacetylglutamine
monoisotopic molecular weight: 264.1110
M+H M+Na
2M+Na
M+H-NH3
M+H-HCOOH
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Figure 6.9 a) 2D statistical heterospectroscopy (SHY) map between UPLC-MS HSS ESI- (relevant 
features) and 
1
H NMR (full resolution spectra) of the same urine samples. Correlation results are 
shown for hippurate, in which a sample deviating from linearity is highlighted. A threshold of 
r>0.7 and p<0.01 was applied. b) Expansion of the total ion chromatogram (TIC) of the same urine 
sample (red) showing the ion suppression effect observed for hippurate and corresponding 
extracted ion chromatogram (EIC) of m/z 179.04 (green, M-H hippurate). 
 
Pearson correlation (r 0.84) was obtained. This graph also shows that one of the samples 
(highlighted with a red circle) deviated from the linear relationship observed for the other 
b) 
a) 
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samples. Ion suppression effects arising from the competition for ionization between the 
analyte of interest and other species may have contributed for this observation. Indeed, 
these effects, illustrated in Figure 6.9b, were also observed in several other cases (e.g., 
creatinine, citrate), which may help explaining the reduced number of significant 
correlations resulting from SHY analysis. Other than that, the different nature of the 
metabolites detected by the two methods (NMR and UPLC-MS) may also account for the 
observed inefficiency of SHY in further helping the assignment of MS features. 
Amongst assigned metabolites, negative variations (decreased levels in patients‟ 
urine) were found for trigonelline, pyrocathecol sulphate, hippurate and p-
hydroxyhippurate; whereas positive variations (increased levels in patients‟ urine) were 
found for choline, creatinine, pseudouridine, uric acid, pantothenic acid and 
phenylacetylglutamine. Interestingly, some of these variations, namely those of 
trigonelline, hippurate, creatinine and phenylacetylglutamine, were also detected by 
1
H 
NMR profiling of urine, as presented in the previous chapter, while others were newly 
detected by UPLC-MS, thus showing the complementary nature of the two analytical 
platforms. 
Compared to NMR, the more sensitive UPLC-MS methof highlighted a much higher 
number of discriminat features. However, their assignment to specific compounds was 
found to be a very difficult task, which could not be fully explored within the framework 
of this thesis. Future work should therefore entail the more thorough identification of MS 
features, namely with the help of MS/MS experiments to provide information on ion 
fragmentation patterns. Moreover, it would also be important to extend this analysis to an 
enlarged number of samples and to assess the influence of possible confounding factors. 
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7 FINAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In this work, the metabolic signature of lung cancer has been investigated through a 
metabolomics approach involving the analysis of preoperative tissues and biofluids (blood 
plasma and urine) from patients with primary lung tumours. An overview of the main 
variations entailing this signature, either considering the whole dataset, or each of the two 
main histological types included in this study, is presented in Figures 7.1 and 7.2, 
respectively. 
The 
1
H HRMAS NMR analysis of intact tissues (from 56 patients) enabled the 
composition of human lung tumours to be thoroughly characterized and offered a direct 
window into altered cellular metabolism. Over fifty metabolites have been identified, of 
which bonded amino acids (in peptides), polyamines and three other compounds were, to 
our knowledge, newly reported in this thesis, adding novel information about the metabolic 
composition of human lung tissue. Multivariate modelling of tissue spectra enabled lung 
tumours to be discriminated from adjacent, non-involved parenchyma with high accuracy 
(classification rate 97%) and predictive power (Q
2
 0.83), as assessed by Monte Carlo cross 
validation (MCCV) of the classification model built. This discrimination was mainly due 
to significant differences in the levels of thirteen metabolites, namely glucose and acetate 
(decreased in tumours), together with lactate, alanine, glutamate, GSH, taurine, creatine, 
phospholipid-related compounds (PC, GPC and PE), uracil nucleotides and peptides 
(increased in tumours). While some of these differences corroborated typical features of 
cancer metabolism (e.g., upregulated glycolysis and glutaminolysis, altered lipid 
metabolism), other newly reported variations suggested less known pathways (e.g., 
antioxidant protection, protein degradation) to play important roles in lung cancer biology. 
The tumour samples analysed differed in several parameters (as seen by microscopic 
observation of their mirror sections), namely the amount of tumour vs. stromal cells, the 
percentage of necrosis, the progression stage and the histological type of the tumour; 
hence, the possible influence of such parameters on the tumours‟ metabolic profile has 
been assessed. Interestingly, the variable proportion of tumour cells was found to be 
weakly correlated with the resulting spectral profiles, and the malignancy signature could 
be detected even in tissue samples with higher amounts of stroma. This result underlines 
the potential usefulness of real-time HRMAS NMR analysis of tissue fragments during 
CHAPTER 7 – FINAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
206 
surgery to assist decisions on tumour resection margins and reduce the risk of local 
recurrence. In regard to the percentage of necrosis, it correlated with lipid abundance, 
which in turn had low importance in tumour vs. control discrimination. Concerning stage, 
tumour samples of stages I, II and III could not be distinguished, as they shared a similar 
discriminant signature in relation to control tissues, meaning that metabolic alterations 
were present even in small, locally confined tumours, showing little change as the tumour 
progressed. However, this statement should not be generalized as the large majority of 
tumours included in this study were from stages I and II, with only six cases of stage III 
and no stage IV samples. The tumour histological type, on the other hand, was found to be 
strongly reflected on the metabolic profiles measured. In particular, although having many 
variations in common, the two most prevalent subtypes – adenocarcinoma (AdC) and 
squamous cell carcinoma (SqCC) – showed distinct metabolic behaviour, especially when 
considering the inter-metabolite correlation patterns. Major alterations in AdC were related 
to phospholipid metabolism (as seen by elevated levels of PC, GPC and PE) and protein 
catabolism (increased peptide moieties), whereas SqCC had stronger glycolytic and 
glutaminolytic profiles (as shown by the negatively correlated variations in glucose and 
lactate and the positively correlated increases in glutamate and alanine). These results 
provided new, clear evidence of distinct metabolic signatures for AdC and SqCC, which 
could have important implications in the selective definition of new therapy targets or 
imaging tracers. Furthermore, the two subtypes could be discriminated with high accuracy, 
based on a set of six metabolites (mainly related to lipid metabolism and oxidative 
protection), thus showing that NMR metabolomics may indeed be valuable in tumour 
subtyping, which is a critical diagnostic requirement. 
Based on the hypothesis that altered tumour metabolism may impact systemic 
metabolism and be reflected on the composition of biofluids, blood plasma and urine from 
over 100 patients (including those for which tissue samples were available) and near 100 
controls were analysed by 
1
H NMR spectroscopy. Multivariate analysis of plasma spectra 
allowed a robust classification model to be built, which discriminated lung cancer and 
healthy subjects with about 86% sensitivity and 88% specificity. The main discriminant 
features in the patients‟ plasma were found to be increased levels of lactate, pyruvate and 
acetoacetate, together with decreased levels of several amino acids (glutamine, histidine, 
valine, arginine/lysine and serine), methanol and two unassigned compounds. Moreover, 
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compared to controls, the plasma of patients was characterized by relatively higher levels 
of LDL+VLDL lipoproteins and N-acetylated glycoproteins, together with reduced levels 
of HDL lipoproteins and, possibly, albumin (this latter variation not being confirmed, as 
albumin signals were too broad to be unequivocally assigned and integrated). Besides 
confirming some of the suspected metabolic alterations in lung cancer, also reported by 
others and relating to glycolysis, amino acids and lipoproteins metabolism, these findings 
also provided new clues on the possible importance of fatty acid oxidation and protein 
glycosylation. Also notably, all of these changes were present from initial disease stages 
and some of them, like increased lactate and pyruvate or decreased glutamine, nicely 
matched the variations observed in tissues. Regarding the dependency of plasma alterations 
on tumour histological type, only subtle differences were noted: AdC additionally showed 
increased levels of β-hydroxybutyrate and a more relevant valine decrease (relatively to 
controls), while the plasma of SqCC patients showed a significant decrease in alanine (not 
observed in AdC). The distinction between AdC and SqCC through plasma NMR 
metabolomics was however not possible. Likewise, no clear differentiation was found 
between disease stages.  
The classification model built with urine NMR spectra afforded even better 
discrimination between lung cancer patients and healthy controls, as shown by the high 
sensitivity and specificity levels obtained (97% and 96%, respectively). In this case, the list 
of metabolites contributing for this discrimination was more extensive and comprised β-
hydroxybutyrate, α-hydroxyisobutyrate, allantoin, methylguanidine, p-cresol sulphate, six 
N-acetylated metabolites and 3 unknowns (increased in patients), together with 
trigonelline, tartrate, hippurate, 4-deoxythreonate and fatty acids (decreased in patients). 
Interestingly, these changes, detected from initial disease stages, corroborated the possible 
importance of biochemical events like fatty acid oxidation, oxidative stress and protein 
metabolism, also highlighted through tissue and/or plasma analysis (even if based on 
changes in different metabolites). Moreover, urinary profiling suggested a number of 
compounds typically associated with diet or gut microflora to be relevant in the cancer 
signature, thus reinforcing the increasingly recognised idea that gut microbiome-host 
interactions may play an important role in cancer pathogenesis and progression. Regarding 
patient discrimination by histological type or stage, urinary profiles seemed to comprise 
subtle differences that could be captured by multivariate analysis, resulting in MCCV-
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validated models with modest predictive ability, although individual marker metabolites 
could not be identified. 
One of the limitations of this study, in what concerns the analysis of biofluids, was 
the imperfect matching between cancer and control groups in terms of demographic and 
environmental factors. For instance, the cancer group comprised more males and older 
subjects than the control group. To deal with this problem, the possible influence of a few 
unmatched parameters, namely gender, age and smoking habits, on cancer vs. control 
discrimination was assessed. As previously reported in the literature, the levels of some 
metabolites in both biofluids were found to be gender-dependent (as assessed within 
controls). Hence, by confronting the list of gender-related variables with that of putative 
cancer markers, possibly biased variations (i.e., variations showing the same direction in 
male and cancer groups) have been highlighted and their importance in cancer vs. control 
discrimination re-assessed by considering separate models for males and females. In the 
case of plasma, all previously identified discriminant features remained important 
regardless of gender, whereas, in urine, creatine and creatinine were found to be gender-
biased, as they were no longer significantly different between controls and patients, when 
considering each gender separately. A similar strategy has been devised to evaluate the 
possibly confounding effect of age mismatch between control and cancer groups. After 
identifying age-related variables in the control group, for both biofluids, the metabolites 
found to be simultaneously increased or decreased in both older subjects and patients were 
highlighted as possibly biased and their importance as putative cancer markers was 
reassessed in a subset of samples having better age-matching between control and cancer 
groups. The resulting plasma-based classification model decreased its MCCV quality 
parameters; therefore, although all previously identified discriminant metabolites in plasma 
held their importance in the age-matched model, age-bias could not be ruled out as an 
important influencing factor. On the other hand, in the case of urine, the age-matched 
model maintained high accuracy and predictive power, thus allowing age to be excluded as 
a strong confounding factor. Still, a few metabolites, namely citrate, histidine and 
phenylacetylglutamine, were found to be age-biased (as they were not important for cancer 
vs. control discrimination in the new age-matched model). In regard to the influence of 
smoking, no relation was found between smoke exposure and the plasma profile of control 
subjects, whereas some urinary metabolites (mostly unknowns) seemed to be associated 
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with smoking habits. Nevertheless, discrimination between controls and cancer patients 
was equally good when the control group comprised both smokers and never smokers or 
each of these subsets separately, thus showing the negligible influence of smoking habits 
on cancer vs. control discrimination. 
Following the analysis of possible confounders and the exclusion of possibly biased 
variables (in the case of urine), the classification ability of multivariate models was further 
evaluated by preliminary external validation. For this purpose, the sample cohort was 
divided into a validation set used for model building and a prediction set comprising 40 
samples collected more recently in time. In the case of plasma, the best external prediction 
was achieved when using the integrals of twelve metabolites, previously identified as 
cancer-related markers (rather than using the whole spectral profile). Only three out of 
twenty controls and three out of twenty patients were misclassified (85% sensitivity and 
specificity), which is a promising result, especially considering that currently explored 
blood markers, like the carcinoembryonic antigen (CEA) and the cytokeratin 19 fragment 
CYFRA 21-1, have lower performance. The results of external validation for urinary 
markers were even more exciting as all patients were correctly classified and only two 
controls were misclassified as cancer cases. Although being exploratory and requiring 
further confirmation in an enlarged sample set, with improved control over possible 
confounders, the novelty and possible clinical impact of these findings, together with the 
easiness and non-invasiveness of urine collection, make it extremely encouraging to pursue 
further work on the validation of a urinary signature for lung cancer. For instance, an 
envisaged useful application would be to use the urinary metabolic profile (eventually in 
tandem with the plasma profile) as a pre-screening tool for selecting subjects who should 
undergo more specific or advanced radiological testing, namely within population groups 
at increased risk (e.g., chronic smokers). 
In face of the promising results obtained by NMR profiling of urine (described 
above), the use of an alternative, complementary profiling technique (UPLC-MS) has also 
been explored for a subset of samples. The classification models built (for data obtained 
with different chromatographic columns, ionization modes and processing methods) 
showed sensitivities higher than 87% and specificities above 89% for cancer vs. control 
discrimination, which corroborates the value of urine as a rich source of disease markers. 
Over 600 MS features were selected as being important for class discrimination, although 
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only 10 of those features could be assigned to specific metabolites, thus underlying the 
importance of carrying out further studies (namely MS/MS analysis) to improve the 
structural information retrieved. Identified metabolites were choline, creatinine, 
pseudouridine, uric and pantothenic acids and phenylacetylglutamine (increased in 
patients), together with trigonelline, pyrocathecol sulphate, hippurate and p-
hydroxyhippurate (decreased in patients). Compared to 
1
H NMR profiling of the same 
samples, common variations were observed for trigonelline, hippurate, 
phenylacetylglutamine and creatinine, although the last two metabolites were found to be 
age and gender-related, respectively. 
Overall, the metabolomics approach used in this thesis enabled a number of 
significant metabolite variations to be highlighted as part of a putative lung cancer 
metabolic signature. To our knowledge, this is the first time that the information derived 
from three biological matrices (tissues, blood plasma and urine) is brought together for 
defining a global signature for lung cancer; the complementary nature of the metabolic 
information revealed in this way, even if not completely understood at the moment, 
underlines the importance of such an integrative approach. In regard to the validation of 
this signature, which is crucial to drive the results of this work into clinical applications 
that can improve patients care, it would be important to pursue future work along the 
following avenues: i) enlargement of the sample set in order to verify the robustness of 
findings; ii) modelling of possible confounders not considered in this work, such as body 
mass, diet, comorbidities (e.g., diabetes, cerebrovascular and peripheral vascular diseases); 
iii) more thorough investigation of the dependence on the histological subtype, with a view 
to develop new tools for the differential diagnosis of lung tumours; iv) assessment of the 
specificity of the metabolic alterations found to be associated with lung cancer, as 
compared to other lung diseases (e.g., chronic obstructive pulmonary disease, asthma, 
fibrosis, pneumonia, tuberculosis); v) biological validation of the metabolic alterations 
observed, for instance by measuring the expression/activity of specific enzymes and by 
performing stable isotope-resolved metabolomics (SIRM) to follow the fate of selected 
substrates; vi) correlation of metabolomics results with proteomics and genomics data, 
with a view to achieve a more comprehensive understanding of lung cancer biology. 
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Figure 7.1 Heatmap of main metabolite variations found to differentiate lung tumours from control 
tissues or lung cancer patients from healthy controls (considering the whole dataset). The colour 
scale reflects the direction and magnitude of these variations (%) and the metabolites are grouped 
according to hypothesized altered metabolic pathways. Only the metabolites highlighted through 
NMR profiling, confirmed to show statistically significant differences in their levels and to be free 
of age- or gender-bias are included. GSH: reduced glutathione; GPC: glycerophosphocholine; 
HDL: high-density lipoproteins; LDL: low-density lipoprotein; PC, phosphocholine; PE: 
phosphoethanolamine; UDP/UTP: uridine di/triphosphate; VLDL: very low-density lipoprotein. 
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Figure 7.2 Heatmap of main metabolite variations found to differentiate lung tumours from control 
tissues or lung cancer patients from healthy controls, considering each of the two main histological 
types (AdC – adenocarcinoma and SqCC – squamous cell carcinoma). The colour scale reflects the 
direction and magnitude of these variations (%) and the metabolites are grouped according to 
hypothesized altered metabolic pathways. Only the metabolites highlighted through NMR 
profiling, confirmed to show statistically significant differences in their levels and to be free of age- 
or gender-bias are included. GSH: reduced glutathione; GPC: glycerophosphocholine; HDL: high-
density lipoproteins; LDL: low-density lipoprotein; PC, phosphocholine; PE: 
phosphoethanolamine; UDP/UTP: uridine di/triphosphate; VLDL: very low-density lipoprotein. 
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ANNEX I: Histological classification of lung tumours 
Table A1 World Health Organisation (WHO) histological classification of malignant epithelial 
tumours of the lung (Travis et al. 2004). 
Histological classification of tumours 
Squamous cell carcinoma  
 Papillary 
 Clear cell 
 Small cell 
 Basaloid 
Small cell carcinoma  
 Combined small cell carcinoma 
Adenocarcinoma  
 Adenocarcinoma, mixed subtype 
 Acinar adenocarcinoma 
 Papillary adenocarcinoma 
 Bronchioloalveolar carcinoma 
  Nonmucinous 
  Mucinous 
  Mixed nonmucinous and mucinous or indeterminate 
 Solid adenocarcinoma with mucin production 
  Fetal adenocarcinoma 
  Mucinous (‘colloid’) carcinoma 
  Mucinous cystadenocarcinoma 
  Signet ring adenocarcinoma 
  Clear cell adenocarcinoma 
Large cell carcinoma  
 Large cell neuroendocrine carcinoma 
  Combined large cell neuroendocrine carcinoma 
 Basaloid carcinoma 
 Lymphoepithelioma-lyke carcinoma 
 Clear cell carcinoma 
 Large cell carcinoma with rhabdoid phenotype 
Adenosquamous carcinoma  
Sarcomatoid carcinoma  
 Pleomorphic carcinoma 
 Spindle cell carcinoma 
 Giant cell carcinoma 
 Carcinosarcoma 
 Pulmonary blastoma 
Carcinoid tumour  
 Typical carcinoid 
 Atypical carcinoid 
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ANNEX II: TNM classification and stage grouping of lung tumours 
Table A2 TNM (Tumour, Node, Metastasis) classification of carcinomas of the lung (Travis et al. 
2004). 
TNM classification of the lung 
T Primary tumour 
Tx Primary tumour cannot be assessed, or tumour assessed by positive cytology only 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 ≤3 cm 
T1a ≤2 cm 
T1b >2-3 cm 
T2 Main bronchus ≥2 cm from carina invades pleura, partial atelectasis 
T2a >3-5 cm 
T2b >5-7 cm 
T3 
>7 cm; chest wall, diaphragm, pericardium, mediastinal pleura, main bronchus >2 cm from carina, total 
atelectasis, separate nodule(s) in the same lobe 
T4 
Mediastinum, heart, great vessels, carina, trachea, oesophagus, vertebra; separate tumour nodule(s) in a 
ipsilateral lobe 
N Regional lymph nodes 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Ipsilateral peribronchial, ipsilateral hilar 
N2 Subcarinal, ipsilateral mediastinal 
N3 Contralateral mediastinal or hilar, scalene, or supraclavicular 
M Distant metastasis 
Mx Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Presence of distant metastasis 
M1a 
Separate tumour nodule(s) in a contralateral lobe; pleural nodules or malignant pleural, or pericardial 
effusion 
M1b Distant metastasis 
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Table A3 Stage grouping of carcinomas of the lung (Travis et al. 2004). 
Stage grouping 
Occult carcinoma Tx N0 M0 
Stage 0 Tis N0 M0 
Stage IA T1a,b N0 M0 
Stage IB T2a N0 M0 
Stage IIA T2b N0 M0 
 T1a,b N1 M0 
 T2a N1 M0 
Stage IIB T2b N1 M0 
 T3 N0 M0 
Stage IIIA 
T1a,b, 
T2a,b 
N2 M0 
 T3 N1, N2 M0 
 T4 N0, N1 M0 
Stage IIIB T4 N2 M0 
 Any T N3 M0 
Stage IV Any T Any N M1 
 
  
ANNEX III: List of lung cancer metabolic profiling studies available in the literature 
Table A4 Main characteristics of the metabolic profiling studies of lung cancer (LC) reported in the literature. Only studies involving the analysis of 
human tissues and/or biofluids are included (studies using animal models or cultured cells are not contemplated in this list). 
Subject groups (no. samples) 
Analytical 
technique 
MVA methods 
Metabolic profiles compared 
Reference 
controls 
LC 
patients 
other 
cancer vs. 
control 
histological 
types 
disease 
stages 
other 
Tissue extracts 
27 30  1H NMR 
Discriminant factor 
analysis 
    Hanaoka et al. 1993 
0 19  1H NMR n.a.    
18F-FDG uptake; 
survival probability 
Guo et al. 2004 
20 21  1H NMR n.a.    
recurrence; survival 
probability 
Yokota et al. 2007 
10 10  
1D and 2D NMR; 
GC-MS 
n.a.     Fan et al. 2009 
9 9 PC CE-ToF MS PCA    PC Kami et al. 2013 
Tissue 
7a 14  1H HRMAS NMR PCA, CA     Jordan et al. 2010 
12 12  1H HRMAS NMR PCA, HCA     Rocha et al. 2010 
24 24  1H HRMAS NMR PCA, PLS-DA     Duarte et al. 2010 
0 17  1H HRMAS NMR PCA, OPLS-DA    tumour location Chen et al. 2011 
56 56  1H HRMAS NMR PCA, PLS-DA, PLS-R    
tumour and necrotic 
fractions 
Rocha et al. 2014 
Blood serum and plasma 
423 141  HPLC-MS PCA, MLR     Maeda et al. 2010 
200 996 
GCA, CRC, 
BC, PC 
HPLC-MS LDA     Miyagi et al. 2011 
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Table A4 (continued)       
Subject groups (no. samples) 
Analytical 
technique 
MVA methods 
Metabolic profiles compared 
Reference 
controls 
LC 
patients 
other 
cancer vs. 
control 
histological 
types 
disease 
stages 
other 
Blood serum and plasma 
3849 171  HPLC-MS 
Several discrimiant 
functions 
    Shingyoji et al. 2013 
12 12  UPLC-Q-ToF MS PCA     Dong et al. 2010 
495 58  DI-FTICR MS PLS-DA    Gender Guo et al. 2012 
7 14  1H HRMAS NMR PCA, CA     Jordan et al. 2010 
78 85  1H NMR 
PCA, PLS-DA, 
OPLS-DA 
   
Gender, age, 
smoking habits 
Rocha et al. 2011 
29 33  GC-MS PLS-DA     Hori et al. 2011 
28 66  UPLC-MS PLS-DA    
Radiotherapy 
periods 
Cai et al. 2011 
100 100  DI-MS PCA, SVM     Lokhov et al. 2012 
0 29  UPLC-MS PCA, PLS-R    Survival time Vaughan et al. 2012 
28 31  GC-MS, LC-MS OPLS-DA     Wen et al. 2013 
Urine 
 2 RC, HNC 
HPLC, LC-IC-MS, 
FTICR-MS 
n.a.     Bullinger et al. 2008 
22 19  
RRLC-APCI/APPI-
MS 
PLS-DA, OPLS-DA     An et al. 2010 
35 32  HILIC/RPLC-MS OSC PLS-DA     Yang et al. 2010 
20 20  UHPL-MS PCA, OPLS-DA     Wu et al. 2014 
536 469  UPLC-MS 
Unconditional 
logistic regression 
   Smoking status Mathe et al. 2014 
54 71  1H NMR 
PCA, PLS-DA, 
OPLS-DA 
   
Gender, age, 
smoking habits 
Carrola et al. 2011 
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Table A4 (continued)       
Subject groups (no. samples) 
Analytical 
technique 
MVA methods 
Metabolic profiles compared 
Reference 
controls 
LC 
patients 
other 
cancer vs. 
control 
histological 
types 
disease 
stages 
other 
Urine 
0 93 (LC+CC) 1H NMR 
PLS-DA, decision 
tree, SVM, PIA and 
other 
   loss of muscle mass Eisner et al. 2011 
0 55 (LC+CC) 1H NMR, DI-MS 
PLS-DA, SVM, 
LASSO 
   loss of muscle mass Stretch et al. 2012 
Other (EBC and/or BALF) 
22 17  EIA n.a.    Smoking habits Ciebiada et al. 2012 
40 41  1H NMR 
PCA, PLS-DA, OPL-
DA, DFA 
    Zhou et al. 2012 
20 20  HS-SPME-GC-MS n.a.     Liu et al. 2014 
a
 Serum control samples; n.a. not applicable; BALF: bronchoalveolar lavage fluid; BC: breast cancer; CA: canonical analysis; CC: colon cancer; CE: 
capillary electrophoresis; CRC: colorectal cancer; DFA: discriminant function analysis; DI: direct injection; EBC: exhaled breath condensate; EIA: 
enzyme immunoassay; FDG: fluorodeoxyglucose; FTICR: Fourier transform ion cyclotron resonance; GC: gas chromatography; GCA: gastric cancer; 
HCA: hierarchical cluster analysis; HNC: head and neck cancer; HPLC: high performance liquid chromatography; HS-SPME: headspace – solid phase 
microextraction; LASSO: least absolute shrinkage and selection operator, LC: lung cancer; MLR: multiple logistic regression; MS: mass spectrometry; 
MVA: multivariate analysis; NMR: nuclear magnetic resonance; OPLS-DA: orthogonal projection to latent structures –discriminant analysis; PC: 
prostate cancer; PCA: principal component analysis; PLS-DA: partial least squares – discriminant analysis; PLS-R: partial least squares regression; RC: 
rectal cancer; SVM: support vector machines; ToF: time of flight; UHPLC or UPLC: ultrahigh performance liquid  chromatography. 
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ANNEX IV: Demographic and histological information on lung cancer patients enrolled in this study 
Table A5 Demographic and histological information of lung cancer patients enrolled in this work. 
Patient 
no. 
Diagnosis Stage  Age Gender 
Patient 
no. 
Diagnosis Stage  Age Gender 
Patient 
no. 
Diagnosis Stage Age Gender 
1 Adenocarcinoma IIA 62 M 24 Adenocarcinoma IB 55 F 47 Epidermoid IIB 69 M 
2 Adenocarcinoma n.a. 74 F 25 Adenocarcinoma IA 42 F 48 Adenocarcinoma IIB 51 F 
3 Adenocarcinoma IA 68 F 26 Adenocarcinoma IIIB 69 F 49 Carcinoid IIA 62 M 
4 Carcinoid IA 66 M 27 Adenocarcinoma IA 75 M 50 Adenocarcinoma IB 55 F 
5 Adenocarcinoma IB 57 F 28 Adenocarcinoma IB 64 F 51 Sarcomatoid IB 73 M 
6 Adenocarcinoma IIA 51 M 29 Epidermoid IIB 66 M 52 Adenocarcinoma IB 73 M 
7 Adenocarcinoma IB 75 F 30 Sarcomatoid inconclusive 68 M 53 Adenocarcinoma IIA 61 M 
8 Adenocarcinoma IIB 71 M 31 LCC IA 61 M 54 Epidermoid IA 43 M 
9 Adenocarcinoma inconclusive 80 F 32 Carcinoid IIB 61 F 55 SCC IIB 52 F 
10 Adenocarcinoma IIB 49 M 33 Adenocarcinoma IB 49 M 56 Epidermoid IIB 66 M 
11 Epidermoid IA 59 M 34 Epidermoid IB 65 F 57 Adenocarcinoma IIB 70 F 
12 Adenocarcinoma IB 81 M 35 Epidermoid IB 58 M 58 Carcinoid IB 57 F 
13 Adenocarcinoma IIB 59 M 36 Adenocarcinoma IB 71 M 59 Adenocarcinoma IA 54 F 
14 Sarcomatoid IA 58 F 37 Adenocarcinoma IA 68 M 60 Carcinoid IA 58 F 
15 LCC IIIA 79 M 38 Adenocarcinoma IIIA 68 M 61 Epidermoid IB 71 M 
16 Epidermoid IB 58 M 39 Sarcomatoid IIB 46 M 62 Epidermoid IA 66 M 
17 Sarcomatoid IIIA 63 M 40 Epidermoid IA 63 M 63 SCC IIIA 63 F 
18 Epidermoid IB 74 M 41 Adenocarcinoma n.a. 75 M 64 Adenocarcinoma IA 71 F 
19 Epidermoid IIA 62 M 42 Sarcomatoid IA 57 M 65 Adenocarcinoma IIB 64 F 
20 Adenocarcinoma IIB 77 F 43 Epidermoid IIB 65 M 66 Sarcomatoid IA 61 M 
21 Carcinoid IA 71 M 44 Carcinoid IA 64 M 67 Carcinoid IB 70 M 
22 Adenocarcinoma IB 72 F 45 Epidermoid IIIA 48 M 68 LCC IA 73 M 
23 Adenosquamous IA 73 M 46 LCC IIB 60 M 69 Sarcomatoid IB 68 M 
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Table A5 (continued) 
       
 
Patient 
no. 
Diagnosis Stage  Age Gender 
Patient 
no. 
Diagnosis Stage  Age Gender 
Patient 
no. 
Diagnosis Stage Age Gender 
70 LCC IIB 78 M 87 Epidermoid IB 60 M 104 Adenocarcinoma IB 74 M 
71 Carcinoid inconclusive 71 M 88 SCC n.a. 70 M 105 Adenocarcinoma IB 72 M 
72 Adenocarcinoma IIIB 60 F 89 Epidermoid IIB 58 M 106 Epidermoid IIIA 63 M 
73 Carcinoid n.a. 50 F 90 SCC IIIA 52 M 107 Adenocarcinoma n.a. 41 F 
74 Epidermoid IIB 64 M 91 Adenocarcinoma IA 64 M 108 Epidermoid IA 58 M 
75 Adenocarcinoma IA 71 F 92 LCC IB 68 M 109 Adenocarcinoma IIB 59 M 
76 Carcinoid IA 30 F 93 Adenocarcinoma IB 75 F 110 Adenosquamous IIB 36 F 
77 Sarcomatoid IA 57 M 94 Epidermoid IB 62 M 111 Carcinoid IA 72 M 
78 Adenocarcinoma IB 59 F 95 Adenocarcinoma n.a. 61 M 112 Adenosquamous IB 68 M 
79 Adenocarcinoma n.a. 52 F 96 Adenocarcinoma IIA 56 F 113 Adenocarcinoma IA 78 F 
80 Adenocarcinoma IA 54 F 97 Epidermoid IB 63 M 114 Carcinoid IA 31 F 
81 Epidermoid IB 64 M 98 Carcinoid IA 55 F 115 Adenosquamous IB 56 M 
82 LCC IB 54 M 99 Adenocarcinoma IIIA 66 M 116 Carcinoid IA 32 M 
83 Epidermoid IA 59 M 100 Epidermoid IB 61 F 117 Epidermoid IIIA 46 M 
84 Adenocarcinoma IA 77 M 101 Adenosquamous IB 70 M 118 Epidermoid IA 68 M 
85 SCC n.a. 77 M 102 Adenocarcinoma IIIA 60 M 119 Epidermoid IA 72 M 
86 Adenocarcinoma n.a. 75 M 103 Adenocarcinoma IIIA 55 M 120 Epidermoid IB 48 M 
n.a. not available 
 
2
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Table A6 Histological characteristics of lung tumours from which tissue samples were available 
for HRMAS NMR analysis. 
 
 
Histology 
group 
/subject no.
a
 
Tumour 
size
b
 (cm) 
TNM Stage
c
 
Tumor cells
d
 
(%) 
Necrosis
d
 
(%) 
Adenocarcinoma (AdC) 
5 3.5 T2N0Mx IB 80 20 
7 3 T2N0Mx IB n.a. n.a. 
8 4 T2N1Mx IIB 40 0 
12 3.4 T2N0Mx IB 80 0 
20 3 T2N1Mx IIB 30 0 
25 2.5 T1N0Mx IA 40 0 
28 2.8 T2N0Mx IB 40 0 
33 7 T2N0Mx IB 90 5 
38 3.5 T2N2Mx IIIA 5 90 
48 9 T2N1Mx IIB 70 5 
50 5 T2N0Mx IB 50 0 
52 10 T2N0Mx IB 40 0 
57 4 T2N1Mx IIB 40 0 
64 2.3 T1N0Mx IA 90 0 
65 8 T3N0Mx IIB 50 0 
93 1.9 T2N0Mx IB 30 0 
95 3 n.a. n.a. 90 0 
102 2.2 T1N2Mx IIIA 30 0 
109 5.5 T2N1Mx IIB 50 0 
Squamous cell carcinoma (SqCC) 
19 3 T1N1Mx IIA 10 20 
29 4 T2N1Mx IIB 30 0 
34 5.5 T2N0Mx IB 5 0 
35 9 T2N0Mx IB 80 0 
43 5 T2N1Mx IIB 20 0 
47 n.a. T2N1Mx IIB 65 10 
54 3 T1N0Mx IA 40 5 
56 6.5 T3N0Mx IIB 30 30 
61 3.5 T2N0Mx IB 50 0 
74 4 T2N1Mx IIB 50 0 
81 4.5 T2N0Mx IB 10 90 
87 1.8 T2N0Mx IB 50 10 
97 4 T2N0Mx IB 100 0 
100 5 T2N0Mx IB 35 35 
106 8 T3N1Mx IIIA n.a. n.a. 
117 6 T2N2Mx IIIA 90 5 
118 3.5 T1N0Mx IA 90 5 
119 2.3 T1N0Mx IA 5 5 
120 3.3 T2N0Mx IB 10 90 
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n.a. not available; 
a 
subject number according to Table A5; 
btumour‟s greatest dimension; c stage 
according to the TNM classification system; 
d 
obtained by microscopic observation of mirror 
sections of the tissues analysed by NMR. 
 
 
 
 
Table A6 (continued) 
Histology 
group 
/subject no.
a
 
Tumour 
size
b
 (cm) 
TNM Stage
c
 
Tumor cells
d
 
(%) 
Necrosis
d
 
(%) 
Sarcomatoid 
14 3 T1N0Mx IA 20 0 
30 3 T1NxMx n.a. 50 0 
39 4 T2N1Mx IIB 80 0 
42 2.5 T1N0Mx IA 10 0 
66 2 T1N0Mx IA 60 0 
68 4.5 T2N0Mx IB 80 0 
Large cell 
15 5 T2N2Mx IIIA 10 40 
46 5.2 T2N1Mx IIB 80 0 
70 7 T3N0Mx II 50 50 
82 2.7 T2N0Mx IB 70 0 
Adenosquamous 
110 4.5 T2N1Mx IIA n.a. n.a. 
115 5 T2N0Mx IB 55 20 
Carcinoid 
4 3.7 T1N0Mx IA 5 0 
44 3 T1N0Mx IA 90 0 
49 2 T1N1Mx IIA 99 0 
111 2.3 T1N0Mx IA 90 0 
Small cell (SCLC) 
55 6 T2N1Mx IIB 80 0 
90 6 T2N2Mx IIIA 90 1 
  
ANNEX V: Demographic information on healthy volunteers 
Table A7 Demographic and smoking status information on healthy volunteers enrolled in this work. 
Control 
no. 
Gender Age 
Smoking 
status 
Control 
no. 
Gender Age 
Smoking 
status 
Control 
no. 
Gender Age 
Smoking 
status 
1 M 52 former smoker 24 M 27 former smoker 47 F 29 non-smoker 
2 F 26 non-smoker 25 M 48 former smoker 48 F 49 non-smoker 
3 F 44 smoker 26 M 30 smoker 49 F 37 non-smoker 
4 F 45 non-smoker 27 M 44 smoker 50 M 56 smoker 
5 F 42 former smoker 28 F 44 former smoker 51 F 30 non-smoker 
6 F 29 non-smoker 29 F 38 non-smoker 52 F 38 smoker 
7 F 51 smoker 30 M 48 non-smoker 53 M 52 non-smoker 
8 F 40 smoker 31 M 30 smoker 54 F 48 smoker 
9 F 42 non-smoker 32 F 38 smoker 55 M 59 non-smoker 
10 F 47 non-smoker 33 F 49 non-smoker 56 F 35 non-smoker 
11 M 50 former smoker 34 M 45 non-smoker 57 M 35 smoker 
12 M 51 non-smoker 35 F 28 N 58 M 30 former smoker 
13 F 52 former smoker 36 F 44 smoker 59 F 47 non-smoker 
14 M 33 non-smoker 37 F 37 non-smoker 60 F 22 smoker 
15 F 26 non-smoker 38 F 48 non-smoker 61 M 35 smoker 
16 F 56 former smoker 39 F 33 smoker 62 F 54 non-smoker 
17 M 56 former smoker 40 F 34 smoker 63 M 48 former smoker 
18 M 36 smoker 41 F 45 non-smoker 64 M 35 smoker 
19 F 49 non-smoker 42 M 25 smoker 65 M 40 non-smoker 
20 M 50 non-smoker 43 M 57 smoker 66 M 32 smoker 
21 M 46 non-smoker 44 M 38 non-smoker 67 M 23 non-smoker 
22 F 
 
non-smoker 45 M 28 smoker 68 M 30 non-smoker 
23 M 28 non-smoker 46 M 51 smoker 69 M 43 smoker 
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Table A7 (continued) 
     
 
Control 
no. 
Gender Age 
Smoking 
status 
Control 
no. 
Gender Age 
Smoking 
status 
Control 
no. 
Gender Age 
Smoking 
status 
70 M 60 former smoker 79 M 34 non-smoker 88 M 49 non-smoker 
71 F 47 non-smoker 80 M 36 non-smoker 89 F 51 former smoker 
72 M 45 former smoker 81 F 30 former smoker 90 M 36 non-smoker 
73 F 53 former smoker 82 F 54 non-smoker 91 M 48 non-smoker 
74 F 48 non-smoker 83 F 54 non-smoker 92 M 43 smoker 
75 M 52 former smoker 84 M 53 smoker 93 F 50 non-smoker 
76 M 46 former smoker 85 M 58 former smoker 94 F 50 smoker 
77 M 45 former smoker 86 F 53 smoker 95 M 40 non-smoker 
78 M 26 smoker 87 F 50 former smoker 
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ANNEX VI: T1 and T2 measurements 
Table A8 
1
H T1 and T2 relaxation time constants measured for selected metabolites of human 
tumour tissue. 
δ (ppm) Assignment T1±SD (ms) T2±SD (ms) 
0.88 Lipids, -CH3 208.8±10.8 101.4±5.6
 
1.00 Isoleucine 439.3±14.6a 440.9±77.3a 
 Broad peak underneath 92.1±3.7 26.9±4.6 
1.04 Valine 621.1±19.4a 505.2±16.7a 
 Broad peak underneath 101.0±4.6 52.9±6.5 
1.28 Lipids, -CH2 300.4±10.5 88.6±3.3
 
1.33 Lactate 934.1±10.4a 368.7±10.2a 
 Broad peak underneath 202.2±10.0 27.6±3.0 
1.48 Alanine 888.7±19.5a 632.0±15.4 a 
 Broad peak underneath 145±8.3 19.0±2.3 
1.72 Lysine 504.3±20.2a 311.8±8.6a 
 Broad peak underneath 120.3±10.6 33.2±1.2 
2.35 Glutamate 828.2±29.2a 483.2±11.0a 
 Broad peak underneath 186.9±16.9 40.3±2.7 
2.45 Glutamine 637.5±10.6a 463.4±15.2a 
 Broad peak underneath 99.0±3.5 5.3±0.8 
2.56 Glutathione reduced 455.2±17.6a 231.8±22.0a 
 Broad peak underneath 90.1±5.1 6.4±1.2 
2.81 Aspartate 556.5±13.3a 430.0±43.2a 
 Broad peak underneath 91.4±4.8 21.1±2.7 
2.89 Asparagine 600.2±3.2a b 
 Broad peak underneath 96.4±4.9  
3.21 Choline 1407.0±47.5a 657.4±38.5 
 Broad peak underneath 130.5±9.1  
3.22 Phosphocholine b 266.1±12.5 
3.23 Glycerophosphocholine 533.8±9.8 436.9±15.3 
3.35 scyllo-Inositol 1038.5±51.3 417.4±25.0 
3.43 Taurine 1563.2±40.3 553.4±13.9 
3.56 Glycine 2005.1±22.6 580.8±12.3 
3.85 Serine 1568.0±112.8a 579.5±13.9a 
 Broad peak underneath 280.2±18.6 69.6±3.8 
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Table A8 (continued) 
δ (ppm) Assignment T1±SD (ms) T2±SD (ms) 
3.93 Creatine 755.3±9.8 491.1±4.6a 
 Broad peak underneath  48.3±2.9 
3.97 Phosphoethanolamine 861.7±39.6a 547.8±10.2a 
 Broad peak underneath 164.8±19.4 58.7±3.4 
4.06 myo-Inositol 781.2±24.7a 523.8±23.3a 
 Broad peak underneath 154.9±9.8 48.3±4.5 
4.26 Threonine 1098.0±60.2a 352.7±17.0a 
 Broad peak underneath 231.9±20.7 19.8±1.4 
4.65 β-Glucose 689.1±29.3a 511.4±22.2a 
 Broad peak underneath 54.5±6.6 35.7±7.1 
5.24 α-Glucose 1342.4±69.8a 572.2±58.9a 
 Broad peak underneath 92.8±7.7 69.5±7.1 
5.43 Glycogen 997.5±86.0a 236.5±37.5a 
 Broad peak underneath 145.9±11.7 70.1±20.9 
6.88 Tyrosine 1387.1±43.6a 462.8±15.8 
 Broad peak underneath 123.9±4.4  
7.32 Phenylalanine 1775.2±48.9a 688.5±28.8 
 Broad peak underneath 97.3±5.1  
a
 Bi-exponential decay was observed and evaluated. 
b
 Peaks not detected or with low intensity 
originating poor data were not fitted. SD: fitting standard deviation. 
 
Table A9 
1
H T1 and T2 relaxation time constants measured for selected metabolites of human blood 
plasma. 
 
(ppm) 
Assignment 
T1±SD 
(ms) 
T2±SD 
(ms) 
0.69 Cholesterol 219.9±3.9 6.0±0.4 
0.84 Fatty acyl chains of phospholipids (CH3, mainly in HDL) 289.0±4.6
a 4.3±0.4a 
 Mobile lipids  61.7±3.7 
0.87 Fatty acyl chains of triglycerides (CH3, mainly in LDL+VLDL) 357.6±7.3
 a 11.9±0.8a 
 Mobile lipids  180.4±10.0 
1.03 Valine 528.3±25.5 a 399.8±96.2a 
 Broad peak underneath 164.0±6.5 6.3±0.5 
1.46 Alanine 1205.4±72.5 a 1014.2±144.0a 
 Broad peak underneath 221.1±5.2 12.0±0.7 
1.56 Fatty acyl chains in lipoproteins (CH2-CH2-CO) 269.0±3.4 16.5±0.9 
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Table A9 (continued)   
 
(ppm) 
Assignment 
T1±SD 
(ms) 
T2±SD 
(ms) 
2.02 N-acetyl groups in glycoproteins 850.8±22.3 a 221.9±16.3a 
 Broad peak underneath 259.0±6.5 18.9±1.4 
2.36 Pyruvate 1971.6±94.8 a 718.1±138.4a 
 Broad peak underneath 226.8±3.2 10.8±1.0 
2.45 Glutamine 1013.8±53.7 a 713.15±249.2a 
 Broad peak underneath 211.8±3.7 10.0±0.9 
3.00 Albumin 241.5±2.6 13.6±0.7 
3.03 Creatine 1867.6±80.2 a 636.9±82.7a 
 Broad peak underneath 227.0±3.6 12.7±0.7 
3.04 Creatinine 2070.8±89.1 a 1377.1±203.8a 
 Broad peak underneath 233.2±3.7 12.8±0.7 
3.21 Choline 435.1±19.2 a 149.6±4.9a 
 Choline of phospholipids in lipoproteins 200.5±12.2 7.5±0.6 
3.35 Methanol 2436.5±127.5 713.8±73.7 
3.49 -Glucose 1423.8±20.9 a 623.3±19.1a 
 Broad peak underneath 249.1±4.4 14.0±0.5 
3.56 Glycine 2252.2±89.2 732.2±69.9 
4.11 Lactate 2038.7±57.9 a 749.9±20.6a 
 Broad peak underneath 264.6±3.8 9.0±0.1 
5.23 -Glucose 2136.7±298.6 a 397.5±37.5a 
 Broad peak underneath 641.1±132.6 14.6±2.3 
5.26 Fatty acyl chains of phospholipids (CH=CH, mainly in HDL) 507.0±10.0 a 27.9±2.3 
5.30 
Fatty acyl chains of triglycerides (CH=CH, mainly in 
LDL+VLDL) 
592.6±9.1 29.7±4.5 
7.72 Protein 269.6±6.6 3.2±0.6 
a
 Bi-exponential decay was observed and evaluated. SD: fitting standard deviation. 
 
Table A10 
1
H T1 and T2 relaxation time constants measured for selected metabolites of human 
urine. 
δ 
(ppm) 
Assignment 
T1±SD  
(ms) 
δ 
(ppm) 
Assignment 
T1±SD  
(ms) 
2.24a Acetone 3.378±0.327 1.36 α-Hydroxyisobutyrate 1230.1±20.3 
1.99 N-acetylated metabolite 1568.1±44.5 1.27 β-Hydroxyisovalerate 967.9±12.2 
2.01 N-acetylated metabolite 1501.0±68.0 6.98 p-Hydroxyhippurate 2.738±0.083 
2.03 N-acetylated metabolite 1165.2±26.0 6.87 p-Hydroxyphenylacetate 3.406±0.104 
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Table A10 (continued) 
δ 
(ppm) 
Assignment 
T1±SD  
(ms) 
δ 
(ppm) 
Assignment 
T1±SD  
(ms) 
2.05 N-acetylated metabolite 1067.8±20.9 7.71 Indoxyl sulfate 6.110±0.202 
2.07 N-acetylated metabolite 1062.5±21.4 3.36 scyllo-Inositol 1.373±0.009 
2.08 N-acetylated metabolite 0.886±0.012 1.33 Lactate 951.8±15.8 
1.48 Alanine 973.6±19.5 7.06 1-Methylhistidine 2.812±0.050 
2.56 Citrate 0.764±0.003 7.15 3- Methylhistidine 3.180±0.048 
2.68 Citrate 0.772±0.003 7.43 Phenylacetylglutamine 3.831±0.047 
3.05 Creatinine 2.824±0.023 4.35 Tartrate  2.862±0.064 
4.06 Creatinine 2.274±0.011 3.43 Taurine 1.988±0.018 
2.36 p-Cresol 2.092±0.030 1.33 Threonine 748.8±7..5 
1.23 4-DEA 0.841±0.013 3.27 TMAO 2.318±0.006 
2.73 Dimethylamine 3.694±0.017 4.44 Trigonelline 1.861±0.068 
1.11 4-DTA 777.8±16.6 1.07 Unknown 940.6±25.0 
1.55 Fatty acids 0.531±0.010 1.15 Unknown 0.643±0.017 
8.46 Formate 10.195±0.166 2.46 Unknown 1.177±0.014 
3.57 Glycine 2.218±0.035 4.10 Unknown 2.101±0.039 
7.56 Hippurate 3.196±0.014 4.30 Unknown 1.433±0.034 
7.64 Hippurate 4.561±0.043 5.35 Unknown 1.238±0.294 
7.84 Hippurate 3.220±0.010 6.67 Unknown 7.411±0.775 
2.42 β-Hydroxybutyrate 4.468±0.228
 a 7.68 Unknown 1.902±0.014 
 Broad peak underneath 0.718±0.038 2.78 Unknown 1.324±0.016 
a
 Bi-exponential decay was observed and evaluated. 
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ANNEX VII: Schematic representation of the 1D 
1
H NMR pulse 
programmes used 
Pulse programme noesypr1d (standard 1D) from Bruker library
1
: 
 
pl9: power level for presaturation; d1: relaxation delay; d8: mixing time. 
 
Pulse programme cpmgpr (CPMG) from Bruker library
1
: 
 
pl9: power level for presaturation; d1: relaxation delay; d20: fixed echo time; l4: loop for T2 filter. 
 
Pulse programme ledbpgp2s1d (diffusion-edited) from Bruker library
1
: 
 
d1: relaxation delay; d20: diffusion time; d21 eddy current delay; G6, G7, G8: z-gradients. A pulse 
for presaturation (with pl9 power) is also applied during d1 (not shown in the scheme) 
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Pulse programme t1irpr (T1 measurement) from Bruker library
1
: 
 
d1: relaxation delay; vd: variable delay obtained from the vd list. A pulse for presaturation (with 
pl9 power) is also applied during d1 (not shown in the scheme). 
 
Pulse programme t2zgpr (T2 measurement) from Bruker library
1
: 
 
d1: relaxation delay; d20: fixed echo time; c: counter the number of loops obtained from the vc list. 
A pulse for presaturation (with pl9 power) is also applied during d1 (not shown in the scheme). 
 
  
ANNEX VIII: List of UPLC-MS features relevant to cancer vs. control discrimination 
 
Table A11 List of significant UPLC-MS HSS ESI+ features (Wilcoxon rank sum test, p<0.01) obtained for the comparison of the cancer group 
compared to controls. Features intensities are indicated as: very high (>10
5
), high (>10
4
, <10
5
), low (>10
3
, <10
4
) and very low (<10
3
). 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
1 0.43 520.77 very low 82.3±14.6 1.1×10-4 0.82±0.41 22 1.00 474.04 very low 51.6±5.2 3.9×10-12 1.61±0.46 
2 0.43 316.87 very low 105.3±16.5 1.9×10-4 0.86±0.41 23 1.00 315.05 very low 44.6±8.3 1.0×10-4 0.90±0.42 
3 0.44 248.88 very low 55.0±11.4 8.1×10-4 0.77±0.41 24 1.00 576.09 very low 54.7±10.3 1.3×10-4 0.86±0.41 
4 0.46 456.71 very low 55.7±10.7 2.0×10-4 0.83±0.41 25 1.00 458.07 low 43.5±9.0 3.3×10-4 0.82±0.41 
5 0.47 256.82 very low 61.6±12.1 1.0×10-4 0.80±0.41 26 1.00 442.09 very low 44.5±6.8 6.4×10-7 1.10±0.43 
6 0.50 104.11 very low 26.5±6.0 5.6×10-4 0.79±0.41 27 1.00 155.04 very low 17.8±3.9 2.1×10-4 0.85±0.41 
7 0.50 257.00 very low 43.7±6.4 2.6×10-7 1.15±0.43 28 1.00 203.55 very low 35.7±3.7 7.5×10-12 1.69±0.46 
8 0.55 114.07 high 22.1±3.4 8.2×10-8 1.18±0.43 29 1.00 245.08 low 89.8±15.0 8.6×10-7 0.85±0.41 
9 0.57 139.06 low -59.6±14.9 7.6×10-8 -1.13±0.43 30 1.00 513.11 low 68.3±7.5 3.4×10-9 1.40±0.44 
10 0.65 335.10 low 86.9±10.4 1.0×10-7 1.20±0.43 31 1.00 386.58 low 53.6±5.0 8.8×10-14 1.72±0.46 
11 0.85 285.23 low 66.4±8.3 2.6×10-7 1.22±0.43 32 1.00 573.11 low 57.2±5.3 1.3×10-13 1.72±0.46 
12 0.86 203.03 low 39.2±4.2 2.4×10-10 1.58±0.45 33 1.00 386.08 low 55.8±6.6 1.3×10-8 1.36±0.44 
13 0.99 460.08 very low 57.4±9.9 3.9×10-5 0.93±0.42 34 1.00 345.00 very low 69.0±10.3 5.5×10-6 1.02±0.42 
14 0.99 219.14 low -44.3±10.4 4.9×10-8 -1.09±0.42 35 1.00 264.55 very low 56.2±6.8 2.9×10-8 1.33±0.44 
15 0.99 285.57 very low 51.6±5.2 3.9×10-12 1.61±0.46 36 1.00 264.05 very low 56.5±7.0 2.0×10-8 1.30±0.44 
16 1.00 444.09 very low 33.7±4.2 7.5×10-12 1.41±0.44 37 1.00 557.12 very low 74.3±7.5 4.3×10-10 1.50±0.45 
17 1.00 575.12 very low 57.0±9.4 3.5×10-5 0.97±0.42 38 1.01 543.06 very low 59.6±6.2 1.3×10-10 1.53±0.45 
18 1.00 515.12 very low 49.0±8.5 3.4×10-5 0.94±0.42 39 1.01 373.08 very low 28.4±7.9 1.3×10-3 0.65±0.41 
19 1.00 577.09 very low 51.6±7.2 5.5×10-7 1.17±0.43 40 1.01 284.56 low 58.2±8.8 5.0×10-6 1.06±0.42 
20 1.00 387.09 low 52.2±6.2 8.1×10-9 1.36±0.44 41 1.01 313.06 low 31.0±6.3 5.3×10-5 0.88±0.41 
21 1.00 387.09 low 35.3±6.8 1.9×10-5 0.91±0.42 42 1.01 289.04 very low 66.6±12.7 5.2×10-4 0.81±0.41 
A
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Table A11 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
43 1.01 405.05 very low 76.1±10.1 4.6×10-6 1.13±0.43 69 1.98 448.06 low -60.3±17.3 5.7×10-9 -0.98±0.42 
44 1.01 308.09 very low 33.9±6.0 2.0×10-5 0.99±0.42 70 1.99 171.06 very low -64.8±23.6 1.1×10-6 -0.80±0.41 
45 1.01 347.05 very low 51.5±12.6 1.1×10-3 0.66±0.41 71 1.99 341.01 low 46.5±7.2 2.7×10-6 1.07±0.42 
46 1.01 329.03 low 70.3±10.5 5.5×10-6 1.02±0.42 72 2.18 361.21 very low -64.1±17.9 2.5×10-10 -1.03±0.42 
47 1.01 370.05 very low 60.3±14.8 5.2×10-3 0.64±0.41 73 2.40 185.09 very low -46.1±14.4 2.0×10-6 -0.83±0.41 
48 1.09 241.12 very low -56.5±15.1 6.8×10-8 -1.04±0.42 74 2.42 424.25 very low 121.8±16.9 1.2×10-4 0.92±0.42 
49 1.15 438.98 low 59.6±11.5 6.4×10-5 0.81±0.41 75 2.44 347.16 very low -75.3±27.7 3.4×10-9 -0.86±0.41 
50 1.15 308.01 low 85.4±17.1 5.0×10-5 0.72±0.41 76 2.47 343.06 low -81.5±24.8 2.6×10-10 -1.09±0.42 
51 1.15 232.52 very low -70.8±37.6 1.3×10-5 -0.57±0.40 77 2.49 410.04 very low 99.6±11.7 2.0×10-7 1.17±0.43 
52 1.23 169.04 high 48.4±8.8 5.8×10-5 0.90±0.42 78 2.49 470.07 very low 90.7±13.7 1.7×10-5 0.94±0.42 
53 1.24 393.02 very low 71.5±12.8 3.8×10-5 0.84±0.41 79 2.49 451.06 very low 139.1±17.3 9.9×10-7 0.98±0.42 
54 1.25 417.03 very low 86.4±15.6 4.7×10-5 0.79±0.41 80 2.52 284.15 low 143.9±15.9 2.0×10-7 1.08±0.42 
55 1.25 604.98 very low 71.5±16.9 9.2×10-4 0.64±0.41 81 2.52 279.10 low 93.2±8.2 2.4×10-10 1.59±0.45 
56 1.26 368.16 very low -64.0±16.6 7.2×10-12 -1.12±0.43 82 2.52 182.08 low 78.7±8.5 6.3×10-9 1.36±0.44 
57 1.27 261.09 low 846.3±22.0 9.4×10-13 1.54±0.45 83 2.53 425.20 very low -69.1±24.4 2.3×10-11 -0.85±0.41 
58 1.27 323.06 very low 1823.8±26.0 6.4×10-14 1.45±0.45 84 2.56 306.03 very low 72.5±9.9 2.3×10-6 1.10±0.42 
59 1.32 296.05 very low 89.7±14.2 6.7×10-6 0.90±0.42 85 2.58 508.14 very low -59.9±30.1 4.3×10-10 -0.57±0.40 
60 1.33 255.03 very low 88.5±13.5 4.7×10-5 0.93±0.42 86 2.59 275.11 low -70.4±38.0 4.2×10-8 -0.56±0.40 
61 1.34 302.09 low -71.2±31.1 3.2×10-7 -0.70±0.41 87 2.60 441.15 very low 126.9±14.2 5.3×10-7 1.13±0.43 
62 1.59 317.08 very low -60.1±20.2 2.5×10-6 -0.84±0.41 88 2.65 302.16 very low -53.3±14.1 8.9×10-7 -1.01±0.42 
63 1.63 293.05 low 74.9±11.6 1.8×10-5 0.96±0.42 89 2.70 256.12 low -73.9±33.6 9.2×10-7 -0.68±0.41 
64 1.82 272.13 low 148.6±21.2 5.7×10-9 0.84±0.41 90 2.70 321.06 low 36.0±6.8 6.0×10-5 0.92±0.42 
65 1.90 221.54 very low 91.1±10.9 9.6×10-8 1.18±0.43 91 2.70 346.11 low 34.1±6.7 3.1×10-5 0.89±0.42 
66 1.91 401.05 low 89.5±10.8 2.2×10-7 1.17±0.43 92 2.73 384.18 low -83.3±47.1 8.4×10-9 -0.59±0.40 
67 1.96 170.09 low -33.0±17.6 5.0×10-4 -0.45±0.40 93 2.77 303.07 very low -86.0±74.0 2.1±×10-9 -0.40±0.40 
68 1.96 508.08 very low -63.9±25.6 1.3×10-6 -0.72±0.41 94 2.77 375.22 low -74.2±23.5 2.4×10-12 -0.98±0.42 
A
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Table A11 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
95 2.81 285.14 very low -74.6±28.2 4.3×10-9 -0.83±0.41 107 3.42 244.15 high -30.6±7.0 1.1×10-6 -1.03±0.42 
96 2.85 369.08 very low -61.6±18.1 1.3×10-6 -0.98±0.42 108 3.87 522.09 very low 136.1±14.7 4.6×10-9 1.14±0.43 
97 2.95 334.11 high 27.6±4.6 5.0×10-7 1.08±0.42 109 3.88 341.18 low -68.4±20.1 5.8×10-11 -1.02±0.42 
98 2.96 375.14 low 34.7±6.7 2.1×10-5 0.90±0.42 110 3.88 764.21 very low 42.2±9.9 1.2×10-7 0.71±0.41 
99 2.99 207.02 very low -89.6±40.2 1.1×10-7 -0.79±0.41 111 3.88 171.08 low 46.9±6.0 4.5×10-8 1.30±0.44 
100 3.01 409.21 very low -54.7±22.0 9.3×10-8 -0.67±0.41 112 3.88 780.19 low 122.5±12.6 5.1×10-9 1.24±0.43 
101 3.05 277.10 low -56.0±12.0 8.1×10-10 -1.28±0.43 113 4.35 319.13 very low -73.0±16.9 1.7×10-12 -1.33±0.44 
102 3.05 237.12 low -72.5±17.1 6.4×10-10 -1.31±0.44 114 4.67 289.11 low -85.8±26.5 5.3×10-12 -1.11±0.43 
103 3.05 237.12 low -69.1±17.2 2.7×10-9 -1.20±0.43 115 4.68 267.12 low -72.5±20.8 8.8×10-9 -1.08±0.42 
104 3.05 175.12 low -67.6±16.1 3.3×10-9 -1.25±0.43 116 5.32 244.19 low -63.2±24.0 7.3×10-8 -0.77±0.41 
105 3.05 255.13 low -72.5±17.1 6.4×10-10 -1.31±0.44 117 6.95 409.16 low 572.5±13.6 2.1×10-15 2.27±0.51 
106 3.40 343.10 low -68.4±14.3 6.2×10-12 -1.43±0.44 118 6.96 425.14 low 641.9±14.9 5.2×10-15 2.14±0.50 
 
Table A12 List of assigned significant UPLC-MS HSS ESI- features (Wilcoxon rank sum test, p<0.01) obtained for the comparison of the cancer group 
compared to controls. Features intensities are indicated as: very high (>10
5
), high (>10
4
, <10
5
), low (>10
3
, <10
4
) and very low (<10
3
). 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
1 1.68 513.99 very low 68.5±14.5 1.9×10-4 0.72±0.41 9 1.87 561.96 very low 54.9±8.0 4.0×10-7 1.10±0.42 
2 1.68 452.02 very low 78.2±19.3 4.8×10-4 0.60±0.40 10 1.88 515.96 very low 78.3±8.6 1.0×10-8 1.34±0.44 
3 1.76 401.06 low 60.6±9.3 3.2×10-6 1.02±0.42 11 1.88 462.94 very low 60.8±7.8 3.6×10-8 1.24±0.43 
4 1.76 337.93 very low 56.8±9.3 1.2×10-5 0.97±0.42 12 1.88 499.99 low 47.2±7.7 1.9×10-5 1.02±0.42 
5 1.81 408.95 low -82.1±36.5 7.9×10-8 -0.75±0.41 13 1.88 583.94 very low 85.6±11.1 1.1×10-6 1.11±0.43 
6 1.82 192.98 high -54.9±17.6 6.2×10-7 -0.85±0.41 14 1.94 417.98 low 71.7±14.1 5.6×10-4 0.77±0.41 
7 1.87 410.03 high 35.4±13.3 1.1×10-7 0.47±0.40 15 1.95 547.93 very low 108.0±21.0 2.4×10-3 0.69±0.41 
8 1.87 493.98 low 49.4±7.9 4.2×10-6 1.02±0.42 16 1.95 196.05 low 85.0±8.4 3.3×10-9 1.45±0.45 
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Table A12 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
17 1.96 204.98 low -73.7±23.2 1.1×10-8 -0.99±0.42 43 2.5 460.99 low -72.3±23.5 2.9×10-6 -0.95±0.42 
18 1.96 171.03 low 52.2±11.9 1.1×10-3 0.71±0.41 44 2.5 219 high -63.4±13.6 6.0×10-9 -1.35±0.44 
19 1.97 537.98 very low 63.7±8.2 6.0×10-7 1.20±0.43 45 2.52 204 very low -60.2±16.3 2.8×10-7 -1.05±0.42 
20 1.97 185.96 very low 55.7±8.9 1.7×10-5 1.00±0.42 46 2.52 310.01 very low 331.2±17.2 2.9×10-10 1.50±0.45 
21 1.97 233 low 53.3±10.6 7.4×10-5 0.81±0.41 47 2.52 361.11 low 177.1±10.9 9.8×10-11 1.78±0.47 
22 1.97 229.07 low 95.4±13.8 8.8×10-6 0.96±0.42 48 2.52 267.13 low 166.5±10.1 1.1×10-11 1.85±0.47 
23 1.99 479.95 low 81.9±14.5 8.2×10-6 0.82±0.41 49 2.52 196.05 low 177.2±11.8 7.7×10-11 1.65±0.46 
24 2.39 282.08 very low 67.3±7.6 1.1×10-8 1.35±0.44 50 2.52 153.04 very low 142.8±21.9 3.0×10-8 0.79±0.41 
25 2.4 287.07 low 63.2±11.1 3.0×10-5 0.89±0.42 51 2.52 180.05 low 121.8±8.0 1.4×10-12 1.93±0.48 
26 2.4 296.14 very low 197.1±13.2 1.6×10-11 1.55±0.45 52 2.52 248.04 low 162.9±13.8 3.9×10-9 1.34±0.44 
27 2.42 312.09 low 73.9±10.8 3.9×10-6 1.03±0.42 53 2.53 302.1 very low -73.0±26.2 1.4×10-8 -0.86±0.41 
28 2.44 212.05 low 73.4±15.2 6.4×10-4 0.73±0.41 54 2.55 305.06 low 45.7±6.4 2.5×10-6 1.19±0.43 
29 2.44 406.01 very low 43.3±7.7 1.6×10-5 0.94±0.42 55 2.55 414 very low 90.2±9.8 7.9×10-8 1.30±0.44 
30 2.44 342.02 very low 106.6±17.5 1.1×10-4 0.82±0.41 56 2.55 269.08 low 53.3±7.5 1.4×10-7 1.14±0.43 
31 2.45 341.07 low -57.4±16.2 1.3×10-6 -0.98±0.42 57 2.55 447.1 low 35.3±5.9 2.6×10-6 1.04±0.42 
32 2.48 523.09 very low -78.8±24.1 6.2×10-7 -1.06±0.42 58 2.55 377.03 low 52.4±9.2 7.4×10-6 0.92±0.42 
33 2.48 587.15 very low -62.3±34.2 8.4×10-5 -0.52±0.40 59 2.6 351.06 low 75.4±7.8 3.2×10-9 1.43±0.44 
34 2.48 590.05 very low 87.5±17.5 3.6×10-4 0.72±0.41 60 2.6 435.01 very low 123.7±11.5 1.4×10-9 1.37±0.44 
35 2.48 529.1 low 81.8±13.1 9.1×10-6 0.91±0.42 61 2.6 331.03 very low 168.0±18.1 1.8×10-10 1.05±0.42 
36 2.49 423.03 low 43.5±14.3 5.3×10-7 0.51±0.40 62 2.66 433.12 low 55.8±6.9 2.4×10-9 1.30±0.44 
37 2.49 469 very low 127.1±17.0 8.2×10-6 0.95±0.42 63 2.67 355.13 very low 162.4±19.5 7.7×10-7 0.95±0.42 
38 2.49 739.12 very low 231.4±25.1 3.2×10-6 0.89±0.42 64 2.67 239.08 low 64.6±9.1 1.1×10-6 1.09±0.42 
39 2.49 454.03 very low 179.4±20.6 5.1×10-7 0.95±0.42 65 2.67 314.06 very low -55.3±24.7 3.8×10-6 -0.62±0.41 
40 2.49 392.06 low 131.1±15.5 2.5×10-7 1.05±0.42 66 2.67 402.99 low -83.7±28.4 3.1×10-11 -1.00±0.42 
41 2.49 490.04 very low 104.6±13.6 3.2×10-6 1.04±0.42 67 2.72 204.98 high -79.1±21.6 1.3×10-9 -1.19±0.43 
42 2.49 518.98 very low 135.8±19.3 3.3×10-5 0.87±0.41 68 2.73 455.97 very low -82.7±27.8 1.6×10-8 -0.99±0.42 
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Table A12 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
69 2.74 491.15 very low -88.6±49.3 4.1×10-9 -0.63±0.41 92 3.28 331.06 low 55.6±6.0 8.8×10-10 1.48±0.45 
70 2.78 301.05 low -74.5±42.6 5.3×10-6 -0.55±0.40 93 3.4 319.1 low -55.8±10.8 1.1×10-10 -1.42±0.44 
71 2.85 382.02 very low -60.0±22.4 1.6×10-7 -0.76±0.41 94 3.72 303.02 low -76.9±21.0 8.4×10-10 -1.17±0.43 
72 2.86 477.1 very low -46.0±17.3 1.4×10-6 -0.70±0.41 95 3.82 277.02 low -67.0±25.8 1.6×10-7 -0.77±0.41 
73 2.86 493.01 low -27.9±18.9 3.0×10-8 -0.34±0.40 96 3.86 178.05 very high -31.1±6.7 3.8×10-7 -1.11±0.43 
74 2.86 573.05 very low -80.1±42.6 3.8×10-7 -0.61±0.41 97 3.87 443.17 low -57.5±12.5 7.9×10-8 -1.28±0.43 
75 2.91 546.1 very low -69.9±27.3 9.9×10-7 -0.77±0.41 98 3.87 274.01 low -90.0±24.5 8.7×10-12 -1.30±0.44 
76 2.91 124.04 very low -76.4±40.3 3.0×10-8 -0.60±0.40 99 3.87 580.14 low 49.1±11.3 6.1×10-4 0.72±0.41 
77 2.94 218.1 high 41.8±11.9 2.8×10-3 0.60±0.40 100 3.87 273.01 high -87.9±23.0 3.7×10-12 -1.33±0.44 
78 2.94 354.08 very low 98.9±14.9 5.3×10-5 0.91±0.42 101 3.87 615.21 low 66.1±10.0 5.9×10-6 1.02±0.42 
79 2.95 378.1 low 78.7±10.1 5.7×10-9 1.15±0.43 102 3.87 626.14 low 55.0±8.9 4.6×10-6 0.99±0.42 
80 2.95 505.07 very low -86.5±33.6 2.1×10-10 -0.89±0.42 103 3.87 861.3 low 68.1±10.1 5.3×10-6 1.03±0.42 
81 2.96 445.1 very low -79.0±27.4 5.8×10-8 -0.93±0.42 104 3.87 245.1 low 69.7±12.5 1.5×10-4 0.85±0.41 
82 2.96 203 low -85.7±21.2 1.2×10-16 -1.38±0.44 105 3.87 844.25 low 66.9±10.2 2.4×10-6 1.01±0.42 
83 2.99 403.03 very low -75.8±22.3 1.0×10-8 -1.08±0.42 106 3.88 835.3 low 46.3±8.5 1.3×10-5 0.91±0.42 
84 2.99 307.05 very low -81.4±32.0 1.3×10-7 -0.84±0.41 107 3.88 829.27 low 37.9±6.7 3.4×10-6 0.98±0.42 
85 2.99 220 low -59.1±21.7 1.1×10-5 -0.77±0.41 108 3.88 363.03 high 55.7±8.0 2.8×10-7 1.11±0.43 
86 2.99 218.99 high -77.0±24.6 2.0×10-9 -1.00±0.42 109 3.88 813.31 low -68.9±18.2 3.4×10-6 -1.13±0.43 
87 2.99 218.99 high -75.8±22.3 1.0×10-8 -1.08±0.42 110 3.88 611.18 low 62.0±11.8 4.9×10-5 0.83±0.41 
88 3 283.11 low 110.7±14.2 1.5×10-6 1.03±0.42 111 3.89 784.2 low 103.8±15.0 5.0×10-7 0.94±0.42 
89 3.05 262.03 low 67.0±9.8 1.6×10-8 1.05±0.42 112 3.89 498.09 high 75.3±10.1 1.1×10-7 1.11±0.43 
90 3.08 295.99 low 163.0±15.9 2.7×10-8 1.17±0.43 113 3.91 331.1 low 116.9±11.9 5.7×10-9 1.28±0.43 
91 3.1 416.94 low -79.6±19.0 8.3×10-12 -1.36±0.44 
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Table A13 List of assigned significant UPLC-MS HILIC ESI+ features (Wilcoxon rank sum test, p<0.01) obtained for the comparison of the cancer 
group compared to controls. Features intensities are indicated as: very high (>10
5
), high (>10
4
, <10
5
), low (>10
3
, <10
4
) and very low (<10
3
). 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
1 0.44 643.02 very low -75.9±27.8 2.23×10-9 -0.87±0.41 26 4.16 449.17 very low -66.4±21.5 5.54×10-8 -0.91±0.42 
2 0.46 315.04 very low -29.0±25.9 8.29×10-3 -0.26±0.40 27 4.21 463.15 low -50.8±15.8 1.17×10-11 -0.87±0.41 
3 0.46 274.14 high 378.7±19.6 8.31×10-12 1.39±0.44 28 4.21 591.08 very low -48.7±11.0 1.28×10-8 -1.16±0.43 
4 0.48 299.01 low 119.0±14.0 1.32×10-7 1.10±0.42 29 4.29 365.02 low -71.5±19.4 1.50×10-9 -1.13±0.43 
5 0.49 369.12 very low -55.1±20.8 5.34×10-7 -0.72±0.41 30 4.3 327.07 low -69.5±20.2 1.37×10-7 -1.04±0.42 
6 0.59 387.18 low 2055.7±135.0 1.42×10-6 0.28±0.40 31 4.59 406.13 low 63.0±7.6 4.19×10-8 1.29±0.44 
7 0.79 392.04 low -69.4±35.1 4.29×10-10 -0.60±0.40 32 4.59 389.13 low 41.1±5.7 2.62×10-7 1.22±0.43 
8 0.79 351.01 very low -74.1±27.9 8.47×10-11 -0.83±0.41 33 4.59 403.16 very low -61.4±19.5 1.11×10-6 -0.89±0.42 
9 2.47 444.13 very low -57.3±12.2 4.26×10-9 -1.30±0.44 34 4.77 319.12 low -65.2±20.2 6.24×10-8 -0.95±0.42 
10 2.49 206.05 low -71.7±22.1 5.88×10-10 -0.99±0.42 35 5 246.01 very low 120.5±16.9 1.28×10-6 0.92±0.42 
11 2.5 372.1 low -57.4±10.5 3.26×10-10 -1.52±0.45 36 5.19 341.17 low -56.8±11.8 2.13×10-9 -1.33±0.44 
12 2.78 457.1 very low -61.4±12.7 2.48×10-10 -1.38±0.44 37 5.2 177.02 very low -65.7±18.4 3.43×10-11 -1.04±0.42 
13 2.78 532.11 very low -51.1±10.5 2.23×10-9 -1.29±0.44 38 5.2 194.05 very low -60.2±16.6 3.91×10-9 -1.02±0.42 
14 2.79 180.07 low -53.4±13.1 4.91×10-10 -1.10±0.42 39 5.29 187.11 low -41.0±8.2 3.59×10-9 -1.24±0.43 
15 3.73 881.28 low 140.6±24.0 5.85×10-5 0.71±0.41 40 5.83 417.2 low 88.9±8.6 3.11×10-11 1.47±0.45 
16 3.73 595.18 high 83.1±18.5 2.05×10-4 0.65±0.41 41 5.83 399.19 low 103.6±11.5 3.96×10-11 1.23±0.43 
17 3.74 897.25 very low 132.3±22.8 1.04×10-5 0.72±0.41 42 5.94 191.07 high -41.2±9.6 1.93×10-7 -1.06±0.42 
18 3.75 859.29 very low 136.9±19.0 3.66×10-6 0.88±0.41 43 6.12 251.15 low 63.6±15.0 5.18×10-5 0.66±0.41 
19 3.86 509.14 very low -65.4±17.0 1.33×10-8 -1.12±0.43 44 6.3 317.17 very low -77.7±26.4 3.02×10-9 -0.95±0.42 
20 3.86 331.01 very low -54.5±10.4 9.18×10-12 -1.41±0.44 45 6.34 384.19 low -76.6±38.4 2.33×10-9 -0.63±0.41 
21 3.89 475.04 low -81.5±37.8 1.02×10-10 -0.71±0.41 46 6.38 133.1 very low 35.0±4.3 3.37×10-4 1.40±0.44 
22 3.9 477.09 low -76.0±23.5 2.59×10-10 -1.02±0.42 47 6.4 203.42 high 36.5±5.4 8.91×10-7 1.16±0.43 
23 3.91 437.07 low -77.8±27.1 1.75×10-12 -0.92±0.42 48 6.41 158.13 low 23.1±3.5 1.15×10-6 1.19±0.43 
24 3.92 364.1 low 45.4±6.5 2.52×10-7 1.17±0.43 49 6.57 320.22 very low 120.2±12.5 4.53×10-8 1.22±0.43 
25 4.14 272.14 very low 105.2±13.7 3.05×10-7 1.04±0.42 50 6.74 410.17 low -49.4±18.3 4.80×10-6 -0.71±0.41 
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Table A13 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
51 6.74 171.15 high 38.9±6.3 9.24×10-7 1.07±0.42 59 7.16 421.18 very low -58.9±15.7 2.37×10-8 -1.06±0.42 
52 6.82 419.17 very low 214.1±19.7 1.51×10-8 1.08±0.42 60 7.17 225.12 high -54.5±14.3 2.62×10-7 -1.03±0.42 
53 6.83 271.1 low -62.6±25.7 2.83×10-7 -0.70±0.41 61 7.27 189.42 low -33.9±6.3 2.58×10-8 -1.29±0.44 
54 6.9 275.21 very low 71.7±9.6 2.01×10-7 1.13±0.43 62 7.42 282.18 low 217.5±14.5 1.74×10-11 1.49±0.45 
55 6.91 221.15 very low 72.9±7.3 3.59×10-11 1.51±0.45 63 7.42 246.18 high 56.1±5.8 4.57×10-11 1.54±0.45 
56 7.02 328.13 low 81.8±19.0 1.06×10-4 0.63±0.41 64 7.42 268.16 low 378.1±30.3 2.91×10-8 0.90±0.42 
57 7.14 589.3 very low 229.3±15.5 2.11×10-11 1.42±0.44 65 7.94 395.21 very low 135.8±16.0 6.42×10-7 1.05±0.42 
58 7.16 368.16 low -68.3±15.6 7.16×10-12 -1.30±0.44 66 7.94 379.23 low 142.9±15.1 4.27×10-7 1.14±0.43 
 
Table A14 List of assigned significant UPLC-MS HILIC ESI- features (Wilcoxon rank sum test, p<0.01) obtained for the comparison of the cancer 
group compared to controls. Features intensities are indicated as: very high (>10
5
), high (>10
4
, <10
5
), low (>10
3
, <10
4
) and very low (<10
3
). 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
1 0.44 597.03 low -84.1±37.5 9.2×10-10 -0.76±0.41 13 0.45 397.01 high 147.4±15.0 4.5×10-10 1.17±0.43 
2 0.44 109.03 low -56.4±15.3 4.7×10-10 -1.01±0.42 14 0.49 548.94 low 142.9±16.1 8.2×10-6 1.07±0.42 
3 0.44 125.03 low -78.0±23.7 2.2×10-10 -1.06±0.42 15 0.49 604.03 very low -81.3±31.3 5.3×10-9 -0.87±0.41 
4 0.44 291.01 low -78.8±34.4 1.7×10-9 -0.74±0.41 16 0.49 526.96 low 83.0±12.2 2.3×10-8 0.98±0.42 
5 0.44 207.06 low -90.9±38.4 1.1×10-10 -0.85±0.41 17 0.49 423.01 low 129.7±17.5 1.5×10-8 0.93±0.42 
6 0.44 163.06 low -79.7±30.7 3.7×10-10 -0.84±0.41 18 0.49 681.99 low 143.6±22.1 1.7×10-9 0.78±0.41 
7 0.44 441.99 low 169.6±19.6 1.0×10-8 0.96±0.42 19 0.49 313.95 low 103.3±14.3 1.2×10-7 0.98±0.42 
8 0.45 508.58 low 171.8±18.1 1.8×10-11 1.05±0.42 20 0.49 343.04 high 64.9±12.2 8.4×10-5 0.82±0.41 
9 0.45 506.58 low 178.1±18.9 3.5×10-6 1.03±0.42 21 0.49 446.99 high 75.9±13.8 2.7×10-7 0.82±0.41 
10 0.45 413 low 121.8±13.8 4.8×10-7 1.13±0.43 22 0.52 383.05 high -73.2±35.0 1.4×10-7 -0.64±0.41 
11 0.45 398.01 low 171.3±16.0 7.7×10-11 1.19±0.43 23 0.52 284.96 low -82.5±46.2 3.2×10-6 -0.59±0.40 
12 0.45 397.01 high 147.4±15.0 5.3×10-8 1.17±0.43 24 0.52 465 low 136.7±17.5 8.6×10-7 0.96±0.42 
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Table A14 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
25 0.53 206.99 high -70.3±23.4 1.2×10-5 -0.91±0.42 49 0.75 324.02 low 120.4±20.1 2.0×10-9 0.78±0.41 
26 0.55 192.98 high -62.5±16.9 5.9×10-12 -1.06±0.42 50 0.75 438.9 very low -83.2±33.2 1.0×10-8 -0.84±0.41 
27 0.56 399.04 low -67.6±25.4 1.5×10-6 -0.79±0.41 51 0.75 267.75 very low 100.5±27.4 6.8×10-8 0.50±0.40 
28 0.56 692.14 very low 93.3±13.9 3.2×10-6 0.94±0.42 52 0.76 560.99 very low -70.8±24.8 2.1×10-8 -0.87±0.41 
29 0.56 226.81 low 164.2±14.7 6.6×10-3 1.26±0.43 53 0.76 545 low -56.5±28.0 7.0×10-8 -0.56±0.40 
30 0.58 224.81 low 229.8±21.8 1.1×10-7 1.01±0.42 54 0.76 426.98 low 154.7±20.6 5.3×10-6 0.88±0.4 
31 0.6 124.99 low -74.4±55.6 1.4×10-7 -0.42±0.40 55 0.77 218.98 high -30.8±10.4 1.1×10-4 -0.70±0.41 
32 0.64 261.01 very high -69.0±20.7 2.1×10-8 -1.00±0.42 56 0.77 275.02 high -59.0±34.7 1.4×10-9 -0.48±0.40 
33 0.65 245.01 high -58.1±29.5 4.1×10-13 -0.55±0.40 57 0.77 573.03 low -61.8±37.0 1.5×10-8 -0.48±0.40 
34 0.68 185.82 very low 79.0±12.9 5.3×10-6 0.90±0.42 58 0.78 603.04 very low -62.5±38.6 2.5×10-9 -0.47±0.40 
35 0.68 274.18 very low -71.8±22.5 1.0×10-8 -0.98±0.42 59 0.78 633.05 low -90.7±47.4 1.3×10-11 -0.68±0.41 
36 0.69 419.68 very low -81.1±59.2 6.4×10-3 -0.45±0.40 60 0.78 540.02 low -74.6±30.4 6.2×10-8 -0.77±0.41 
37 0.69 309.71 low 95.7±17.6 6.2×10-10 0.76±0.41 61 0.78 406.97 very low -92.8±41.4 3.5×10-7 -0.81±0.41 
38 0.69 416.6 very low 719.7±40.7 1.4×10-7 0.80±0.41 62 0.84 305.03 high -88.6±31.0 2.0×10-9 -1.00±0.42 
39 0.69 268.76 low 387.5±31.1 4.6×10-6 0.89±0.42 63 0.84 589.02 very low -82.3±37.8 1.2×10-8 -0.72±0.41 
40 0.69 414.6 very low 341.1±28.5 2.0×10-6 0.92±0.42 64 0.85 575.01 low -79.8±33.5 1.4×10-10 -0.78±0.41 
41 0.69 311.7 low 80.1±16.9 2.0×10-4 0.70±0.41 65 0.85 556.99 very low -82.6±27.4 1.3×10-8 -1.01±0.42 
42 0.7 169.85 very low 60.9±14.0 3.1×10-4 0.68±0.41 66 0.9 516.97 low -78.0±27.0 1.1×10-6 -0.93±0.42 
43 0.71 203.82 low 143.3±21.5 3.9×10-6 0.80±0.41 67 0.93 246.99 very high -63.0±15.8 3.0×10-11 -1.15±0.43 
44 0.71 204.98 high -28.1±35.1 1.6×10-5 -0.19±0.40 68 0.98 188.99 very high -33.3±13.7 4.9×10-3 -0.58±0.40 
45 0.72 270.76 low 540.9±43.1 1.5×10-10 0.71±0.41 69 1.19 245.07 high 44.8±8.4 2.3×10-8 0.89±0.42 
46 0.72 343.67 low 224.6±38.7 1.6×10-10 0.57±0.40 70 1.33 238.06 low 121.5±12.4 1.5×10-7 1.26±0.43 
47 0.74 571.02 very low -74.0±23.8 1.7×10-7 -0.97±0.42 71 1.4 303.02 high -71.5±19.7 6.0×10-8 -1.12±0.43 
48 0.74 232.98 high -78.2±25.4 3.3×10-4 -0.99±0.42 72 1.49 284.09 high 61.4±9.1 5.3×10-8 1.05±0.42 
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Table A14 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
73 1.52 317.06 high 60.9±8.0 6.2×10-8 1.20±0.43 99 3.24 258.82 low 142.1±18.6 5.6×10-10 0.92±0.42 
74 1.53 322.07 low 96.0±9.8 8.0×10-7 1.36±0.44 100 3.28 194.05 very high -47.2±20.7 4.7×10-5 -0.60±0.40 
75 1.56 186.04 very low 130.0±12.5 9.7×10-5 1.30±0.44 101 3.29 224.06 high -69.2±16.8 6.7×10-6 -1.24±0.43 
76 1.57 324.03 low 82.1±11.8 5.5×10-7 1.01±0.42 102 3.29 256.82 low 178.4±19.1 5.0×10-7 1.02±0.42 
77 1.79 317.01 very low -73.5±28.1 3.2×10-8 -0.81±0.41 103 3.3 267.85 low 95.7±12.9 4.4×10-8 1.03±0.42 
78 2.07 289.16 low -71.0±24.6 4.7×10-10 -0.88±0.41 104 3.38 189.2 very low 43.4±6.2 1.4×10-4 1.17±0.43 
79 2.76 209.84 low 261.3±31.6 3.4×10-8 0.75±0.41 105 3.38 432 low 123.6±15.5 7.4×10-14 1.01±0.42 
80 2.82 178.05 very high -33.5±11.0 2.0×10-3 -0.73±0.41 106 3.51 295.13 high -48.3±10.3 6.2×10-12 -1.23±0.43 
81 2.82 360.13 low -77.3±22.7 9.6×10-7 -1.09±0.42 107 3.52 425.16 low -67.8±17.7 8.1×10-13 -1.14±0.43 
82 2.83 441.06 low -64.6±14.0 6.0×10-5 -1.35±0.44 108 3.53 439.16 low -77.3±18.2 3.6×10-4 -1.36±0.44 
83 2.83 134.28 low -75.5±22.9 1.1×10-5 -1.04±0.42 109 3.55 447.09 low -64.6±41.9 1.0×10-4 -0.45±0.40 
84 2.84 381.11 very low -68.5±20.9 3.3×10-6 -0.98±0.42 110 3.63 276.05 low -59.7±14.3 3.3×10-5 -1.17±0.43 
85 2.85 400.15 low -70.8±59.5 2.3×10-7 -0.36±0.40 111 3.65 387.17 low -50.1±19.6 1.7×10-4 -0.68±0.41 
86 2.85 367.23 low -88.5±36.0 1.6×10-9 -0.86±0.41 112 3.66 298.14 very low -73.2±21.4 1.2×10-5 -1.06±0.42 
87 2.86 399.14 low -67.6±53.5 4.0×10-8 -0.37±0.40 113 3.72 383.16 low -65.0±17.2 2.8×10-9 -1.10±0.42 
88 2.86 457.05 low -78.8±24.0 1.6×10-7 -1.06±0.42 114 3.74 657.2 very low -41.7±28.3 2.0×10-9 -0.38±0.40 
89 2.94 184.1 high -56.3±18.4 7.1×10-9 -0.84±0.41 115 3.75 263.1 very high 34.7±11.7 9.8×10-3 0.52±0.40 
90 3.01 277.86 low 189.0±19.3 1.6×10-5 1.05±0.42 116 3.76 330.05 low -74.0±34.2 3.9×10-12 -0.67±0.41 
91 3.02 241.89 low 178.6±19.9 6.5×10-8 0.99±0.42 117 3.76 367.12 low -93.9±84.7 7.0×10-10 -0.41±0.40 
92 3.02 279.86 low 175.5±19.1 1.4×10-9 1.02±0.42 118 3.77 835.31 low 65.0±13.5 6.4×10-4 0.75±0.41 
93 3.03 281.86 low 212.7±20.7 8.0×10-7 1.04±0.42 119 3.77 417.22 low -78.1±27.2 4.4×10-7 -0.92±0.42 
94 3.04 243.88 low 138.8±19.3 4.4×10-8 0.88±0.41 120 3.79 385.19 low -73.8±51.3 5.8×10-11 -0.45±0.40 
95 3.06 265.12 low -83.5±22.9 8.0×10-7 -1.22±0.43 121 3.81 431.21 low -66.9±19.9 2.0×10-8 -0.99±0.42 
96 3.09 223.84 low 145.3±18.8 1.4×10-10 0.93±0.42 122 3.83 405.13 high 44.3±10.1 6.1×10-4 0.73±0.41 
97 3.14 250.07 low -55.5±24.5 1.8×10-9 -0.63±0.41 123 3.85 389.22 low -71.7±24.7 1.5×10-5 -0.89±0.42 
98 3.22 253.83 very low 161.4±19.4 2.8×10-6 0.95±0.42 124 3.85 401.18 low -70.3±24.0 1.9×10-8 -0.89±0.42 
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Table A14 (continued) 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
Feature 
No. 
RT 
(min) 
m/z 
feature 
intensity 
% 
variation 
p-value 
effect size 
±CI 
125 3.89 397.1 low -72.6±34.2 4.6×10-9 -0.66±0.41 137 4.6 378.11 low 79.2±12.5 9.3×10-11 0.93±0.42 
126 3.89 399.17 low -69.7±27.0 2.2×10-7 -0.78±0.41 138 4.61 449.21 low -56.4±15.4 8.5×10-11 -1.01±0.42 
127 3.9 205.13 very low -76.9±29.8 1.1×10-9 -0.82±0.41 139 4.61 401.15 low -63.4±17.9 2.1×10-12 -1.02±0.42 
128 3.9 483.14 very low -59.3±24.4 5.5×10-9 -0.69±0.41 140 4.61 394.13 high 261.2±22.7 1.0×10-4 1.04±0.42 
129 3.91 467.07 low -84.0±41.1 1.5×10-9 -0.69±0.41 141 4.61 406.19 low -73.7±22.9 3.9×10-9 -1.00±0.42 
130 4.03 499.21 very low -80.6±25.8 3.9×10-10 -1.02±0.42 142 4.61 365.14 low 63.5±6.1 3.4×10-11 1.62±0.46 
131 4.33 371.06 low -65.2±18.4 4.6×10-9 -1.04±0.42 143 5.01 282.12 low 120.4±13.2 1.2×10-6 1.16±0.43 
132 4.35 471.19 low -66.1±23.7 5.6×10-10 -0.82±0.41 144 5.46 284.12 low -48.3±13.9 3.9×10-8 -0.91±0.42 
133 4.41 299.1 low -55.1±13.7 3.2×10-9 -1.10±0.42 145 5.47 302.13 low -51.3±12.7 2.5×10-8 -1.08±0.42 
134 4.43 282.01 high 31.8±4.4 9.2×10-12 1.26±0.43 146 5.79 345.15 low -85.0±38.4 3.9×10-9 -0.75±0.41 
135 4.54 253.12 low -62.5±14.5 4.1×10-9 -1.24±0.43 147 6.43 201.13 high 45.7±6.1 5.5×10-6 1.24±0.43 
136 4.59 261.03 low 54.9±8.5 4.1×10-12 1.05±0.42 
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